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Astrocytomas are some of the most lethal diffuse gliomas, and glioblastoma (GBM, Grade IV 
astrocytoma) has a median survival of 12-15 months with therapy.  The last decade has seen increased 
efforts to define the molecular landscape of human GBM, and led to a focus on genetic abnormalities 
within the receptor tyrosine kinase (RTK), RB cell cycle, and P53 signaling pathways.  Genetically-
engineered mouse (GEM) models have been designed based upon the data from these studies and have 
helped determine some of the requirements for gliomagenesis depending on the cellular and 
developmental context.  Despite these efforts gliomagenesis requirements and progression are not 
completely defined, and more importantly, it is often unclear which molecular subtype is modeled by 
these GEM.  In this work, we employ GEM with conditional, inducible mutations in the RB cell cycle, 
MAPK, and PI3K pathways to effect astrocytoma initiation followed by stochastic progression in 
astrocytes throughout the brain in adult mice.  We define the requirements for astrocytoma initiation 
and the effect they have on gene expression and copy number.  Stochastic progression to high-grade 
astrocytoma (HGA) and GBM are characterized by detection via contrast-enhancing MRI, rapid growth, 
genotype-dependent survival, acquisition of copy number abnormalities (CNA), and gene expression 
subtypes that resemble human GBM.  These subtypes correlate with brain region rather than original 
genotype.   
 In parallel, we isolated astrocytes from pups containing the same genetic mutations and induced 
recombination in culture to create G1/S-defective astrocytes with activated Kras and/or Pten deletion. 
 iv 
 We examined how these individual and combined mutations affected gene expression and phenotypic 
hallmarks of astrocytoma tumorigenesis including cell growth, migration, and invasion.  Combined 
disruption of MAPK and PI3K signaling led to the most aggressive, invasive astrocytes (TRP) with stem-
like and proneural expression profiles.  These TRP astrocytes were confirmed to have stem cell 
properties in vitro and in vivo.  After orthotopic injection into syngeneic mice, these TRP astrocytes 
formed HGA with high incidence, short latency, and reproducible survival, supporting its utility as a 
preclinical model.  We replicated standard of care GBM treatment consisting of radiation with 
concurrent temozolomide and showed that TRP allografts were susceptible to radiation but not 
temozolomide.  Similar to TRP astrocytes in vitro, the allograft HGA expression profiles were proneural, 
but after radiation treatment most were most similar to the mesenchymal subtype.  Overall, this 
research defines the requirements for astrocytoma in adult murine astrocytes and raises important 
questions about whether mutations, cell type, or location determines molecular subtype.  We develop 
several models which will be useful to further elucidate the molecular nuances of astrocytoma and their 
effects on initiation, progression, and signaling pathways.  These models will also serve as the basis for 
future subtype specific preclinical models in which to develop novel gene signatures, biomarkers, and 
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CHAPTER I  
Introduction 
 
GENE EXPRESSION PROFILING OF GLIOMAS:  MERGING GENOMIC AND HISTOPATHOLOGICAL 
CLASSIFICATION FOR PERSONALIZED THERAPY1,2 
 
Summary 
The development of DNA microarray technologies over the past decade has revolutionized 
translational cancer research.  These technologies were originally hailed as more objective, 
comprehensive replacements for traditional histopathological cancer classification systems based on 
microscopic morphology.  Although DNA microarray-based gene expression profiling (GEP) remains 
unlikely in the near term to completely replace morphological classification of primary brain tumors, 
specifically the diffuse gliomas, GEP has confirmed that significant molecular heterogeneity exists within 
the various morphologically-defined gliomas, particularly glioblastoma (GBM).  Herein we provide a ten 
year progress report on human glioma GEP, with a focus on development of clinical diagnostic tests to 
identify molecular subtypes uniquely responsive to adjuvant therapies.  Such progress may lead to a 
more precise classification system that accurately reflects the cellular, genetic, and molecular basis of 
                                                          
 
1A version of this work was previously published as Vitucci M, Hayes DN, Miller CR. Gene expression 
profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J 
Cancer. 2011;104(4):545-53. 
 
2 A version of this work was previously published as Schmid RS, Vitucci M, Miller CR. Genetically 
engineered mouse models of diffuse gliomas. Brain Res Bull. 2012;88(1):72-9 
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gliomagenesis, a prerequisite for identifying subsets uniquely responsive to specific adjuvant 
therapies and ultimately in achieving individualized clinical care of glioma patients.   
 
Introduction 
Morphological evaluation of cancers by light microscopy has been the foundation for diagnosis, 
prognostication, and therapeutic stratification for well over a century.  Yet patients with morphologically 
identical tumors can have significantly different clinical outcomes.  To address the pressing medical need 
for more accurate outcome predictions, a variety of transformative technologies have been developed 
over the last four decades – electron microscopy, molecular biology, immunohistochemistry, and 
quantitative RT-PCR – to refine traditional cancer classification or as outright replacements.  The newest 
such technology, DNA microarrays, was introduced in 1995, and its potential clinical utility in oncology 
was quickly recognized.  In fact, the Director of the U.S. National Cancer Institute issued a challenge to 
the scientific community in 1999 (1) to “harness the power of comprehensive molecular analysis 
technologies to make the classification of tumors vastly more informative.  This challenge is intended to 
lay the groundwork for changing the basis (emphasis added) of tumor classification from morphological 
to molecular characteristics.” 
The response from the cancer research community has been intense:  nearly 14,000 publications 
have utilized DNA microarrays for genome-wide gene expression profiling (GEP) in all aspects of cancer 
research, from basic to translational to clinical.  GEP has unequivocally established that significant 
molecular heterogeneity exists within morphologically-defined cancers and that potentially clinically-
relevant molecular subtypes can be identified.  Yet to date, only two molecular diagnostic tests 
developed using DNA microarrays have either been approved by the U.S. Food and Drug Administration 
(MammaPrint®) or incorporated into practice guidelines (Oncotype Dx®) for clinical use in breast cancer 
(2).   
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This discordance between scientific productivity and clinical implementation over the course of a 
decade is not unexpected, given the stringent sample requirements, pace of technology development, 
data volume and complexity, continually evolving data analysis techniques, lack of defined best practices 
for analysis, and levels of evidence required for clinical use.  A number of excellent review articles have 
discussed these and other impediments to implementing GEP clinically (2-4).  Herein, we review a 
decade of DNA microarray-based GEP on the most common and biologically aggressive group of primary 
brain tumors, the diffuse gliomas (hereafter referred to simply as gliomas).  The discussion will revisit 
morphological classification and address the potential role of GEP in identifying clinically-relevant 
molecular subtypes of gliomas.  We will then primarily focus on studies that have examined the 
prognostic impact of multi-gene signatures for the most deadly glioma, glioblastoma (GBM).   
   
Morphological classification of gliomas 
Bailey and Cushing established the first diagnostic classification system for primary brain tumors in 
1926, based upon their understanding of the histogenetic basis of brain development and the 
morphological resemblance of primary brain tumors to their presumed developmental counterparts by 
light microscopy.  This system has been refined periodically, culminating in the current World Health 
Organization (WHO) scheme (5).  Seven gliomas are currently recognized as distinct clinicopathological 
entities, each characterized by cytological and immunohistochemical evidence of differentiation along 
astrocytic, oligodendroglial, or both glial lineages (Table 1.1).  Further refinement into distinct 
prognostic groups is dictated by histological grading (II-IV) based on morphological features associated 
with more aggressive biology, including mitoses, microvascular proliferation, and necrosis (6).  
Molecular and genetic features constitute an additional level of detail utilized not only to diagnostically 
differentiate among these entities, but increasingly to predict clinical outcomes and response to 
adjuvant therapies. 
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The prognostic power of the current WHO glioma classification has facilitated its widespread 
adoption for clinical patient management.  However, it has long been recognized that individual patients 
within each diagnostic category can have vastly different outcomes that are not otherwise accounted for 
by established prognostic factors, including age, Karnofsky performance status (KPS), and therapy.  This 
prognostic variability can be visualized using the 95% confidence intervals of Kaplan-Meier survival 
curves (Fig. 1.1).  The extent to which prognostic factors account for outcome variability in multivariate 
Cox proportional hazards models can be quantified with metrics such as Harrell's C statistic (Table 1.1) 
(7).  Using these two measurements, prognostic variability is least pronounced in astrocytic gliomas (Fig. 
1.1A), particularly GBM, and is substantially higher in mixed (Fig. 1.1B) and pure oligodendroglial (Fig. 
1.1C) gliomas.  Prognostic variability is most pronounced among the lower grade gliomas (Fig. 1.1D, E).  
For these gliomas in particular, accurate classification and prognostication have become increasingly 
dependent on molecular assays.  The most notable test detects co-deletion of chromosomal arms 1p 
and 19q, a genetic signature and favorable prognostic factor strongly associated with oligodendroglial 
differentiation (7).  Yet even with ancillary molecular testing, classification of a subset of 
morphologically-ambiguous grade II and III gliomas remains challenging, even among experienced 
neuropathologists (6, 7).  Clearly, more objective, molecular methods for diagnostic discrimination 
among gliomas are needed.    
The clinicopathological variables central to the WHO 2007 classification - patient age at diagnosis, 
differentiation (cytology), histological grade, and 1p19q co-deletion status - account for 70-80 percent of 
the prognostic variability among each of the three major types of gliomas, based on the C index (Table 
1.1).  Inclusion of additional clinical factors (e.g. KPS, therapy) not otherwise available in this 
retrospective dataset would likely account for even more of the prognostic variability.  Despite the 
inability to accurately predict outcomes for individual patients, this example clearly illustrates that 
existing clinicopathological factors account for the vast majority of prognostic variability in gliomas.  It is 
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in this context – the ability to provide prognostic information independent of established factors - that 
the clinical utility of GEP  must be defined (3).  The key for clinical implementation of GEP will therefore 
be to quantify the remaining 20-30% of prognostic variability by one of two means:  1) utilizing GEP as a 
diagnostic adjunct to more accurately classify morphologically-ambiguous gliomas, or 2) to identify 
prognostically distinct molecular subtypes within otherwise morphologically-homogeneous gliomas. 
 
Molecular classification of gliomas 
The earliest GEP studies utilized class comparison to identify differentially expressed genes among 
morphologically-defined gliomas.  Such genes were found in low-grade versus high-grade astrocytomas 
(8), high-grade oligodendrogliomas versus GBM (9, 10), primary versus secondary GBM (11-13), adult 
versus pediatric GBM (14), or a variety of morphologically-defined glioma subtypes (12, 13, 15).  Using 
primarily hierarchical clustering on differentially expressed genes, transcriptomal profiles of individual 
tumors were shown to be most similar to those from the same diagnostic category, i.e. gliomas of 
similar differentiation and grade.  These studies confirmed that morphological differences among 
gliomas are reflected at the mRNA transcript level and that differentially-expressed genes could be 
utilizedto distinguish among morphologically-defined subtypes.  However, discordance between 
morphological diagnosis and GEP-defined molecular subtype was frequent, likely due in part to inclusion 
of difficult-to-classify, morphologically-ambiguous gliomas.   
Nutt, Louis, and colleagues provided a glimpse of the potential clinical utility of GEP as an ancillary 
diagnostic test for more accurate glioma classification (9).  These investigators identified genes 
significantly correlated with either morphologically classical GBM or anaplastic oligodendroglioma in a 
training set of 21 tumors and built a class prediction model that showed 86% accuracy in assigning 29 
diagnostically-challenging GBM and anaplastic oligodendrogliomas to their respective diagnostic 
categories.  More importantly, a statistically significant difference in overall survival for the GEP- but not 
 6 
the morphologically-defined groups was found, suggesting that GEP may provide more accurate 
classification and prognostication, particularly for morphologically-ambiguous gliomas.  These findings 
were confirmed by Shirahata and colleagues (10), who identified 168 differentially-expressed genes 
from PCR array data on 32 GBM and anaplastic oligodendrogliomas and a weighted voting algorithm to 
develop a 67-gene diagnostic assay with 96.6% accuracy in distinguishing between these two 
prognostically-distinct high-grade gliomas using the published Nutt dataset (9) for validation. 
Li, Fine, and colleagues provided the first report of a comprehensive, molecular classification of all 
gliomas (16).  These authors utilized two unsupervised machine learning methods on a large training set 
(N=159) of WHO grade II-IV gliomas from all three histological categories.  Guided only by molecular 
data, without influence of prior morphological diagnosis, they identified six hierarchically nested 
subtypes, divided into two main categories (O and G).  The first category contained two subgroups (OA 
and OB) and the second had four nested subgroups (GA1, GA2, GB1, and GB2).  These data confirmed 
that morphological differences among gliomas are reflected at the mRNA transcript level.  Survival 
analyses showed that the O and G main groups and the OA and OB subgroups of O-type tumors, but not 
the four G subgroups, were prognostically distinct.  Importantly, the prognostic impact of the two main 
subgroups was confirmed in an independent dataset from The Cancer Genome Atlas (TCGA) consisting 
entirely of GBM (17), while that of the six subgroups was confirmed in the REMBRANDT and Phillips, et 
al. datasets consisting of all seven gliomas (18, 19).  However, the concordance between GEP-defined 
subtypes and histopathological diagnoses was not assessed and multivariate survival analyses with 
known prognostic factors were not conducted.  
In retrospect, the aforementioned studies utilized small (N<100 per diagnostic category), ostensibly 
convenience cohorts of previously banked, frozen gliomas.  As such, individual studies were statistically 
underpowered to assess the diagnostic discriminatory power of GEP vis-à-vis morphological 
classification.  Moreover, the relatively small sample sizes and lack of data on known prognostic 
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covariates precluded comprehensive multivariable analyses.  Particularly for the earlier studies, the 
prognostic impact of GEP signatures could not be validated in large, external datasets (4).  Fortunately, 
most data have been deposited in publically-available online repositories, including the Gene Expression 
Omnibus and REMBRANDT (19).  These data have already been instrumental in both novel hypothesis-
driven, mechanistic studies (20) and subsequent GEP studies described below.  Only through collection 
of GEP data on a sufficient number of all seven morphologically-defined gliomas will it be possible to 
assess whether GEP will be diagnostically robust enough to replace morphology as the basis for glioma 
classification.  
 
GEP identifies prognostically-distinct molecular subtypes of gliomas 
A number of GEP studies have identified prognostically-distinct molecular subtypes of gliomas.  In 
2004, Freije, Nelson, and colleagues analyzed 74 gliomas from four histological types and identified 595 
differentially-expressed genes that correlated with overall survival (21).  Hierarchical clustering showed 
four molecular subtypes (labeled HC1A, HC1B, HC2A, and HC2B) that segregated into two distinct 
(P=0.00011) survival clusters (SC):  SC1 (93% HC1A/B and 62% non-GBM) and SC2 (76% HC2A/B and 89% 
GBM) with 4.8 and 0.6 year (y) median overall survival, respectively.  Prognostic significance was 
confirmed in the independent Nutt dataset (9) and multivariate analysis showed that survival cluster 
was independent of patient age and histological grade.  Functional annotation of the gene lists showed 
that HC1A subtype tumors were enriched for genes involved in neurogenesis (22), suggesting a more 
differentiated phenotype.  In contrast, the poor survival subtypes were enriched for proliferation (HC2A) 
and extracellular matrix/invasion-related (HC2B) genes.  A similar list of survival-related genes 
implicated in neurogenesis was identified by Liang, et al. (23), who also showed that GBM could be 
divided into two prognostically distinct molecular subtypes (median overall survival 2.1 vs. 0.3 y). 
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In 2006, Phillips, Aldape, and colleagues analyzed 76 high-grade astrocytomas and identified 108 
differentially-expressed genes significantly associated with overall survival (18).  Hierarchical and k-
means clustering with those genes showed three distinct subtypes termed proneural, proliferative, and 
mesenchymal based upon functional annotation of representative genes.  Like Frieje HC1A, the 
proneural subtype was defined by genes implicated in neurogenesis, composed predominantly (69%) of 
non-GBM, and associated with significantly more favorable median overall survival (3.6 vs. ≤ 1.3 y), 
independent of histological grade.  In contrast, the proliferative and mesenchymal gene signatures were 
enriched for proliferation- and extracellular matrix/invasion-related genes, similar to the Frieje HC2A 
and HCA2B subtypes, respectively.  Prognostic significance of molecular subtype was validated in an 
independent cohort of 184 gliomas of various histological types.  Taken together, these results suggest 
that 1) the molecular subtype of a majority of WHO grade II-III gliomas is HC1A/proneural, and 2) 
HC1A/proneural GBM may be more prognostically favorable. 
Using published datasets and new GEP data on 86 GBM, a subsequent meta-analysis by Lee, et al. 
utilized 377 differentially-expressed genes that divided GBM into four distinct subtypes on hierarchical 
clustering:  HC1A/proneural, HC2A/proliferative, HC2B/mesenchymal, and a fourth with hybrid 
HC2A/HC2B features termed ProMes (24).  Survival analysis confirmed the more favorable prognosis of 
HC1A/proneural GBM versus the remaining three molecular subtypes (median 1.4 vs. 0.9 y).  With this 
larger dataset of 267 GBM, the authors also confirmed an association first identified by Phillips (18), 
namely that the mean age at diagnosis of proneural GBM patients was significantly younger (51 vs. 55 y, 
P=0.02).  Moreover, in multivariable analyses, only molecular subtype, but not age, was significantly 
associated with overall survival.  These data suggest a molecular basis for the known association of 
younger age with improved overall survival in GBM patients.   
However, it is of critical note that none of these prognostic studies distinguished among recognized 
morphological variants of GBM.  As shown in Table 1.1, GBM with oligodendroglial features occur in 
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younger patients and have a significantly prolonged overall survival compared to their GBM 
counterparts (P<0.0001).  Similarly, another morphological variant of GBM, small cell GBM (6), 
characterized by frequent gains of chromosome 7 (EGFR) and loss of chromosome 10q (PTEN), is 
morphologically similar to the prognostically more favorable anaplastic oligodendroglioma but lacks 
1p19q codeletion.  The recent recognition of these morphological patterns of GBM (5, 6), prognostically-
distinct from anaplastic oligoastrocytoma and anaplastic oligodendroglioma, respectively, raises the 
possibility that earlier studies were “contaminated” with tumors  known to have different prognoses.  In 
addition, at least two significant design flaws were common in these studies (3, 4): 1) subtype-specific 
signature genes were identified using heterogeneous training sets composed of various histological 
subtypes (e.g. anaplastic astrocytoma and GBM) with known differences in overall survival (Table 1.1) 
and 2) signature genes were defined based upon their association with outcome in training sets and 
their prognostic significance was reanalyzed in independent test sets, raising the possibility that the 
correlation between GEP-defined subtypes and overall survival were a consequence of prior selection 
for outcome-related genes (3).  To avoid the first problem, future studies should ideally define 
prognostic signatures in morphologically- and hence prognostically-homogeneous cohorts of gliomas.  
Moreover, consensus diagnosis among multiple, experienced neuropathologists and/or utilization of 
ancillary molecular testing such as 1p19q status for accurate assignment of morphologically-ambiguous 
cases into established diagnostic categories will be important quality control measures.   
The second problem is likely mitigated by two recently published studies that have identified the 
HC1A/proneural subset of GBM using gene signatures defined completely by unsupervised methods.  In 
the largest single-institution study conducted to date (25), Gravendeel and colleagues defined molecular 
subtypes for 276 gliomas of all histological types.  Using 5,000 genes with highly-variable expression, 
these authors identified six molecular subtypes with distinct prognoses.  GBM largely (73-86%) fell into 
three clusters (18, 22, and 23) and these tumors showed inferior prognosis relative to GBM in other 
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clusters (9, 16, 17) (median overall survival 0.7 vs. 2.1 y).  Cluster 9 consisted primarily (86%) of 
oligodendroglial neoplasms and the vast majority (82%) appropriately harbored combined 1p19q loss-
of-heterozygosity (LOH).  Notably, the prognostically superior cluster 17 (median overall survival 3.3 and 
2.1 y for all C17 gliomas and GBM, respectively) significantly (97%) overlapped with the Phillips 
proneural subtype, suggesting that detection of a subgroup of GBM with improved prognosis and 
transcriptional profiles similar to lower grade gliomas was not a consequence of prior selection of 
outcome-related genes (18).  Notably, cluster 22 was enriched (38%) for secondary GBM, tumors that 
progress from lower grade precursors, arise in younger patients (6), and feature IHD1 mutations (26), 
but lack EGFR amplification (5).  These findings confirm those from a previous study that demonstrated 
distinct molecular profiles in primary versus secondary GBM (11).  Clusters 18 and 23 contained 
predominantly GBM (78 and 86%, respectively) and showed significant overlap with Phillips proliferative 
(52%) and mesenchymal (93%) subtypes (18).  Upon analysis of data (27) from the definitive phase III 
clinical trial that established concomitant chemoradiotherapy and adjuvant temozolomide as the 
standard-of-care for newly-diagnosed GBM patients (28), these clusters were found to selectively 
benefit from combined chemoradiation versus radiation alone.  Importantly, multivariate analysis 
included most known prognostic factors, including age, gender, histological type, grade, KPS, surgery, 
chemotherapy, EGFR amplification, 1p19q status, and IDH1 mutation (26).  Only molecular subtype, KPS, 
and gender were significant, independent prognostic factors in this dataset (P≤0.02), suggesting that 
molecular subtyping may be more prognostically accurate than morphological classification.  Moreover, 
these authors validated the prognostic significance of their signatures in four independent datasets (16, 
18, 19, 29). 
The TCGA, established by the U.S. National Cancer Institute and National Human Genome Research 
Institute in December 2005 with the mission of understanding “the molecular basis of cancer through 
the application of genome analysis technologies,” selected GBM as its first cancer type for study, based 
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on its uniformly poor prognosis and limited treatment options.  As part of this multi-institutional project, 
we analyzed 200 GBM on three different GEP platforms (17).  Unsupervised hierarchical cluster analysis 
defined four subtypes, termed proneural, neural, classical, and mesenchymal based on functional gene 
annotation and prior convention (18).  Significant overlap in molecular subtypes was found for TCGA 
mesenchymal/Phillips mesenchymal/Freije HC2B and TCGA proneural/Phillips proneural/Freije HC1A 
(18, 21).  Unlike previous studies, the TCGA proneural subtype was not associated with improved 
prognosis in the TCGA dataset consisting solely of GBM, but was in the validation datasets (18, 19) 
containing lower grade gliomas.  Conversely, reanalysis of the TCGA GBM data with Phillips molecular 
subtype designations confirmed a slightly more favorable prognosis of the Phillips proneural GBM 
(median overall survival 1.2 y) relative to Phillips mesenchymal/proliferative GBM subtypes (1.0 and 0.6 
y, respectively, P=0.03).  These findings suggest that subtyping based on prognosis-defined, but not 
“intrinsic”, unsupervised gene signatures may identify a subset of GBM with more favorable prognosis.  
However, similar to previous findings (25), the TCGA classical and mesenchymal subtypes showed 
significantly improved overall survival after conventional chemoradiation or ≥ four cycles of cytotoxic 
chemotherapy (P=0.02), suggesting that these subtypes may be particularly sensitive to DNA damaging 
agents.  These hypotheses will be tested further in two ongoing phase III clinical trials conducted by the 
Radiation Therapy Oncology Group (RTOG), as discussed below. 
Capitalizing on the unprecedented level of molecular data available for these tumors (29), we 
identified recurrent genomic aberrations in each molecular subtype.  The classical subtype was 
characterized by frequent EGFR amplification and EGFRvIII mutations, CDKN2A deletion, and a lack of 
TP53 mutations, while the mesenchymal subtype was characterized by NF1, TP53, and PTEN mutations.  
Consensus neuropathological review of a subset of TCGA cases has shown that the proneural, classical, 
and mesenchymal subtypes are enriched for GBM with oligodendroglial features, small cell GBM, and 
gliosarcoma (a morphological variant of GBM with mesenchymal differentiation (6)), respectively 
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(Cameron Brennan, personal communication).  Moreover, pseudopalisading necrosis and to a lesser 
extent florid microvascular proliferation are frequent in mesenchymal GBM, but the proneural subtype 
typically lacks necrosis.  These findings suggest that mesenchymal GBM may be uniquely susceptible to 
angiogenesis inhibitors, a hypothesis currently being tested in the RTOG 0825 trial discussed below.  The 
proneural subtype, which like previous studies (18, 24) was found in younger patients, harbored 
frequent PDGFRA amplification and mutations in IDH1, TP53, and PIK3CA/PIK3R1, suggesting 
susceptibility to PDGFRA- and PI3K-targeted therapies.  A recent proteomic analysis confirmed protein- 
and phosphorylation-level signaling abnormalities in the EGFR, PDGFR, and NF1 pathways in classical, 
proneural, and mesenchymal subtypes of GBM, respectively, further suggesting that these GBM 
subtypes may be uniquely susceptible to targeted agents (20). 
A recent TCGA effort utilized methylation profiling to identify a GBM CpG island methylator 
phenotype (G-CIMP) in a significant fraction (29%) of proneural GBM, particularly secondary, IDH1 
mutation-positive GBM that progressed from lower grade tumors (30).  This implies that G-CIMP might 
be common in lower-grade gliomas, the vast majority of which cluster with the proneural molecular 
subtype of GBM (18, 25).  To further investigate this hypothesis, Noushmehr and colleagues analyzed 
eight G-CIMP gene regions in seven hypermethylated loci in an independent cohort of 152 WHO grade II 
and III gliomas by a MethyLight real-time PCR assay and found 46% of astrocytomas and 93% of 
oligodendrogliomas to be G-CIMP-positive.  Furthermore, G-CIMP-positive GBM patients were younger 
(median 36 vs. 59 y, P<0.0001) and survived longer than G-CIMP-negative GBM of both proneural and 
non-proneural subtypes (median overall survival 2.9 vs. 0.8 and 1.0 y, P=7E-7).  Importantly, G-CIMP 
positivity was independent of age and histological grade on multivariable analysis.  These findings 
suggest that G-CIMP defines a subset of proneural GBM and can be utilized to further refine expression-
defined subtypes.  The co-occurrence of G-CIMP/IDH1 mutation positivity in the proneural, 
neurogenesis-related subtype further suggests that IDH1 mutation and/or G-CIMP may confer 
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neoplastic susceptibility to a common neuron/oligodendrocyte precursor cell-of-origin (22), a hypothesis 
supported by the comparative expression profiling data that showed enrichment of genes expressed in 
purified, cultured murine oligodendrocytes in proneural GBM (17). 
 
Clinical implementation of GEP for glioma classification 
GEP-based diagnostic tests are currently being evaluated in prospective, randomized clinical trials in 
breast cancer (2).  Similar progress in clinical neuro-oncology has recently been made.  Based upon a 
previous report (18), Colman, Aldape, and colleagues (31) identified a consensus 38-gene signature from 
four independent datasets and from this set chose 9 genes (AQP1, CHI3L1, EMP3, GPNMB, IGFBP2, 
LGALS3, OLIG2, PDPN, and RTN1) based on their survival correlation and technical compatibility, for 
development of a quantitative, reverse transcription-polymerase chain reaction assay.  Based on the 
logistical difficulties in obtaining fresh frozen tumors for DNA microarray-based assays, such an assay is 
absolutely critical for successful clinical implementation with formalin-fixed, paraffin-embedded (FFPE) 
GBM, which constitute the vast majority of clinical samples.  The prognostic impact of this 9-gene profile 
was uniformly associated with both progression-free and overall survival and independent of clinical 
(age and KPS) and molecular factors, including MGMT methylation status.  This assay is currently being 
tested in two prospective, randomized, phase III clinical trials conducted by the RTOG.  RTOG0525 is 
investigating the use of dose-intensive adjuvant temozolomide versus standard-of-care (28) in patients 
stratified on the basis of MGMT promoter methylation status.  Prospectively-banked FFPE tissue from 
this trial will be retrospectively analyzed using the 9-gene predictor to confirm its prognostic significance 
relative to MGMT status in a uniformly-treated patient population.  RTOG0825 is investigating the 
benefit of adjuvant bevacizumab, a humanized, anti-angiogenesis monoclonal antibody, to standard-of-
care and will prospectively randomize patients on the basis of both MGMT methylation status and the 9-
gene assay.  The study will address, as a secondary end-point, the hypothesis that mesenchymal GBM 
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will selectively benefit from the addition of bevacizumab to standard-of-care.  Results from these 
important clinical trials are expected in 2011-2012.  In summary, molecular subtyping now has the 
potential to become a readily implemented clinical test that may guide future treatment decisions, 
particularly in identifying those patients most likely to benefit from standard-of-care versus novel, 
molecularly targeted agents.  
 
Conclusion 
As we have outlined above and summarized in Table 1.2, tremendous progress in DNA microarray-
based GEP of gliomas has been made over the past decade.  In the next decade, next-generation 
sequencing technologies such as RNA-seq (32) promise to accelerate the pace and depth of discovery, 
further strengthening GEP as a method for cancer classification by directly determining transcript 
identity, structure, and abundance at the single-base level.  Yet while GEP has provided significant 
insights into the molecular heterogeneity of morphologically-defined gliomas, its role in clinical neuro-
oncology still remains to be established.  Thus, ten years after the Director’s Challenge, the need for a 
“vastly more informative classification system” for gliomas still exists.  In this review, we have argued 
that GEP and the established morphological classification system are complementary, not mutually 
exclusive.  The most clinically appropriate uses of GEP will be as a diagnostic adjunct to more accurately 
classify morphologically-ambiguous gliomas and the identification of molecular subtypes within 
otherwise morphologically-homogeneous gliomas.  There has been substantial progress in defining 
molecular subtypes of GBM.  However, unlike commercially-available genomic tests for breast cancer, 
molecular subtyping in GBM is unlikely to be utilized for risk stratification due to this tumor’s limited 
prognostic variability.  Rather, as illustrated by the RTOG clinical trials, molecular subtyping in GBM 
shows promise in identifying subsets that may be uniquely responsive to specific adjuvant therapies.  
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Thus, the recent merger of genomic and histopathological classification bodes well for the future of 
personalized medicine in neuro-oncology. 
 
GENETICALLY-ENGINEERED MOUSE MODELS OF DIFFUSE GLIOMAS 
Summary 
Over the last decade, genetically-engineered mouse models have been extensively used to dissect 
the genetic requirements for neoplastic initiation and progression of diffuse gliomas.  While these 
models faithfully recapitulate the histopathological features of human gliomas, comparative genomic 
analyses are increasingly being utilized to comprehensively assess their fidelity to recently identified 
molecular subtypes of these tumors.  Future progress with these models will rely on incorporating 
insights not only from oncogenomics studies of cancer, but also from the developmental neuroscience 
and stem cell biology fields to design accurate and experimentally tractable models for use in 
translational cancer research, particularly for experimental therapeutics studies of molecularly defined 





Diffuse gliomas are the most common primary brain tumors (33, 34).  They are classified clinically 
into three histological subtypes and malignancy grades (35, 36) and together account for more than 80% 
of all malignant brain tumors in the US (37).  Gliomas represent some of the most devastating and 
difficult-to-treat of all human cancers.  In fact, median survival for glioblastoma (GBM), the most 
common and biologically-aggressive glioma, has not improved significantly over the last four decades 
and still averages 12-15 months (37, 38).  Currently, standard therapy for newly-diagnosed GBM patients 
 16 
consists of surgical resection followed by fractionated radiotherapy with concomitant and adjuvant 
temozolomide (TMZ) chemotherapy, a regimen that results in a modest, three month improvement in 
median overall survival compared to radiation alone, but invariably fails to prevent tumor recurrence 
(28).  Although effective treatment is complicated by the blood-brain barrier and the intrinsic resistance 
of tumor cells to radiation and cytotoxic chemotherapy (39), development of more successful treatment 
regimens has largely been impaired by the lack of understanding of glioma biology.  Genetically-
engineered mouse models (GEMM) of gliomas that faithfully recapitulate the genetics and biology of 
their human counterparts have therefore emerged as an essential experimental tool not only for the 
investigation of the genetics and cell and molecular biology of glioma initiation and progression, but also 
for the development of novel therapies (reviewed in (40-46)). 
In this review, we will briefly describe our current understanding of the pathology and genetics of 
human gliomas and how this knowledge has fueled development of GEMM, particularly with regard to 
the genes involved in dysregulated cell-autonomous intracellular signaling pathways in human gliomas 
and the cell(s) from which they may arise.  We will then review the advantages and disadvantages of 
existing glioma GEMM, and lastly, identify recent and new directions for translational research using 
these important model systems. 
 
 Histopathological classification of human gliomas 
Modeling human gliomas in mice must carefully aim to approximate the complex genetics and 
biology of both the human tumor and its microenvironment.  Gliomas show marked heterogeneity in 
their cellular morphology and identity, differentiation potential, proliferation rate, prognosis, and 
therapeutic response (47, 48).  Based upon the latest World Health Organization (WHO) classification, 
gliomas are grouped into seven distinct clinicopathological entities by cytological and 
immunohistochemical evidence of differentiation along astrocytic, oligodendroglial, or both glial 
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lineages (35).  Histological grading (II-IV) based upon the presence of morphological features associated 
with more aggressive biology, including mitoses, microvascular proliferation, and necrosis, yields further 
refinement into distinct prognostic groups (36, 48), with WHO grade IV GBM representing the most 
malignant glioma.  Two distinct neoplastic progression pathways for GBM have been recognized: 
primary GBM constitute over 95% of all GBM and arise without evidence of a previously-existing lower-
grade glioma, and secondary GBM develop through progression from low-grade or anaplastic gliomas.  
Though histopathologically indistinguishable, the molecular pathology of primary and secondary GBM 
differs (35).  Primary GBM are characterized by frequent EGFR amplification and PTEN mutations, 
whereas secondary GBM typically contain TP53 mutations and MDM2 gene amplifications (35).  Both 
frequently harbor DNA copy number and sequence abnormalities in G1 cell cycle checkpoint pathway 
genes (64% in (49) and 87% in (29)), including RB1, CDK4, CCND1 (cyclin D1), and CDKN2A (p16INK4A), and 
PI3K/PTEN/AKT pathway genes (50% in (49) and 53% in (29)), including PTEN loss of heterozygosity and 
PIK3CA mutation (29, 49). 
 
 Molecular genetic classification of human gliomas 
Over the last decade, molecular genetic analyses have identified significant molecular heterogeneity 
within various morphologically-defined human gliomas and have helped identify biologically distinct 
human glioma subtypes (48).  For instance, gene expression profiling via microarrays has been used to 
identify genes differentially expressed between GBM and anaplastic oligodendroglioma (9, 10), 
prognostically distinct molecular subtypes of anaplastic astrocytoma and GBM (17, 18, 21), and 
molecular subtypes of all diffuse gliomas (16, 25).  Most molecular characterization efforts though have 
focused solely on GBM.  In the largest molecular profiling effort conducted to date, The Cancer Genome 
Atlas (TCGA) project (17, 29) has generated a comprehensive molecular catalog of human GBM and 
confirmed that recurrent genomic abnormalities occur in genes involved in four key intracellular 
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signaling pathways: cell cycle, mitogenic (receptor tyrosine kinase (RTK)), pro-survival (PI3K-PTEN), and 
TP53 pathways (17, 29, 30).  Notably, specific genomic abnormalities were associated with one of four 
molecular subtypes (proneural, neural, classical, and mesenchymal), and the mesenchymal and classical 
subtypes showed improved survival after intense adjuvant therapy (17).  Proneural GBM contained a 
subset of tumors that shared a genomic hypermethylation phenotype with lower grade gliomas, 
occurred in younger patients, showed improved overall survival, and were associated with IDH1 
mutations (30).  Taken together, these reports have convincingly shown the biological heterogeneity 
within human GBM.  However, profiling human tumor samples only provides a static perspective of 
genomic alterations and cannot yet readily differentiate molecular genetic “drivers” of gliomagenesis 
from “passenger” events that occur during neoplastic progression (50).  While sophisticated 
bioinformatic analyses can provide critical clues to possible cell(s) of origin and the genetics of tumor 
initiation and progression, experimental models are required to definitively address these important 
issues.  GEMM are uniquely suited to fill this need.  For example, the heterozygous IDH1/2 mutations 
frequently found in the majority of low-grade gliomas and secondary GBM have been proposed to be 
involved in glioma initiation (26, 49), a question GEM modeling is ideally suited to address. 
To date, GEMM have defined the importance in neoplastic initiation and progression of the 
frequently-altered genes in four key intracellular signaling pathways observed in human gliomas (40, 
46).  Although model design, cellular targets, and specific genetic modifications vary considerably, the 
entire morphological spectrum of diffuse gliomas has been recapitulated in these model systems (Table 
1.3). 
 
Human gliomas and the cancer stem cell hypothesis 
The cancer stem cell (CSC) hypothesis postulates that tumor initiation and maintenance is governed 
by a subpopulation of tumor cells with the functional properties of normal stem cells, namely unlimited 
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self-renewal and multi-lineage differentiation potential (51).  GBM was among the first solid cancers 
where evidence of a hierarchy of phenotypically distinct tumor cells was identified.  Employing principles 
and methods from the study of normal and neoplastic hematopoiesis, several groups identified a 
subpopulation of GBM cells (brain tumor stem cells, BTSC) with NSC-like properties (52, 53).  Moreover, 
these BTSC could initiate tumors that phenotypically resembled the GBM from which they were isolated 
upon orthotopic injection of as few as 100 BTSC into the brains of immunodeficient mice (54).  
Subsequent work showed that CD133+ BTSC from human GBM displayed enhanced DNA repair capacity 
relative to CD133- cells and resistance to radiation in vitro and in vivo (55).  Moreover, the percentage of 
CD133 immunoreactive cells in WHO grade II-IV gliomas has been shown to inversely correlate with 
progression-free and overall survival as well as the time-to-recurrence for grades II and III gliomas (56).  
Despite debate over the suitability of xenotransplantation assays (see below), the poorly characterized 
function of CD133 and controversy over its use to prospectively identify human BTSC (57), the CSC 
hypothesis has transformed glioma research in at least two ways:  1) in contrast to the stochastic model 
of tumorigenesis in which all tumor cells are assumed capable of initiating and maintaining 
tumorigenesis, it suggests that BTSC are unique in these capabilities and thus their specific therapeutic 
targeting will be required for prevention of tumor recurrence and improving patient outcomes; and 2) it 
suggests that the elusive cell-of-origin for gliomas may be a true NSC or a more terminally-differentiated 
glial cell that has reacquired NSC-like properties through de-differentiation (57-60). 
 
Developmental neurobiology and the glioma cell(s) of origin 
Though recent scientific and technical advances have yielded much progress, cellular targets for 
glioma initiation, progression, and maintenance remain the focus of intense investigation and debate 
(61, 62).  It is widely accepted that identification of the differences and similarities between the cell(s) 
from which a tumor arises (cell(s) of origin) and their normal counterparts would permit development of 
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new therapeutic approaches to overcome the lack of success with currently available treatments 
(reviewed in (63)).  In support of the hypothesis that gliomas arise from cells with NSC-like properties, 
developmentally-important transcription factors required for NSC self-renewal and multipotency have 
been shown to be reactivated in gliomas (reviewed in (64)) and gene expression signatures in GBM have 
been shown to match developmental templates (17, 27). 
The largest germinal region in the adult brain resides in the subventricular zone (SVZ), located 
between the ependymal layer of the lateral ventricles and the parenchyma of the striatum. The SVZ 
contains astrocyte-like stem cells, which can be identified by the astroglial marker GFAP.  Thus, the SVZ 
is widely viewed as a potential source of glioma initiating cells (59, 65-67).  In support of this hypothesis, 
a recent clinical study has found that 93% of gliomas contacted at least one region of the lateral 
ventricular wall (68).  However, more research is required to establish the relationships between CSC 
and NSC and whether the latter can serve as cell(s) of origin for gliomas (reviewed in (58, 61, 62, 69).  
Recently, support for the NSC or progenitor cell origin of both astrocytomas (67, 70) and 
oligodendrogliomas (71) has been obtained using GEMM.  Most glioma GEMM have utilized human glial 
fibrillary acid protein (hGFAP), nestin, or S100β promoters (Table 1.3), all of which are active in multiple 
cell types in the developing and adult brain.  It would be highly desirable to target specific 
subpopulations of stem or progenitor cells to further define their potential for tumor initiation and 
maintenance.  More specific lineage-restricted promoters that have been utilized in 
neurodevelopmental genetic fate mapping and lineage tracing studies will be important tools for 
addressing these issues in the future (72, 73). 
 
Glioma GEMM design 
It has become evident that overall design, the targeted cells and their inherent differentiation 
capacity, and the specific genetic modification(s) and pathways targeted are required to achieve 
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accurate modeling of human gliomas (46).  In general, glioma GEMM have been constructed using seven 
design strategies: 1) traditional knockout models in which exons of a tumor suppressor gene are 
deleted; 2) knock-in models whereby oncogenes are replaced by mutant, constitutively active alleles 
within their native locus, under control of endogenous promoter elements; 3) transgenic models in 
which expression of an oncogene is spatially restricted to specific cell types through use of a cell type-
specific promoter; 4) spatially restricted induction models that employ localized viral delivery to induce 
either somatic gene transfer in non-transgenic animals or cell type-specific gene transfer in transgenic 
animals engineered to express the cognate viral receptor under control of a cell type-specific promoter; 
5) spatially restricted induction of conditional genetic events through viral vector delivery of a DNA 
recombinase; 6) conditional models in which genetic events are induced through cell-specific expression 
of a DNA recombinase using cell type-specific promoters; and 7) conditional, systemic induction models 
that employ cell type-specific expression of drug-inducible DNA recombinase activity.  Choice of model 
design influences the timing and cellular targets of genetically-induced oncogenesis, specifically during 
development or adulthood, as well as experimental tractability, i.e. how easily the model system is 
manipulated in labs with variable technical capabilities, which in turn influences model dissemination 
through the research community and the utility of GEM for preclinical studies. 
 
Dissecting the genetics of glioma initiation and progression in GEMM 
The first glioma GEMM utilized knockout or conventional transgenic strategies (46).  In contrast to 
the majority of cancers that develop sporadically, these models more accurately mimic inherited tumor 
predisposition syndromes in which initiating mutations are present throughout the body.  Although 
some of these GEMM showed increased susceptibility to gliomagenesis, embryonic or early post-natal 
lethality, widespread neoplasia in various organ systems, incomplete penetrance (<100% of GEMM 
develop tumors of interest), and long latency (time to development of tumors of interest) posed 
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significant hurdles to investigation of organ-specific genetic mechanisms of neoplasia.  For example, 
homozygous deletion of Pten, one of the most frequently mutated genes in human gliomas (29), proved 
to be embryonically lethal, whereas heterozygous loss induced tumors or pre-neoplastic changes in 
colon, gonads, prostate, skin, and thyroid, but not the brain (74).  Similarly Ink4a/Arf deletion produced 
largely sarcomas or lymphomas, but no brain tumors (75).  One of the first GEMM that specifically 
developed gliomas utilized simultaneous (cis) deletion of the Nf1 and Trp53 tumor suppressor genes 
(76).  Spatial restriction of transgenic oncogene expression using cell-specific regulatory elements 
improved, but did not completely eliminate these problems.  Transgenic expression of the oncogene v-
Src from a murine GFAP promoter uniformly led to perinatal astrogliosis, but only 14% subsequently 
developed low-grade astrocytomas , leading the authors to conclude that v-Src alone was insufficient for 
astrocytoma initiation (77, 78).  Simultaneous inactivation of pRb, p107, and p130 in hGFAP+ cells 
engineered to express an N-terminal SV40 large T antigen (T121) truncation mutant transgene led to 
perinatal death from neurodevelopmental abnormalities in 10 of 13 founder mice (79).  hGFAP-directed 
expression of constitutively active HRAS alone rapidly induced low-grade astrocytomas in 85-100% of 
mice and these tumors invariably progressed to high-grade astrocytomas upon spontaneous acquisition 
of karyotypic abnormalities (80), Trp53 mutation, or loss of INK4A or PTEN protein expression (80-82). 
 
Several groups have utilized viral gene transfer to spatially restrict induction of oncogenesis.  The 
advantages and disadvantages of this modeling approach have been reviewed in detail elsewhere (46, 
83).  The main advantages to this approach are the targeting of somatic cells in adult animals and 
experimental flexibility, specifically the ability to transfer multiple genes, either simultaneously or 
sequentially, in specific regions of the brain.  One of the original GEMM employing this design strategy 
utilized Maloney murine leukemia retrovirus (MoMuLV) to deliver Pdgfb (PDGFβ protein) into dividing 
cells in the forebrains of newborn mouse pups (84), which resulted in tumors with a wide range of 
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histologies, 14-29 week latency, and 40% penetrance.  More recently, GEMM utilizing avian retroviral 
(RCAS) vectors have been generated.  In contrast to the traditional retroviral system, RCAS requires the 
use of conventional transgenic GEM engineered to express its cognate receptor, tva, typically with 
spatial restriction to specific cell types using either hGFAP or nestin promoters (G-tva or N-tva, 
respectively) (85).  Histologically diverse gliomas form in these GEMM, with tumor type, penetrance, 
and latency dictated by the oncogene(s) delivered and the cell types targeted.  For example, RCAS-
mediated expression of PDGFβ in either GFAP+ or nestin+ cells yielded low- to high-grade 
oligodendrogliomas, with histological grade, penetrance, and latency depending on the injected viral 
dose (86, 87).  In contrast, RCAS-delivery of constitutively active KRAS and AKT1 produced GBM in ~25% 
of injected mice when targeted to nestin+ cells, but did not initiate gliomagenesis when targeted to 
GFAP+ cells (88, 89).  In both of these model systems, concomitant loss of one or both Ink4a/Arf alleles 
accelerated tumor progression, generally with increased penetrance and shorter latency (89, 90). 
Conditional GEMM, the latest models developed to explore the genetic mechanisms of glioma 
initiation and progression, more faithfully mimic sporadic tumor development.  As reviewed in detail 
elsewhere (46, 91), these models employ mice (Cre-drivers) engineered to express a transgenic DNA 
recombinase, mostly commonly the bacteriophage Cre enzyme, driven by cell-specific regulatory 
elements.  Whereas embryonic lethality in conventional transgenic and knockout mice precluded 
investigation of many important genes in gliomagenesis, conditional GEMM utilized oncogenes 
preceded by transcriptional stop elements flanked (floxed) by Cre recognition sequences (loxP sites), or 
floxed exons of tumor suppressor genes, to phenotypically silence these genetic modifications during 
development.  Crossbreeding with a transgenic Cre-driver mouse or somatic induction via viral delivery 
of Cre thus permitted investigation of tissue-specific genetic mechanisms of neoplasia.  An additional 
advantage of this latter technique has been the targeting of spatially- and biologically-distinct areas of 
the brain (70). 
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A variety of conditional glioma GEM models have been described.  One of the first utilized T121 to 
selectively inactivate pRb, p107, and p130 in GFAP+ cells (79).  Whereas embryonic expression of 
conventional transgenic GFAP-T121 was lethal, conditional expression using a β-actin Cre-driver induced 
WHO grade III anaplastic astrocytomas, with decreased latency upon simultaneous, conditional, 
heterozygous deletion of Pten.  Similar results were obtained upon somatic induction of Pten loss 
through stereotactic injection of retroviral (MSCV)-Cre into floxed GFAP-T121/Pten mouse brains, where 
~75% developed GBM (92).  Conditional deletion of the Nf1 tumor suppressor, a negative regulator of 
RAS signaling and frequent mutational target in human GBM (29), specifically in GFAP+ astrocytes 
resulted in development of optic nerve astrocytomas (93).  When combined with loss of Trp53 (94) or 
Pten (95), conditional Nf1 deletion in GFAP+ cells resulted in progression to high-grade gliomas, 
including GBM, with complete penetrance.  The conditional modeling approach has recently been 
extended to include oncogenes.  In particular, conditional transgenic over-expression of wild-type EGFR 
or a constitutively active extracellular domain truncation mutant of EGFR, events frequently found in 
human GBM (29), resulted in de novo GBM formation within 5-12 weeks of adenoviral-Cre-mediated 
recombination in the presence, but not absence, of simultaneous deletion of Ink4a/Arf and Pten (96). 
The newest development in glioma GEMM modeling has been the use of drug-inducible Cre-drivers, 
which permit tight spatial as well as temporal control of somatic recombination.  The most common 
system utilizes Cre recombinase genetically fused to a mutated estrogen receptor ligand-binding domain 
(CreERT2) (97), an enzyme that remains unresponsive to endogenous estrogens such as estradiol (98), but 
is activated upon systemic administration (intraperitoneal injection) of the synthetic estrogen 4-
hydroxy-tamoxifen (4OHT).  This system requires minimal technical expertise and provides control over 
the timing of genetic induction.  We have utilized this system with a GFAP-CreERT2 driver that directs 
gene expression in GFAP+ cells throughout the neuroaxis, with no activity in non-astrocytic cell 
populations (99), and a series of six GEMM with conditional alleles that inactivate RB (T121) and/or PTEN 
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and/or constitutively activate KRAS specifically in adult astrocytes (40).  All models with inactivated RB 
(T121 expression) were fully penetrant and resulting tumors showed the histopathological features of 
human astrocytomas, including perineuronal and perivascular satellitosis.  A similar approach using 
conditional deletion of Pten and Trp53, with or without Rb1 deletion, in GFAP+ cells resulted in 
development of high-grade (WHO grade III and IV) astrocytomas (100) which acquired widespread 
genomic copy number abnormalities during tumor progression (see Section 9 below). 
 
Glioma GEMM in translational cancer research:  comparative oncogenomics 
With the advent of sophisticated molecular technologies, such as high-throughput, genome-wide 
microarray-based analyses and genomic re-sequencing, cross-species comparisons between GEMM and 
their corresponding human cancers have recently become feasible.  As previously discussed, genomic 
techniques have identified heretofore unrecognized molecular heterogeneity in otherwise histologically 
homogeneous tumor types, including gliomas such as GBM (48).  Thus, the next generation of cancer 
GEMM will require not only standard comparative histopathology, but genomic molecular analyses to 
identify “best-fit” GEMM with specific molecular subtypes of their corresponding human cancers.  
Integration of mouse modeling and bioinformatics has been proposed to investigate coordinate gene 
regulation, discovery of novel biomarkers, and development of targeted drug therapy based upon 
prominent cancer signaling pathways in molecularly defined GEMM (101). 
With the exception of one recent study described below, comprehensive, genome-wide molecular 
characterization of the majority of glioma GEMM has yet to be performed.  However, progress has been 
made in other tumor types and these studies provide a blueprint for future work using glioma GEMM.  
In the most straightforward analyses, cancer GEMM have been validated by showing similar patterns of 
co-expressed genes as their human counterparts.  Sawyers and colleagues defined differentially 
expressed genes between wild-type murine prostate and a transgenic Myc-driven prostate cancer 
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GEMM and identified a subset of these in MYC-driven human prostate cancers that co-expressed PIM1, 
a kinase known to cooperate with MYC in tumorigenesis (102).  A similar type of comparison using a 
Kras-driven lung cancer GEMM identified a KRAS expression signature in human lung adenocarcinomas 
that was unidentifiable based on KRAS mutational status alone (103).  Wong and colleagues performed 
gene expression profiling on primary Lkb1-deficient/Kras-mutated GEM lung cancers and their 
corresponding spontaneous metastases to define a metastasis signature that showed prognostic 
significance in human lung adenocarcinomas and identify a subset of LKB1-deficient human cancers that 
may be amenable to combined inhibition of SRC, PI3K, and MEK signaling pathways (104).  These 
findings suggest that genomic analyses of GEMM tumors can be used to discover novel genes co-
expressed with signature mutations in human cancers. 
In an effort to define “best-fit” GEMM for molecular subtypes of hepatocellular carcinoma (HCC), 
Thorgeirsson and colleagues performed comparative gene expression profiling of seven GEMM and two 
molecularly-defined, prognostically-distinct subtypes of human HCC (105).  They discovered three 
GEMM with expression profiles similar to human HCC with better prognosis and two GEMM similar to 
the subtype with poor prognosis.  This same experimental design was subsequently applied to breast 
cancer (106), where several GEMM showed gene expression profiles similar to either basal-like or 
luminal subtypes of human breast cancer.  Subsequent comparative GEMM/human gene expression 
profiling has suggested luminal, but not basal progenitor cells to be the likely cell of origin for sporadic 
basal-like and hereditary BRCA1-deficient breast cancers (107). 
Two recently published reports have utilized comparative genomics to study human gliomas.  The 
TCGA utilized transcriptomal profiles of fluorescent-activated cell sorting (FACS)-purified neurons, 
astrocytes, and oligodendrocytes from a transgenic GEM that expressed enhanced green fluorescent 
protein from the S100β promoter (108), a GEM previously used in neurodevelopmental fate mapping 
studies (109), to identify potential lineage relationships among the four distinct molecular subtypes of 
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human GBM (17).  Baker and colleagues performed microarray-based gene expression profiling and 
copy number analysis on two GEMM of adult high-grade astrocytomas with conditional inactivation of 
Pten and Trp53, with or without concomitant Rb1 deletion (100).  The murine tumors cluster into three 
groups that show similarity to molecularly-defined subtypes of human GBM (17, 18).  Notably, brain 
region-, but not genotype-specific signatures were evident in these murine tumors, suggesting that 
regional differences in gene expression profiles within the adult brain (110), or possibly the cell(s) of 
origin, may dictate molecular subtype-specification.  Regardless, this first comparative genomics 
between GEMM and human glioma represents a significant milestone (111).  However, more 
comparative genomics studies using of GEMM and human tumors, similar in design to the one cited 
above for breast cancer (107), will be required to define the role of different cell(s) of origin or brain 
regions on molecular subtype-specification of human gliomas.  The extensive GEMM resources of the 
developmental neuroscience community will thus be critical not only for defining the cell of origin for 
specific molecular subtypes of human gliomas, but also the identification of “best-fit” glioma GEMM of 
these subtypes for future translational studies. 
 
Glioma GEMM in translational cancer research:  experimental therapeutics 
Preclinical cancer drug development has relied upon immunodeficient mouse xenografts of human 
tumor cell lines since the 1950s (112, 113).  For gliomas in particular, cell lines such as U87MG (114) 
have been widely used in both subcutaneous and orthotopic xenograft experiments because of their 
reproducible growth rates and uniformly high penetrance, which enables generation of large tumor-
bearing cohorts for experimental therapeutics (reviewed in (42)).  However, there are several serious 
flaws with this approach.  The most important shortcomings are the requirement for immunodeficient 
host and genetic and phenotypic divergence from the original tumor after in vitro cell culture (115).  
Moreover, these systems are poorly predictive of drug efficacy (reviewed in (45)) and ill-suited for 
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continued use in prioritizing drugs for clinical development, particularly for molecularly defined tumor 
subtypes.  Although much has been written about the promise of GEMM in this regard (45, 116, 117), 
they remain experimentally less amenable to therapy studies (118) and their utility in prioritizing drug 
candidates for human clinical trials has not been systematically examined.  Progress has been hampered 
by variable penetrance and latency in vivo, the requirement for small animal imaging to monitor 
spontaneous GEM tumor development, and the lack of GEM tumor cell culture systems for in vitro drug 
screening. 
With their highly penetrant, short latency tumor development in the appropriate anatomical 
location of immunocompetent hosts, the latest glioma GEMM overcome some of these shortcomings.  
Multiple groups have utilized small animal imaging, including conventional magnetic resonance imaging 
(119) and bioluminescence imaging (120-122), to longitudinally monitor the growth of GEM gliomas and 
investigate the efficacy of either standard cytotoxic drugs like TMZ (120) or novel targeted agents (121, 
122).  However, these GEMM have yet to be used to define chemotherapeutic efficacy of specific 
molecular subtypes of gliomas. 
 
Non-germline glioma GEMM for experimental therapeutics 
Recently, non-germline GEMM (nGEMM) have been proposed as an important resource for 
translational and preclinical experimental therapeutics studies due to their flexibility, speed and reduced 
cost (reviewed in (123)).  These models utilize germline GEM as the source of specific genetically-
engineered cell populations, including stem/progenitor and terminally-differentiated cells, and 
orthotopic implantation into syngeneic, immunocompetent hosts to investigate the cellular and 
molecular requirements for tumor initiation and maintenance.  Cortical injection of Ink4a/Arf-null neural 
stem cells (NSC) or primary astrocytes transfected with an activated EGFR into SCID mice produced 
invasive, high-grade astrocytomas within 2 months (124).  Similarly, injection of Ink4c/Trp53-null 
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cerebellar granular precursor cells (CGPCs) into the cortex of nude mice produced medulloblastomas 
with gene expression profiles similar to those that arose spontaneously in these GEM (125).  While these 
two examples illustrate the utility of nGEMM, these studies suffer from one issue that has plagued 
conventional human tumor xenograft studies, specifically the use of immunodeficient recipients (45).  
To overcome this issue, we have recently developed a completely syngeneic nGEMM system (40) which 
should prove to be more amenable to preclinical experimental therapeutics studies than conventional 
GEMM. 
 
Summary and conclusions 
Major improvements in GEM modeling over the last decade have produced a variety of glioma 
GEMM that faithfully recapitulate the genetics and biology of their human counterparts.  Coupled with 
increasingly sophisticated histopathological and comparative genomic analyses, insights from 
developmental neuro- and stem cell biology will fuel development of the next generation of 
experimentally tractable GEMM not only to further define the cellular and molecular basis of 








Figure 1.1.  Overall survival of patients with newly-diagnosed gliomas. Overall survival of patients with newly-diagnosed gliomas grouped 
on the basis of the two main components of the WHO classification system:  differentiation (cytology) - astrocytic (A), mixed oligoastrocytic (B), 
or oligodendroglial (C); and histological grade - WHO grade II (D), III (E), or IV (F).  Clinicopathological parameters, statistics, and abbreviations 




Table 1.1. Prognostic utility of the WHO 2007 classification for diffuse gliomas 
 
Table 1.  Prognostic utility of the WHO 2007 classification for diffuse gliomas 
 WHO Grade  Multivariate analysis 
 II  III  IV  
Prognostic 
factor 
HR P value 
ΔC or Overall 
C* 
Astrocytomas 
 DA, A2  AA, A3  GBM, A4   
N 78  161  748  Grade 1.9 < 0.001 0.61 
Median OS 
(y) 
10.0  2.2  0.9  Age** 1.9 <0.001 0.08 
95% CI 6.9-13.0  1.7-2.7  0.8-1.0  All (N=987) 0.69 
Mean age 33  39  57      
Grading 
criteria 
  Mitoses  MVP ± necrosis      
Oligoastrocytomas 
 OA, MOA2  AOA, MOA3  
GBM-O, 
MOA4*** 
     
N 400  218  71  1p19q codel 2.6 <0.001 0.54 
Median OS 
(y) 
11.1  3.9  2.2  Age** 2.1 < 0.001 0.15 
95% CI 9.0-15.0  2.8-4.6  1.3-3.4  Grade 2.2 0.007 0.10 
Mean age 38  42  48  All (N=559) 0.79 
Grading 
criteria 
  Mitoses ± MVP  Necrosis      
Oligodendrogliomas 
 ODG, O2  AO, O3        
N 395  273    1p19q codel 2.1 0.020 0.54 
Median OS 
(y) 
16.4  8.8    Age** 2.4 <0.001 0.17 
95% CI 12.9-21.1  6.5-ND    Grade 2.5 0.004 0.03 




Mitoses ± MVP ± 
necrosis 
       
All diffuse gliomas 
N 2344  1p19q codel 1.9 0.002 0.63 
Median OS 
(y) 
2.9  Age** 1.8 <0.001 0.13 




Mean age 46  Grade 2.0 <0.001 0.03 
   All (N=1363) 0.83 
Abbreviations:  anaplastic astrocytomas (AA, A3); anaplastic oligodendroglioma (AO, O3); co-deletion (codel); confidence interval (CI); diffuse 
astrocytoma (DA, A2); hazard ratio (HR); glioblastoma (GBM, A4); glioblastoma with oligodendroglial features (GBM-O, MOA4); mixed 
oligoastrocytoma (OA, MOA2); mixed anaplastic oligoastrocytoma (AOA, MOA3); microvascular proliferation (MVP); olidodendroglioma (ODG); 
overall survival (OS); years (y). 
Data from adult patients (≥ 20 y) with newly diagnosed gliomas at Washington University School of Medicine (1977-2009 and (Miller et al, 
2006)).   
* Harrell's C statistic for the multivariable Cox proportional hazards model with all factors (C) or ΔC for each individual factor in the model 
(Miller et al, 2006). 
** Age at diagnosis trichotomized as follows:  ≤ 40, 40-60, ≥ 60 y (Miller et al, 2006). 
***Note that GBM-O (MOA4) is not currently recognized as a distinct clinicopathological entity by the WHO; instead, it is considered a 





Table 1.2 Summary of glioma microarray studies 
 
Table 2.  Summary of glioma microarray studies 
Reference 




Source  Findings 
Genes 
(N) 
Biological Process or 
Molecular Subtype 
Rickman, 2001  19 PA, 21 GBM 40    Distinguishes PA and GBM. 360  
Nutt, 2003 
T 7 O3, 14 GBM 21    Distinguishes O3 and GBM. 
19  
V 
15 nonclassic O3 
14 nonclassic GBM 
29   
 86% predictive accuracy for morphologically-ambiguous cases. 
 Improved prognostic stratification vs. histological classification. 
Shai, 2003  5 A2, 3 O2, 18 priGBM, 9 secGBM 35    Distinguishes among histological subtypes. 170  
van den Boom, 
2003 
T 
6 A2, 2 MOA2 → 4 secGBM, 2 A3, 2 
MOA3 
16    Correlates with malignant progression. 66 
 
V 9 A2, 10 A3, 17 priGBM, 7 secGBM 43    Progression-associated signature confirmed. 9 
Godard, 2003 
T 12 A2, 14 priGBM, 5 secGBM 31   
 Confirmed findings of Shai, 2003 and van den Boom, 2003. 





V 12 A2, 4 pri GBM, 4 secGBM 20    93% prediction accuracy.  72  
Tso, 2006  
4 A2, 9 A3, 8 O2, 11 O3, 46 priGBM, 
14 secGBM 
92   
 Distinguishes priGBM and non-GBM astrocytomas. 58 Cell cycle 
 Distinguishes secGBM and non-GBM astrocytomas. 21 ECM 
 84% predictive accuracy for 25 similarly-treated priGBM and secGBM. 79  
Faury, 2007  
32 pediatric GBM 
7 adult GBM 
39   




 Distinguishes pediatric and adult GBM. 1569 




T 12 O3, 20 GBM 32    Distinguishes O3 and GBM. 168 
 




 96.6% predictive accuracy. 





52 A2, 29 A3, 55 GBM, 11 O2, 11 
O3, 1 MOA2 
159   
 Defined 6 hierarchically-nested molecular subtypes with 3 distinct prognoses.  








7 A2, 18 A3, 68 GBM, 12 O2, 9 O3, 
7 MOA2, 68 gliomas 
187    Reproduced six molecular subtypes. 
 
 




 Prognostic significance confirmed. 
 O subtype perfectly overlapped Phillips proneural GBM, but with 2 distinct 
prognoses. 
V 265 GBM 265 TCGA   Prognostic significance confirmed.  
Freije, 2004 
T 8 A3, 7 O2, 9 O3,50 GBM 74   
 Defined 4 molecular subtypes with 2 distinct prognoses. 
 Improved prognostic stratification vs. histological classification. 




HC1A – neurogenesis 
HC1B – synaptic 
transmission 
HC2A – proliferation 
HC2B – ECM 
V 22 O3, 28 GBM 50 
Nutt, 
2003 
  Prognostic independence from patient age and histological grade. 344 
Liang, 2005  2 O2, 4 MOA2, 25 GBM 31    Defined 2 prognostic GBM subtypes, 1 similar to HC1A from Freije, 2004. 70 Survival 
Phillips, 2006 




Proneural – neurogenesis 
Proliferative – cell cycle 
Mesenchymal – ECM 
V 22 O3, 28 GBM 50 
Nutt, 
2003 
  Prognostic significance validated. 
35 
V 
31 A3, 1 O2, 13 O3, 7 MOA3, 132 
GBM 
184   
 Prognostic independence from patient age and histological grade. 
 89% of 73 WHO grade III gliomas are proneural. 
 Proneural subtype correlates with younger age at diagnosis. 
Murat, 2008 
T 
80 GBM from TMZ/XRT→TMZ 
phase II/III clinical trials 
80   
 Prognostic independence from patient age and MGMT methylation. 














Lee, 2008  
86 GBM  















 Defined 4 molecular GBM subtypes:  3 from Freije, 2004 and 1 hybrid ProMes. 
 Proneural subtype correlates with younger age at diagnosis. 












8 PA, 13 A2, 16 A3, 106 priGBM, 53 
secGBM, 8 O2, 44 O3, 3 MOA2, 25 MOA3 
276   
 Defined 6 “intrinsic” molecular subtypes with distinct prognoses. 
 Cluster 9 prognostically favorable, enriched for oligodendroglial neoplasms. 
 Cluster 17 prognostically intermediate, histologically diverse, overlapped with 
Phillips, 2006 proneural. 
 Clusters 18 and 23 prognostically inferior, enriched for GBM, overlapped with 
Phillips, 2006 proliferative and mesenchymal. 
 Prognostic independence from Karnofsky performance status and gender. 
5000  
V 80 GBM 80 
Murat, 
2008 













  Prognostic significance confirmed. 
Verhaak, 2010 
T 200 GBM 200 TCGA  
 Defined 4 “intrinsic” molecular subtypes; not prognostic in TCGA dataset. 
 Proneural: frequent PDGFRA amplification and mutations in IDH1, TP53, and 
PIK3CA/PIK3R1. 
 Classical: frequent EGFR amplification, EGFRvIII mutations, and CDKN2A 
deletions. 
 Mesenchymal: frequent mutations in NF1, TP53, and PTEN. 
 TCGA proneural, Phillips proneural, and Freije HC1A overlap. 




Neural – synaptic 
transmission 





21 A3, 56 GBM 














 Prognostic significance in five datasets with both GBM and lower grade gliomas. 
 Molecular subtypes reproducible in four independent datasets. 
 Proneural subtype correlates with younger age at diagnosis. 
 Molecular subtype-copy number correlations confirmed in Beroukhim, 2007 
dataset. 




T 272 GBM 272 TCGA  
 GBM CpG island methylator phenotype (G-CIMP) in 29% of proneural GBM. 
 G-CIMP correlated with younger age at diagnosis and more favorable prognosis. 




60 and 92 WHO grade II and III 
gliomas 
152   














 Defined consensus 38-gene signature using top 200 survival-associated genes 
from each of four datasets. 
38 
Survival 
V 68 GBM with FFPE tissues 68   
 Selected 9 genes based on survival correlation and technical compatibility with 
FFPE tissues. 
 Prognostic significance confirmed for both progression-free and overall survival. 9 
V 
101 GBM from patients treated 
with standard-of-care TMZ/XRT→TMZ 
101   





 Prognostic independence from patient age and Karnofsky performance status in 
both validation datasets. 
Studies listed in order of appearance in the text.  *See Table 1.1 for histological subtype abbreviations.  Abbreviations:  concomitant temozolomide/radiation 
therapy and adjuvant temozolomide (TMZ/XRT→TMZ); dataset types: training (T), validation (V); extracellular matrix (ECM); formalin-fixed, paraffin-embedded 





Table 1.3.  Diffuse glioma GEMM 
 
   
Cell-of-origin 
Genetic modification(s) in key signaling pathways 
Ref(s) 
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Progression from low- to high-grade astrocytoma is characterized by transcriptomal heterogeneity 
and genomic number copy changes.  
 
INTRODUCTION 
Diffuse astrocytomas, the most common brain cancers, are characterized by extensive 
morphological, molecular, genomic, and biological heterogeneity.  Patients with the most frequent 
histological subtype, glioblastoma (GBM, WHO Grade IV), have a median survival of 12-15 m (138).  The 
dismal survival of GBM patients has fueled research to define its sources of heterogeneity.  Numerous 
studies within the last decade have shown that gene expression profiling can differentiate between 
various histological subtypes of gliomas, including low-grade and high-grade gliomas and primary and 
secondary GBM (reviewed in (48)).  The Cancer Genome Atlas (TCGA) utilized array comparative 
genomic hybridization (aCGH) and DNA sequencing to define commonly mutated genes in primary GBM 
and concluded that GBM tumorigenesis requires genetic alterations in three core signaling pathways: 
the RB regulated G1/S cell cycle checkpoint, receptor tyrosine kinase (RTK) signaling, and TP53 signaling 
(29).  TCGA also examined the genomic heterogeneity of primary GBM and defined four transcriptomal 
subtypes – proneural, neural, classical, and mesenchymal (17) – that were similar to subtypes previously 
identified in multiple histological subtypes of gliomas (16, 18, 25).  Putative oncogenic driver mutations 
were enriched in each GBM subtype, but none were exclusive.  These data suggest that factors other 
than driver mutations may significantly contribute to GBM transcriptomal heterogeneity.  Such factors 
include the differentiation state and fate potential of the cells harboring tumor-initiating mutations, and 




Defining the sources of genomic heterogeneity in GBM requires tractable model systems where 
oncogenic driver mutations and their cellular targets can be experimentally defined to induce de novo 
tumorigenesis in the complex microenvironment of the brain.  In this regard, genetically engineered 
mouse (GEM) models have proven critical in understanding the genetic and cellular basis of GBM 
pathogenesis (reviewed in (139)).  A number of GEM models with core signaling pathway mutations 
have established the roles of these genes in astrocytoma initiation and/or progression. 
Most astrocytoma GEM models disrupted the G1/S checkpoint using Cdkn2a (Ink4a/Arf) or Rb1 
deletion mutations.  Functional inactivation of three Rb family proteins in embryonic/neonatal mice led 
to astrocytoma tumorigenesis that was accelerated in a Pten-null background (79) and focal, somatic 
Pten deletion increased angiogenesis and invasion in this model (92).  Others showed that conditional 
deletion of Pten and Trp53 in adult murine astrocytes led to development of high-grade astrocytomas 
(HGA) with shortened latency in the presence of Rb1 deletion, but that Rb1 and Pten deletions failed to 
produce astrocytomas in the absence of Trp53 deletions (100).  To activate the MAPK pathway, most 
GEM models used constitutively activated Kras or Nf1 deletion.  Nf1 deletion alone is insufficient to 
initiate astrocytoma tumorigenesis (94, 140), but Kras activation in embryonic/neonatal neural 
progenitors inefficiently produces low-grade astrocytomas (LGA) (126).  In contrast, Kras activation 
requires additional oncogenic mutations, such as Ink4a/Arf with or without Trp53/Pten deletions, to 
form HGA in adult GFAP-positive astrocytes (129).  To activate the PI3K pathway, the majority of GEM 
models used Pten deletion.  Whereas deleting Pten in embryonic and adult mouse brains does not 
produce astrocytomas (100, 141), Pten cooperates with Trp53 and Nf1 deletion in embryonic and adult 
neural stem cells to produce HGA (70). 
However, because no oncogenic driver mutations are exclusive to any of the four human GBM 
subtypes, it is difficult to classify GEM as subtype-specific models based solely on their oncogenic driver 
mutations.  Therefore, it remains unclear how the majority of GEM recapitulate the underlying 
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molecular features of the human disease, including genome-wide gene expression, copy number, and 
mutational landscapes.  Studies comparing expression profiles of GBM GEM to their human 
counterparts have only recently begun to emerge (100, 142-145) and only one of these examined 
genomic copy number abnormalities (CNA) (100).  Furthermore, all three of these reports only examined 
tumors harvested from terminally-aged mice.  Thus, the molecular features of astrocytoma initiation 
and progression in adult mice have yet to be characterized using genomic methods. 
There are at least three potential sources of genomic heterogeneity in GBM: the oncogenic 
mutations that initiate tumorigenesis and drive malignant progression, the intrinsic biology and fate 
potential of the mutated cell (the cell of origin), and the developmental stage during which 
transformation occurs.  In the current report, we used conditional, inducible GEM models to target 
constitutive RTK effector pathway (KrasG12D and/or Pten deletion) mutations in G1/S checkpoint-
defective adult mouse astrocytes with GFAP-CreER (99).  We examined the influence of cell of origin, 
specifically with regard to regional astrocyte heterogeneity in the adult mouse brain (146), on the 
genomic heterogeneity of astrocytomas before and after malignant progression.
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MATERIALS AND METHODS 
Genetically-engineered mice 
Heterozygous TgGZT121 (79), Kras
G12D+/lsl (147), GFAP-CreER (99), and Rosa26-tdTomato mice 
(148) as well as homozygous PtenloxP/loxP (149), p53loxP/loxP (150), Rb1loxP/loxP (150), and Nf1loxP/loxP (151) mice 
were maintained on a C57/Bl6 background.  PCR genotyping was performed as previously described (79, 
99, 147-151).  All experimental animals were >94% C57/Bl6.  Animal studies were approved by the 
University of North Carolina Institutional Animal Care and Use Committee. 
Tamoxifen induction 
  Cre-mediated recombination in adult mice at approximately 3 m of age was induced with 1 mg 
of 4-hydroxytamoxifen (4OHT) (Sigma, St. Louis, MO) per day for five consecutive days by 
intraperitoneal injection.  Kaplan-Meier plots and log-rank analyses were conducted in Stata 12 (College 
Station, TX).  Comparisons at α ≤ 0.05 were considered significant. 
Histopathological evaluation 
Serial sagittal sections (4 µm) of formalin-fixed, paraffin embedded brains were stained with 
hematoxylin and eosin (H&E) on a Leica Autostainer XL (Buffalo Grove, IL).  Histopathological grading 
was performed according to WHO 2007 criteria for human astrocytomas (5) and defined as LGA (WHO 
grade II) or HGA (WHO grade III and IV (GBM)) by CRM, who was blinded to initiating genotype, 
induction status, and survival. 
 
Quantification of LGA burden 
H&E stained slides were scanned on an Aperio ScanScope XT (Vista, CA) using a 20X objective 
and the resulting svs files were imported into an Aperio Spectrum web database.  Brains were manually 
segmented into cortex, diencephalon, brainstem, and olfactory bulb regions with Aperio ImageScope 
using the Allen Brain Atlas as a reference (152).  Quantification of nuclei was performed as previously 
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described with the following modifications (153).  The Aperio color deconvolution v9 algorithm was used 
to quantify the area occupied by hematoxylin-positive nuclei in each region on 1-3 serial sagittal brain 
sections per mouse (mean 1.9, SEM 0.4).  Because LGA was detected in the cerebellum of 1 of 282 
(0.4%) 4OHT-induced, GFAP-CreER mice with T, R, and/or P alleles examined histologically (Tables S2.1 
and S2.5), the cerebellum was excluded from further analyses.  Percent nuclear area was calculated as 
hematoxylin-positive pixels divided by total region pixels for each section and graphed as mean ± SEM.  
Because regional nuclear density could be affected by the distance of the section from the sagittal 
midline, the brains from three wild-type C57Bl/6 mice were completely serially sectioned and every odd 
numbered section was scanned and analyzed as described above.  The distance from midline was 
estimated using the Allen Brain Atlas.  Although no significant distance-related effects were evident for 
the cortex, diencephalon, and brainstem by linear regression (Fig. S2.6C, P≥0.21), OFB nuclear density 
significantly decreased after 300 µm lateral to sagittal midline.  Therefore, only sections within the 
medial-most 300 µm were used for morphometric analyses in Figs. 2B and S6.  No significant differences 
in nuclear density of the cortex, diencephalon, brainstem, or olfactory bulb were evident in genotypes 
with histologically normal brains (N=25, Figs. S6AB, one-way ANOVA P≤0.15), therefore relative LGA 
burden was calculated as the regional nuclear area for each LGA-bearing mouse (N=19, Figs. 2B, S6D, 
and Table S2.1) relative to the mean for all non-tumor bearing genotypes (N=25, Fig. S2.6AB and Table 
S2.1).  The effects of initiating genotype and brain region on LGA burden in Figs. 2B and S6A were 
analyzed using two-way ANOVA and the effects of genotype for each of the four regions in Fig. 2.6D 
were analyzed using one-way ANOVA in GraphPad Prism 5 (San Diego, CA). 
 
Genetic lineage tracing and fate mapping 
GFAP-CreER; Rosa26-tdTomato with or without TgGZT121; Kras
G12D+/lsl; Pten+/loxP were induced 
with 4OHT at 3.5 m of age (mean 105, SD 38 d) as described above.  Phenotypically wild-type GFAP-
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CreER; Rosa26-tdTomato mice were sacrificed 7 d (N=3) and GFAP-CreERT2; Rosa26-tdTomato; TgGZT121; 
KrasG12D+/lsl; Pten+/loxP mice were sacrificed approximately 3 w (N=3, mean 18.7 d) and 2 m (N=2, mean 60 
d) post-induction.  All mice received a single intraperitoneal injection with EdU (5mg/kg) 4 h before 
perfusion.  Mice were perfused with 4% paraformaldehyde and their brains were immersion fixed in 4% 
paraformaldehyde overnight.  Fixed brains were embedded in agarose and sagittal 50 µm sections cut 
using a Leica VT1000S vibratome. 
 
Immunofluorescence staining 
 Floating brain sections were permeabilized and blocked for 1 h using phosphate buffered saline 
(PBS) with 0.5% Triton X-100, 0.01 M glycine, and 5% goat serum.  Primary antibodies were added for 18 
h in staining buffer (PBS with 0.1% Triton X-100 and 0.5% bovine serum albumin) using the following 
concentrations: BLBP (rabbit 1:1000, Millipore, #ABN-14), GFAP (chicken 1:2000, Aves, #GFAP), GFAP 
(rabbit 1:1000, DAKO, #Z0334), Ki-67 (mouse 1:1000, Cell Signaling Technologies, #9449S), MAP2 
(chicken 1:1000, Thermo #PA1-16751), NeuN (mouse 1:500, Chemicon, #MAB377), NSE (chicken 1:250, 
AbCam, #ab39369), P16 (mouse 1:500, Santa Cruz, #sc-1661), Sox2 (rabbit 1:500, Chemicon, #ab5603), 
and SV40 T antigen (mouse, 1:100, Calbiochem, #DP02).  Sections were rinsed twice with wash buffer 
(PBS with 0.1% Triton X-100) and then washed twice for 30 min. Slices were stained for 4 h with DAPI 
(1:2000) and the following secondary antibodies: Alexa Fluor 488 (anti-rabbit A11034, anti-mouse 
A11029, and anti-chicken A11039, 1:1000), Alexa Fluor 568 (anti-rabbit A11036, 1:1000), Alexa Fluor 633 
(anti-mouse, A21236, 1:500) and Alexa Fluor 647 (anti-rabbit A21071 and anti-chicken, A21103, 1:500).  
EdU was detected using the Invitrogen Click-iT EdU Cell Proliferation Assay (#C10338) according the 
manufacturer’s instructions.  Sections were washed and mounted onto glass slides.  Images were 





Four random images of the cortex, diencephalon, brainstem, and olfactory bulb, and two images 
of the subventricular zone (SVZ), were taken using a 20X objective from each of three consecutive 
sagittal sections, located approximately 1.35 mm lateral to midline, from N=2-3 replicate mice per 
genotype and time point examined.  TdTomato- and DAPI-positive nuclei were counted using ImageJ 
and their ratio was calculated to determine the percent tdTomato-positive cells for each image.  The 
mean percent tdTomato-positive cells ± SEM from 24-36 images was then calculated for each brain 
region.  The percent EdU-positive cells were calculated similarly from 1-3 consecutive sagittal sections 
(mean 1.6, SEM 0.4 sections/mouse), located approximately 0.875 mm lateral to midline, for each 
mouse brain.  The effects of genotype and time from induction on % tdTomato- (Fig. 2.2C) or EdU-
positive cells (Fig. 2.2D) were analyzed using two-way ANOVA in GraphPad Prism 5.  To determine GFAP-
CreER recombination efficiency and specificity for astrocytes, the percentages of BLBP-positive 
astrocytes and NeuN-positive neurons in the cortex, diencephalon, brainstem, and olfactory bulb that 
were tdTomato/BLBP- and tdTomato/NeuN-double positive were determined from 2-5 random 
images/region in a sagittal brain slice from a 4OHT-induced GFAP-CreER; Rosa26-tdTomato mouse. 
 
Microarrays 
Total DNA or RNA was isolated from flash frozen brains or tumors (Tables S2.1, S2.5, S2.8, and 
S2.13) using DNeasy® or RNeasy® Mini Kits (Qiagen, Valencia, CA).  RNA quality was confirmed on an 
Agilent Bioanalyzer (RNA Integrity Number > 7) and labeled using the Agilent Low RNA Input Linear 
Amplification Kit (Santa Clara, CA).  RNA from mouse brains harvested 2 m after 4-OHT induction were 
hybridized to Agilent Whole Mouse Genome 4×44K microarrays (G4122F) while tumors and brains from 
terminally sacrificed mice were hybridized to 4x44Kv2 (G4846A) per the manufacturer's protocol.  
Stratagene Universal Mouse Reference RNA (Agilent, #740100) was co-hybridized to each array as a 
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reference.  DNA was hybridized to Agilent Mouse 244A microarrays (G4415A) using a pooled DNA 
reference made from wild-type C57/Bl6 and syngeneic, phenotypically wild-type littermates.  DNA 
labeling and hybridization were performed in the UNC LCCC Genomics Core using Agilent CGH ULS 
Protocol v.3.1 according to manufacturer’s instructions.  Microarrays were scanned on an Agilent DNA 
Microarray Scanner (G2565CA).  Images were analyzed using Agilent Feature Extraction Software. 
 
Microarray analyses 
All original raw microarray data are publically available at both the UNC Microarray Database 
(http://genome.unc.edu) and the NCBI GEO (GSE49269).  Microarray data was normalized using Lowess.  
Analyses were performed on data present in at least 70% of experimental samples using genes with an 
absolute signal intensity of at least 10 units in both the Cy3 and Cy5 channels (154).  Replicate probes 
were collapsed to genes by averaging.  Further analyses were performed in R (R Development Core 
Team, http://www.R-project.org).  For the 2 m LGA cohort, 78 olfactory bulb and prosencephalon 
samples (Table S2.1) from eight microarray batches were combined in CombatR (155) using a parametric 
adjustment to remove batch effects and form a data matrix on which all further analyses were 
performed.  Forty-three HGA (Table S2.5) from three microarray batches were analyzed similarly.  
Probes were annotated with gene symbols using Agilent eArray 
(https://earray.chem.agilent.com/earray).  Cluster v3.0 and JavaTreeview were used for hierarchical 
clustering analyses (156, 157).  Genes were median centered and the 2000 and 5000 most variable 
genes across all samples were identified by median absolute deviation (MAD) scores.  Consensus 
clustering (158) was performed using the R package ConsensusClusterPlus (159) with 1000 iterations 
and an 80% resample rate and gave identical results using 2000 and 5000 genes.  Core subtype 
membership was verified by silhouette width analysis (17, 160).  ClaNC was used to define a 600 gene 
classifier (200 per subtype) to distinguish among three (S1-S3) HGA subtypes (161).  Single sample Gene 
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Set Enrichment Analysis (ssGSEA) was performed as previously described (162, 163).  For human TCGA 
GBM signatures, the 250 genes most highly expressed in each subtype, as determined by TCGA in one 
versus rest comparisons, were used (17).  The murine neural lineage dataset GSE9566 was downloaded 
from NCBI GEO.  Neural lineage-specific gene signatures were the top 500 genes associated with each 
cell type (108).  The human lower-grade astrocytoma dataset GSE35158 was downloaded from NCBI 
GEO and signature genes were taken from Table S2.3 of Gorovets, et al. (164).  For comparison to 
human gene sets, mouse genes were converted to the human orthologs using the MGI database 
(ftp://ftp.informatics.jax.org/pub/reports/index.html#orthology). 
 
Array CGH analyses 
Lowess-normalized data were analyzed and plotted using the R script SWITCHdna (165) with 
alpha=16 and Fthresh=12.  Probe level analysis of the Pten locus indicated that loss of exon 5 was 
detectable in LGA with deleted Pten, suggesting tumor cell density was sufficient to detect potential 
CNA in LGA. Raw Agilent 244A copy number data from GSE22927 (100) was downloaded from NCBI 
GEO, normalized, and analyzed similarly.   
 
Prediction of TCGA GBM subtypes in GEM HGA 
TCGA GBM subtypes of 42 core TR(P) HGA (Fig. S2.15) were predicted using the murine 
orthologs of the TCGA GBM ClaNC 840 gene classifier (17, 163).  Murine HGA and TCGA GBM mRNA 
expression data were combined using Distance Weighted Discrimination (DWD) (166).  Heat maps were 






GEM HGA validation set analyses 
Three adult murine HGA datasets were downloaded from NCBI GEO (GSE22927, GSE35917, and 
GSE29458; Table S2.11) (100, 142, 144).  Data were limited to 8105 genes common to all three datasets 
and batch effects were removed using parametric adjustment in CombatR using the TCGA GBM subtype 
predictions determined in the original manuscripts as covariates.  Hierarchical clustering and single 
sample prediction of S1-S3 HGA subtypes using the ClaNC 600 gene classifier defined in the discovery set 
were performed on the validation set. 
 
Significance analysis of microarrays (SAM) 
Genes significant to LGA versus normal brain or LGA with and without KrasG12D were determined 
by one versus rest SAM with a false discovery rate (FDR) of 0.001 (Table S2.3).  Genes significant to each 
murine HGA subtype were determined by one versus rest SAM with FDR of 0.001, 0.01, and 0 for S1, S2, 
and S3, respectively (Table S2.9).  FDR were chosen in order to define 1000-2000 of the most significant 
differentially expressed genes. 
 
G1/S checkpoint (RB pathway) mutations in human GBM 
Data from 236 TCGA human GBM with aCGH, sequencing, and mRNA and protein expression 
data were analyzed using the cBio Cancer Genomics Portal (167).  Copy number abnormalities were 
determined by GISTIC 2.0; mRNA and protein expression Z-scores beyond ± 2 were considered 






G1/S cell cycle checkpoint genes are mutated in virtually all human GBM 
Significant alterations in G1/S cell cycle checkpoint (RB pathway) genes occur in 98% of adult human 
GBM in the TCGA dataset (Fig. S2.1).  Reduced RB1 mRNA or protein expression, inactivating mutations, 
or copy number losses trend towards co-occurrence with similar alterations in its pocket protein family 
members RBL1 or RBL2, suggesting that functional compensation amongst these proteins may require 
elimination to disrupt the G1/S checkpoint in the absence of CDKN2A/CDKN2B alterations, which occur 
in 68-70% of cases.  Rb1 deletion in adult GFAP-positive mouse brain cells fails to initiate astrocytoma 
tumorigenesis, in both the presence and absence of concomitant Pten deletion (100).  However, 
inactivation of all three Rb family proteins (Rb1, p107, p130) by T121 expression in GFAP-positive 
embryonic brain cells is sufficient for LGA development and tumorigenesis is accelerated when 
combined with heterozygous Pten deletion (79).  We have recently shown that T121 expression ablates 
the G1/S checkpoint in murine astrocytes (163).  It remains unknown whether functional ablation of Rb 
family members in the adult mouse brain is sufficient for astrocytoma development and whether 
concomitant Pten loss accelerates tumorigenesis in this developmental context.  To study the individual 
and combined loss of Rb family and Pten activity in adult mouse brains, we used conditional, inducible 
transgenic GFAP-CreER mice (99). 
 
GFAP-CreER targets astrocytes in multiple regions of the adult mouse brain 
Genetic lineage tracing in 3 m adult GFAP-CreER; Rosa26-tdTomato mice showed that 4OHT induced 
recombination throughout the brain (Figs. 2.1, S2.2).  Multiplex immunofluorescence showed that 
recombination occurred in 59 ± 2% of BLBP-positive astrocytes in the cortex, diencephalon, and 
brainstem (Fig. S2.3).  In contrast, only 0.2 ± 0.1% of NeuN-positive neurons in these regions co-




Ablation of all Rb family members is sufficient for tumorigenesis in adult murine astrocytes 
GFAP-CreER;T121 ± Pten
loxP/loxP mice were induced to generate GFAP-CreER;T121 ± Pten
-/- mice 
(hereafter referred to as T and TP-/-, respectively).  T and TP (TP+/- and TP-/-) mice were sacrificed 2 m 
after induction and the effects of these mutations on astrocytoma initiation and penetrance were 
analyzed.  All mice remained neurologically asymptomatic, but histopathological analysis showed 100% 
incidence of LGA throughout the brain (Figs. 2.2A, S2.5).  In contrast, Pten deletion alone was insufficient 
for tumorigenesis, as P mice displayed no hypercellularity, nuclear atypia, or abnormal brain 
architecture (Table S2.1), consistent with a previous report (100).  Quantification of nuclei showed that T 
and TP-/- mice had similar overall hypercellularity, but different regional LGA distribution (Figs. 2.2B, 
S2.5). 
 
KrasG12D potentiates tumorigenesis in G1/S-defective adult murine astrocytes 
Because RTK genes such as EGFR, PDGFRA, ERBB2, and MET are commonly overexpressed, 
amplified, or mutationally activated in human GBM and uniformly activate Ras signaling (168), we used 
a conditional KrasG12D knock-in allele to model the downstream RAS-MAPK pathway activation elicited 
by RTK gene alterations.  KRAS mutations occur in only 2% of human GBM (29), but KRAS and other 
RAS/RAF genes are gained and overexpressed in both human GBM and cell lines (168, 169) and the 
negative RAS regulator NF1 is deleted or mutationally inactivated in 17% of GBM (29).  Kras, but not 
other Ras isoforms, is activated upon Nf1 deletion in murine astrocytes, and KrasG12D phenocopies Nf1 
deletion in vitro and in vivo (170).  Moreover, we have recently shown that KrasG12D potentiates MAPK 
signaling, growth, migration, and invasion of G1/S-defective murine astrocytes expressing T121 in vitro 
and facilitates development of GBM in syngeneic mouse brains (163). 
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KrasG12D has been shown to inefficiently induce LGA in neonatal mouse neural progenitors (126).  To 
investigate whether KrasG12D alone was tumorigenic or cooperated with Rb family and/or Pten 
dysfunction in adult murine astrocytes, we crossed GFAP-CreER;KrasG12D+/lsl ± T121 ± Pten
loxP/loxP mice, 
induced recombination, and sacrificed R, RP, TR, and TRP mice at 2 m after induction.  In this context, 
KrasG12D alone or in combination with Pten deletion was insufficient for tumorigenesis, as R and RP mice 
displayed no increased cellularity and had normal brain architecture (Fig. S2.6AB and Table S2.1).  Both 
TR and TRP mice developed neurologically asymptomatic LGA with 100% incidence (Figs. 2.2A, S2.5).  In 
contrast to Pten deletion, KrasG12D significantly increased LGA burden in T mice (18% in TR versus 11% in 
TP-/-) (Figs. 2.2B, S2.5, S2.6D).  TRP-/- mice had the highest LGA burden and 25% harbored anaplastic 
astrocytomas (WHO Grade III) after 2 m (Figs. 2.2AB, S2.5, S2.6D).  ANOVA showed that both initiating 
genotype and brain region significantly affected tumor burden.  These findings demonstrate that 
KrasG12D potentiates tumorigenesis in G1/S-defective astrocytes and that Pten deletion further increases 
LGA burden throughout the adult mouse brain. 
 
Ablation of all Rb family members is required for tumorigenesis in adult murine astrocytes 
Rb1 deletion, Rb1;Pten co-deletion ± KrasG12D, or Nf1 ± Rb1 ± Pten co-deletion showed no evidence 
of tumorigenesis in adult astrocytes.  In contrast, similar to TR(P), all T mice with Nf1 ± Pten deletions 
developed astrocytomas (Fig. S2.7, Table S2.2).  Collectively, these results demonstrate that Rb1 
deletion alone is insufficient for tumorigenesis, even in the presence of activating MAPK (KrasG12D or Nf1 
deletion) and PI3K (Pten deletion) pathway mutations.  Rather, they suggest that inhibition of all three 
Rb family proteins is required to ablate the G1/S checkpoint and initiate astrocytoma tumorigenesis in 
adult murine astrocytes.  These results also demonstrate that KrasG12D and Nf1 deletion have similar 




TRP-transformed astrocytes maintain their astrocytic identity and develop into hypercellular foci 
over time 
In order to fate map transformed astrocytes, we used fluorescent lineage tracing with GFAP-CreER; 
Rosa26-tdTomato crossed with TRP+/- mice.  TRP significantly increased tdTomato cell density from 4-6% 
in the normal cortex, diencephalon, brainstem, and olfactory bulb at 7 d to 18-27% and 42-47% in these 
regions 21 and 60 d after induction (Fig. 2.2C, S2.8, S2.9).  A temporal increase in perineuronal 
satelitosis, a histopathological hallmark of human astrocytomas, was also evident (Figs. S2.10 and 
S2.11D).  Furthermore, these cells expressed T121 (Fig. S2.11AB) and the astrocytic markers BLBP (Fig. 
S2.11C) and Gfap (data not shown) and hypercellular foci developed by 60 d (Fig. S2.11E).  A single pulse 
labeling with EdU showed increased proliferation of tdTomato-positive cells in all brain regions over 
time (Fig. 2.2D, S2.9).  Ki-67 staining showed that proliferation was heterogeneous at 60 d (43-52% CV).  
Hypercellular foci had 5-fold increased proliferation relative to surrounding diffuse astrocytoma (Fig. 
S2.11DE). These results show that TRP initiates tumorigenesis in astrocytes in four distinct brain regions, 
that transformed cells maintain their astrocytic identity, and that proliferation and histopathological 
hallmarks of human astrocytomas increase over time.  The fact that hypercellular areas with markedly 
increased proliferation develop suggests that that these foci progress to HGA upon stochastic 
acquisition of additional mutations. 
 
T(RP) LGA transcriptomes have KrasG12D oncogenic driver- and astrocyte location-specific 
signatures 
To understand how Rb, Kras, and Pten affect tumorigenesis at the molecular level, we examined 
gene expression and copy number in high tumor burden areas - olfactory bulbs and forebrains - 
harvested from mice at 2 m after induction (Table S2.1).  Principal components analysis (PCA) showed 
separation of normal olfactory bulb, normal forebrain, and LGA in both regions.  Moreover, LGA with 
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and without KrasG12D grouped separately in both locations (Fig. 2.3A), but there was no KrasG12D effect in 
non-tumor olfactory bulbs (Fig. 3B).  Consensus clustering (158) of transcriptome data confirmed the 
distinction between brain regions and LGA with or without KrasG12D (Fig. S2.12).  Notably, there were 
minimal and infrequent copy number alterations (CNA) in LGA, including those with KrasG12D (Fig. 
S2.13A).  These findings demonstrate that T(RP) LGA have not acquired significant CNA, and their 
transcriptomes have KrasG12D oncogenic driver- and astrocyte location-specific signatures. 
 
T(RP) LGA transcriptomes recapitulate subtypes of non-GBM astrocytomas 
Significance analysis of microarray (SAM) (171) was conducted to identify genes differentially 
expressed between T(RP) LGA and normal brain (Table S2.3).  Gene ontology (GO) analysis showed that 
the most highly expressed LGA genes functioned in multiple cell cycle checkpoints (Fig S2.13B).  We 
confirmed aberrant G1/S signaling by performing p16 immunofluorescence.  At 5 m, p16 is normally 
absent in wild-type cortical murine astrocytes, but is expressed in neurons (172).  Unlike wild-type mice, 
TRP induced p16 expression in transformed astrocytes, consistent with microarray data (Fig. S2.14).  
Upregulation of G1/S checkpoint genes is consistent with Rb pathway disruption in T(RP) LGA.  SAM and 
GO analysis of LGA with versus without KrasG12D showed that the most highly expressed genes were 
enriched in immune response and cell membrane biology (Table S2.3).  To determine if this KrasG12D 
signature was differentially expressed among human astrocytomas, we assessed its enrichment in non-
GBM human astrocytomas (164).  The KrasG12D signature was highly expressed in the pre-glioblastoma 
(PG) subtype (Fig. 2.3C), which has shorter survival than neuroblastic and early progenitor-like subtypes, 
contains mostly HGA (anaplastic astrocytomas), and has a genomic landscape similar to GBM, including 
frequent EGFR amplification and CDKN2A and chromosome 10 (PTEN) deletions (164).  Taken together, 
these data suggested that murine LGA with KrasG12D would rapidly progress to HGA and show worse 




LGA with KrasG12D stochastically progress to HGA and acquire CNA 
To determine whether LGA progress to HGA, we induced recombination in all LGA-bearing 
genotypes and aged mice until neurological morbidity.  Astrocytoma incidence was 100% for all six T-
containing genotypes (Fig. 2.4A).  LGA in T and TP mice infrequently progressed to high-grade anaplastic 
astrocytoma (WHO Grade III), but none of these mice exhibited neurological symptoms when sacrificed 
up to 18 m after induction.  Furthermore, terminal T and TP LGA contained few and infrequent CNA (Fig. 
2.5I).  Taken together with the two-month LGA aCGH data (Fig. S2.13A), these results indicate that T(P) 
LGA rarely acquire CNA regardless of their age. 
In contrast, TR mice frequently progressed to HGA, including GBM (Fig. 2.4A), and median survival 
was 4.5 m after induction. (Fig. 2.4B).  These results indicate that while Rb family dysregulation is 
required to initiate tumorigenesis in adult murine astrocytes, KrasG12D facilitates progression to HGA.  
Furthermore, deleting Pten in TRP+/- and TRP-/- mice resulted in frequent HGA progression.  Although the 
frequencies of HGA in TRP mice were not statistically different from TR, Pten deletion led to increased 
incidence of GBM, which all contained pseudopalisading necrosis, but rarely microvascular proliferation 
(Figs. 2.4A, S2.15, 2.5A-F).  TRP+/- and TRP-/- mice survived a median of 4.0 and 2.8 m, respectively (Fig. 
2.4B), and HGA occurred in all brain regions except cerebellum (Fig. S2.15). 
The variable survival in TR(P) mice with HGA suggested that progression occurred stochastically.  We 
therefore monitored the development of HGA in TRP+/- mice with contrast-enhanced magnetic 
resonance imaging (MRI) over time.  HGA, but not LGA were visible by T1- and T2-weighted MRI and 
enhanced with gadolinium.  Therefore, contrast enhancement (Fig. 2.5A) was used as a surrogate for 
histological progression.  All mice had MRI-undetectable LGA (Fig. 2.5B-F), but also developed focal, 
contrast-enhancing HGA (Fig. 2.5B-F) at 3-5 m after induction.  Onset was variable, but HGA growth and 
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lethality were uniformly high (Fig. 2.5G-H).  These findings suggest that TRP LGA progress into rapidly 
proliferating, lethal HGA upon the stochastic acquisition of additional mutations. 
Because HGA had variable onset and grew rapidly after initial MRI identification, we performed copy 
number analysis to investigate genomic instability.  Array CGH of 41 terminal TR(P) HGA detected 
abnormalities throughout the genome (Fig. 2.5J-L).  All three genotypes had prevalent copy number 
gains throughout chromosome 6, which contains the established oncogenes Braf, Kras, and Met.  
Among Rb, RTK/MAPK/PI3K, and Trp53 pathway genes, Ccnd2, Stat1, Met, Braf, Kras, Raf1, and Mdm4 
were gained in >20% of HGA.  Other notable, but less frequent CNA were gains of Egfr, Erbb2, Pdgfrb, 
and Pik3ca oncogenes and loss of Pten, Cdkn2a, and Trp53 tumor suppressors (Table S2.6).  TRP-/- HGA 
had the lowest frequency of these CNA. Similar chromosomal distributions of CNA were evident in TR 
and TRP+/- HGA, but CNA were more frequent in TR HGA (Fig. S2.16).  Only 3 HGA (7%) had no CNA and 
all were from TRP-/- mice with short, 1.9-2.1 m survivals, including one asymptomatic TRP-/- mouse 
sacrificed for inclusion in the 2 m cohort that harbored a grossly visible mass.  These results suggest that 
most HGA acquire CNA during malignant progression. 
 
Gene expression profiling identifies three HGA subtypes that correlate with astrocyte location 
In order examine the heterogeneity of murine HGA gene expression, we performed microarray-
based expression profiling on 43 terminal TR(P) HGA and identified three subtypes using consensus 
clustering (Fig. S2.17)  Silhouette width analysis (160) identified 42 core HGA samples with expression 
profiles most representative of each subtype (Fig. S2.17D).  HGA subtype did not correlate with initiating 
oncogenic mutations (Table S2.8).  Similarly, no Pten deletion-related effect was evident in LGA 
transcriptomes (Figs. 2.3AB and S2.12), suggesting that Pten deletion does not significantly contribute to 
transcriptomal heterogeneity either before or after malignant progression in this model.  Whereas 
initiating genotype correlated with survival (Fig. 2.4B), HGA subtype did not (Fig. S2.18A).  However, 
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HGA subtype correlated with brain region (Fig. S2.18B).  Subtype 1 (S1) tumors were primarily located in 
the brainstem (72%), some of which developed as exophytic masses that extended into the fourth 
ventricle.  Subtype 2 (S2) tumors were primarily located in the olfactory bulb (50%).  Subtype 3 (S3) 
tumors were located in all brain regions.  These results suggest that GFAP-positive astrocytes in different 
brain regions give rise to transcriptomally distinct HGA. 
Moreover, HGA transcriptomes were distinct from their genotype-matched LGA counterparts (Fig. 
S2.18C).  This finding confirms that, despite identical initiating oncogenic mutations, progression from 
LGA to HGA is associated with significant transcriptomal changes.  These results are consistent with the 
transcriptomal differences between non-genotype-matched human LGA and HGA (12, 13, 15) and 
suggest that the secondary mutations acquired during malignant progression significantly influence 
astrocytoma transcriptomes. 
 
Murine HGA phenocopy human HGA transcriptomal subtypes 
A classifier consisting of 600 genes, the 200 most representative of each subtype, correctly 
predicted subtype with 0% cross validation and error rates (Fig. 2.6A, Table S2.9).  In order to further 
characterize these subtypes, we examined differentially expressed genes using SAM (171) and defined 
their biological functions using gene ontology analyses (Table S2.11).  Immune and cytokine response, 
NF-ĸB pathway, and extracellular matrix genes were significantly expressed in S1, suggesting that this 
subtype was similar to human mesenchymal HGA (17, 18).  We therefore predicted the human GBM 
subtype of individual murine HGA using the 840-gene TCGA classifier and found that 94% of S1 HGA 
were predicted as mesenchymal GBM (Figs. 2.6C, S2.19, and Table S2.8).  S1 HGA were also enriched in a 
cultured murine astrocyte signature (108) (Fig. 2.6E), similar to human mesenchymal GBM (17). 
Cell cycle, proliferation, and RNA processing genes were significantly expressed in S2 HGA.  The 
majority (75%) of S2 HGA were predicted as proneural GBM using the TCGA classifier.  S2 HGA also 
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expressed a previously identified proliferation signature (173) and a murine oligodendrocyte precursor 
signature (108), similar to human proneural GBM (17). 
Genes highly expressed in S3 HGA were enriched in synaptic transmission, ion channel and 
glutamate signaling, and other neuronal processes.  TCGA classifier predicted 65, 29, and 6% of S3 HGA 
as human neural, proneural, and mesenchymal GBM, respectively, and all were enriched in a murine 
neuronal signature (108).  These results imply that the transcriptomes of S3 HGA are the most 
heterogeneous, but are most similar to human neural GBM. 
Seven TR(P) mice developed two distinct HGA in different brain regions; of these, four had different 
S1-S3 HGA subtypes (Table S2.8).  Six of these HGA pairs were analyzed by aCGH and none contained 
identical genomic copy number landscapes (Table S2.7).  Together, these data suggest that CNA 
acquired stochastically during malignant progression significantly contribute to HGA transcriptomal 
heterogeneity. 
 
Validation of S1-S3 HGA subtypes in different adult GEM HGA models 
S1-S3 HGA subtypes were validated in an independent test set of transcriptome data from adult 
GEM HGA models with different initiating oncogenic mutations (100, 142, 144).  The 600-gene classifier 
showed similar expression in both the discovery and test sets (Figs. 2.6AB).  Furthermore, test set 
samples clustered by both predicted human GBM and mouse HGA subtypes.  Similar to the results with 
TR(P) HGA, S1, S2, and S3 HGA in the test set were primarily predicted as mesenchymal, proneural, and 
neural GBM, respectively (Fig. 2.6D, Table S2.11).  Two datasets contained normal brain samples and 
these clustered with neural S3 HGA.  This finding recapitulates the clustering of human non-neoplastic 
brain with neural GBM (17). 
 
Deletion of p53 affects the CNA landscapes of murine HGA upon malignant progression 
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Because HGA from both TR(P) and Rb1/Pten/p53 triple KO (100) models reproduce multiple human 
GBM subtypes, we compared their CNA landscapes.  Rb1/Pten/p53 triple KO HGA harbored CNA in all 
autosomes, but the chromosomal pattern of CNA was more restricted in TR(P) HGA (Fig. S2.20).  
Because the role of p53 in maintenance of genomic integrity is well established (174), we hypothesized 
that p53 deletion contributed to the difference between genomic landscapes in these models.  To test 
this hypothesis, we bred a floxed p53 allele into T(RP) mice (Table S2.12).  At 2-6 m after induction, all 
T(RP);p53+/- mice harbored LGA and 4/14 had progressed to HGA (Fig. S2.21).  Similar to T(RP) mice 
without p53 deletion (Fig. S2.13A), T(RP);p53+/- astrocytomas harvested 2 m after induction were largely 
devoid of CNA (Fig. S2.22).  In contrast to T mice without KrasG12D in which LGA failed to progress (Fig. 
2.4A) and lacked CNA even when aged over a year (Fig. 2.5I), at 11 m after induction, a T;p53+/- mouse 
developed GBM with widespread CNA similar to Rb1/Pten/p53 triple KO HGA (Fig. S2.23).  These data 





In this study, we genetically disrupted Rb, Ras, and Pten signaling in adult murine astrocytes and 
systematically investigated tumorigenesis in all relevant genotype combinations.  Functional ablation of 
the Rb family of pocket proteins was sufficient for low-grade astrocytoma (LGA) initiation throughout 
the brain, but KrasG12D, deletions of Rb1, Nf1, and Pten, and double and triple combinations of these 
mutations were insufficient for tumorigenesis.  LGA transcriptomes were distinct from histologically 
normal brains and clustered by anatomic brain region and KrasG12D status.  We identified a KrasG12D-
associated immune response signature that was enriched in the pre-glioblastoma subtype of human 
lower-grade astrocytomas.  When aged to neurological morbidity, mice with Rb pathway and Kras + 
Pten dysfunction developed contrast enhancing HGA with variable latency, rapid growth kinetics, and 
CNA in Rb, RTK/MAPK/PI3K, and Trp53 pathway genes.  Three transcriptomal HGA subtypes were 
identified and subsequently validated in an independent test set of HGA from adult GEM models with 
different initiating oncogenic mutations.  These murine HGA subtypes phenocopy human GBM 
transcriptomes and were enriched for similar biological processes and showed human subtype-specific 
signatures.  Single sample prediction using human GBM subtype-specific genes, single sample gene set 
enrichment, and hierarchical clustering with combined mouse and human expression data, confirmed 
the similarities between murine HGA and human GBM transcriptomal subtypes. 
 
The role of Rb family proteins in astrocytoma initiation and progression 
In contrast to previous studies that inactivated Rb family proteins in embryonic mice (79) or 
conditionally deleted Rb1 in adult mouse brains (100), we found that inactivation of the Rb family of 
pocket proteins – Rb1, Rbl1/p107, and Rbl2/p130 – with T121 was sufficient to initiate astrocytoma 
tumorigenesis in adult murine astrocytes.  Deletion of Rb1 alone could not substitute for T121 or combine 
with KrasG12D, Nf1 deletion, or Pten deletion to initiate tumorigenesis.  Together, this evidence suggests 
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that functional compensation amongst Rb pocket proteins renders Rb1 deletion insufficient for 
astrocytoma initiation in adult murine astrocytes, even when paired with MAPK or PI3K pathway 
mutations.  G1/S cell cycle checkpoint function is critical for cell growth regulation; thus, virtually all 
human GBM acquire RB pathway mutations.  Although RBL1 and RBL2 are infrequently mutated, their 
decreased expression tends to co-occur with inactivating RB1 mutations in human GBM that lack 
CDKN2A/CDKN2B mutations.  These findings suggest that functional compensation amongst Rb family 
proteins may require elimination to disrupt the G1/S checkpoint in both humans and mice.  While T121 
was sufficient for initiation, RB1 mutations are generally thought to be a late event during malignant 
glioma progression in humans (175).  Whether these findings reflect a fundamental difference between 
mice and humans or indicate an unappreciated role for functional compensation amongst Rb pocket 
proteins in human gliomas remains unclear. 
We provide the first report of murine LGA gene expression and CNA data in adult, conditional GEM.  
Expression profiling showed that LGA are distinct from non-tumorigenic brains and can be separated 
into two subtypes based on KrasG12D, but not Pten deletion.  These data suggest that in G1/S-defective 
adult murine astrocytes, KrasG12D has greater effect on gene expression than Pten deletion and are 
consistent with a recent study in which multiple fragments of individual human GBM were sequenced to 
examine clonal evolution (176).  The authors suggest that PTEN loss is a late event in human GBM 
progression and occurs after primary genetic events such as RB and RAS pathway mutations.  Murine 
LGA transcriptome analysis also distinguished between the profiles of LGA that would frequently 
progress to HGA versus those that would not.  One notable difference between this murine subtype and 
its potential human counterpart—the pre-glioblastoma subtype predicted to become GBM (164)—is 
that murine LGA have relatively silent genomes, but human pre-glioblastomas have genomic copy 
number profiles similar to GBM.  The lack of CNA may be attributable to fewer A3 in mice at 2 m versus 
many A3 in human pre-GBM, but it is noteworthy that gene expression indicates LGA with GBM 
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potential before progression.  Additionally, we showed that, regardless of time after induction or 
genotype, all LGA genomes were relatively absent of CNA.  These data suggest that transcriptomal 
signatures may be better conserved across species than patterns of chromosomal instability or 
mutations.   
A detailed genomic and transcriptomal characterization of murine LGA can be used as a foundation 
for further studies.  This model is particularly suited to examining the effects of standard radiotherapy 
and temozolomide on histological and genomic tumor progression and survival.  Progression and 
adaptation studies would only be possible in humans with detailed follow-ups, and long survival of 
patients with A2 makes such studies logistically difficult.  In contrast, this murine LGA model provides a 
unique opportunity to examine treatment induced biological responses in a reasonable timeframe. 
 
Modeling human subtypes and the influence of the cell of origin 
Human GBM have been characterized based on their transcriptomal variation with the ultimate 
hope that subtype-specific features can be used to realize the potential of targeted therapy and 
personalized medicine (16-18, 25).  Using GEM to determine the cellular origin(s) of the four 
transcriptomal GBM subtypes has been complicated by the fact that a variety of different methods and 
genes are used to drive GEM tumorigenesis, and that many GEM employ GFAP or Nestin Cre drivers in 
the developmental context where they have overlapping cellular specificity (139).  As a result, direct 
comparisons between models, cells, and transcriptomes are difficult. 
Proneural-like murine HGA and GBM have been described in a model that embryonically deleted 
p53/Nf1 with GFAP-, Nestin-, or NG2-Cre in fluorescently labeled cells (143), a model that employs PDGF 
and Cre-expressing viral injections in 6-8 w floxed Pten or Pten/p53 mice (142), and a GFAP-CreER-driven 
adult GEM with floxed Pten/p53 + floxed Rb1 (100).  Here, adult GFAP-driven S2 proneural-like HGA 
often occurred in the olfactory bulb and all S2 HGA were enriched in an OPC signature, suggesting a 
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potential cell of origin.  If OPC are the origin it indicates that proneural-like HGA progress similarly in 
embryonic and adult GEM, in that initiating mutations occur in NSC but OPC are the tumorigenic cell 
lineage (143).  However, we cannot yet determine the specific cell of origin for olfactory bulb S2 
proneural-like HGA despite confirmation that GFAP-Cre targets SVZ cells, but we suspect they originate 
from neural stem cells of the SVZ that travel through the RMS in addition to local olfactory bulb 
astrocytes.  TRP brains have RMS tumors, and GFAP-positive proliferation and tumorigenesis occurs in 
the inner region of the olfactory bulb where the RMS deposits.  Ongoing studies involve a detailed origin 
and fate characterization of these cells. 
We also described S1 mesenchymal-like HGA which often occurred in the brainstem and expressed 
signatures resembling cultured astrocytes.  Mesenchymal-like HGA have been described in two other 
adult HGA models—the Baker group deleted Pten/p53 ± Rb1 in GFAP-positive cells (100), and the Verma 
group injected lentivirus expressing HrasV12 and p53-shRNA into SVZ, cortex, and hippocampus of GFAP-
Cre, mice or into the cortex of Syn1-Cre mice (144).  However, when Nestin-Cre mice were used 
hippocampal injections generated neural-like HGA.  The result of different subtypes based on alternate 
Cre-drivers indicates that subtle differences in GFAP and Nestin hippocampal cellular specificity lead to 
transcriptomally distinct HGA even when using identical tumorigenic driver genes.  Notably, none of 
these mesenchymal mouse models included Nf1 deletion, often thought to be a hallmark of 
mesenchymal GBM.  Together, these three adult HGA models show that a variety of driver mutations in 
astrocytes and neurons can form mesenchymal HGA. 
Lastly, we described S3 neural-like HGA that occurred in the cortex, diencephalon, brainstem, and 
olfactory bulb.  S3 neural-like HGA had the most heterogenous transcriptomes—neuron signature genes 
were enriched in S3 HGA, but individual HGA also highly expressed OPC, astrocyte, and oligodendrocyte 
signatures.  Similar transcriptomal heterogeneity existed in neural-like HGA from the Verma group even 
though all those HGA were initiated in the same location in Nestin-Cre mice (144).  These two examples 
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of neural-like HGA suggest hippocampal NSC and differentiated astrocytes as potential sources.  We 
have yet to define the origin of S1 or S3 HGA, but based on the knowledge that most cortical astrocytes 
in mice originate from local proliferation of postnatal astrocytes rather than from glial progenitors 
migrating from the SVZ (177), we suspect that cortical and brainstem HGA arise from locally transformed 
astrocytes and not NSC. 
The classical GBM subtype has been more difficult to reproduce in GEM.  We and others (100) 
showed a few tumors that predicted as classical, but these are part of the S2-proneural subtype rather 
than a unique group like human classical GBM.  However, classical GBM might be one subtype that can 
be more easily defined by its oncogenic mutations because CDKN2A loss, EGFR gain, and EGFR increased 
expression are nearly universal in classical GBM.  Unfortunately comprehensive analysis was precluded 
in the adult HGA GEM that used these genetic drivers because it lacked a brain-specific promoter and 
transcriptome analysis (96). 
Determining how astrocytoma cells of origin, initiating mutations, acquired genomic changes, and 
microenvironment contribute to HGA and GBM has been difficult in part because human GBM 
transcriptomes have not been as instructive as other cancers such as medulloblastoma, where, human 
subtype signatures suggested key driver mutations, which were later confirmed to drive subtype 
specificity when initiated in specific cells of origin in GEM (178).  Yet despite different Cre-drivers, 
initiating mutations, and degrees of CNA, S1-S3 GFAP-Cre TR(P) HGA cover the transcriptomal diversity 
present in previous HGA GEM.  These data suggest that while initiating oncogenic drivers and/or 
acquired CNA, no doubt, contribute to genome-wide transcription, the promoter driving the model, and 
thus brain region and/or cell of origin, play a more prominent role in defining murine HGA subtype.   
In summary, this is the first study to validate murine glioma transcriptome subtypes using a test set 
composed of adult glioma models with diverse oncogenic mutations.  It shows inherent heterogeneity 
that reproduces both the transcriptomal diversity of human GBM and encapsulates the transcriptomal 
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diversity of three recent adult GEM GBM cohorts, each with distinct combinations of oncogenic 
mutations and putative cells of origin.  This study builds on previous GEM genomic analysis to suggest 
that there can be multiple GBM cells of origin and that to discover the conditions for astrocytoma 
transcriptomal heterogeneity researchers must understand the cellular context of tumorigenic 
mutations.  Advances using developmental neurobiology and lineage tracing to identify brain cellular 
hierarchies should facilitate this task.  It will allow researchers to further define the requirements for 









Figure 2.1.  GFAP-CreER mediates recombination throughout the brain  Genetic lineage tracing in a 
GFAP-CreER;Rosa26-tdTomato mouse at 7 d after induction.  DAPI (A, D), tdTomato (B, E), and merged 
(C, G).  Only cells in neurogenic brain regions (panels D-G from the boxed region in B), including the SVZ 




Figure 2.2. Effects of initiating genotype and brain region on LGA tumorigenesis.   All mice 
harbored LGA (blue) and only 25% of TRP-/- mice had progressed to HGA (red) at 2 m after induction (A).  
Nuclear density in the cortex (CTX), diencephalon (DI), brainstem (BS), and olfactory bulb (OFB) was 
examined for each genotype and compared to phenotypically wild-type controls (Fig. S2.6). T and TP-/- 
mice had similar overall hypercellularity, but regional distribution differed: TP-/- mice harbored 
significantly greater OFB LGA (one-way ANOVA P=0.002).  Regional differences were not evident 
between TP-/- and TR or TR and TRP-/-, but both initiating genotype and brain region significantly affected 
LGA burden overall (two-way ANOVA P<0.002).  Genetic lineage tracing in GFAP-CreER;Rosa26-
tdTomato (green) and GFAP-CreER;Rosa26-tdTomato;TRP+/- (red, blue) mice at 7 (green), 21 (red), and 
60 (blue) d showed an increase in tdTomato- (C) and proliferating, EdU-positive cells (D) over time in all 
four brain regions.  Only tdTomato-positive cells in the subventricular zone (SVZ) proliferated in the 
presence and absence of TRP+/-.  Both initiating genotype/time and brain region significantly affected 






Figure 2.3.  LGA transcriptomes show driver mutation- and brain region-associated signatures.  
Principal component analysis (PCA) shows that normal (black) and LGA-containing (red, blue) 
olfactory bulbs (OFB) and forebrains (FB) have distinct transcriptomes, as phenotypically wild-type mice 
(normal brains, Table S) clustered separate from T, TR, TP, TRP LGA (A).  Transcriptomes of OFB and CTX 
LGA with (red) and without (blue) KrasG12D are also distinct.  Although OFB transcriptomes from 
histologically normal mice with (black with red outlines) and without (black) KrasG12D were 
indistinguishable, the transcriptomes of OFB LGA with KrasG12D (red) were distinct from those without 
(blue) (B).  A KrasG12D-related OFB LGA gene signature was enriched in the pre-glioblastoma (PG), but not 





Figure 2.4.  KrasG12D facilitates malignant progression to HGA.   Histopathological examination of 
brains from aged mice (A) showed that only 17-21% of T, TP+/-, and TP-/- mice harbored HGA (all A3).  In 
contrast, 71-76% of TR, TRP+/-, and TRP-/- mice harbored HGA [Chi-squared P≤0.001, TR(P) vs. T(P)].  GBM 
developed in 35, 54, and 62% of TR, TRP+/-, and TRP-/- mice (Chi-squared P=0.065, TRP-/- vs. TR).  Whereas 
TR, TRP+/-, and TRP-/- mice developed HGA-related neurological morbidity and showed significantly 
decreased median survivals of 4.5, 4.0, and 2.8 m, respectively (Log-rank P < 0.009 for all pairwise 





Figure 2.5. LGA stochastically progress to rapidly proliferative, lethal HGA after acquisition of CNA.   
Gadolinium contrast enhancing (A), T121-positive (B) HGA (C) develop focally in the context of 
widespread LGA (C, D, E).  A representative GBM with microvascular proliferation (F) from a TRP+/- 
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mouse is shown (A-F).  Quantification of T2-weighted serial magnetic resonance images showed 
logarithmic increases in HGA volume in 9 TRP+/- mice with mean doubling of 3±1 d (G).  Median time to 
first HGA mass appearance, median survival, and mean time to death after appearance of HGA was 
119±7 (range 84-154), 122±2, and 14±3 d, respectively (H).  Frequency plots of aCGH data show that 
terminal LGA (> 1 year survival) rarely acquire CNA (I).  All TR HGA (J) showed gains of chromosome 6, 
but only 64-72% TRP+/- HGA (K) show similar gains (Fisher P=0.15).  Half of TR, but only 16-20% of TRP+/- 
HGA showed chromosome 1 gains (Fisher P=0.17).  TRP-/- HGA (L) acquire the least CNA and have the 





Figure 2.6.  GEM HGA transcriptomes are heterogeneous, mimic human GBM subtypes, and are 
reminiscent of distinct neural cell types.   Hierarchical clustering of TR(P) HGA discovery set using a 600-
gene classifier (200 per subtype) shows transcriptomal heterogeneity (A).  Hierarchical clustering of an 
independent test set composed of 3 adult GEM HGA models with different initiating mutations shows 
the 600-gene classifier accurately clusters samples according to their predicted TR(P) HGA S1-S3 
subtypes (B).  HGA subtypes S1-S3 correlate with distinct TCGA human GBM subtypes (C, Fisher P=2.2 x 
10-12).  Similar S1-S3 subtype associations with human GBM subtypes were evident in the GEM HGA test 
set (D).  ssGSEA of discovery set samples shows enrichment of distinct neural cell lineage signatures (E).  









Figure S2.1.  RB pathway genes are altered in nearly all human GBM.   TCGA GBM with mRNA and protein expression, aCGH, and 
sequencing data (N=236) were analyzed using the cBio Portal for Cancer Genomics (167).  Ninety-eight percent (N=232) harbored one or more 
significant RB pathway gene alteration(s).  RB1 alterations trend towards co-occurrence with alterations in its pocket protein family members, 
RBL1 or RBL2 (P=0.27 and P=0.007, respectively). 





Figure S2.2. GFAP-CreER mediates recombination throughout the brain.   Genetic lineage tracing in 
a GFAP-CreER;Rosa26-tdTomato mouse at 7 d after induction (Fig. 1) shows recombination (tdTomato 
expression) in the subventricular zone (SVZ), cortex (CTX), diencephalon (DI), brainstem (BS), and 







Figure S2.3.  GFAP-CreER targets astrocytes.   Genetic lineage tracing in a GFAP-CreER;Rosa26-
tdTomato mouse at 7 d after induction shows recombination (tdTomato expression) in cortical (CTX), 
diencephalic (DI), brainstem (BS), and olfactory bulb (OFB) astrocytes as defined by their stellate cellular 





Figure S2.4. GFAP-CreER does not target neurons.   Genetic lineage tracing in a GFAP-CreER;Rosa26-
tdTomato mouse at 7 d after induction shows minimal recombination (tdTomato expression; 0.2 ± 0.1%) 
in cortical (CTX), diencephalic (DI), brainstem (BS), and olfactory bulb (OFB) neurons as defined by their 





Figure S2.5.  Initiating oncogenic mutations (genotype) influence LGA tumor burden.   
Representative H&E (A-E, K-O) and T121 immunohistochemistry (F-J, P-T) images in wild-type (A, F, K, P), T 
(B, G, L, Q), TP-/- (C, H, M, R), TR (D, I, N, S), and TRP-/- (E, J, O, T) mice at 2 m after induction.  T and TP-/- 
mice have similar LGA burden.  TR mice have increased LGA burden.  TRP-/- mice have the greatest LGA 





Figure S2.6.  Morphometric analysis of nuclear density in phenotypically wild-type and LGA-
containing mice.   Adult P+/-, P-/-, R, RP+/-, and RP-/- mice sacrificed at 2 m after induction showed no 
evidence of astrocytoma tumorigenesis and were phenotypically wild-type (A, Table S2.1).  No 
differences in cortical (CTX), diencephalic (DI), brainstem (BS), and olfactory bulb (OFB) nuclear densities 
were evident across these genotypes (one-way ANOVA P≥0.34), but nuclear density in the OFB was 
significantly greater than the other 3 brain regions (B, two-way ANOVA P<0.0001).  The effect of 
distance from sagittal midline on nuclear density was examined in 3 wild-type C57Bl/6 mice (C).  Data 
from Fig. 2B are re-graphed in D to highlight the effects of genotype on LGA burden in all four brain 




Figure S2.7.  Ablation of all Rb family members is required for tumorigenesis in adult murine 
astrocytes.   Histological examination of GFAP-CreER mouse brains with combinations of T121 or Rb1 
deletion, KrasG12D or Nf1 deletion, and Pten deletion (Table S2.2) showed low- or high-grade 





Figure S2.8.  Cortical TRP+/- LGA burden increases over time.   Genetic lineage tracing in GFAP-
CreER;Rosa26-tdTomato (A) and GFAP-CreER;Rosa26-tdTomato;TRP+/- (B, C) mice at 7 (A), 21 (B), and 60 
(C) d after induction showed a time-dependent increase in TRP+/- LGA burden throughout the cortex.  





Figure S2.9.  TRP+/- mice develop LGA in all brain regions.   Increased tdTomato- and proliferating, 
EdU-positive cells were evident in the subventricular zone (SVZ), cortex (CTX), diencephalon (DI), 
brainstem (BS), and olfactory bulb (OFB) in a representative GFAP-CreER;Rosa26-tdTomato;TRP+/- mouse 





Figure S2.10. Perineuronal sattelitosis increases over time in TRP+/- LGA.   Genetic lineage tracing 
in GFAP-CreER;Rosa26-tdTomato (A) and GFAP-CreER;Rosa26-tdTomato;TRP+/- (B, C) mice at 7 (A), 21 
(B), and 60 (C) d after induction showed a time-dependent increase in tdTomato+ cells surrounding 





Figure S2.11.  Local proliferation of transformed cortical astrocytes produces hypercellular TRP+/- 
astrocytoma foci.   Genetic lineage tracing in GFAP-CreER;Rosa26-tdTomato;TRP+/- mice at 21 (A-C) and 
60 (D, E) d after induction shows a transformed tdTomato/ cortical astrocyte in telophase (A), 
development of small foci of T121- (B) and BLBP-positive (C) cortical astrocytoma cells, dense sattelitosis 
around Map2-positive cortical neurons (D), and larger hypercellular foci (E, blue box HC) of astrocytoma 






Figure S2.12. LGA transcriptomes cluster according to initiating genotype and brain region.   
Consensus hierarchical clustering of olfactory bulb (OFB) and forebrain (FB) LGA transcriptomes (Fig. 3A, 
Table S2.1) with the 5000 most variable genes identified four clusters (A) composed largely of normal or 
LGA FB (cluster 1), OFB LGA with KrasG12D (cluster 2), OFB LGA without KrasG12D (cluster 3), and normal 
OFB (cluster 4).  Consensus hierarchical clustering of only FB LGA transcriptomes (Fig. 3A, Table S2.1) 
showed 3 clusters (B) consisting of LGA with KrasG12D (cluster 1), normal FB (cluster 2), and LGA without 






Figure S2.13. LGA have silent genomic landscapes, but transcriptional dysregulation of cell cycle 
genes.   Frequency plot of aCGH data shows minimal acquisition of CNA in T(P) and TR(P) LGA at 2 m 
after induction (A).  mRNA expression (Log2 median-centered) of G1/S and G2/M cell cycle checkpoint 





Figure S2.14.  Transformed TRP+/- astrocytes re-express p16.   p16 is expressed in neuron-specific 
enolase (NSE)-positive cortical neurons, but not Gfap- or tdTomato-positive cortical astrocytes in 3 m 
adult wild-type, C57Bl/6 (A) and GFAP-CreER;Rosa26-tdTomato (B) mice, respectively.  In contrast, p16 is 
expressed in transformed Gfap/tdTomato-positive cortical astrocytes from an age-matched GFAP-





Figure S2.15.  KrasG12D potentiates malignant progression.   H&E (A-D, I-L) and T121 
immunohistochemistry (E-H, M-P) shows LGA throughout the brain in a neurologically asymptomatic T 
mouse sacrificed 13 m after induction (A, E, I, M).  In contrast, multiple HGA (A3) foci are evident 
throughout the brain in symptomatic TR (B, F, J, N) and TRP-/- (C, G, K, O) mice.  A second symptomatic 
TRP-/- mouse (D, H, L, P) developed a diencephalic GBM with central hemorrhage and necrosis.  Scale 




Figure S2.16. Initiating genotype and astrocyte location influence CNA acquired upon malignant 
progression in TR(P) HGA.   Initiating genotype (A) and astrocyte location (B) significantly influence the 
development of CNA in recurrently altered (>20% of samples, Table S2.4) Rb, RTK/MAPK/PI3K, and p53 





Figure S2.17. TR(P) HGA transcriptomes are heterogeneous and consist of three subtypes.   
Consensus clustering using either 2000 or 5000 genes with highest median absolute deviation for k=3-6 
(A). The bimodal distribution at 0 and 1 in the consensus index indicates well-defined subtypes (B).  
Consensus clustering reaches a local maximum at 6 clusters (C), but 3 contain 2 or fewer HGA (A, bottom 
right).  Positive silhouette widths identify 42 of 43 HGA as core subtype members.  One sample with 





Figure S2.18.  HGA transcriptomes are distinct from LGA and subtypes correlate with anatomic 
location.   In contrast to initiating genotype (Fig. 4), HGA subtype does not influence survival (A, Log-
rank P=0.4).  S1 and S2 HGA subtypes are predominantly located in brainstem (BS) and olfactory bulb 
(OFB), respectively (B, Fisher P=0.004).  S3 is composed of HGA from BS, OFB, cortex (CTX) and 
diencephalon (DI).  PCA shows that LGA and HGA transcriptomes are distinct (C).  Separation of OFB and 
forebrain (FB) LGA, LGA with and without KrasG12D (Fig. 3A), and S1-S3 HGA subtypes (Figs. 6 and S17) are 





Figure S2.19. GEM HGA and human GBM have similar transcriptomes.   GEM HGA (black bars) and 
human GBM (colored subtypes) express the TCGA GBM 840-gene classifier similarly (A).  Murine HGA 
are grouped according to their predicted TCGA subtype.  ssGSEA shows enrichment of mesenchymal, 





Figure S2.20.  Copy number landscapes of GEM HGA models with and without p53 deletion are 
distinct.   Frequency plots of aCGH data from TR(P) HGA show frequent CNA only on chromosomes 1 
and 6 (A).  In contrast, Rb1/Pten/p53 triple KO HGA (GSE22927) show frequent CNA across the genome 
(B) (100), suggesting that p53 deletion in Rb1;Pten-deleted murine astrocytes significantly affects the 




Figure S2.21.  Heterozygous deletion of p53 accelerates tumorigenesis in T(RP) mice.   Histological 
examination of 2 m T(RP);GFAP-CreER mouse brains with and without heterozygous p53 deletion (Table 
S2.12) showed that deletion of p53 induced tumorigenesis only in the context of T, but T;p53 and 





Figure S2.22.  T(RP) astrocytomas with p53 deletion show minimal CNA.   Frequency plot of aCGH 
data from 10 astrocytomas from 7 T(RP) mice with heterozygous p53 deletion (Table S2.12) shows 





Figure S2.23.  p53 deletion contributes to widespread genomic instability.   IGV analysis of aCGH 
data from TR(P) (N=41, top, Fig. 5J-L) and Rb1/Pten/p53 triple KO HGA (N=21, bottom, Fig. S20B) shows 
that their genomic CNA landscapes are distinct.  One GBM (arrow) harvested from a terminally-aged, 
neurologically symptomatic T;p53+/- mouse shows a CNA pattern more similar to Rb1/Pten/p53 triple KO 
than TR(P) HGA, suggesting that p53 deletion induces widespread genomic instability and variable CNA 
landscapes upon malignant progression. 
 































207979 TP-/- No Yes M 61 67 Normal     
207967 TRP-/- No Yes F 61 67 Normal 
  
221182 P+/- Yes No M 100 66 Normal   FB 
223979 R Yes No F 127 74 Normal 
 
OFB 
217861 TP+/- Yes No F 119 65 Normal   OFB, FB 
220435 TRP-/- Yes No M 111 66 Normal 
 
OFB 
221699 TRP-/- Yes No M 90 66 Normal   OFB, FB 
219892 P-/- Yes Yes F 98 64 Normal S6AB OFB 
219921 P-/- Yes Yes M 101 64 Normal S6AB OFB 
220057 P-/- Yes Yes F 95 64 Normal S6AB OFB 
221927 P-/- Yes Yes M 116 63 Normal S6AB OFB 
221928 P-/- Yes Yes M 116 63 Normal S6AB OFB 
214254 P+/- Yes Yes F 63 70 Normal S6AB OFB 
217463 P+/- Yes Yes F 99 66 Normal S6AB OFB 
217871 P+/- Yes Yes M 92 66 Normal S6AB OFB, FB 
219899 P+/- Yes Yes M 98 64 Normal S6AB 
 
220724 P+/- Yes Yes F 107 66 Normal S6AB OFB 
217708 R Yes Yes M 94 66 Normal S6AB 
 





220060 R Yes Yes M 95 64 Normal S6AB 
 
225561 R Yes Yes F 87 74 Normal S6AB OFB 
225567 R Yes Yes F 87 74 Normal S6AB 
 
215214 RP-/- Yes Yes F 101 59 Normal S6AB OFB, FB 
219159 RP-/- Yes Yes F 104 65 Normal S6AB OFB 
219898 RP-/- Yes Yes M 98 64 Normal S6AB OFB 
219918 RP-/- Yes Yes M 101 64 Normal S6AB OFB 
220062 RP-/- Yes Yes M 98 45 Normal S6AB OFB 
207970 RP+/- Yes Yes F 61 67 Normal S6AB 
 
214987 RP+/- Yes Yes M 104 59 Normal S6AB OFB 
215216 RP+/- Yes Yes M 101 59 Normal S6AB OFB, FB 
220061 RP+/- Yes Yes M 95 64 Normal S6AB OFB 
221181 RP+/- Yes Yes M 100 66 Normal S6AB OFB 
217872 T Yes Yes M 92 66 A2 2B, 6D   
219147 T Yes Yes F 104 65 A2 2B, 6D OFB, FB 
220727 T Yes Yes F 107 66 A2 2B, 6D OFB, FB 
221184 T Yes Yes M 100 66 A2 2B, 6D OFB, FB 
221940 T Yes Yes M 114 63 A2 2B, 6D OFB, FB 
217857 TP-/- Yes Yes F 91 66 A2 2B, 6D OFB 
219594 TP-/- Yes Yes F 98 65 A2 2B, 6D OFB 
219595 TP-/- Yes Yes M 98 65 A2 2B, 6D OFB 
219699 TP-/- Yes Yes M 98 65 A2 2B, 6D OFB 
221180 TP-/- Yes Yes M 100 66 A2 2B, 6D OFB 
215217 TP+/- Yes Yes M 101 59 A2   OFB, FB 
216188 TP+/- Yes Yes F 85 59 A2 
 
OFB, FB 
219438 TP+/- Yes Yes F 97 65 A2   OFB 







219973 TP+/- Yes Yes M 101 64 A2   OFB, FB 
246036 TP+/- Yes Yes F 98 63 A2 
  
214252 TR Yes Yes F 63 70 A2 2B, 6D OFB 
222912 TR Yes Yes M 147 74 A2 2B, 6D FB 
225569 TR Yes Yes F 87 74 A2 2B, 6D FB 
225800 TR Yes Yes M 82 74 A2 2B, 6D 
 
245121 TR Yes Yes M 134 60 A2 2B, 6D   
245308 TR Yes Yes F 129 60 A2 
  
245310 TR Yes Yes F 129 60 A2 2B, 6D   
215534 TRP-/- Yes Yes M 96 59 A2 2B, 6D OFB, FB 
215697 TRP-/- Yes Yes M 94 59 A2 2B, 6D OFB, FB 
216103 TRP-/- Yes Yes M 89 59 A2 
 
FB 
216498 TRP-/- Yes Yes F 84 44 A2   OFB 
243054 TRP-/- Yes Yes M 129 63 A2 
 
OFB, FB 
246037 TRP-/- Yes Yes M 98 63 A2     
214253 TRP-/- Yes Yes F 63 70 A3 2B, 6D OFB, FB 
245665 TRP-/- Yes Yes M 106 60 A3     
214828 TRP+/- Yes Yes F 133 66 A2 
 
OFB, FB 
216175 TRP+/- Yes Yes F 114 66 A2   OFB, FB 
217494 TRP+/- Yes Yes M 99 66 A2 
 
OFB, FB 
217703 TRP+/- Yes Yes F 87 73 A2     
217706 TRP+/- Yes Yes F 87 73 A2 
 
OFB 
219439 TRP+/- Yes Yes F 97 65 A2   OFB, FB 
219596 TRP+/- Yes Yes F 70 66 A2 
 
OFB, FB 
219695 TRP+/- Yes Yes F 98 65 A2   OFB, FB 
















Normal   
1 










TP+/- 1 1 1 











RP+/- 4 1 5 
RP-/- 5 1 5 
T 
LGA (A2) 
4 4 5 




TR 1 2 7 
TRP+/- 8 6 9 
TRP-/- 
LGA (A2) 4 4 6 
HGA (A3) 1 1 2 
Total 52 26 72 





  Mean SD Min Max  
Age at induction (days) 98.3 17.2 61 147 
 
Post-induction survival (days) 64.7 5.3 44 74 
 
 
Table S2.1.  TRP LGA cohort: Mice sacrificed at 2 m after induction.   Adult GFAP-CreER mice with combinations of T, R, and P alleles were 
induced with 4OHT at ~3 m of age (mean 98, SD 17 d) and sacrificed ~2 m (mean 65, SD 5 d) later.  Uninduced GFAP-CreER mice (N=5), induced 
mice lacking GFAP-CreER (N=2), and induced GFAP-CreER mice with P, R, or RP (N=25) showed no evidence of tumorigenesis.  In contrast, all 






Table S2.2.  GFAP-CreER mice with Rb1 deletion ± KrasG12D ± Pten deletion or Nf1 deletion ± T121 ± Pten deletion 
Mouse ID Genotype Sex 







250564 Rb1+/-;Nf1+/- M 118 Sac 191 Normal 
248559 Rb1+/-;Pten+/- F 173 Sac 119 Normal 
248590 Rb1+/-;Pten+/- M 172 Sac 60 Normal 
248916 Rb1+/-;Pten+/- F 148 Sac 119 Normal 
250700 Rb1+/-;Pten+/- F 113 Sac 191 Normal 
250012 Rb1+/-;Nf1+/-;Pten+/- F 105 Sac 78 Normal 
250630 Rb1+/-;Nf1+/-;Pten+/- M 119 Sac 189 Normal 
250013 Rb1+/-;Nf1+/-;Pten-/- F 105 Sac 78 Normal 
250773 Rb1+/-;Nf1+/-;Pten-/- F 104 Sac 191 Normal 
250358 Rb1+/-;Nf1-/-;Pten+/- M 102 Sac 63 Normal 
250016 Rb1+/-;Nf1-/-;Pten+/- M 252 Sac 183 Normal 
251062 Rb1+/-;Nf1-/-;Pten-/- M 110 Sac 185 Normal 
248558 Rb1+/-;KrasG12D F 173 Sac 119 Normal 
248915 Rb1+/-;KrasG12D;Pten+/- F 148 Sac 119 Normal 
248922 Rb1+/-;KrasG12D;Pten+/- M 148 Sac 60 Normal 
249182 Rb1+/-;KrasG12D;Pten+/- F 135 Sac 60 Normal 
250362 Rb1+/-;KrasG12D;Pten+/- F 101 Sac 63 Normal 
249234 Rb1+/-;KrasG12D;Pten-/- F 131 Sac 63 Normal 
251580 Rb1+/-;KrasG12D;Pten-/- M 117 Sac 70 Normal 





252661 Rb1+/-;KrasG12D;Pten-/- F 98 Sac 94 Normal 
252666 Rb1+/-;KrasG12D;Pten-/- M 115 Sac 38 Normal 
250561 Rb1-/- M 118 Sac 191 Normal 
250628 Rb1-/-;Nf1+/- F 119 Sac 191 Normal 
250356 Rb1-/-;Nf1+/-;Pten+/- F 179 Sac 185 Normal 
251054 Rb1-/-;Nf1+/-;Pten-/- F 114 Sac 185 Normal 
251276 Rb1-/-;Nf1+/-;Pten-/- F 95 Sac 185 Normal 
250017 Rb1-/-;Nf1-/-;Pten-/- M 252 Sac 162 Normal 
252660 Rb1-/-;KrasG12D;Pten-/- F 98 Sac 37 Normal 
250631 Nf1-/- M 119 Sac 189 Normal 
247642 Nf1+/-;Pten+/- M 95 Sac 175 Normal 
249594 Nf1+/-;Pten-/- M 36 Sac 184 Normal 
250612 Nf1-/-;Pten+/- F 118 Sac 191 Normal 
245449 T;Nf1+/-;Pten+/- M 355 Brain tumor 99 GBM 
246071 T;Nf1+/-;Pten+/- M 312 Sac 184 A3 
246522 T;Nf1+/-;Pten+/- M 272 Sac 184 A3 
247171 T;Nf1+/-;Pten+/- F 147 Sac 175 A2 
247472 T;Nf1+/-;Pten+/- M 242 Sac 64 A2 
247641 T;Nf1+/-;Pten+/- M 95 Sac 175 A2 
247658 T;Nf1+/-;Pten+/- M 166 Sac 184 A2 
247965 T;Nf1+/-;Pten+/- M 73 Sac 175 A2 
247967 T;Nf1+/-;Pten+/- M 73 Sac 175 A2 
248900 T;Nf1+/-;Pten+/- F 81 Sac 184 A2 
249328 T;Nf1+/-;Pten+/- F 56 Sac 184 A2 
249589 T;Nf1+/-;Pten+/- F 155 Sac 63 A2 






249591 T;Nf1+/-;Pten-/- F 155 Sac 63 A2 
249870 T;Nf1+/-;Pten-/- M 117 Sac 72 A2 
250765 T;Nf1+/-;Pten-/- M 144 Sac 232 A2 
251496 T;Nf1+/-;Pten-/- F 122 Sac 184 A2 
245462 T;Nf1+/- M 355 Sac 184 A2 
246372 T;Nf1+/- F 211 Sac 175 A2 
247966 T;Nf1+/- M 73 Sac 175 A2 
247640 T;Nf1-/-;Pten+/- M 95 Sac 175 A2 
249890 T;Nf1-/-;Pten+/- M 116 Sac 72 A2 
249871 T;Nf1-/-;Pten-/- M 117 Sac 72 A2 
249961 T;Nf1-/-;Pten-/- M 117 Sac 72 A2 
250898 T;Nf1-/-;Pten-/- M 130 Brain tumor 169 A3 
249593 T;Nf1-/- M 36 Sac 184 A3 
 
Summary 































T;Nf1+/- LGA (A2) 3 
T;Nf1+/-;Pten+/- 
LGA (A2) 10 
HGA (A3) 2 
HGA (GBM) 1 
T;Nf1+/-;Pten-/- LGA (A2) 4 
T;Nf1-/- HGA (A3) 1 
T;Nf1-/-;Pten+/- LGA (A2) 2 
T;Nf1-/-;Pten-/- 
LGA (A2) 2 
HGA (A3) 1 
Total   59 
   Age at induction (days) 
 Mean 138.3 








 Max 355 
  
Table S2.2.  GFAP-CreER mice with Rb1 deletion ± KrasG12D ± Pten deletion or Nf1 deletion ± T121 ± Pten deletion.   Adult GFAP-CreER 
mice were induced with 4OHT at ~4.5 m of age (mean 138, SD 67 d) and sacrificed ~4 m (mean 123, SD 60 d) later.  Rb1-deleted mice, with or 
without KrasG12D, Nf1 or Pten deletions (N=29), and Nf1-deleted mice, with or without Pten deletion (N=4), showed no evidence of 






Table S2.3. One versus rest SAM analysis of T(RP) LGA transcriptomes at 2 m after induction 
 
Comparison Up/Down Gene Row d.value stdev rawp q.value R.fold 
LGA versus normal brain Down Pdlim7 12262 -11.8648 0.048313 0 0 0.672115 
LGA versus normal brain Down Srxn1 15484 -11.86238 0.061941 0 0 0.600915 
LGA versus normal brain Down Srpk2 15459 -11.64601 0.037509 0 0 0.738754 
LGA versus normal brain Down Mtor 10427 -11.579 0.038943 0 0 0.731576 
LGA versus normal brain Down Klhl30 9014 -11.57341 0.110097 0 0 0.413454 
LGA versus normal brain Down D030063E12 4869 -11.4376 0.045203 0 0 0.698818 
LGA versus normal brain Down Adarb1 1812 -11.28855 0.083187 0 0 0.521572 
LGA versus normal brain Down Inpp5a 8553 -11.28443 0.059095 0 0 0.629878 
LGA versus normal brain Down Armc8 2469 -11.22809 0.042497 0 0 0.718391 
LGA versus normal brain Down Atpaf1 2690 -11.17776 0.048432 0 0 0.68712 
LGA versus normal brain Down Got2 7527 -11.1009 0.054372 0 0 0.65812 
LGA versus normal brain Down Akap17b 2007 -11.04388 0.056799 0 0 0.647397 
LGA versus normal brain Down Rcan2 13644 -10.99853 0.069494 0 0 0.588728 
LGA versus normal brain Down Cish 4168 -10.8756 0.080631 0 0 0.544532 
LGA versus normal brain Down Clip1 4245 -10.84813 0.05434 0 0 0.664577 
LGA versus normal brain Down 6030419C18Rik 1167 -10.80144 0.084588 0 0 0.530834 
LGA versus normal brain Down Fam120b 6179 -10.72756 0.048818 0 0 0.695585 
LGA versus normal brain Down Cited2 4171 -10.65492 0.060756 0 0 0.63845 
LGA versus normal brain Down Slmap 15069 -10.63424 0.046931 0 0 0.707561 
LGA versus normal brain Down Mfap3l 10011 -10.59715 0.068636 0 0 0.604012 
LGA versus normal brain Down Npr3 11026 -10.55832 0.05708 0 0 0.658532 
LGA versus normal brain Down Ell2 5849 -10.50984 0.051089 0 0 0.689233 
LGA versus normal brain Down Ppp2r5b 12919 -10.49732 0.058299 0 0 0.654295 
LGA versus normal brain Down Arhgef3 2420 -10.48864 0.053139 0 0 0.679547 
LGA versus normal brain Down Cdc42se2 3851 -10.45468 0.044654 0 0 0.723545 






LGA versus normal brain Down Cyb5r4 4769 -10.35856 0.033562 0 0 0.785862 
LGA versus normal brain Down Leprotl1 9273 -10.33641 0.032106 0 0 0.794512 
LGA versus normal brain Down Rhobtb2 13788 -10.31214 0.046205 0 0 0.718734 
LGA versus normal brain Down Cytl1 4862 -10.28559 0.077127 0 0 0.577025 
LGA versus normal brain Down Ptcd1 13225 -10.26615 0.054141 0 0 0.68027 
LGA versus normal brain Down Igf1 8402 -10.18118 0.061668 0 0 0.647138 
LGA versus normal brain Down Ube2f 16991 -10.15848 0.032359 0 0 0.796246 
LGA versus normal brain Down Tex264 16029 -10.10401 0.034471 0 0 0.785509 
LGA versus normal brain Down Impdh1 8527 -10.02706 0.057147 0 0 0.672208 
LGA versus normal brain Down Slc9a3r2 15039 -10.01538 0.057703 0 0 0.669932 
LGA versus normal brain Down Rnf128 13885 -10.00837 0.061156 0 0 0.654256 
LGA versus normal brain Down Rabgap1l 13450 -9.980746 0.061244 0 0 0.654626 
LGA versus normal brain Down Dnajc27 5383 -9.94855 0.050791 0 0 0.704515 
LGA versus normal brain Down Pppde2 12939 -9.930312 0.034096 0 0 0.790819 
LGA versus normal brain Down Zbtb4 17690 -9.92347 0.067191 0 0 0.629916 
LGA versus normal brain Down B4galnt1 2816 -9.903721 0.061421 0 0 0.655972 
LGA versus normal brain Down 2310061I04Rik 528 -9.90043 0.047184 0 0 0.723396 
LGA versus normal brain Down Bag5 2855 -9.893671 0.044809 0 0 0.735435 
LGA versus normal brain Down Tmtc1 16443 -9.861215 0.07646 0 0 0.592964 
LGA versus normal brain Down Bace1 2846 -9.819497 0.053286 0 0 0.695806 
LGA versus normal brain Down Slc2a6 14885 -9.814645 0.081365 0 0 0.574919 
LGA versus normal brain Down Pptc7 12943 -9.809048 0.056409 0 0 0.681452 
LGA versus normal brain Down Got1 7525 -9.807952 0.072166 0 0 0.612255 
LGA versus normal brain Down Chchd7 4061 -9.795723 0.090205 0 0 0.542005 
LGA versus normal brain Down 2410016O06Rik 550 -9.792571 0.050969 0 0 0.707541 
LGA versus normal brain Down Cyp2s1 4824 -9.786391 0.059391 0 0 0.668397 
LGA versus normal brain Down Tdrd9 15983 -9.78534 0.08718 0 0 0.553598 
LGA versus normal brain Down Cdkl2 3918 -9.765427 0.097656 0 0 0.516322 
LGA versus normal brain Down 5830408C22Rik 1141 -9.754068 0.07844 0 0 0.588407 






LGA versus normal brain Down Rgs11 13753 -9.695361 0.067907 0 0 0.633589 
LGA versus normal brain Down Nme1 10934 -9.687696 0.069177 0 0 0.628436 
LGA versus normal brain Down Qrsl1 13368 -9.676679 0.032099 0 0 0.806298 
LGA versus normal brain Down Insig2 8565 -9.663531 0.044171 0 0 0.743887 
LGA versus normal brain Down Edil3 5700 -9.66081 0.074427 0 0 0.607506 
LGA versus normal brain Down Nceh1 10673 -9.650539 0.064162 0 0 0.651032 
LGA versus normal brain Down Ube2o 17003 -9.648242 0.070726 0 0 0.623138 
LGA versus normal brain Down 6330406I15Rik 1183 -9.631188 0.081983 0 0 0.578508 
LGA versus normal brain Down Ttll7 16877 -9.627232 0.084315 0 0 0.569704 
LGA versus normal brain Down Ppp1r16b 12883 -9.541502 0.083358 0 0 0.576197 
LGA versus normal brain Down Rab37 13415 -9.523755 0.083214 0 0 0.577338 
LGA versus normal brain Down Prkar1a 13000 -9.518387 0.05484 0 0 0.69641 
LGA versus normal brain Down Acsl1 1714 -9.487328 0.059224 0 0 0.677419 
LGA versus normal brain Down Map2k1 9744 -9.484919 0.072884 0 0 0.619295 
LGA versus normal brain Down Wwp1 17577 -9.4818 0.052368 0 0 0.708804 
LGA versus normal brain Down Foxd1 6665 -9.477132 0.084251 0 0 0.574963 
LGA versus normal brain Down Tmem57 16383 -9.430053 0.040275 0 0 0.768547 
LGA versus normal brain Down Chchd10 4055 -9.429511 0.062068 0 0 0.666524 
LGA versus normal brain Down Fkbp1b 6590 -9.426683 0.082913 0 0 0.581722 
LGA versus normal brain Down Aars2 1558 -9.400453 0.052055 0 0 0.71235 
LGA versus normal brain Down Fbxo28 6444 -9.390135 0.033295 0 0 0.805165 
LGA versus normal brain Down Cul3 4723 -9.38448 0.030901 0 0 0.817906 
LGA versus normal brain Down Pdk3 12255 -9.376205 0.055265 0 0 0.698254 
LGA versus normal brain Down Asb11 2522 -9.375862 0.090556 0 0 0.555154 
LGA versus normal brain Down Abca5 1573 -9.374138 0.060237 0 0 0.676111 
LGA versus normal brain Down Thbd 16090 -9.342069 0.095662 0 0 0.538238 
LGA versus normal brain Down Dnajb12 5357 -9.338725 0.039087 0 0 0.776458 
LGA versus normal brain Down Usp31 17174 -9.316142 0.081427 0 0 0.591076 
LGA versus normal brain Down Cmas 4284 -9.308657 0.065685 0 0 0.654544 






LGA versus normal brain Down Ppm1j 12858 -9.283068 0.089481 0 0 0.562274 
LGA versus normal brain Down Mapre3 9796 -9.280378 0.072519 0 0 0.627201 
LGA versus normal brain Down Acvr1b 1749 -9.275793 0.053084 0 0 0.710843 
LGA versus normal brain Down Zfp667 17992 -9.269356 0.07397 0 0 0.621723 
LGA versus normal brain Down Stk24 15593 -9.257199 0.03205 0 0 0.814116 
LGA versus normal brain Down Scyl2 14340 -9.256841 0.038068 0 0 0.783285 
LGA versus normal brain Down Pgam1 12347 -9.249432 0.043836 0 0 0.754995 
LGA versus normal brain Down Cul5 4726 -9.246629 0.038759 0 0 0.780036 
LGA versus normal brain Down Tmem87b 16409 -9.235527 0.060842 0 0 0.677406 
LGA versus normal brain Down Ryr1 14187 -9.23483 0.074295 0 0 0.62153 
LGA versus normal brain Down Slc30a9 14897 -9.223927 0.04847 0 0 0.733523 
LGA versus normal brain Down Lancl3 9180 -9.22268 0.115299 0 0 0.478513 
LGA versus normal brain Down Has1 7907 -9.222039 0.082247 0 0 0.591118 
LGA versus normal brain Down Mdh1 9901 -9.220326 0.054003 0 0 0.708123 
LGA versus normal brain Down Cox5a 4472 -9.21586 0.044524 0 0 0.752452 
LGA versus normal brain Down Il34 8503 -9.204648 0.077093 0 0 0.611484 
LGA versus normal brain Down Fam110c 6164 -9.203584 0.069343 0 0 0.642512 
LGA versus normal brain Down Tm6sf1 16193 -9.20118 0.091427 0 0 0.558166 
LGA versus normal brain Down Mef2a 9948 -9.184175 0.05995 0 0 0.682738 
LGA versus normal brain Down Fhdc1 6561 -9.182867 0.067427 0 0 0.651043 
LGA versus normal brain Down Ecsit 5688 -9.179111 0.035131 0 0 0.799699 
LGA versus normal brain Down Mrvi1 10331 -9.175415 0.07052 0 0 0.638584 
LGA versus normal brain Down Stim1 15584 -9.173184 0.051662 0 0 0.720011 
LGA versus normal brain Down Pip4k2c 12501 -9.166473 0.055877 0 0 0.701157 
LGA versus normal brain Down Napepld 10631 -9.162846 0.056072 0 0 0.700383 
LGA versus normal brain Down Asb2 2526 -9.159581 0.086106 0 0 0.578867 
LGA versus normal brain Down Gnl3l 7493 -9.147765 0.060457 0 0 0.681579 
LGA versus normal brain Down Ube2k 16998 -9.108882 0.034689 0 0 0.803306 
LGA versus normal brain Down Creld1 4555 -9.108 0.054151 0 0 0.710443 






LGA versus normal brain Down Jhdm1d 8735 -9.099067 0.054439 0 0 0.709394 
LGA versus normal brain Down Cnrip1 4340 -9.097265 0.041833 0 0 0.768137 
LGA versus normal brain Down Sema6b 14427 -9.088583 0.080695 0 0 0.601482 
LGA versus normal brain Down Mctp1 9894 -9.086801 0.095934 0 0 0.546489 
LGA versus normal brain Down Tmem163 16286 -9.086452 0.048034 0 0 0.738945 
LGA versus normal brain Down Ap3s2 2272 -9.080996 0.046362 0 0 0.746899 
LGA versus normal brain Down Cnnm2 4320 -9.080891 0.052257 0 0 0.719697 
LGA versus normal brain Down Slc36a2 14929 -9.069554 0.111344 0 0 0.4966 
LGA versus normal brain Down 1810074P20Rik 404 -9.069125 0.031553 0 0 0.820084 
LGA versus normal brain Down Gls2 7072 -9.068891 0.081719 0 0 0.598284 
LGA versus normal brain Down D230025D16Rik 4920 -9.058861 0.054368 0 0 0.710788 
LGA versus normal brain Down Brms1l 3164 -9.04856 0.034527 0 0 0.805292 
LGA versus normal brain Down Dcun1d4 5095 -9.044323 0.070917 0 0 0.641093 
LGA versus normal brain Down Cacna1h 3359 -9.037544 0.036683 0 0 0.794695 
LGA versus normal brain Down Icam4 8325 -9.014051 0.08733 0 0 0.579471 
LGA versus normal brain Down Dcaf11 5050 -9.009606 0.0316 0 0 0.820911 
LGA versus normal brain Down Ypel5 17652 -8.998006 0.06653 0 0 0.660376 
LGA versus normal brain Down Hmga1 8102 -8.961743 0.056162 0 0 0.705487 
LGA versus normal brain Down Arhgap22 2385 -8.958193 0.059799 0 0 0.68983 
LGA versus normal brain Down Xylt2 17622 -8.9535 0.043835 0 0 0.761819 
LGA versus normal brain Down Smarca1 15090 -8.950305 0.070987 0 0 0.643782 
LGA versus normal brain Down 4931408A02Rik 985 -8.949974 0.057533 0 0 0.699831 
LGA versus normal brain Down Fam53c 6312 -8.93955 0.046415 0 0 0.750056 
LGA versus normal brain Down 2310044G17Rik 511 -8.935273 0.040016 0 0 0.780488 
LGA versus normal brain Down Hecw2 7981 -8.931817 0.063246 0 0 0.676001 
LGA versus normal brain Down Lpgat1 9463 -8.92651 0.079994 0 0 0.609601 
LGA versus normal brain Down Kcnab2 8789 -8.915434 0.092512 0 0 0.564565 
LGA versus normal brain Down Znrf1 18175 -8.903776 0.050551 0 0 0.731996 
LGA versus normal brain Down Atp6v0a1 2661 -8.901728 0.047449 0 0 0.746194 






LGA versus normal brain Down Zswim1 18199 -8.872768 0.065762 0 0 0.667347 
LGA versus normal brain Down Morc4 10182 -8.867319 0.045331 0 0 0.756825 
LGA versus normal brain Down Col4a3bp 4393 -8.860035 0.029864 0 0 0.832434 
LGA versus normal brain Down Ptger3 13241 -8.859932 0.119789 0 0 0.479193 
LGA versus normal brain Down Socs5 15243 -8.85248 0.06415 0 0 0.674603 
LGA versus normal brain Down Ccl25 3676 -8.849706 0.077522 0 0 0.621553 
LGA versus normal brain Down Uhrf1bp1l 17085 -8.848564 0.050244 0 0 0.734796 
LGA versus normal brain Down Rassf4 13567 -8.825291 0.047368 0 0 0.748441 
LGA versus normal brain Down Lrp11 9494 -8.821638 0.085704 0 0 0.592114 
LGA versus normal brain Down Ugcg 17069 -8.814562 0.067031 0 0 0.663952 
LGA versus normal brain Down Ptger2 13240 -8.809445 0.083861 0 0 0.599249 
LGA versus normal brain Down Wnk4 17546 -8.806278 0.087662 0 0 0.585613 
LGA versus normal brain Down Snx21 15220 -8.804535 0.031296 0 0 0.826137 
LGA versus normal brain Down Gphn 7554 -8.79952 0.032582 0 0 0.819771 
LGA versus normal brain Down Ccbl1 3545 -8.796207 0.042503 0 0 0.771712 
LGA versus normal brain Down Fbxo25 6442 -8.7956 0.063445 0 0 0.679227 
LGA versus normal brain Down Pdlim3 12259 -8.782783 0.077569 0 0 0.623615 
LGA versus normal brain Down Grb10 7676 -8.78222 0.066794 0 0 0.665909 
LGA versus normal brain Down Mapk14 9776 -8.779496 0.038106 0 0 0.79303 
LGA versus normal brain Down Nap1l3 10626 -8.779168 0.086501 0 0 0.590738 
LGA versus normal brain Down Pgap3 12352 -8.776104 0.06051 0 0 0.692055 
LGA versus normal brain Down B130024G19Rik 2761 -8.773361 0.077683 0 0 0.623501 
LGA versus normal brain Down Csrnp2 4639 -8.76294 0.053284 0 0 0.723504 
LGA versus normal brain Down Obfc2a 11225 -8.761831 0.048235 0 0 0.746064 
LGA versus normal brain Down Bcat1 3008 -8.760209 0.057961 0 0 0.703319 
LGA versus normal brain Down Pparg 12818 -8.74777 0.079705 0 0 0.616749 
LGA versus normal brain Down Tle2 16169 -8.738574 0.073077 0 0 0.642343 
LGA versus normal brain Down Sema3a 14411 -8.728358 0.067991 0 0 0.662757 
LGA versus normal brain Down Adssl1 1873 -8.726025 0.077837 0 0 0.624506 






LGA versus normal brain Down Prdm6 12964 -8.714792 0.090916 0 0 0.577418 
LGA versus normal brain Down Luzp1 9613 -8.705747 0.05251 0 0 0.72843 
LGA versus normal brain Down Synrg 15751 -8.703848 0.074252 0 0 0.638928 
LGA versus normal brain Down Sphk1 15359 -8.695349 0.089793 0 0 0.582051 
LGA versus normal brain Down Phlda1 12412 -8.690931 0.041193 0 0 0.780241 
LGA versus normal brain Down Narf 10635 -8.676213 0.052816 0 0 0.727872 
LGA versus normal brain Down Dlat 5291 -8.673149 0.037264 0 0 0.799295 
LGA versus normal brain Down 1700054N08Rik 305 -8.667779 0.074999 0 0 0.637246 
LGA versus normal brain Down Tm7sf2 16195 -8.663482 0.059336 0 0 0.700249 
LGA versus normal brain Down Dexi 5209 -8.661544 0.049369 0 0 0.743492 
LGA versus normal brain Down Yjefn3 17643 -8.659092 0.104854 0 0 0.532946 
LGA versus normal brain Down Rybp 14185 -8.654406 0.030512 0 0 0.832737 
LGA versus normal brain Down Slc23a2 14806 -8.651394 0.06931 0 0 0.659923 
LGA versus normal brain Down Hmgxb3 8118 -8.648246 0.058538 0 0 0.704049 
LGA versus normal brain Down Prkg2 13020 -8.639922 0.068876 0 0 0.662005 
LGA versus normal brain Down Tubg2 16903 -8.636893 0.069775 0 0 0.658549 
LGA versus normal brain Down Pdxk 12273 -8.635212 0.078376 0 0 0.625556 
LGA versus normal brain Down Cltb 4274 -8.633047 0.044428 0 0 0.766549 
LGA versus normal brain Down Ttc39c 16853 -8.630253 0.058583 0 0 0.704374 
LGA versus normal brain Down Ippk 8598 -8.62834 0.046126 0 0 0.758912 
LGA versus normal brain Down Rnf214 13925 -8.61698 0.043141 0 0 0.772849 
LGA versus normal brain Down 4930555K19Rik 955 -8.607147 0.054982 0 0 0.720347 
LGA versus normal brain Down Pthlh 13257 -8.598678 0.089072 0 0 0.588086 
LGA versus normal brain Down Hagh 7893 -8.597616 0.063711 0 0 0.684082 
LGA versus normal brain Down Vamp2 17222 -8.59724 0.050131 0 0 0.741753 
LGA versus normal brain Down Socs2 15240 -8.59578 0.09087 0 0 0.581923 
LGA versus normal brain Down Nars 10638 -8.595561 0.058508 0 0 0.705682 
LGA versus normal brain Down Nr2f2 11049 -8.594259 0.075794 0 0 0.636664 
LGA versus normal brain Down Scd1 14290 -8.585471 0.087833 0 0 0.592921 






LGA versus normal brain Down Atp6v1h 2678 -8.578576 0.053734 0 0 0.726502 
LGA versus normal brain Down Pdzd4 12280 -8.576401 0.065041 0 0 0.679327 
LGA versus normal brain Down Dnajc5 5388 -8.57432 0.051175 0 0 0.737753 
LGA versus normal brain Down Pip5k1b 12503 -8.573871 0.091134 0 0 0.581815 
LGA versus normal brain Down Gcnt1 6933 -8.566603 0.071414 0 0 0.654392 
LGA versus normal brain Down Atp2c1 2637 -8.565629 0.048919 0 0 0.747931 
LGA versus normal brain Down Dnajb5 5363 -8.561469 0.050625 0 0 0.740502 
LGA versus normal brain Down Tmod1 16425 -8.55622 0.08564 0 0 0.601753 
LGA versus normal brain Down Rasa4 13541 -8.555415 0.049635 0 0 0.745022 
LGA versus normal brain Down Wif1 17533 -8.553017 0.129741 0 0 0.463398 
LGA versus normal brain Down Akap11 2004 -8.550952 0.076527 0 0 0.635348 
LGA versus normal brain Down Btbd3 3189 -8.549091 0.068925 0 0 0.66469 
LGA versus normal brain Down Slc6a8 15015 -8.546494 0.061473 0 0 0.694778 
LGA versus normal brain Down Epm2aip1 5961 -8.540175 0.065525 0 0 0.678493 
LGA versus normal brain Down Klhdc1 8984 -8.531225 0.056709 0 0 0.715092 
LGA versus normal brain Down Clcn3 4193 -8.527379 0.060972 0 0 0.697406 
LGA versus normal brain Down Acsl4 1716 -8.50687 0.055385 0 0 0.721387 
LGA versus normal brain Down Gdpd5 6956 -8.499838 0.081092 0 0 0.620169 
LGA versus normal brain Down D17Wsu92e 4905 -8.487548 0.052718 0 0 0.733341 
LGA versus normal brain Down Tbx18 15908 -8.485708 0.065138 0 0 0.681722 
LGA versus normal brain Down Ogfrl1 11254 -8.483118 0.071504 0 0 0.656752 
LGA versus normal brain Down Pvr 13331 -8.476956 0.042901 0 0 0.777183 
LGA versus normal brain Down Rreb1 14102 -8.474225 0.045654 0 0 0.764781 
LGA versus normal brain Down Aph1b 2293 -8.469501 0.056985 0 0 0.71567 
LGA versus normal brain Down Cbln4 3523 -8.463623 0.096937 0 0 0.566269 
LGA versus normal brain Down Kitl 8960 -8.463027 0.097443 0 0 0.564615 
LGA versus normal brain Down 1700012B15Rik 195 -8.450865 0.055606 0 0 0.722007 
LGA versus normal brain Down Lrp12 9495 -8.441838 0.07616 0 0 0.640412 
LGA versus normal brain Down Tspyl2 16806 -8.440306 0.056698 0 0 0.717698 






LGA versus normal brain Down Hs3st1 8227 -8.433339 0.095222 0 0 0.57314 
LGA versus normal brain Down Pcdhb6 12148 -8.430208 0.045369 0 0 0.767125 
LGA versus normal brain Down Zbtb8b 17706 -8.427379 0.078288 0 0 0.632982 
LGA versus normal brain Down Galntl6 6860 -8.426899 0.076293 0 0 0.640417 
LGA versus normal brain Down Snf8 15166 -8.425863 0.045615 0 0 0.766124 
LGA versus normal brain Down Slc5a6 14999 -8.422896 0.050235 0 0 0.745807 
LGA versus normal brain Down Bsdc1 3174 -8.422238 0.057855 0 0 0.713374 
LGA versus normal brain Down Dennd5b 5195 -8.408107 0.060753 0 0 0.701823 
LGA versus normal brain Down Atp6ap2 2660 -8.406415 0.070498 0 0 0.66313 
LGA versus normal brain Down Eno2 5901 -8.405707 0.076011 0 0 0.642193 
LGA versus normal brain Down Arrb1 2491 -8.399417 0.075371 0 0 0.644803 
LGA versus normal brain Down Cacnb3 3367 -8.399082 0.084681 0 0 0.610794 
LGA versus normal brain Down Slc35e2 14920 -8.398687 0.046784 0 0 0.761584 
LGA versus normal brain Down Rnasek 13864 -8.389628 0.051518 0 0 0.741124 
LGA versus normal brain Down Cpeb3 4498 -8.387539 0.041433 0 0 0.785932 
LGA versus normal brain Down Tmeff2 16232 -8.3809 0.051075 0 0 0.743265 
LGA versus normal brain Down Kcnk3 8836 -8.379609 0.066571 0 0 0.679321 
LGA versus normal brain Down Ankrd12 2178 -8.379228 0.062173 0 0 0.696905 
LGA versus normal brain Down Vps28 17372 -8.378391 0.029075 0 0 0.844633 
LGA versus normal brain Down 5430417L22Rik 1099 -8.374901 0.05175 0 0 0.740515 
LGA versus normal brain Down Adck3 1820 -8.355657 0.062878 0 0 0.694771 
LGA versus normal brain Down Myadml2 10479 -8.349049 0.066807 0 0 0.679349 
LGA versus normal brain Down Gspt2 7748 -8.347266 0.071028 0 0 0.663012 
LGA versus normal brain Down Fgf10 6529 -8.341845 0.098482 0 0 0.565845 
LGA versus normal brain Down Whamm 17527 -8.338893 0.048762 0 0 0.754388 
LGA versus normal brain Down Pard6b 12058 -8.338728 0.047156 0 0 0.761429 
LGA versus normal brain Down Zfp169 17808 -8.337529 0.042212 0 0 0.783526 
LGA versus normal brain Down Nptn 11030 -8.336904 0.074687 0 0 0.649473 
LGA versus normal brain Down Fam117b 6175 -8.335441 0.04994 0 0 0.749359 






LGA versus normal brain Down Rap1gds1 13518 -8.331519 0.053804 0 0 0.732923 
LGA versus normal brain Down A330049M08Rik 1445 -8.328826 0.062848 0 0 0.695705 
LGA versus normal brain Down Fam65b 6328 -8.326667 0.061046 0 0 0.703047 
LGA versus normal brain Down Tchh 15942 -8.323226 0.113765 0 0 0.518748 
LGA versus normal brain Down Ehd3 5767 -8.322545 0.0783 0 0 0.636549 
LGA versus normal brain Down Tomm70a 16535 -8.311385 0.039488 0 0 0.796527 
LGA versus normal brain Down Fmod 6630 -8.307093 0.107593 0 0 0.5382 
LGA versus normal brain Down Apbb3 2284 -8.294144 0.061763 0 0 0.701117 
LGA versus normal brain Down Mapre2 9795 -8.290694 0.071313 0 0 0.663775 
LGA versus normal brain Down B4galt6 2824 -8.290041 0.077851 0 0 0.63932 
LGA versus normal brain Down Gm10914 7113 -8.285936 0.091134 0 0 0.592493 
LGA versus normal brain Down Plcxd2 12593 -8.284349 0.081217 0 0 0.627276 
LGA versus normal brain Down Tspan5 16798 -8.284204 0.042713 0 0 0.782497 
LGA versus normal brain Down Syt7 15768 -8.283253 0.064026 0 0 0.69239 
LGA versus normal brain Down Olfr745 11759 -8.279885 0.076921 0 0 0.643096 
LGA versus normal brain Down Slc25a44 14849 -8.276694 0.047393 0 0 0.761937 
LGA versus normal brain Down Prickle1 12986 -8.276408 0.07336 0 0 0.656488 
LGA versus normal brain Down Abca7 1575 -8.274854 0.08384 0 0 0.618237 
LGA versus normal brain Down BC037034 2958 -8.267058 0.049071 0 0 0.754884 
LGA versus normal brain Down Tbcc 15887 -8.266525 0.034628 0 0 0.820031 
LGA versus normal brain Down Spryd3 15417 -8.265413 0.073152 0 0 0.657638 
LGA versus normal brain Down Fkrp 6600 -8.264617 0.060291 0 0 0.707951 
LGA versus normal brain Down Rnft2 13949 -8.255343 0.056718 0 0 0.722853 
LGA versus normal brain Down Crebl2 4551 -8.250365 0.067225 0 0 0.680831 
LGA versus normal brain Down Ica1 8321 -8.249846 0.06319 0 0 0.696741 
LGA versus normal brain Down Smg7 15120 -8.225836 0.029506 0 0 0.845155 
LGA versus normal brain Down Tspan13 16787 -8.224132 0.092169 0 0 0.591311 
LGA versus normal brain Down Terf2ip 16008 -8.214794 0.054454 0 0 0.733398 
LGA versus normal brain Down Arhgef9 2428 -8.213854 0.072685 0 0 0.661115 






LGA versus normal brain Down Tmem41a 16366 -8.209917 0.046467 0 0 0.767643 
LGA versus normal brain Down Wdr37 17463 -8.199571 0.045641 0 0 0.771512 
LGA versus normal brain Down Prkaa2 12993 -8.19296 0.052613 0 0 0.741719 
LGA versus normal brain Down Prkg1 13019 -8.190365 0.096975 0 0 0.57664 
LGA versus normal brain Down Tmx4 16452 -8.183888 0.075623 0 0 0.651171 
LGA versus normal brain Down Kif26b 8933 -8.167232 0.046447 0 0 0.768787 
LGA versus normal brain Down Npy5r 11034 -8.166729 0.113777 0 0 0.525153 
LGA versus normal brain Down Ndfip1 10703 -8.163252 0.053025 0 0 0.740795 
LGA versus normal brain Down 2900052N01Rik 707 -8.154873 0.095778 0 0 0.581941 
LGA versus normal brain Down Atp1b1 2628 -8.13789 0.093708 0 0 0.58944 
LGA versus normal brain Down 6430548M08Rik 1207 -8.137665 0.070757 0 0 0.670917 
LGA versus normal brain Down Sema3f 14416 -8.135946 0.054096 0 0 0.737072 
LGA versus normal brain Down Epb4.1l1 5930 -8.135614 0.079582 0 0 0.63841 
LGA versus normal brain Down Plekha2 12605 -8.135034 0.050547 0 0 0.751996 
LGA versus normal brain Down Map3k12 9754 -8.134599 0.050478 0 0 0.752299 
LGA versus normal brain Down Tyrp1 16954 -8.131431 0.093331 0 0 0.59094 
LGA versus normal brain Down Tmem180 16306 -8.125506 0.044024 0 0 0.7804 
LGA versus normal brain Down Tmem151a 16279 -8.125106 0.095444 0 0 0.584189 
LGA versus normal brain Down Proca1 13050 -8.120438 0.0993 0 0 0.571824 
LGA versus normal brain Down Bin1 3079 -8.120231 0.050483 0 0 0.752656 
LGA versus normal brain Down Nupl1 11190 -8.119588 0.042454 0 0 0.787468 
LGA versus normal brain Down Deptor 5202 -8.118927 0.099058 0 0 0.572662 
LGA versus normal brain Down Mrps5 10324 -8.115531 0.044013 0 0 0.780684 
LGA versus normal brain Down Slc41a2 14963 -8.111607 0.057523 0 0 0.723668 
LGA versus normal brain Down Abl2 1629 -8.110629 0.085231 0 0 0.619307 
LGA versus normal brain Down Wisp1 17539 -8.10276 0.112092 0 0 0.53283 
LGA versus normal brain Down Cbfa2t3 3514 -8.10217 0.125212 0 0 0.495005 
LGA versus normal brain Down Smyd2 15142 -8.099884 0.052961 0 0 0.742789 
LGA versus normal brain Down Prkacb 12997 -8.097358 0.066655 0 0 0.687901 






LGA versus normal brain Down Armcx3 2473 -8.095793 0.043546 0 0 0.783202 
LGA versus normal brain Down Ush1g 17147 -8.090312 0.070755 0 0 0.672482 
LGA versus normal brain Down Sema3e 14415 -8.083717 0.085432 0 0 0.619594 
LGA versus normal brain Down Dctn6 5090 -8.081719 0.046726 0 0 0.769704 
LGA versus normal brain Down Evl 6060 -8.077865 0.062776 0 0 0.703637 
LGA versus normal brain Down Baz2a 2884 -8.077553 0.061821 0 0 0.707419 
LGA versus normal brain Down Ipo13 8591 -8.072232 0.05995 0 0 0.715027 
LGA versus normal brain Down Darc 5027 -8.070908 0.073076 0 0 0.664439 
LGA versus normal brain Down Klhl18 9002 -8.067448 0.036385 0 0 0.8159 
LGA versus normal brain Down Dgkd 5221 -8.050419 0.061509 0 0 0.709475 
LGA versus normal brain Down Chmp2b 4095 -8.042801 0.057809 0 0 0.724499 
LGA versus normal brain Down Setd4 14530 -8.039385 0.064035 0 0 0.699887 
LGA versus normal brain Down Ankrd50 2208 -8.030483 0.09445 0 0 0.59112 
LGA versus normal brain Down Selm 14408 -8.028467 0.096797 0 0 0.583527 
LGA versus normal brain Down Phldb1 12415 -8.02511 0.055941 0 0 0.732586 
LGA versus normal brain Down Zkscan14 18139 -8.016221 0.055641 0 0 0.734061 
LGA versus normal brain Down Atg16l1 2590 -8.013374 0.059901 0 0 0.716973 
LGA versus normal brain Down A930038C07Rik 1543 -8.012721 0.06764 0 0 0.686827 
LGA versus normal brain Down Egln3 5758 -8.011347 0.061028 0 0 0.712558 
LGA versus normal brain Down Dopey1 5443 -8.007227 0.05091 0 0 0.753852 
LGA versus normal brain Down Tspan10 16784 -8.006526 0.110992 0 0 0.540116 
LGA versus normal brain Down Mark1 9812 -8.005904 0.075285 0 0 0.658508 
LGA versus normal brain Down Armcx1 2471 -8.003801 0.09484 0 0 0.590871 
LGA versus normal brain Down Rab12 13387 -8.002665 0.036382 0 0 0.817247 
LGA versus normal brain Down Txndc11 16932 -8.001486 0.03092 0 0 0.842408 
LGA versus normal brain Down Rspo3 14133 -7.999499 0.092414 0 0 0.599045 
LGA versus normal brain Down Pla2g6 12563 -7.992458 0.049759 0 0 0.759068 
LGA versus normal brain Down 3110057O12Rik 747 -7.981806 0.052172 0 0 0.749278 
LGA versus normal brain Down Alk 2080 -7.979834 0.101562 0 0 0.570205 






LGA versus normal brain Down Kcnab3 8790 -7.975942 0.066732 0 0 0.691474 
LGA versus normal brain Down Hmgcll1 8110 -7.97576 0.06947 0 0 0.681094 
LGA versus normal brain Down Slc6a6 15013 -7.972678 0.086578 0 0 0.619742 
LGA versus normal brain Down Dok3 5436 -7.970527 0.076662 0 0 0.654728 
LGA versus normal brain Down Arhgef15 2412 -7.965539 0.07164 0 0 0.673311 
LGA versus normal brain Down Vdr 17254 -7.965073 0.076199 0 0 0.656591 
LGA versus normal brain Down Numb 11167 -7.95577 0.038525 0 0 0.808603 
LGA versus normal brain Down Btbd2 3188 -7.952137 0.038708 0 0 0.807867 
LGA versus normal brain Down Csnk1g1 4628 -7.950725 0.047093 0 0 0.771415 
LGA versus normal brain Down Trak2 16604 -7.950311 0.058697 0 0 0.723637 
LGA versus normal brain Down Dnajc30 5386 -7.946636 0.032513 0 0 0.836032 
LGA versus normal brain Down Parp6 12075 -7.932859 0.065438 0 0 0.6978 
LGA versus normal brain Down Fam70a 6333 -7.931433 0.061454 0 0 0.713302 
LGA versus normal brain Down Scoc 14325 -7.928258 0.057442 0 0 0.729299 
LGA versus normal brain Down Stx3 15641 -7.92595 0.037855 0 0 0.812232 
LGA versus normal brain Down Igsf3 8432 -7.921636 0.098272 0 0 0.582983 
LGA versus normal brain Down Nfil3 10828 -7.918417 0.091121 0 0 0.606453 
LGA versus normal brain Down Ghitm 6996 -7.917685 0.042597 0 0 0.791539 
LGA versus normal brain Down Rufy2 14160 -7.917259 0.06877 0 0 0.685642 
LGA versus normal brain Down Grb14 7677 -7.911089 0.068803 0 0 0.685721 
LGA versus normal brain Down Klhl8 9023 -7.910227 0.05449 0 0 0.741733 
LGA versus normal brain Down Krt222 9090 -7.909086 0.087352 0 0 0.619477 
LGA versus normal brain Down Lmtk2 9376 -7.905735 0.092117 0 0 0.603634 
LGA versus normal brain Down Zfand5 17773 -7.901581 0.053593 0 0 0.745628 
LGA versus normal brain Down Bean1 3049 -7.899088 0.079047 0 0 0.648691 
LGA versus normal brain Down BC057022 2980 -7.894846 0.066081 0 0 0.696549 
LGA versus normal brain Down Hprt 8205 -7.892334 0.084347 0 0 0.630385 
LGA versus normal brain Down Setd7 14533 -7.89104 0.063674 0 0 0.705906 
LGA versus normal brain Down Cited4 4172 -7.890139 0.078703 0 0 0.650229 






LGA versus normal brain Down Cox5b 4473 -7.888921 0.048712 0 0 0.766157 
LGA versus normal brain Down Plekhm3 12628 -7.884476 0.034963 0 0 0.826071 
LGA versus normal brain Down Snx14 15212 -7.876232 0.038047 0 0 0.812442 
LGA versus normal brain Down Alx3 2105 -7.871299 0.069448 0 0 0.684611 
LGA versus normal brain Down Usp3 17172 -7.870881 0.068572 0 0 0.687902 
LGA versus normal brain Down Palm2 12024 -7.868996 0.106177 0 0 0.560386 
LGA versus normal brain Down BC024659 2937 -7.865209 0.082742 0 0 0.636936 
LGA versus normal brain Down Ttbk2 16822 -7.863768 0.051645 0 0 0.754647 
LGA versus normal brain Down Mfn2 10019 -7.856126 0.08152 0 0 0.64152 
LGA versus normal brain Down Cd47 3790 -7.851425 0.052053 0 0 0.753307 
LGA versus normal brain Down Gabra3 6814 -7.842855 0.070467 0 0 0.681761 
LGA versus normal brain Down Appl1 2335 -7.841077 0.035171 0 0 0.826003 
LGA versus normal brain Down Nipal2 10878 -7.84086 0.076232 0 0 0.660795 
LGA versus normal brain Down Steap2 15579 -7.840394 0.046862 0 0 0.775168 
LGA versus normal brain Down Pclo 12165 -7.839118 0.081997 0 0 0.640474 
LGA versus normal brain Down Yars2 17626 -7.838764 0.02941 0 0 0.852316 
LGA versus normal brain Down Pwp2 13337 -7.837325 0.035059 0 0 0.826583 
LGA versus normal brain Down Ppt2 12942 -7.833046 0.03299 0 0 0.836007 
LGA versus normal brain Down Akap8l 2014 -7.82933 0.066685 0 0 0.696358 
LGA versus normal brain Down ATP6 2658 -7.828071 0.058829 0 0 0.726726 
LGA versus normal brain Down Trim44 16675 -7.825051 0.059427 0 0 0.724461 
LGA versus normal brain Down Dcn 5076 -7.824636 0.120977 0 0 0.518854 
LGA versus normal brain Down Mypop 10564 -7.824142 0.074524 0 0 0.667535 
LGA versus normal brain Down Ankrd29 2191 -7.823321 0.066033 0 0 0.699019 
LGA versus normal brain Down Fam65a 6327 -7.817669 0.080424 0 0 0.646745 
LGA versus normal brain Down Rbp7 13635 -7.809569 0.090518 0 0 0.612631 
LGA versus normal brain Down Amacr 2110 -7.809117 0.036304 0 0 0.821593 
LGA versus normal brain Down Nacad 10600 -7.804731 0.063471 0 0 0.709378 
LGA versus normal brain Down H2-Q1 7861 -7.803826 0.128323 0 0 0.499513 






LGA versus normal brain Down Gpr85 7638 -7.797741 0.077829 0 0 0.656612 
LGA versus normal brain Down Prg4 12983 -7.797418 0.093497 0 0 0.603306 
LGA versus normal brain Down Pak1 12015 -7.794743 0.079214 0 0 0.651821 
LGA versus normal brain Down Col13a1 4374 -7.794171 0.080317 0 0 0.647967 
LGA versus normal brain Down 9630001P10Rik 1372 -7.792267 0.073612 0 0 0.671936 
LGA versus normal brain Down Cnst 4341 -7.78689 0.060622 0 0 0.720938 
LGA versus normal brain Down Wdr59 17479 -7.783472 0.050994 0 0 0.759482 
LGA versus normal brain Down Uso1 17151 -7.77989 0.036243 0 0 0.822471 
LGA versus normal brain Down Cds1 3937 -7.776377 0.08062 0 0 0.647552 
LGA versus normal brain Down Lrrc24 9517 -7.771095 0.069556 0 0 0.687519 
LGA versus normal brain Down Strbp 15624 -7.769865 0.053011 0 0 0.75164 
LGA versus normal brain Down Slc2a5 14884 -7.762938 0.096443 0 0 0.595147 
LGA versus normal brain Down 2310046A06Rik 514 -7.762783 0.065743 0 0 0.702053 
LGA versus normal brain Down Mef2d 9951 -7.762434 0.050411 0 0 0.762436 
LGA versus normal brain Down Supt6h 15690 -7.761858 0.059975 0 0 0.724212 
LGA versus normal brain Down Rnf113a1 13876 -7.759607 0.047276 0 0 0.775479 
LGA versus normal brain Down Chrna2 4119 -7.758547 0.058923 0 0 0.72842 
LGA versus normal brain Down 4921507P07Rik 809 -7.756641 0.06301 0 0 0.712645 
LGA versus normal brain Down Avpi1 2730 -7.75184 0.072529 0 0 0.677252 
LGA versus normal brain Down Acot7 1694 -7.751547 0.08679 0 0 0.627305 
LGA versus normal brain Down Syn3 15734 -7.751366 0.058403 0 0 0.730673 
LGA versus normal brain Down Ryr3 14189 -7.746897 0.05794 0 0 0.732622 
LGA versus normal brain Down Ube2q1 17004 -7.746268 0.037586 0 0 0.817249 
LGA versus normal brain Down Grsf1 7729 -7.743323 0.03961 0 0 0.808482 
LGA versus normal brain Down Ept1 5975 -7.74274 0.029674 0 0 0.852776 
LGA versus normal brain Down March11 9800 -7.74022 0.069001 0 0 0.690599 
LGA versus normal brain Down 2310057M21Rik 523 -7.737921 0.047271 0 0 0.776051 
LGA versus normal brain Down Ccdc92 3659 -7.734166 0.076489 0 0 0.663616 
LGA versus normal brain Down Prkca 13004 -7.733444 0.075115 0 0 0.668547 






LGA versus normal brain Down Cyfip2 4779 -7.729828 0.061019 0 0 0.72113 
LGA versus normal brain Down Npy1r 11033 -7.728783 0.093675 0 0 0.60542 
LGA versus normal brain Down Chmp7 4101 -7.728741 0.030793 0 0 0.847924 
LGA versus normal brain Down Prrt3 13110 -7.726481 0.065821 0 0 0.702921 
LGA versus normal brain Down Shisa9 14652 -7.721198 0.074612 0 0 0.670777 
LGA versus normal brain Down Pnrc1 12708 -7.7093 0.058858 0 0 0.730142 
LGA versus normal brain Down Lrch1 9475 -7.708801 0.068453 0 0 0.693665 
LGA versus normal brain Down Dusp14 5541 -7.707941 0.08896 0 0 0.621706 
LGA versus normal brain Down Slc24a3 14809 -7.706827 0.073838 0 0 0.674057 
LGA versus normal brain Down Gga3 6981 -7.705657 0.060766 0 0 0.722846 
LGA versus normal brain Down Fam3a 6296 -7.704974 0.028079 0 0 0.860742 
LGA versus normal brain Down Klf16 8974 -7.704075 0.058828 0 0 0.730413 
LGA versus normal brain Down Ptprk 13300 -7.700587 0.031618 0 0 0.844706 
LGA versus normal brain Down 5730403B10Rik 1109 -7.699979 0.041307 0 0 0.802146 
LGA versus normal brain Down Aph1c 2294 -7.699456 0.091358 0 0 0.61412 
LGA versus normal brain Down Asb13 2523 -7.698616 0.038899 0 0 0.812553 
LGA versus normal brain Down Cpeb1 4496 -7.696189 0.096605 0 0 0.597292 
LGA versus normal brain Down Nkrf 10900 -7.690044 0.05749 0 0 0.736064 
LGA versus normal brain Down Slc38a2 14939 -7.686994 0.049158 0 0 0.769569 
LGA versus normal brain Down Bbs5 2898 -7.684531 0.068365 0 0 0.694788 
LGA versus normal brain Down Entpd3 5919 -7.680281 0.115565 0 0 0.540522 
LGA versus normal brain Down Dip2c 5277 -7.679495 0.078019 0 0 0.660146 
LGA versus normal brain Down Ngfrap1 10852 -7.675597 0.050531 0 0 0.764263 
LGA versus normal brain Down Mtap1a 10378 -7.675083 0.070456 0 0 0.687411 
LGA versus normal brain Down Dgke 5222 -7.670892 0.075186 0 0 0.670475 
LGA versus normal brain Down Cacna2d1 3362 -7.670146 0.095616 0 0 0.601489 
LGA versus normal brain Down App 2333 -7.667023 0.071926 0 0 0.68233 
LGA versus normal brain Down Tmem64 16391 -7.664168 0.051597 0 0 0.760252 
LGA versus normal brain Down Zbtb7a 17702 -7.655281 0.065756 0 0 0.705452 






LGA versus normal brain Down Zfp523 17933 -7.651687 0.056935 0 0 0.73936 
LGA versus normal brain Down Orai2 11890 -7.64826 0.060664 0 0 0.724986 
LGA versus normal brain Down Rab3gap2 13424 -7.647851 0.051016 0 0 0.763045 
LGA versus normal brain Down Fam110b 6163 -7.637202 0.076009 0 0 0.668735 
LGA versus normal brain Down Farp2 6384 -7.636408 0.050338 0 0 0.766098 
LGA versus normal brain Down Med16 9927 -7.63349 0.0572 0 0 0.738854 
LGA versus normal brain Down Pitpna 12510 -7.6333 0.04748 0 0 0.777854 
LGA versus normal brain Down Nr6a1 11057 -7.632658 0.076898 0 0 0.665757 
LGA versus normal brain Down Ap4s1 2276 -7.631853 0.041762 0 0 0.801779 
LGA versus normal brain Down Fabp3 6130 -7.614589 0.106197 0 0 0.570919 
LGA versus normal brain Down Atp6v1d 2672 -7.614436 0.069542 0 0 0.692783 
LGA versus normal brain Down B230337E12Rik 2787 -7.613838 0.091661 0 0 0.616473 
LGA versus normal brain Down Ttc19 16831 -7.61341 0.060041 0 0 0.728441 
LGA versus normal brain Down Ube2w 17012 -7.608726 0.048268 0 0 0.775256 
LGA versus normal brain Down Epn1 5962 -7.608623 0.058076 0 0 0.736175 
LGA versus normal brain Down Rnf150 13899 -7.603447 0.073228 0 0 0.679814 
LGA versus normal brain Down Smtnl2 15136 -7.591068 0.114613 0 0 0.547134 
LGA versus normal brain Down Scyl3 14341 -7.589163 0.04551 0 0 0.787099 
LGA versus normal brain Down Rheb 13782 -7.587246 0.043527 0 0 0.795397 
LGA versus normal brain Down Ppm1b 12852 -7.586352 0.038195 0 0 0.818039 
LGA versus normal brain Down Tmem85 16405 -7.584679 0.045947 0 0 0.785405 
LGA versus normal brain Down Grin1 7701 -7.58465 0.100166 0 0 0.590611 
LGA versus normal brain Down 2900056M20Rik 711 -7.582341 0.061697 0 0 0.723062 
LGA versus normal brain Down Ttll11 16870 -7.57888 0.090394 0 0 0.62197 
LGA versus normal brain Up Slc2a4 14883 27.42 0.12 0 0 10.46 
LGA versus normal brain Up Rarres1 13534 26.60 0.10 0 0 6.76 
LGA versus normal brain Up Nuf2 11163 26.58 0.12 0 0 8.50 
LGA versus normal brain Up Ckap2 4174 26.57 0.13 0 0 10.52 
LGA versus normal brain Up Pbk 12097 26.36 0.17 0 0 23.40 






LGA versus normal brain Up 1190002F15Rik 87 25.70 0.13 0 0 9.83 
LGA versus normal brain Up Mboat1 9854 25.02 0.10 0 0 6.16 
LGA versus normal brain Up 9630013D21Rik 1375 24.97 0.13 0 0 8.80 
LGA versus normal brain Up Cdkn2c 3928 24.81 0.11 0 0 6.59 
LGA versus normal brain Up Lxn 9615 24.76 0.06 0 0 2.86 
LGA versus normal brain Up Cenpi 3978 24.30 0.14 0 0 9.81 
LGA versus normal brain Up Fignl1 6577 23.91 0.15 0 0 11.54 
LGA versus normal brain Up Kif18a 8920 23.80 0.15 0 0 12.00 
LGA versus normal brain Up Dhfr 5232 23.59 0.11 0 0 5.83 
LGA versus normal brain Up Smc4 15108 23.56 0.08 0 0 3.43 
LGA versus normal brain Up Tcf19 15933 23.55 0.08 0 0 3.76 
LGA versus normal brain Up Esco2 6021 23.51 0.19 0 0 22.17 
LGA versus normal brain Up 2610021K21Rik 598 23.36 0.12 0 0 7.05 
LGA versus normal brain Up Tyms-ps 16951 23.25 0.11 0 0 5.45 
LGA versus normal brain Up Chaf1b 4052 23.03 0.11 0 0 5.85 
LGA versus normal brain Up Aard 1556 23.01 0.08 0 0 3.86 
LGA versus normal brain Up Nde1 10701 23.00 0.06 0 0 2.73 
LGA versus normal brain Up Tyms 16950 22.76 0.08 0 0 3.72 
LGA versus normal brain Up Cks2 4183 22.59 0.12 0 0 6.86 
LGA versus normal brain Up Ckap2l 4175 22.44 0.16 0 0 12.83 
LGA versus normal brain Up Neil3 10775 22.28 0.12 0 0 6.64 
LGA versus normal brain Up Rad51 13469 21.92 0.12 0 0 5.89 
LGA versus normal brain Up Ccdc34 3605 21.86 0.09 0 0 3.82 
LGA versus normal brain Up Sept10 14445 21.85 0.06 0 0 2.66 
LGA versus normal brain Up Hmgb2 8107 21.81 0.11 0 0 5.53 
LGA versus normal brain Up Pipox 12506 21.79 0.07 0 0 2.83 
LGA versus normal brain Up Psph 13215 21.77 0.09 0 0 3.75 
LGA versus normal brain Up Uhrf1 17083 21.77 0.15 0 0 9.84 
LGA versus normal brain Up Pcna 12170 21.74 0.09 0 0 3.92 






LGA versus normal brain Up Cklf 4179 21.72 0.08 0 0 3.50 
LGA versus normal brain Up Birc5 3083 21.58 0.12 0 0 6.10 
LGA versus normal brain Up Zfp367 17877 21.36 0.08 0 0 3.13 
LGA versus normal brain Up Ccnb1 3689 21.31 0.14 0 0 8.45 
LGA versus normal brain Up Spc25 15330 21.26 0.16 0 0 9.99 
LGA versus normal brain Up Ect2 5689 21.21 0.13 0 0 7.25 
LGA versus normal brain Up Zwilch 18207 21.17 0.09 0 0 3.73 
LGA versus normal brain Up Cenpk 3980 21.13 0.14 0 0 7.72 
LGA versus normal brain Up Rpa2 13978 21.11 0.07 0 0 2.71 
LGA versus normal brain Up Spink2 15369 21.04 0.16 0 0 9.61 
LGA versus normal brain Up Nedd1 10765 20.90 0.07 0 0 2.64 
LGA versus normal brain Up Kif23 8930 20.87 0.06 0 0 2.26 
LGA versus normal brain Up Ccnb2 3691 20.84 0.08 0 0 3.00 
LGA versus normal brain Up Gins1 7010 20.83 0.12 0 0 5.31 
LGA versus normal brain Up Aurkb 2722 20.80 0.17 0 0 12.23 
LGA versus normal brain Up Rbl1 13591 20.61 0.10 0 0 4.35 
LGA versus normal brain Up 2810442I21Rik 687 20.61 0.09 0 0 3.48 
LGA versus normal brain Up Casc5 3482 20.60 0.16 0 0 9.57 
LGA versus normal brain Up Fam64a 6326 20.55 0.10 0 0 4.16 
LGA versus normal brain Up Cep55 4000 20.46 0.12 0 0 5.65 
LGA versus normal brain Up Gas2l3 6880 20.40 0.10 0 0 4.13 
LGA versus normal brain Up Chek1 4074 20.40 0.16 0 0 9.78 
LGA versus normal brain Up Gja1 7021 20.38 0.08 0 0 2.89 
LGA versus normal brain Up Cenph 3977 20.31 0.12 0 0 5.49 
LGA versus normal brain Up Myb 10480 20.31 0.10 0 0 4.28 
LGA versus normal brain Up Cdc20 3830 20.26 0.09 0 0 3.61 
LGA versus normal brain Up Nusap1 11194 20.05 0.13 0 0 6.29 
LGA versus normal brain Up Lrrc56 9542 19.97 0.10 0 0 4.18 
LGA versus normal brain Up Fam111a 6165 19.95 0.12 0 0 4.97 






LGA versus normal brain Up Ncapg 10666 19.83 0.14 0 0 7.15 
LGA versus normal brain Up Tpx2 16586 19.82 0.11 0 0 4.42 
LGA versus normal brain Up Cdca8 3863 19.77 0.10 0 0 3.77 
LGA versus normal brain Up Hells 7984 19.75 0.11 0 0 4.32 
LGA versus normal brain Up D930014E17Rik 4986 19.71 0.05 0 0 2.05 
LGA versus normal brain Up Top2a 16539 19.66 0.11 0 0 4.47 
LGA versus normal brain Up Tacc3 15790 19.61 0.11 0 0 4.27 
LGA versus normal brain Up Mcm6 9882 19.61 0.13 0 0 5.76 
LGA versus normal brain Up Mns1 10157 19.45 0.13 0 0 6.15 
LGA versus normal brain Up Mxd3 10473 19.42 0.11 0 0 4.28 
LGA versus normal brain Up E2f7 5637 19.38 0.11 0 0 4.66 
LGA versus normal brain Up Plch1 12588 19.33 0.11 0 0 4.52 
LGA versus normal brain Up Melk 9965 19.26 0.13 0 0 6.06 
LGA versus normal brain Up Ascl1 2537 19.19 0.10 0 0 3.57 
LGA versus normal brain Up Kif4 8940 19.16 0.13 0 0 5.29 
LGA versus normal brain Up Rad51l1 13472 19.14 0.09 0 0 3.46 
LGA versus normal brain Up Nek2 10778 19.14 0.14 0 0 6.13 
LGA versus normal brain Up Rad54l 13476 19.13 0.11 0 0 4.15 
LGA versus normal brain Up Fam47e 6305 19.13 0.13 0 0 5.93 
LGA versus normal brain Up Aif1l 1980 19.12 0.09 0 0 3.26 
LGA versus normal brain Up E130303B06Rik 5610 19.11 0.04 0 0 1.81 
LGA versus normal brain Up Gins2 7011 18.99 0.11 0 0 4.41 
LGA versus normal brain Up Kntc1 9061 18.98 0.11 0 0 4.27 
LGA versus normal brain Up Mis18bp1 10083 18.92 0.09 0 0 3.41 
LGA versus normal brain Up Ncapg2 10667 18.92 0.12 0 0 4.63 
LGA versus normal brain Up Ccna2 3688 18.91 0.13 0 0 5.79 
LGA versus normal brain Up Gmnn 7450 18.80 0.10 0 0 3.77 
LGA versus normal brain Up Tuba1c 16889 18.69 0.07 0 0 2.37 
LGA versus normal brain Up Atad2 2569 18.67 0.11 0 0 3.91 






LGA versus normal brain Up Ucma 17058 18.65 0.12 0 0 4.62 
LGA versus normal brain Up Hn1l 8128 18.64 0.09 0 0 3.05 
LGA versus normal brain Up Kif20b 8926 18.63 0.13 0 0 5.11 
LGA versus normal brain Up Dsn1 5510 18.59 0.10 0 0 3.57 
LGA versus normal brain Up Ezh2 6102 18.56 0.11 0 0 4.20 
LGA versus normal brain Up Rrm1 14103 18.55 0.08 0 0 2.92 
LGA versus normal brain Up Cenpf 3976 18.54 0.14 0 0 5.94 
LGA versus normal brain Up Hmmr 8121 18.53 0.11 0 0 3.92 
LGA versus normal brain Up Tipin 16156 18.49 0.09 0 0 3.27 
LGA versus normal brain Up Shcbp1 14641 18.44 0.14 0 0 6.05 
LGA versus normal brain Up Prim2 12990 18.43 0.08 0 0 2.82 
LGA versus normal brain Up Hist1h2aa 8056 18.42 0.09 0 0 3.22 
LGA versus normal brain Up Fbxo5 6460 18.40 0.08 0 0 2.91 
LGA versus normal brain Up Fanci 6376 18.40 0.13 0 0 5.45 
LGA versus normal brain Up Kpna2 9063 18.36 0.07 0 0 2.44 
LGA versus normal brain Up Sgol1 14586 18.34 0.09 0 0 3.02 
LGA versus normal brain Up Hist1h2af 8060 18.32 0.13 0 0 4.90 
LGA versus normal brain Up Kif20a 8925 18.32 0.12 0 0 4.84 
LGA versus normal brain Up Sgol2 14587 18.30 0.13 0 0 5.18 
LGA versus normal brain Up Racgap1 13461 18.21 0.10 0 0 3.44 
LGA versus normal brain Up Depdc1b 5199 18.19 0.13 0 0 5.47 
LGA versus normal brain Up Mcm4 9880 18.15 0.12 0 0 4.72 
LGA versus normal brain Up Prdx4 12969 18.14 0.07 0 0 2.46 
LGA versus normal brain Up Tcf7l2 15941 18.14 0.07 0 0 2.32 
LGA versus normal brain Up Prim1 12989 18.13 0.09 0 0 3.00 
LGA versus normal brain Up Mcm7 9883 18.07 0.09 0 0 3.00 
LGA versus normal brain Up Cks1b 4182 18.03 0.11 0 0 3.93 
LGA versus normal brain Up Echdc2 5679 18.01 0.08 0 0 2.72 
LGA versus normal brain Up Brip1 3161 17.96 0.11 0 0 3.78 






LGA versus normal brain Up Tmem98 16420 17.91 0.07 0 0 2.26 
LGA versus normal brain Up Kif14 8916 17.90 0.09 0 0 3.14 
LGA versus normal brain Up Pole3 12733 17.90 0.05 0 0 1.75 
LGA versus normal brain Up Aurka 2720 17.89 0.07 0 0 2.41 
LGA versus normal brain Up Hist1h2ai 8061 17.87 0.15 0 0 6.36 
LGA versus normal brain Up Foxj1 6674 17.87 0.07 0 0 2.30 
LGA versus normal brain Up Stx2 15640 17.87 0.05 0 0 1.97 
LGA versus normal brain Up Pkmyt1 12537 17.85 0.07 0 0 2.30 
LGA versus normal brain Up Exo1 6067 17.81 0.16 0 0 7.62 
LGA versus normal brain Up Psmc3ip 13186 17.73 0.08 0 0 2.70 
LGA versus normal brain Up Cdc6 3854 17.73 0.13 0 0 4.78 
LGA versus normal brain Up Clspn 4269 17.68 0.14 0 0 5.63 
LGA versus normal brain Up Plk1 12638 17.66 0.09 0 0 3.02 
LGA versus normal brain Up Nek5 10781 17.61 0.14 0 0 5.70 
LGA versus normal brain Up Rfc4 13718 17.59 0.09 0 0 3.00 
LGA versus normal brain Up Bmper 3110 17.59 0.09 0 0 2.89 
LGA versus normal brain Up Slbp 14726 17.58 0.08 0 0 2.58 
LGA versus normal brain Up Ska1 14706 17.57 0.14 0 0 5.80 
LGA versus normal brain Up Carhsp1 3472 17.55 0.06 0 0 2.15 
LGA versus normal brain Up Mamdc2 9719 17.54 0.13 0 0 4.81 
LGA versus normal brain Up Fancb 6370 17.51 0.07 0 0 2.22 
LGA versus normal brain Up Asf1b 2541 17.49 0.08 0 0 2.56 
LGA versus normal brain Up Cdt1 3940 17.48 0.14 0 0 5.56 
LGA versus normal brain Up Psrc1 13217 17.40 0.13 0 0 5.07 
LGA versus normal brain Up Gsg2 7743 17.35 0.12 0 0 4.00 
LGA versus normal brain Up Pmp22 12679 17.34 0.08 0 0 2.61 
LGA versus normal brain Up Cd9 3817 17.33 0.12 0 0 4.06 
LGA versus normal brain Up Sox9 15284 17.33 0.08 0 0 2.54 
LGA versus normal brain Up Cdca5 3860 17.32 0.10 0 0 3.31 






LGA versus normal brain Up Mcm2 9877 17.27 0.16 0 0 6.88 
LGA versus normal brain Up Rfc5 13719 17.27 0.08 0 0 2.52 
LGA versus normal brain Up Nfia 10825 17.26 0.06 0 0 1.97 
LGA versus normal brain Up Cenpl 3981 17.23 0.09 0 0 3.10 
LGA versus normal brain Up Cenpp 3985 17.20 0.08 0 0 2.57 
LGA versus normal brain Up Gdpd2 6954 17.19 0.10 0 0 3.36 
LGA versus normal brain Up Mtbp 10389 17.18 0.08 0 0 2.58 
LGA versus normal brain Up Cdca2 3857 17.15 0.10 0 0 3.14 
LGA versus normal brain Up Dek 5182 17.15 0.08 0 0 2.44 
LGA versus normal brain Up Cenpm 3982 17.14 0.09 0 0 2.99 
LGA versus normal brain Up Bub1 3206 17.10 0.10 0 0 3.11 
LGA versus normal brain Up Topbp1 16543 17.10 0.11 0 0 3.65 
LGA versus normal brain Up Ift80 8396 17.07 0.04 0 0 1.52 
LGA versus normal brain Up Fanca 6369 17.06 0.09 0 0 2.89 
LGA versus normal brain Up Cdc45 3852 17.03 0.12 0 0 3.96 
LGA versus normal brain Up Trim59 16683 17.01 0.07 0 0 2.31 
LGA versus normal brain Up Mcm5 9881 17.01 0.08 0 0 2.61 
LGA versus normal brain Up Pask 12082 16.99 0.10 0 0 3.40 
LGA versus normal brain Up Arl4c 2450 16.94 0.07 0 0 2.39 
LGA versus normal brain Up 2810417H13Rik 678 16.94 0.12 0 0 4.19 
LGA versus normal brain Up Mki67 10087 16.93 0.16 0 0 6.42 
LGA versus normal brain Up Kif11 8912 16.93 0.08 0 0 2.70 
LGA versus normal brain Up Mlf1ip 10103 16.92 0.09 0 0 2.92 
LGA versus normal brain Up 2610020H08Rik 596 16.90 0.09 0 0 2.84 
LGA versus normal brain Up Mcm3 9878 16.87 0.12 0 0 3.94 
LGA versus normal brain Up Emp1 5885 16.82 0.09 0 0 2.89 
LGA versus normal brain Up Trip13 16702 16.80 0.11 0 0 3.74 
LGA versus normal brain Up E2f8 5638 16.79 0.13 0 0 4.31 
LGA versus normal brain Up 2010317E24Rik 433 16.78 0.16 0 0 6.67 






LGA versus normal brain Up Mms22l 10153 16.77 0.12 0 0 4.09 
LGA versus normal brain Up Ptplad2 13272 16.77 0.06 0 0 2.07 
LGA versus normal brain Up Phf19 12393 16.76 0.12 0 0 3.99 
LGA versus normal brain Up Tmpo 16429 16.74 0.08 0 0 2.46 
LGA versus normal brain Up Fam54a 6313 16.73 0.13 0 0 4.30 
LGA versus normal brain Up Rab13 13388 16.73 0.09 0 0 2.97 
LGA versus normal brain Up Zfp503 17922 16.73 0.13 0 0 4.77 
LGA versus normal brain Up Tk1 16163 16.71 0.11 0 0 3.66 
LGA versus normal brain Up Rpa1 13977 16.69 0.07 0 0 2.36 
LGA versus normal brain Up Pole2 12732 16.66 0.12 0 0 4.03 
LGA versus normal brain Up Aspm 2556 16.64 0.13 0 0 4.24 
LGA versus normal brain Up Icosl 8330 16.63 0.10 0 0 3.11 
LGA versus normal brain Up Rnaseh2b 13862 16.63 0.08 0 0 2.39 
LGA versus normal brain Up Gemin8 6962 16.62 0.06 0 0 2.01 
LGA versus normal brain Up Armc3 2465 16.61 0.16 0 0 6.61 
LGA versus normal brain Up Cdca3 3858 16.58 0.11 0 0 3.66 
LGA versus normal brain Up Acot1 1686 16.53 0.13 0 0 4.52 
LGA versus normal brain Up Naprt1 10633 16.52 0.08 0 0 2.39 
LGA versus normal brain Up Ddit4l 5110 16.50 0.10 0 0 3.27 
LGA versus normal brain Up E130306D19Rik 5613 16.47 0.10 0 0 3.15 
LGA versus normal brain Up Rbbp8 13583 16.46 0.06 0 0 2.05 
LGA versus normal brain Up Cep57l1 4002 16.45 0.04 0 0 1.50 
LGA versus normal brain Up Phgdh 12405 16.40 0.05 0 0 1.86 
LGA versus normal brain Up Iqcg 8606 16.39 0.13 0 0 4.21 
LGA versus normal brain Up H2afv 7874 16.38 0.08 0 0 2.61 
LGA versus normal brain Up Ccdc46 3614 16.37 0.06 0 0 2.05 
LGA versus normal brain Up Katnal2 8771 16.37 0.10 0 0 3.08 
LGA versus normal brain Up Brca2 3146 16.35 0.07 0 0 2.29 
LGA versus normal brain Up C330027C09Rik 3305 16.34 0.11 0 0 3.59 






LGA versus normal brain Up 4930422G04Rik 841 16.33 0.07 0 0 2.23 
LGA versus normal brain Up Plk4 12642 16.30 0.13 0 0 4.14 
LGA versus normal brain Up Ccne2 3698 16.25 0.11 0 0 3.39 
LGA versus normal brain Up Itgb3bp 8688 16.23 0.07 0 0 2.25 
LGA versus normal brain Up Prkcdbp 13008 16.22 0.05 0 0 1.77 
LGA versus normal brain Up Troap 16721 16.21 0.08 0 0 2.47 
LGA versus normal brain Up Pold1 12725 16.18 0.08 0 0 2.49 
LGA versus normal brain Up Cdca7 3861 16.15 0.10 0 0 3.06 
LGA versus normal brain Up Lig1 9311 16.14 0.08 0 0 2.40 
LGA versus normal brain Up Mcm10 9876 16.12 0.13 0 0 4.18 
LGA versus normal brain Up Smc2 15106 16.11 0.10 0 0 3.14 
LGA versus normal brain Up Nek8 10784 16.11 0.08 0 0 2.53 
LGA versus normal brain Up Oat 11220 16.08 0.05 0 0 1.78 
LGA versus normal brain Up Depdc1a 5198 16.07 0.15 0 0 5.41 
LGA versus normal brain Up Soat1 15236 16.07 0.07 0 0 2.11 
LGA versus normal brain Up Oip5 11258 16.03 0.10 0 0 2.97 
LGA versus normal brain Up Dut 5558 16.02 0.07 0 0 2.06 
LGA versus normal brain Up BC055324 2978 16.02 0.11 0 0 3.39 
LGA versus normal brain Up Chek2 4075 15.99 0.09 0 0 2.83 
LGA versus normal brain Up Cenpe 3975 15.99 0.14 0 0 4.79 
LGA versus normal brain Up Zfp36l1 17879 15.98 0.08 0 0 2.41 
LGA versus normal brain Up Haus4 7913 15.96 0.09 0 0 2.84 
LGA versus normal brain Up Cntln 4345 15.96 0.07 0 0 2.14 
LGA versus normal brain Up Syce2 15724 15.96 0.08 0 0 2.48 
LGA versus normal brain Up Rfc2 13716 15.95 0.05 0 0 1.74 
LGA versus normal brain Up Hist1h1b 8051 15.94 0.17 0 0 6.73 
LGA versus normal brain Up Hc 7932 15.92 0.10 0 0 3.10 
LGA versus normal brain Up C730049O14Rik 3329 15.89 0.07 0 0 2.24 
LGA versus normal brain Up Cd109 3737 15.88 0.10 0 0 3.03 






LGA versus normal brain Up Kif22 8929 15.86 0.09 0 0 2.75 
LGA versus normal brain Up Ube2c 16983 15.85 0.11 0 0 3.32 
LGA versus normal brain Up Col9a3 4409 15.79 0.09 0 0 2.77 
LGA versus normal brain Up Fbln7 6409 15.77 0.10 0 0 2.94 
LGA versus normal brain Up Fam33a 6291 15.76 0.06 0 0 1.89 
LGA versus normal brain Up Stil 15583 15.73 0.08 0 0 2.48 
LGA versus normal brain Up Rad51ap1 13470 15.73 0.12 0 0 3.90 
LGA versus normal brain Up D330028D13Rik 4932 15.71 0.09 0 0 2.67 
LGA versus normal brain Up Slc43a1 14965 15.68 0.11 0 0 3.33 
LGA versus normal brain Up Rarres2 13535 15.68 0.11 0 0 3.21 
LGA versus normal brain Up Gen1 6963 15.68 0.08 0 0 2.28 
LGA versus normal brain Up Cenpn 3983 15.68 0.10 0 0 2.88 
LGA versus normal brain Up Hist2h2ac 8077 15.64 0.09 0 0 2.75 
LGA versus normal brain Up Pole 12731 15.63 0.10 0 0 3.00 
LGA versus normal brain Up Ropn1l 13968 15.63 0.09 0 0 2.66 
LGA versus normal brain Up Spc24 15329 15.62 0.14 0 0 4.46 
LGA versus normal brain Up Haus1 7910 15.59 0.06 0 0 1.90 
LGA versus normal brain Up Plin3 12635 15.49 0.05 0 0 1.74 
LGA versus normal brain Up Kif15 8917 15.48 0.12 0 0 3.73 
LGA versus normal brain Up Nsmce1 11094 15.48 0.05 0 0 1.69 
LGA versus normal brain Up Dscc1 5501 15.43 0.11 0 0 3.11 
LGA versus normal brain Up Cenpq 3986 15.40 0.12 0 0 3.42 
LGA versus normal brain Up Kifc1 8948 15.33 0.13 0 0 3.94 
LGA versus normal brain Up Thbs4 16094 15.32 0.12 0 0 3.47 
LGA versus normal brain Up Galnt10 6845 15.30 0.06 0 0 1.99 
LGA versus normal brain Up Dapp1 5026 15.28 0.12 0 0 3.57 
LGA versus normal brain Up Dnali1 5397 15.27 0.12 0 0 3.71 
LGA versus normal brain Up Spata6 15322 15.25 0.07 0 0 2.04 
LGA versus normal brain Up Mad2l1 9677 15.25 0.12 0 0 3.45 






LGA versus normal brain Up Tspan6 16799 15.22 0.06 0 0 1.95 
LGA versus normal brain Up 4930547N16Rik 948 15.21 0.11 0 0 3.30 
LGA versus normal brain Up Itgb5 8690 15.17 0.07 0 0 2.06 
LGA versus normal brain Up Athl1 2602 15.17 0.08 0 0 2.31 
LGA versus normal brain Up 4632434I11Rik 776 15.15 0.14 0 0 4.56 
LGA versus normal brain Up Nsl1 11092 15.14 0.10 0 0 2.74 
LGA versus normal brain Up Gtse1 7808 15.12 0.10 0 0 2.97 
LGA versus normal brain Up Gemin6 6960 15.12 0.07 0 0 2.09 
LGA versus normal brain Up Gm8096 7398 15.11 0.07 0 0 2.02 
LGA versus normal brain Up Timeless 16137 15.07 0.11 0 0 3.02 
LGA versus normal brain Up Ncaph 10668 15.02 0.15 0 0 4.61 
LGA versus normal brain Up Mybl1 10482 14.99 0.12 0 0 3.39 
LGA versus normal brain Up BC048355 2962 14.98 0.10 0 0 2.84 
LGA versus normal brain Up 6720463M24Rik 1227 14.96 0.09 0 0 2.66 
LGA versus normal brain Up Tmem47 16372 14.95 0.06 0 0 1.80 
LGA versus normal brain Up Lhpp 9301 14.94 0.04 0 0 1.58 
LGA versus normal brain Up Kif18b 8921 14.92 0.13 0 0 3.90 
LGA versus normal brain Up Ccdc99 3664 14.89 0.09 0 0 2.60 
LGA versus normal brain Up Gbp2 6905 14.89 0.11 0 0 3.10 
LGA versus normal brain Up Gins4 7013 14.85 0.04 0 0 1.53 
LGA versus normal brain Up Twsg1 16925 14.83 0.03 0 0 1.41 
LGA versus normal brain Up Hmgn2 8115 14.83 0.09 0 0 2.60 
LGA versus normal brain Up Tonsl 16536 14.82 0.08 0 0 2.19 
LGA versus normal brain Up Trim30a 16664 14.79 0.15 0 0 4.59 
LGA versus normal brain Up Kif2c 8936 14.79 0.10 0 0 2.83 
LGA versus normal brain Up Col4a4 4394 14.77 0.08 0 0 2.28 
LGA versus normal brain Up Casp7 3494 14.76 0.09 0 0 2.45 
LGA versus normal brain Up Cchcr1 3665 14.74 0.07 0 0 2.14 
LGA versus normal brain Up 4933404M02Rik 1019 14.74 0.08 0 0 2.16 






LGA versus normal brain Up Gtf3c5 7797 14.73 0.04 0 0 1.52 
LGA versus normal brain Up Cenpj 3979 14.73 0.09 0 0 2.52 
LGA versus normal brain Up Lair1 9161 14.68 0.05 0 0 1.71 
LGA versus normal brain Up 1700040L02Rik 290 14.67 0.08 0 0 2.33 
LGA versus normal brain Up Ptma 13262 14.67 0.05 0 0 1.71 
LGA versus normal brain Up Arhgap11a 2377 14.64 0.12 0 0 3.40 
LGA versus normal brain Up Pola1 12722 14.61 0.12 0 0 3.39 
LGA versus normal brain Up Ung 17113 14.61 0.10 0 0 2.78 
LGA versus normal brain Up Ccdc96 3662 14.60 0.08 0 0 2.21 
LGA versus normal brain Up Lrr1 9505 14.60 0.16 0 0 4.91 
LGA versus normal brain Up Ptgr1 13250 14.59 0.07 0 0 2.00 
LGA versus normal brain Up H2afx 7875 14.57 0.10 0 0 2.63 
LGA versus normal brain Up Gas1 6877 14.55 0.09 0 0 2.39 
LGA versus normal brain Up Eda2r 5691 14.55 0.12 0 0 3.33 
LGA versus normal brain Up Ccdc138 3578 14.54 0.05 0 0 1.73 
LGA versus normal brain Up Ppil6 12847 14.52 0.09 0 0 2.53 
LGA versus normal brain Up Dtymk 5526 14.52 0.07 0 0 2.08 
LGA versus normal brain Up 2810408B13Rik 673 14.50 0.08 0 0 2.17 
LGA versus normal brain Up Bcl2l12 3024 14.50 0.08 0 0 2.21 
LGA versus normal brain Up Cenpa 3972 14.46 0.08 0 0 2.29 
LGA versus normal brain Up D17H6S56E-5 4903 14.45 0.11 0 0 3.09 
LGA versus normal brain Up Spag5 15304 14.44 0.14 0 0 3.97 
LGA versus normal brain Up Mastl 9828 14.43 0.10 0 0 2.60 
LGA versus normal brain Up Emp2 5886 14.42 0.10 0 0 2.84 
LGA versus normal brain Up Ccdc61 3627 14.41 0.07 0 0 1.92 
LGA versus normal brain Up Pycard 13346 14.38 0.12 0 0 3.38 
LGA versus normal brain Up Efhb 5730 14.34 0.17 0 0 5.18 
LGA versus normal brain Up Ttk 16866 14.33 0.12 0 0 3.23 
LGA versus normal brain Up Tead2 15986 14.33 0.08 0 0 2.27 






LGA versus normal brain Up 2700094K13Rik 643 14.31 0.09 0 0 2.35 
LGA versus normal brain Up Pon3 12780 14.29 0.10 0 0 2.72 
LGA versus normal brain Up Plk1s1 12639 14.20 0.04 0 0 1.53 
LGA versus normal brain Up E2f1 5631 14.17 0.08 0 0 2.30 
LGA versus normal brain Up D2Ertd750e 4927 14.16 0.11 0 0 2.82 
LGA versus normal brain Up Trim30d 16666 14.15 0.15 0 0 4.29 
LGA versus normal brain Up Cenpw 3989 14.14 0.10 0 0 2.70 
LGA versus normal brain Up G2e3 6793 14.14 0.08 0 0 2.09 
LGA versus normal brain Up 1110034A24Rik 64 14.12 0.06 0 0 1.80 
LGA versus normal brain Up Gli3 7052 14.12 0.05 0 0 1.56 
LGA versus normal brain Up Dtl 5516 14.09 0.12 0 0 3.18 
LGA versus normal brain Up 2610039C10Rik 612 14.04 0.08 0 0 2.20 
LGA versus normal brain Up F630043A04Rik 6117 14.03 0.09 0 0 2.39 
LGA versus normal brain Up Gjc1 7032 14.02 0.07 0 0 2.04 
LGA versus normal brain Up Lin9 9334 14.01 0.06 0 0 1.82 
LGA versus normal brain Up Chtf18 4145 13.99 0.08 0 0 2.24 
LGA versus normal brain Up Ugp2 17073 13.98 0.05 0 0 1.56 
LGA versus normal brain Up Cenpo 3984 13.97 0.07 0 0 1.91 
LGA versus normal brain Up Hist1h2ab 8057 13.97 0.15 0 0 4.20 
LGA versus normal brain Up Eri1 6002 13.96 0.06 0 0 1.83 
LGA versus normal brain Up Lpar4 9456 13.96 0.08 0 0 2.21 
LGA versus normal brain Up Lrdd 9479 13.92 0.06 0 0 1.82 
LGA versus normal brain Up Mlf1 10102 13.92 0.16 0 0 4.66 
LGA versus normal brain Up Trim56 16682 13.89 0.08 0 0 2.20 
LGA versus normal brain Up Armc2 2464 13.88 0.10 0 0 2.52 
LGA versus normal brain Up Idh2 8338 13.86 0.06 0 0 1.86 
LGA versus normal brain Up Gpx7 7666 13.83 0.09 0 0 2.41 
LGA versus normal brain Up Phkg1 12410 13.79 0.09 0 0 2.36 
LGA versus normal brain Up Akr1c19 2029 13.77 0.07 0 0 2.01 






LGA versus normal brain Up Wdhd1 17441 13.74 0.10 0 0 2.53 
LGA versus normal brain Up Hacl1 7889 13.72 0.07 0 0 1.88 
LGA versus normal brain Up Cyp39a1 4827 13.68 0.14 0 0 3.89 
LGA versus normal brain Up Olfml2b 11265 13.68 0.08 0 0 2.06 
LGA versus normal brain Up Rbm43 13617 13.67 0.05 0 0 1.56 
LGA versus normal brain Up Igsf10 8429 13.67 0.12 0 0 3.04 
LGA versus normal brain Up Foxm1 6680 13.65 0.12 0 0 3.04 
LGA versus normal brain Up Haus8 7917 13.65 0.08 0 0 2.03 
LGA versus normal brain Up Gna13 7458 13.65 0.08 0 0 2.08 
LGA versus normal brain Up Mad2l2 9679 13.64 0.07 0 0 1.87 
LGA versus normal brain Up Nfe2l2 10823 13.61 0.06 0 0 1.72 
LGA versus normal brain Up Alg14 2073 13.60 0.05 0 0 1.54 
LGA versus normal brain Up Arhgef26 2419 13.57 0.05 0 0 1.62 
LGA versus normal brain Up Ube2t 17009 13.55 0.08 0 0 2.14 
LGA versus normal brain Up Spin4 15367 13.55 0.11 0 0 2.90 
LGA versus normal brain Up Skp2 14716 13.54 0.07 0 0 1.91 
LGA versus normal brain Up Fam167a 6231 13.53 0.11 0 0 2.79 
LGA versus normal brain Up Iqgap3 8611 13.53 0.11 0 0 2.74 
LGA versus normal brain Up 6720489N17Rik 1232 13.52 0.05 0 0 1.65 
LGA versus normal brain Up Zfp185 17812 13.51 0.07 0 0 2.01 
LGA versus normal brain Up Tspo 16803 13.51 0.06 0 0 1.68 
LGA versus normal brain Up Pmf1 12674 13.48 0.06 0 0 1.81 
LGA versus normal brain Up Ruvbl2 14172 13.46 0.03 0 0 1.35 
LGA versus normal brain Up Zfp41 17894 13.45 0.07 0 0 1.93 
LGA versus normal brain Up Ccdc153 3587 13.44 0.23 0 0 8.72 
LGA versus normal brain Up Capsl 3447 13.44 0.14 0 0 3.59 
LGA versus normal brain Up Cox6b2 4476 13.43 0.09 0 0 2.29 
LGA versus normal brain Up BC051019 2970 13.43 0.11 0 0 2.78 
LGA versus normal brain Up Slc43a3 14967 13.40 0.11 0 0 2.67 






LGA versus normal brain Up Ccdc111 3558 13.38 0.08 0 0 2.06 
LGA versus normal brain Up Wdr16 17447 13.37 0.10 0 0 2.53 
LGA versus normal brain Up Olfml1 11264 13.36 0.08 0 0 2.19 
LGA versus normal brain Up Egfr 5755 13.35 0.10 0 0 2.63 
LGA versus normal brain Up Vrk1 17392 13.34 0.07 0 0 1.90 
LGA versus normal brain Up Bub1b 3207 13.33 0.10 0 0 2.45 
LGA versus normal brain Up Dnajb13 5358 13.32 0.12 0 0 3.15 
LGA versus normal brain Up Cdc25b 3833 13.32 0.05 0 0 1.62 
LGA versus normal brain Up Nt5dc2 11108 13.28 0.11 0 0 2.87 
LGA versus normal brain Up Slc25a10 14814 13.28 0.04 0 0 1.46 
LGA versus normal brain Up 1700029F09Rik 267 13.28 0.07 0 0 1.93 
LGA versus normal brain Up Chic2 4084 13.28 0.05 0 0 1.64 
LGA versus normal brain Up Vim 17267 13.27 0.11 0 0 2.73 
LGA versus normal brain Up Frem2 6705 13.26 0.11 0 0 2.70 
LGA versus normal brain Up Cxcr4 4752 13.25 0.07 0 0 1.90 
LGA versus normal brain Up Prdx6 12971 13.22 0.06 0 0 1.66 
LGA versus normal brain Up Ssr3 15501 13.19 0.04 0 0 1.41 
LGA versus normal brain Up 2810055G20Rik 667 13.15 0.05 0 0 1.59 
LGA versus normal brain Up Tmed10 16223 13.14 0.04 0 0 1.49 
LGA versus normal brain Up Lmnb1 9367 13.12 0.15 0 0 4.02 
LGA versus normal brain Up Haus3 7912 13.09 0.10 0 0 2.54 
LGA versus normal brain Up Cdk2 3900 13.07 0.11 0 0 2.78 
LGA versus normal brain Up Cdk5rap2 3910 13.02 0.07 0 0 1.87 
LGA versus normal brain Up 4932438H23Rik 1009 13.01 0.09 0 0 2.24 
LGA versus normal brain Up Vwa5a 17409 13.00 0.07 0 0 1.80 
LGA versus normal brain Up Gng5 7486 13.00 0.07 0 0 1.93 
LGA versus normal brain Up Lmf2 9364 13.00 0.06 0 0 1.74 
LGA versus normal brain Up Cd63 3800 12.99 0.05 0 0 1.56 
LGA versus normal brain Up Zfp936 18085 12.99 0.07 0 0 1.84 






LGA versus normal brain Up 4933436C20Rik 1059 12.97 0.12 0 0 2.95 
LGA versus normal brain Up Hist1h2bp 8068 12.97 0.11 0 0 2.73 
LGA versus normal brain Up Enkur 5899 12.96 0.14 0 0 3.43 
LGA versus normal brain Up Zfp934 18083 12.96 0.04 0 0 1.45 
LGA versus normal brain Up Ctf1 4670 12.93 0.06 0 0 1.69 
LGA versus normal brain Up Haus7 7916 12.91 0.08 0 0 2.05 
LGA versus normal brain Up Fads2 6136 12.88 0.08 0 0 2.09 
LGA versus normal brain Up Fen1 6507 12.87 0.08 0 0 1.98 
LGA versus normal brain Up Cbs 3528 12.86 0.05 0 0 1.63 
LGA versus normal brain Up Fam100b 6148 12.86 0.06 0 0 1.78 
LGA versus normal brain Up Ccna1 3687 12.85 0.09 0 0 2.27 
LGA versus normal brain Up 2310015B20Rik 488 12.84 0.16 0 0 4.10 
LGA versus normal brain Up Prdx6b 12972 12.82 0.07 0 0 1.87 
LGA versus normal brain Up Rcbtb2 13647 12.80 0.04 0 0 1.45 
LGA versus normal brain Up Rnf125 13883 12.78 0.06 0 0 1.77 
LGA versus normal brain Up Serpinh1 14513 12.78 0.08 0 0 2.10 
LGA versus normal brain Up Scml2 14309 12.76 0.12 0 0 2.82 
LGA versus normal brain Up Asrgl1 2560 12.75 0.05 0 0 1.60 
LGA versus normal brain Up Ednrb 5705 12.75 0.07 0 0 1.89 
LGA versus normal brain Up Retsat 13708 12.74 0.08 0 0 1.99 
LGA versus normal brain Up P2ry1 11976 12.74 0.11 0 0 2.53 
LGA versus normal brain Up 4833427G06Rik 801 12.73 0.23 0 0 7.41 
LGA versus normal brain Up Rtkn2 14145 12.72 0.07 0 0 1.85 
LGA versus normal brain Up Limd1 9320 12.72 0.06 0 0 1.63 
LGA versus normal brain Up Ak7 2000 12.70 0.24 0 0 8.55 
LGA versus normal brain Up Sox6 15281 12.69 0.09 0 0 2.15 
LGA versus normal brain Up Tnc 16453 12.69 0.07 0 0 1.82 
LGA versus normal brain Up Fkbp10 6585 12.69 0.06 0 0 1.72 
LGA versus normal brain Up Acat3 1660 12.67 0.06 0 0 1.65 






LGA versus normal brain Up Akr1c12 2026 12.67 0.08 0 0 2.00 
LGA versus normal brain Up Depdc7 5201 12.67 0.10 0 0 2.32 
LGA versus normal brain Up Cmtm2a 4294 12.65 0.09 0 0 2.17 
LGA versus normal brain Up H2-Q8 7867 12.63 0.19 0 0 5.16 
LGA versus normal brain Up Mdfic 9898 12.63 0.16 0 0 4.04 
LGA versus normal brain Up Erh 6001 12.62 0.05 0 0 1.49 
LGA versus normal brain Up D330045A20Rik 4935 12.61 0.17 0 0 4.33 
LGA versus normal brain Up Npepl1 11008 12.60 0.08 0 0 1.95 
LGA versus normal brain Up Mt2 10370 12.59 0.11 0 0 2.71 
LGA versus normal brain Up Tceanc 15925 12.58 0.08 0 0 1.96 
LGA versus normal brain Up 4930427A07Rik 842 12.58 0.11 0 0 2.61 
LGA versus normal brain Up Kdelr2 8881 12.56 0.05 0 0 1.54 
LGA versus normal brain Up Ccdc37 3607 12.54 0.08 0 0 1.98 
LGA versus normal brain Up Smo 15123 12.53 0.06 0 0 1.62 
LGA versus normal brain Up Lpin3 9469 12.52 0.10 0 0 2.44 
LGA versus normal brain Up Ncapd2 10664 12.52 0.10 0 0 2.47 
LGA versus normal brain Up Usp1 17152 12.51 0.09 0 0 2.12 
LGA versus normal brain Up Mif4gd 10070 12.51 0.07 0 0 1.84 
LGA versus normal brain Up Heph 7992 12.50 0.14 0 0 3.39 
LGA versus normal brain Up Fas 6388 12.49 0.10 0 0 2.29 
LGA versus normal brain Up Nmi 10941 12.49 0.09 0 0 2.26 
LGA versus normal brain Up Rdh11 13665 12.49 0.03 0 0 1.33 
LGA versus normal brain Up Ang3 2152 12.49 0.08 0 0 1.94 
LGA versus normal brain Up Nckap5 10681 12.48 0.11 0 0 2.66 
LGA versus normal brain Up Ikbip 8442 12.48 0.04 0 0 1.44 
LGA versus normal brain Up Nqo1 11035 12.47 0.09 0 0 2.11 
LGA versus normal brain Up Gm16499 7197 12.47 0.10 0 0 2.38 
LGA versus normal brain Up Rfc3 13717 12.45 0.08 0 0 2.04 
LGA versus normal brain Up Rplp0 14033 12.44 0.04 0 0 1.37 






LGA versus normal brain Up Mlxipl 10122 12.42 0.08 0 0 1.91 
LGA versus normal brain Up Ccdc102a 3549 12.40 0.05 0 0 1.58 
LGA versus normal brain Up Rdbp 13663 12.40 0.05 0 0 1.48 
LGA versus normal brain Up Lingo4 9338 12.39 0.09 0 0 2.11 
LGA versus normal brain Up Tom1l1 16525 12.38 0.04 0 0 1.45 
LGA versus normal brain Up Rad54b 13475 12.37 0.08 0 0 1.92 
LGA versus normal brain Up Cdkn2b 3927 12.36 0.15 0 0 3.51 
LGA versus normal brain Up H3f3a 7880 12.36 0.05 0 0 1.54 
LGA versus normal brain Up Prrx1 13111 12.35 0.07 0 0 1.76 
LGA versus normal brain Up Rftn2 13727 12.33 0.05 0 0 1.60 
LGA versus normal brain Up Brca1 3145 12.32 0.09 0 0 2.22 
LGA versus normal brain Up Hmg20b 8101 12.30 0.08 0 0 1.95 
LGA versus normal brain Up Psat1 13150 12.30 0.06 0 0 1.71 
LGA versus normal brain Up Polh 12737 12.30 0.07 0 0 1.82 
TR(P) versus T(P) LGA Down 2310022B05Rik 492 -8.15 0.09 0 0 0.59 
TR(P) versus T(P) LGA Down Pdlim7 12262 -7.84 0.05 0 0 0.78 
TR(P) versus T(P) LGA Down Senp2 14432 -6.99 0.05 5.49E-07 3.46E-05 0.79 
TR(P) versus T(P) LGA Down Rheb 13782 -6.75 0.04 5.49E-07 3.46E-05 0.83 
TR(P) versus T(P) LGA Down 1700094D03Rik 336 -6.71 0.13 5.49E-07 3.46E-05 0.55 
TR(P) versus T(P) LGA Down Morn5 10189 -6.61 0.12 5.49E-07 3.46E-05 0.57 
TR(P) versus T(P) LGA Down Ube2w 17012 -6.44 0.04 1.10E-06 5.02E-05 0.82 
TR(P) versus T(P) LGA Down Gli1 7050 -6.43 0.04 1.10E-06 5.02E-05 0.84 
TR(P) versus T(P) LGA Down Morn4 10188 -6.39 0.06 1.10E-06 5.02E-05 0.75 
TR(P) versus T(P) LGA Down Ccdc65 3631 -6.38 0.08 1.10E-06 5.02E-05 0.69 
TR(P) versus T(P) LGA Down Uox 17116 -6.36 0.09 1.10E-06 5.02E-05 0.68 
TR(P) versus T(P) LGA Down Parp6 12075 -6.27 0.08 1.65E-06 6.19E-05 0.71 
TR(P) versus T(P) LGA Down Prkar1a 13000 -6.19 0.06 1.65E-06 6.19E-05 0.78 
TR(P) versus T(P) LGA Down Nkain4 10891 -6.18 0.10 1.65E-06 6.19E-05 0.65 
TR(P) versus T(P) LGA Down Fam154b 6213 -6.16 0.10 1.65E-06 6.19E-05 0.65 






TR(P) versus T(P) LGA Down Atp6v0d1 2665 -6.06 0.05 2.20E-06 7.83E-05 0.82 
TR(P) versus T(P) LGA Down Dmkn 5324 -6.05 0.12 2.20E-06 7.83E-05 0.60 
TR(P) versus T(P) LGA Down 1700007G11Rik 167 -6.03 0.18 2.74E-06 8.50E-05 0.46 
TR(P) versus T(P) LGA Down Celsr3 3970 -6.02 0.06 2.74E-06 8.50E-05 0.78 
TR(P) versus T(P) LGA Down Fbxl2 6423 -5.99 0.07 2.74E-06 8.50E-05 0.73 
TR(P) versus T(P) LGA Down Cd24a 3761 -5.99 0.16 2.74E-06 8.50E-05 0.52 
TR(P) versus T(P) LGA Down Got1l1 7526 -5.83 0.15 4.94E-06 1.39E-04 0.54 
TR(P) versus T(P) LGA Down Crygn 4600 -5.82 0.14 4.94E-06 1.39E-04 0.57 
TR(P) versus T(P) LGA Down Aph1b 2293 -5.81 0.07 5.49E-06 1.50E-04 0.76 
TR(P) versus T(P) LGA Down Letm2 9275 -5.78 0.08 6.04E-06 1.56E-04 0.72 
TR(P) versus T(P) LGA Down Hsph1 8287 -5.77 0.13 6.04E-06 1.56E-04 0.60 
TR(P) versus T(P) LGA Down Dnm1l 5407 -5.71 0.04 7.14E-06 1.69E-04 0.85 
TR(P) versus T(P) LGA Down Fam183b 6258 -5.68 0.23 7.14E-06 1.69E-04 0.41 
TR(P) versus T(P) LGA Down Hspa4l 8270 -5.68 0.09 7.14E-06 1.69E-04 0.70 
TR(P) versus T(P) LGA Down Atp6v1h 2678 -5.64 0.07 7.14E-06 1.69E-04 0.77 
TR(P) versus T(P) LGA Down Spag6 15305 -5.63 0.11 7.14E-06 1.69E-04 0.64 
TR(P) versus T(P) LGA Down Myst1 10566 -5.61 0.04 7.69E-06 1.78E-04 0.85 
TR(P) versus T(P) LGA Down Nxn 11200 -5.61 0.12 7.69E-06 1.78E-04 0.62 
TR(P) versus T(P) LGA Down Rpl27a 14012 -5.61 0.07 7.69E-06 1.78E-04 0.77 
TR(P) versus T(P) LGA Down Ccdc75 3640 -5.60 0.05 9.88E-06 2.18E-04 0.84 
TR(P) versus T(P) LGA Down Zfp773 18030 -5.59 0.09 9.88E-06 2.18E-04 0.72 
TR(P) versus T(P) LGA Down 1700028P14Rik 266 -5.58 0.18 9.88E-06 2.18E-04 0.49 
TR(P) versus T(P) LGA Down Atp6v1d 2672 -5.56 0.09 1.10E-05 2.40E-04 0.72 
TR(P) versus T(P) LGA Down Rdh5 13671 -5.56 0.10 1.15E-05 2.45E-04 0.68 
TR(P) versus T(P) LGA Down Gcg 6923 -5.56 0.09 1.15E-05 2.45E-04 0.71 
TR(P) versus T(P) LGA Down Hprt 8205 -5.55 0.10 1.15E-05 2.45E-04 0.67 
TR(P) versus T(P) LGA Down Appl1 2335 -5.55 0.04 1.21E-05 2.53E-04 0.87 
TR(P) versus T(P) LGA Down Ube2v2 17011 -5.55 0.06 1.21E-05 2.53E-04 0.79 
TR(P) versus T(P) LGA Down Zmynd10 18160 -5.52 0.15 1.26E-05 2.61E-04 0.57 






TR(P) versus T(P) LGA Down Ift88 8398 -5.48 0.07 1.48E-05 2.89E-04 0.77 
TR(P) versus T(P) LGA Down Atg16l1 2590 -5.48 0.07 1.48E-05 2.89E-04 0.76 
TR(P) versus T(P) LGA Down Kif6 8944 -5.45 0.08 1.54E-05 2.89E-04 0.75 
TR(P) versus T(P) LGA Down Pgrmc1 12370 -5.44 0.07 1.54E-05 2.89E-04 0.78 
TR(P) versus T(P) LGA Down Greb1l 7682 -5.43 0.12 1.54E-05 2.89E-04 0.64 
TR(P) versus T(P) LGA Down Mycbpap 10492 -5.43 0.17 1.54E-05 2.89E-04 0.53 
TR(P) versus T(P) LGA Down Tspyl2 16806 -5.42 0.07 1.54E-05 2.89E-04 0.77 
TR(P) versus T(P) LGA Down Ccdc113 3560 -5.35 0.16 1.65E-05 2.93E-04 0.56 
TR(P) versus T(P) LGA Down Dnajb6 5364 -5.35 0.05 1.65E-05 2.93E-04 0.82 
TR(P) versus T(P) LGA Down Vti1b 17405 -5.32 0.08 1.81E-05 3.09E-04 0.74 
TR(P) versus T(P) LGA Down Morf4l2 10184 -5.32 0.07 1.81E-05 3.09E-04 0.79 
TR(P) versus T(P) LGA Down 5730469M10Rik 1124 -5.31 0.06 1.81E-05 3.09E-04 0.79 
TR(P) versus T(P) LGA Down Atp6ap2 2660 -5.29 0.08 1.87E-05 3.10E-04 0.74 
TR(P) versus T(P) LGA Down Clip1 4245 -5.29 0.06 1.92E-05 3.10E-04 0.79 
TR(P) versus T(P) LGA Down Zfp523 17933 -5.28 0.07 1.92E-05 3.10E-04 0.77 
TR(P) versus T(P) LGA Down Bbs5 2898 -5.27 0.09 1.92E-05 3.10E-04 0.73 
TR(P) versus T(P) LGA Down Cluap1 4277 -5.27 0.05 1.92E-05 3.10E-04 0.82 
TR(P) versus T(P) LGA Down Chia 4082 -5.25 0.12 1.98E-05 3.10E-04 0.66 
TR(P) versus T(P) LGA Down Lmod1 9374 -5.23 0.10 1.98E-05 3.10E-04 0.69 
TR(P) versus T(P) LGA Down Klf16 8974 -5.21 0.07 2.09E-05 3.19E-04 0.78 
TR(P) versus T(P) LGA Down B4galnt4 2818 -5.21 0.09 2.09E-05 3.19E-04 0.73 
TR(P) versus T(P) LGA Down Odf3b 11240 -5.21 0.19 2.09E-05 3.19E-04 0.50 
TR(P) versus T(P) LGA Down Trim2 16654 -5.20 0.08 2.14E-05 3.27E-04 0.75 
TR(P) versus T(P) LGA Down AI428936 1950 -5.19 0.09 2.25E-05 3.42E-04 0.72 
TR(P) versus T(P) LGA Down Ddx25 5129 -5.18 0.09 2.42E-05 3.58E-04 0.73 
TR(P) versus T(P) LGA Down Mllt11 10114 -5.18 0.15 2.42E-05 3.58E-04 0.59 
TR(P) versus T(P) LGA Down Synj2bp 15745 -5.17 0.06 2.47E-05 3.66E-04 0.81 
TR(P) versus T(P) LGA Down 1700024G13Rik 249 -5.16 0.12 2.53E-05 3.67E-04 0.65 
TR(P) versus T(P) LGA Down Ypel5 17652 -5.15 0.08 2.58E-05 3.72E-04 0.75 






TR(P) versus T(P) LGA Down Mdh1b 9902 -5.14 0.14 2.74E-05 3.93E-04 0.60 
TR(P) versus T(P) LGA Down Plin4 12636 -5.13 0.20 2.80E-05 3.97E-04 0.49 
TR(P) versus T(P) LGA Down Riiad1 13817 -5.12 0.20 2.85E-05 4.04E-04 0.49 
TR(P) versus T(P) LGA Down Tmtc4 16446 -5.12 0.10 2.91E-05 4.07E-04 0.69 
TR(P) versus T(P) LGA Down Asb6 2530 -5.12 0.04 2.91E-05 4.07E-04 0.86 
TR(P) versus T(P) LGA Down Sfxn3 14571 -5.11 0.09 2.91E-05 4.07E-04 0.73 
TR(P) versus T(P) LGA Down 5033411D12Rik 1071 -5.11 0.08 2.91E-05 4.07E-04 0.77 
TR(P) versus T(P) LGA Down Ecsit 5688 -5.09 0.04 3.18E-05 4.21E-04 0.86 
TR(P) versus T(P) LGA Down Polr2g 12755 -5.08 0.05 3.18E-05 4.21E-04 0.85 
TR(P) versus T(P) LGA Down Fam166b 6230 -5.08 0.18 3.18E-05 4.21E-04 0.54 
TR(P) versus T(P) LGA Down Snx16 15214 -5.08 0.08 3.18E-05 4.21E-04 0.75 
TR(P) versus T(P) LGA Down Inpp5a 8553 -5.08 0.06 3.18E-05 4.21E-04 0.80 
TR(P) versus T(P) LGA Down Zfp772 18029 -5.07 0.08 3.18E-05 4.21E-04 0.75 
TR(P) versus T(P) LGA Down Ppp1r32 12891 -5.07 0.14 3.18E-05 4.21E-04 0.62 
TR(P) versus T(P) LGA Down CYTB 4856 -5.07 0.09 3.18E-05 4.21E-04 0.72 
TR(P) versus T(P) LGA Down Polb 12724 -5.06 0.09 3.18E-05 4.21E-04 0.72 
TR(P) versus T(P) LGA Down Gm13629 7158 -5.05 0.11 3.29E-05 4.34E-04 0.69 
TR(P) versus T(P) LGA Down Fdps 6498 -5.04 0.06 3.46E-05 4.51E-04 0.81 
TR(P) versus T(P) LGA Down Dhx57 5259 -5.04 0.08 3.46E-05 4.51E-04 0.75 
TR(P) versus T(P) LGA Down Efhc2 5732 -5.03 0.09 3.57E-05 4.60E-04 0.74 
TR(P) versus T(P) LGA Down Efhd2 5734 -5.03 0.08 3.62E-05 4.64E-04 0.76 
TR(P) versus T(P) LGA Down Sln 15071 -5.02 0.17 3.68E-05 4.70E-04 0.56 
TR(P) versus T(P) LGA Down Pex13 12318 -5.02 0.05 3.79E-05 4.77E-04 0.85 
TR(P) versus T(P) LGA Down Slco4a1 15052 -5.02 0.13 3.79E-05 4.77E-04 0.64 
TR(P) versus T(P) LGA Down 1500011H22Rik 121 -5.02 0.05 3.79E-05 4.77E-04 0.84 
TR(P) versus T(P) LGA Down Pgbd5 12353 -5.01 0.07 3.79E-05 4.77E-04 0.77 
TR(P) versus T(P) LGA Down A430108G06Rik 1464 -5.01 0.13 3.79E-05 4.77E-04 0.64 
TR(P) versus T(P) LGA Down BC022687 2929 -5.01 0.07 3.90E-05 4.89E-04 0.77 
TR(P) versus T(P) LGA Down Armcx1 2471 -5.01 0.13 3.95E-05 4.93E-04 0.64 






TR(P) versus T(P) LGA Down Ubash3b 16978 -4.99 0.09 4.12E-05 5.02E-04 0.73 
TR(P) versus T(P) LGA Down Fam189b 6268 -4.99 0.07 4.12E-05 5.02E-04 0.79 
TR(P) versus T(P) LGA Down Dnajb2 5360 -4.98 0.08 4.12E-05 5.02E-04 0.76 
TR(P) versus T(P) LGA Down Setd4 14530 -4.97 0.09 4.12E-05 5.02E-04 0.75 
TR(P) versus T(P) LGA Down Spef2 15349 -4.97 0.14 4.12E-05 5.02E-04 0.62 
TR(P) versus T(P) LGA Down Sirt7 14697 -4.97 0.05 4.23E-05 5.11E-04 0.85 
TR(P) versus T(P) LGA Down Aox4 2251 -4.96 0.08 4.28E-05 5.16E-04 0.76 
TR(P) versus T(P) LGA Down Fam98c 6367 -4.96 0.09 4.28E-05 5.16E-04 0.74 
TR(P) versus T(P) LGA Down Cfp 4038 -4.95 0.09 4.34E-05 5.16E-04 0.73 
TR(P) versus T(P) LGA Down Fam164a 6227 -4.95 0.11 4.34E-05 5.16E-04 0.68 
TR(P) versus T(P) LGA Down Rap1gds1 13518 -4.95 0.07 4.34E-05 5.16E-04 0.78 
TR(P) versus T(P) LGA Down Rgs11 13753 -4.95 0.09 4.34E-05 5.16E-04 0.74 
TR(P) versus T(P) LGA Down Cnn1 4316 -4.95 0.10 4.34E-05 5.16E-04 0.70 
TR(P) versus T(P) LGA Down Fhad1 6560 -4.94 0.08 4.50E-05 5.34E-04 0.77 
TR(P) versus T(P) LGA Down Ccdc39 3609 -4.94 0.13 4.56E-05 5.39E-04 0.63 
TR(P) versus T(P) LGA Down C85492 3335 -4.94 0.09 4.61E-05 5.44E-04 0.74 
TR(P) versus T(P) LGA Down Pim2 12491 -4.94 0.06 4.61E-05 5.44E-04 0.83 
TR(P) versus T(P) LGA Down Gm88 7405 -4.93 0.09 4.67E-05 5.46E-04 0.73 
TR(P) versus T(P) LGA Down Spryd3 15417 -4.93 0.10 4.67E-05 5.46E-04 0.72 
TR(P) versus T(P) LGA Down Wdr16 17447 -4.92 0.12 4.94E-05 5.73E-04 0.66 
TR(P) versus T(P) LGA Down A830019P07Rik 1513 -4.90 0.09 5.44E-05 6.17E-04 0.75 
TR(P) versus T(P) LGA Down Kcnab2 8789 -4.90 0.11 5.44E-05 6.17E-04 0.68 
TR(P) versus T(P) LGA Down Dalrd3 5017 -4.89 0.06 5.49E-05 6.17E-04 0.83 
TR(P) versus T(P) LGA Down Fam92b 6362 -4.89 0.22 5.49E-05 6.17E-04 0.48 
TR(P) versus T(P) LGA Down Zmat2 18147 -4.89 0.08 5.49E-05 6.17E-04 0.75 
TR(P) versus T(P) LGA Down Dynlrb2 5575 -4.89 0.10 5.49E-05 6.17E-04 0.70 
TR(P) versus T(P) LGA Down Tmem212 16338 -4.89 0.31 5.49E-05 6.17E-04 0.35 
TR(P) versus T(P) LGA Down Tspan15 16789 -4.88 0.09 5.54E-05 6.21E-04 0.74 
TR(P) versus T(P) LGA Down Acot7 1694 -4.88 0.11 5.60E-05 6.24E-04 0.69 






TR(P) versus T(P) LGA Down Ccdc148 3582 -4.87 0.12 5.82E-05 6.43E-04 0.66 
TR(P) versus T(P) LGA Down Kif9 8946 -4.87 0.14 5.82E-05 6.43E-04 0.63 
TR(P) versus T(P) LGA Down B930095I24Rik 2838 -4.87 0.12 5.82E-05 6.43E-04 0.66 
TR(P) versus T(P) LGA Down Farp2 6384 -4.87 0.07 5.87E-05 6.47E-04 0.80 
TR(P) versus T(P) LGA Down Rusc2 14170 -4.86 0.06 5.93E-05 6.52E-04 0.81 
TR(P) versus T(P) LGA Down Ccdc74a 3639 -4.86 0.15 6.04E-05 6.60E-04 0.61 
TR(P) versus T(P) LGA Down Card10 3467 -4.85 0.07 6.15E-05 6.66E-04 0.80 
TR(P) versus T(P) LGA Down Ube2b 16982 -4.85 0.05 6.15E-05 6.66E-04 0.84 
TR(P) versus T(P) LGA Down Rb1cc1 13577 -4.84 0.06 6.42E-05 6.87E-04 0.83 
TR(P) versus T(P) LGA Down Meig1 9961 -4.84 0.21 6.42E-05 6.87E-04 0.49 
TR(P) versus T(P) LGA Down Ttc19 16831 -4.84 0.07 6.42E-05 6.87E-04 0.79 
TR(P) versus T(P) LGA Down Mthfsd 10409 -4.84 0.06 6.42E-05 6.87E-04 0.81 
TR(P) versus T(P) LGA Down Nme1 10934 -4.83 0.09 6.48E-05 6.91E-04 0.75 
TR(P) versus T(P) LGA Down Coq4 4448 -4.83 0.06 6.53E-05 6.96E-04 0.82 
TR(P) versus T(P) LGA Down Ptchd1 13230 -4.83 0.12 6.70E-05 7.08E-04 0.67 
TR(P) versus T(P) LGA Down Calm1 3395 -4.82 0.07 6.70E-05 7.08E-04 0.80 
TR(P) versus T(P) LGA Down 1700026D08Rik 257 -4.81 0.24 6.86E-05 7.20E-04 0.45 
TR(P) versus T(P) LGA Down Spns2 15385 -4.81 0.09 7.08E-05 7.38E-04 0.74 
TR(P) versus T(P) LGA Down A230006K03Rik 1423 -4.80 0.09 7.19E-05 7.44E-04 0.75 
TR(P) versus T(P) LGA Down Camk4 3415 -4.80 0.16 7.19E-05 7.44E-04 0.59 
TR(P) versus T(P) LGA Down Tmem64 16391 -4.79 0.06 7.41E-05 7.63E-04 0.81 
TR(P) versus T(P) LGA Down Ppp2r5b 12919 -4.79 0.07 7.41E-05 7.63E-04 0.78 
TR(P) versus T(P) LGA Down Insl5 8566 -4.79 0.08 7.69E-05 7.89E-04 0.77 
TR(P) versus T(P) LGA Down Dgat2 5214 -4.78 0.07 7.74E-05 7.89E-04 0.80 
TR(P) versus T(P) LGA Down Srxn1 15484 -4.77 0.07 7.85E-05 7.97E-04 0.78 
TR(P) versus T(P) LGA Down Pmvk 12684 -4.77 0.05 7.96E-05 8.03E-04 0.85 
TR(P) versus T(P) LGA Down Hmga1 8102 -4.77 0.08 8.02E-05 8.03E-04 0.78 
TR(P) versus T(P) LGA Down Spata7 15323 -4.76 0.09 8.02E-05 8.03E-04 0.73 
TR(P) versus T(P) LGA Down Puf60 13318 -4.76 0.04 8.02E-05 8.03E-04 0.87 






TR(P) versus T(P) LGA Down Morc2b 10180 -4.76 0.10 8.07E-05 8.06E-04 0.72 
TR(P) versus T(P) LGA Down Zfp692 18002 -4.75 0.05 8.23E-05 8.17E-04 0.84 
TR(P) versus T(P) LGA Down Calml4 3399 -4.75 0.27 8.23E-05 8.17E-04 0.42 
TR(P) versus T(P) LGA Down 4930506M07Rik 906 -4.75 0.09 8.34E-05 8.27E-04 0.74 
TR(P) versus T(P) LGA Down Fibin 6571 -4.74 0.15 8.51E-05 8.42E-04 0.62 
TR(P) versus T(P) LGA Down Wdr13 17446 -4.73 0.06 8.78E-05 8.61E-04 0.81 
TR(P) versus T(P) LGA Down B230217C12Rik 2779 -4.73 0.09 9.17E-05 8.95E-04 0.74 
TR(P) versus T(P) LGA Down Mdh1 9901 -4.72 0.07 9.33E-05 9.06E-04 0.80 
TR(P) versus T(P) LGA Down Igfbp5 8413 -4.72 0.13 9.33E-05 9.06E-04 0.66 
TR(P) versus T(P) LGA Down 1700049E17Rik1 299 -4.72 0.15 9.61E-05 9.25E-04 0.61 
TR(P) versus T(P) LGA Down Inpp5f 8557 -4.72 0.07 9.61E-05 9.25E-04 0.80 
TR(P) versus T(P) LGA Down 6330406I15Rik 1183 -4.71 0.11 9.66E-05 9.28E-04 0.70 
TR(P) versus T(P) LGA Down Rsph10b2 14127 -4.71 0.08 9.66E-05 9.28E-04 0.77 
TR(P) versus T(P) LGA Down Map3k12 9754 -4.70 0.07 1.02E-04 9.75E-04 0.81 
TR(P) versus T(P) LGA Down Pak3 12018 -4.69 0.12 1.04E-04 9.84E-04 0.69 
TR(P) versus T(P) LGA Down Cldn2 4208 -4.69 0.08 1.06E-04 9.97E-04 0.76 
TR(P) versus T(P) LGA Down Sub1 15657 -4.68 0.06 1.06E-04 9.97E-04 0.82 
TR(P) versus T(P) LGA Down Ttll5 16875 -4.68 0.05 1.07E-04 1.00E-03 0.86 
TR(P) versus T(P) LGA Down Snap47 15152 -4.68 0.10 1.07E-04 1.00E-03 0.72 
TR(P) versus T(P) LGA Down Madd 9681 -4.68 0.10 1.07E-04 1.00E-03 0.71 
TR(P) versus T(P) LGA Down Zfp341 17865 -4.68 0.09 1.08E-04 1.00E-03 0.76 
TR(P) versus T(P) LGA Down Acot5 1692 -4.66 0.12 1.17E-04 1.09E-03 0.67 
TR(P) versus T(P) LGA Down Kcnj14 8822 -4.66 0.11 1.17E-04 1.09E-03 0.70 
TR(P) versus T(P) LGA Down Klhl8 9023 -4.65 0.07 1.21E-04 1.12E-03 0.80 
TR(P) versus T(P) LGA Down Dixdc1 5286 -4.65 0.08 1.25E-04 1.15E-03 0.78 
TR(P) versus T(P) LGA Down Sh3glb2 14621 -4.65 0.08 1.26E-04 1.16E-03 0.78 
TR(P) versus T(P) LGA Down Wdr44 17468 -4.65 0.07 1.26E-04 1.16E-03 0.79 
TR(P) versus T(P) LGA Down Ccdc92 3659 -4.64 0.11 1.28E-04 1.17E-03 0.70 
TR(P) versus T(P) LGA Down Rbfox2 13588 -4.63 0.11 1.32E-04 1.20E-03 0.70 






TR(P) versus T(P) LGA Down Mfi2 10017 -4.62 0.13 1.37E-04 1.24E-03 0.67 
TR(P) versus T(P) LGA Down Rps6kl1 14083 -4.62 0.09 1.38E-04 1.24E-03 0.75 
TR(P) versus T(P) LGA Down Lpar1 9453 -4.61 0.12 1.40E-04 1.24E-03 0.68 
TR(P) versus T(P) LGA Down 1700029J07Rik 272 -4.61 0.13 1.41E-04 1.24E-03 0.66 
TR(P) versus T(P) LGA Down 4931428F04Rik 990 -4.61 0.04 1.41E-04 1.25E-03 0.88 
TR(P) versus T(P) LGA Down Fam132a 6196 -4.60 0.11 1.42E-04 1.25E-03 0.71 
TR(P) versus T(P) LGA Down Wipi2 17538 -4.60 0.03 1.43E-04 1.26E-03 0.92 
TR(P) versus T(P) LGA Down Fhdc1 6561 -4.60 0.09 1.44E-04 1.26E-03 0.76 
TR(P) versus T(P) LGA Down Pclo 12165 -4.59 0.10 1.44E-04 1.26E-03 0.73 
TR(P) versus T(P) LGA Down Dnahc5 5345 -4.59 0.10 1.45E-04 1.27E-03 0.73 
TR(P) versus T(P) LGA Down Atpif1 2693 -4.59 0.06 1.45E-04 1.27E-03 0.83 
TR(P) versus T(P) LGA Down 1190002N15Rik 89 -4.59 0.09 1.47E-04 1.28E-03 0.76 
TR(P) versus T(P) LGA Down Wdr63 17485 -4.59 0.15 1.48E-04 1.29E-03 0.61 
TR(P) versus T(P) LGA Down Fbxo33 6449 -4.58 0.09 1.51E-04 1.31E-03 0.76 
TR(P) versus T(P) LGA Down Orc4 11896 -4.58 0.05 1.53E-04 1.32E-03 0.85 
TR(P) versus T(P) LGA Down Pcgf6 12161 -4.58 0.07 1.53E-04 1.32E-03 0.81 
TR(P) versus T(P) LGA Down Meaf6 9914 -4.57 0.04 1.56E-04 1.34E-03 0.89 
TR(P) versus T(P) LGA Down 1700009P17Rik 180 -4.57 0.17 1.57E-04 1.34E-03 0.58 
TR(P) versus T(P) LGA Down Prnp 13048 -4.56 0.09 1.57E-04 1.34E-03 0.75 
TR(P) versus T(P) LGA Down Cyb561 4761 -4.56 0.12 1.59E-04 1.34E-03 0.67 
TR(P) versus T(P) LGA Down Eno4 5903 -4.56 0.14 1.59E-04 1.35E-03 0.64 
TR(P) versus T(P) LGA Down Ttc8 16858 -4.56 0.10 1.60E-04 1.35E-03 0.72 
TR(P) versus T(P) LGA Down Cdk5r1 3907 -4.56 0.08 1.60E-04 1.35E-03 0.78 
TR(P) versus T(P) LGA Down Arid3a 2432 -4.55 0.09 1.61E-04 1.35E-03 0.76 
TR(P) versus T(P) LGA Down Wnt10a 17548 -4.55 0.10 1.61E-04 1.35E-03 0.72 
TR(P) versus T(P) LGA Down Grm7 7722 -4.55 0.10 1.61E-04 1.35E-03 0.74 
TR(P) versus T(P) LGA Down Ttc33 16845 -4.55 0.09 1.61E-04 1.35E-03 0.76 
TR(P) versus T(P) LGA Down Dnttip1 5418 -4.55 0.04 1.63E-04 1.35E-03 0.88 
TR(P) versus T(P) LGA Down 4930451C15Rik 864 -4.55 0.18 1.63E-04 1.36E-03 0.57 






TR(P) versus T(P) LGA Down Ppp1r42 12901 -4.54 0.18 1.65E-04 1.37E-03 0.57 
TR(P) versus T(P) LGA Down Nop56 10978 -4.54 0.06 1.65E-04 1.37E-03 0.82 
TR(P) versus T(P) LGA Down Eno2 5901 -4.54 0.11 1.65E-04 1.37E-03 0.71 
TR(P) versus T(P) LGA Down Gm9856 7430 -4.53 0.09 1.67E-04 1.37E-03 0.76 
TR(P) versus T(P) LGA Down Ube2q2 17005 -4.53 0.06 1.67E-04 1.37E-03 0.82 
TR(P) versus T(P) LGA Down Ttll7 16877 -4.53 0.11 1.67E-04 1.37E-03 0.70 
TR(P) versus T(P) LGA Down Nae1 10605 -4.53 0.06 1.68E-04 1.37E-03 0.82 
TR(P) versus T(P) LGA Down Nek1 10776 -4.53 0.05 1.69E-04 1.38E-03 0.86 
TR(P) versus T(P) LGA Down Unc13a 17097 -4.52 0.06 1.70E-04 1.38E-03 0.83 
TR(P) versus T(P) LGA Down Zmym5 18158 -4.52 0.05 1.70E-04 1.38E-03 0.86 
TR(P) versus T(P) LGA Down Bnip3l 3121 -4.52 0.05 1.71E-04 1.38E-03 0.85 
TR(P) versus T(P) LGA Down Ift46 8392 -4.52 0.04 1.71E-04 1.38E-03 0.89 
TR(P) versus T(P) LGA Down Ric8b 13814 -4.52 0.06 1.71E-04 1.38E-03 0.83 
TR(P) versus T(P) LGA Down Zfp512 17926 -4.52 0.04 1.71E-04 1.38E-03 0.89 
TR(P) versus T(P) LGA Down 1700003E16Rik 162 -4.52 0.10 1.71E-04 1.38E-03 0.73 
TR(P) versus T(P) LGA Down Cpeb1 4496 -4.52 0.13 1.71E-04 1.38E-03 0.67 
TR(P) versus T(P) LGA Down 9030425E11Rik 1268 -4.52 0.16 1.71E-04 1.38E-03 0.60 
TR(P) versus T(P) LGA Down Entpd2 5918 -4.51 0.18 1.72E-04 1.39E-03 0.56 
TR(P) versus T(P) LGA Down Anxa7 2243 -4.51 0.09 1.74E-04 1.39E-03 0.76 
TR(P) versus T(P) LGA Down Xbp1 17583 -4.50 0.07 1.77E-04 1.41E-03 0.80 
TR(P) versus T(P) LGA Down Pcyt2 12195 -4.49 0.06 1.81E-04 1.43E-03 0.83 
TR(P) versus T(P) LGA Down Nmt2 10947 -4.49 0.08 1.83E-04 1.45E-03 0.79 
TR(P) versus T(P) LGA Down Dlk2 5307 -4.48 0.12 1.88E-04 1.47E-03 0.69 
TR(P) versus T(P) LGA Down Ppp2r2b 12911 -4.47 0.07 1.91E-04 1.48E-03 0.80 
TR(P) versus T(P) LGA Down Ccdc89 3654 -4.47 0.08 1.91E-04 1.48E-03 0.77 
TR(P) versus T(P) LGA Down Ddhd2 5106 -4.47 0.07 1.93E-04 1.50E-03 0.80 
TR(P) versus T(P) LGA Down Clec3b 4229 -4.46 0.10 1.97E-04 1.52E-03 0.74 
TR(P) versus T(P) LGA Down Hrk 8223 -4.46 0.10 1.97E-04 1.52E-03 0.73 
TR(P) versus T(P) LGA Down Rbm4b 13620 -4.46 0.05 1.97E-04 1.52E-03 0.84 






TR(P) versus T(P) LGA Down Hdac5 7953 -4.45 0.10 2.03E-04 1.56E-03 0.73 
TR(P) versus T(P) LGA Down 6820408C15Rik 1235 -4.45 0.08 2.03E-04 1.56E-03 0.78 
TR(P) versus T(P) LGA Down Syngr3 15741 -4.45 0.10 2.04E-04 1.56E-03 0.74 
TR(P) versus T(P) LGA Down Nfil3 10828 -4.45 0.10 2.04E-04 1.56E-03 0.73 
TR(P) versus T(P) LGA Down Nenf 10789 -4.45 0.09 2.04E-04 1.56E-03 0.76 
TR(P) versus T(P) LGA Down Flrt3 6613 -4.45 0.11 2.05E-04 1.57E-03 0.72 
TR(P) versus T(P) LGA Down Fam92a 6361 -4.44 0.06 2.09E-04 1.59E-03 0.84 
TR(P) versus T(P) LGA Down 2210408I21Rik 458 -4.44 0.06 2.10E-04 1.59E-03 0.84 
TR(P) versus T(P) LGA Down Lass4 9198 -4.44 0.08 2.10E-04 1.59E-03 0.79 
TR(P) versus T(P) LGA Down 8430410K20Rik 1251 -4.44 0.06 2.10E-04 1.59E-03 0.84 
TR(P) versus T(P) LGA Down Slc45a1 14972 -4.44 0.07 2.10E-04 1.59E-03 0.80 
TR(P) versus T(P) LGA Down Ankrd13b 2180 -4.43 0.13 2.13E-04 1.61E-03 0.66 
TR(P) versus T(P) LGA Down Atp1b1 2628 -4.43 0.11 2.14E-04 1.61E-03 0.71 
TR(P) versus T(P) LGA Down Zscan18 18191 -4.43 0.06 2.14E-04 1.61E-03 0.82 
TR(P) versus T(P) LGA Down Lrrc48 9535 -4.43 0.16 2.14E-04 1.61E-03 0.62 
TR(P) versus T(P) LGA Down Ccdc81 3645 -4.42 0.22 2.16E-04 1.62E-03 0.51 
TR(P) versus T(P) LGA Down Hdc 7958 -4.42 0.17 2.16E-04 1.62E-03 0.60 
TR(P) versus T(P) LGA Down 9330159F19Rik 1307 -4.42 0.10 2.16E-04 1.62E-03 0.74 
TR(P) versus T(P) LGA Down Ankzf1 2220 -4.42 0.05 2.17E-04 1.62E-03 0.85 
TR(P) versus T(P) LGA Down Ift81 8397 -4.42 0.09 2.18E-04 1.62E-03 0.75 
TR(P) versus T(P) LGA Down Ube2e2 16989 -4.41 0.08 2.22E-04 1.65E-03 0.77 
TR(P) versus T(P) LGA Down Ppid 12838 -4.41 0.06 2.22E-04 1.65E-03 0.83 
TR(P) versus T(P) LGA Down Acan 1654 -4.41 0.11 2.22E-04 1.65E-03 0.72 
TR(P) versus T(P) LGA Down Bag5 2855 -4.41 0.06 2.25E-04 1.66E-03 0.84 
TR(P) versus T(P) LGA Down Ube2q1 17004 -4.40 0.04 2.26E-04 1.67E-03 0.88 
TR(P) versus T(P) LGA Down March11 9800 -4.40 0.09 2.29E-04 1.68E-03 0.75 
TR(P) versus T(P) LGA Down Tmem216 16341 -4.40 0.06 2.33E-04 1.70E-03 0.82 
TR(P) versus T(P) LGA Down Ube2k 16998 -4.39 0.04 2.35E-04 1.71E-03 0.88 
TR(P) versus T(P) LGA Down Ttll3 16873 -4.39 0.14 2.36E-04 1.71E-03 0.65 






TR(P) versus T(P) LGA Down Efcab1 5717 -4.39 0.14 2.39E-04 1.73E-03 0.65 
TR(P) versus T(P) LGA Down Jkamp 8736 -4.39 0.05 2.39E-04 1.73E-03 0.85 
TR(P) versus T(P) LGA Down Ccl25 3676 -4.38 0.09 2.42E-04 1.74E-03 0.76 
TR(P) versus T(P) LGA Down 9630003H22Rik 1373 -4.38 0.15 2.43E-04 1.75E-03 0.64 
TR(P) versus T(P) LGA Down Cdcp1 3864 -4.38 0.06 2.43E-04 1.75E-03 0.84 
TR(P) versus T(P) LGA Down C230091D08Rik 3285 -4.38 0.07 2.44E-04 1.75E-03 0.80 
TR(P) versus T(P) LGA Down Trp53bp1 16725 -4.38 0.06 2.44E-04 1.75E-03 0.84 
TR(P) versus T(P) LGA Down St3gal1 15520 -4.37 0.07 2.50E-04 1.78E-03 0.80 
TR(P) versus T(P) LGA Down Dus3l 5535 -4.36 0.06 2.50E-04 1.78E-03 0.84 
TR(P) versus T(P) LGA Down Pitpna 12510 -4.36 0.07 2.53E-04 1.79E-03 0.82 
TR(P) versus T(P) LGA Down Chordc1 4105 -4.36 0.09 2.56E-04 1.81E-03 0.77 
TR(P) versus T(P) LGA Down Rnmt 13953 -4.36 0.06 2.56E-04 1.81E-03 0.84 
TR(P) versus T(P) LGA Down Pcsk1 12181 -4.36 0.13 2.56E-04 1.81E-03 0.67 
TR(P) versus T(P) LGA Down BC005764 2911 -4.35 0.10 2.57E-04 1.81E-03 0.74 
TR(P) versus T(P) LGA Down Abca8a 1576 -4.35 0.09 2.57E-04 1.81E-03 0.76 
TR(P) versus T(P) LGA Down Adra1a 1860 -4.34 0.08 2.67E-04 1.87E-03 0.80 
TR(P) versus T(P) LGA Down Rnft2 13949 -4.34 0.07 2.68E-04 1.88E-03 0.81 
TR(P) versus T(P) LGA Down Trnp1 16718 -4.34 0.09 2.70E-04 1.89E-03 0.76 
TR(P) versus T(P) LGA Down Dnalc1 5395 -4.33 0.10 2.78E-04 1.93E-03 0.74 
TR(P) versus T(P) LGA Down 5033430I15Rik 1075 -4.33 0.14 2.78E-04 1.93E-03 0.66 
TR(P) versus T(P) LGA Down Slc25a14 14818 -4.33 0.08 2.78E-04 1.93E-03 0.78 
TR(P) versus T(P) LGA Down Dctn3 5087 -4.33 0.08 2.80E-04 1.95E-03 0.78 
TR(P) versus T(P) LGA Down 2900009J20Rik 698 -4.32 0.11 2.91E-04 2.01E-03 0.71 
TR(P) versus T(P) LGA Down Agpat4 1911 -4.32 0.08 2.95E-04 2.03E-03 0.78 
TR(P) versus T(P) LGA Down Rprd1a 14043 -4.32 0.05 2.95E-04 2.03E-03 0.86 
TR(P) versus T(P) LGA Down Mapre3 9796 -4.32 0.09 2.95E-04 2.03E-03 0.77 
TR(P) versus T(P) LGA Down Fam179a 6253 -4.31 0.07 3.00E-04 2.06E-03 0.80 
TR(P) versus T(P) LGA Down Dcc 5065 -4.31 0.08 3.00E-04 2.06E-03 0.80 
TR(P) versus T(P) LGA Down Armc3 2465 -4.31 0.23 3.01E-04 2.06E-03 0.50 






TR(P) versus T(P) LGA Down Dnaja1 5351 -4.31 0.06 3.04E-04 2.07E-03 0.83 
TR(P) versus T(P) LGA Down Necap1 10763 -4.31 0.08 3.05E-04 2.07E-03 0.79 
TR(P) versus T(P) LGA Down Hyou1 8315 -4.31 0.07 3.05E-04 2.08E-03 0.80 
TR(P) versus T(P) LGA Down Krt222 9090 -4.30 0.12 3.06E-04 2.08E-03 0.69 
TR(P) versus T(P) LGA Down 0610010O12Rik 15 -4.30 0.13 3.09E-04 2.10E-03 0.68 
TR(P) versus T(P) LGA Down Fkbp3 6592 -4.30 0.07 3.13E-04 2.12E-03 0.82 
TR(P) versus T(P) LGA Down Api5 2295 -4.29 0.04 3.13E-04 2.12E-03 0.88 
TR(P) versus T(P) LGA Down LOC100504423 9405 -4.29 0.11 3.13E-04 2.12E-03 0.72 
TR(P) versus T(P) LGA Down Syt13 15760 -4.29 0.13 3.13E-04 2.12E-03 0.68 
TR(P) versus T(P) LGA Down Tmem191c 16319 -4.29 0.08 3.14E-04 2.12E-03 0.78 
TR(P) versus T(P) LGA Down Cc2d1a 3540 -4.29 0.05 3.14E-04 2.12E-03 0.85 
TR(P) versus T(P) LGA Down Sc4mol 14268 -4.29 0.09 3.16E-04 2.13E-03 0.76 
TR(P) versus T(P) LGA Down Ywhaz 17663 -4.29 0.06 3.20E-04 2.15E-03 0.83 
TR(P) versus T(P) LGA Down Gnl3l 7493 -4.29 0.08 3.21E-04 2.15E-03 0.79 
TR(P) versus T(P) LGA Down Ankrd34b 2196 -4.29 0.12 3.21E-04 2.15E-03 0.70 
TR(P) versus T(P) LGA Down Ppm1l 12860 -4.28 0.09 3.22E-04 2.15E-03 0.75 
TR(P) versus T(P) LGA Down Uckl1 17057 -4.28 0.05 3.25E-04 2.16E-03 0.85 
TR(P) versus T(P) LGA Down Mtap6 10383 -4.28 0.12 3.26E-04 2.16E-03 0.71 
TR(P) versus T(P) LGA Down S100a10 14191 -4.28 0.10 3.26E-04 2.16E-03 0.75 
TR(P) versus T(P) LGA Down Kcnj6 8828 -4.28 0.10 3.26E-04 2.16E-03 0.73 
TR(P) versus T(P) LGA Down Wls 17543 -4.28 0.09 3.26E-04 2.16E-03 0.76 
TR(P) versus T(P) LGA Down Arl16 2445 -4.27 0.08 3.29E-04 2.18E-03 0.80 
TR(P) versus T(P) LGA Down Pip5k1b 12503 -4.27 0.13 3.33E-04 2.20E-03 0.68 
TR(P) versus T(P) LGA Down Lime1 9322 -4.27 0.09 3.35E-04 2.22E-03 0.76 
TR(P) versus T(P) LGA Down Nap1l2 10625 -4.26 0.15 3.44E-04 2.27E-03 0.65 
TR(P) versus T(P) LGA Down Enpp5 5912 -4.26 0.10 3.46E-04 2.27E-03 0.75 
TR(P) versus T(P) LGA Down Neu2 10797 -4.26 0.12 3.46E-04 2.27E-03 0.70 
TR(P) versus T(P) LGA Down Fank1 6379 -4.26 0.14 3.49E-04 2.28E-03 0.67 
TR(P) versus T(P) LGA Down Ttc18 16830 -4.25 0.12 3.52E-04 2.30E-03 0.70 






TR(P) versus T(P) LGA Down Gckr 6928 -4.25 0.11 3.54E-04 2.30E-03 0.73 
TR(P) versus T(P) LGA Down Trappc4 16616 -4.25 0.05 3.56E-04 2.31E-03 0.86 
TR(P) versus T(P) LGA Down 1190003J15Rik 90 -4.24 0.15 3.58E-04 2.32E-03 0.64 
TR(P) versus T(P) LGA Down Sbno1 14264 -4.24 0.06 3.61E-04 2.33E-03 0.85 
TR(P) versus T(P) LGA Down Sc5d 14269 -4.24 0.07 3.61E-04 2.33E-03 0.81 
TR(P) versus T(P) LGA Down Ces5a 4024 -4.24 0.06 3.61E-04 2.33E-03 0.83 
TR(P) versus T(P) LGA Down Tekt1 15997 -4.24 0.12 3.62E-04 2.33E-03 0.70 
TR(P) versus T(P) LGA Down Mterfd3 10396 -4.23 0.09 3.67E-04 2.35E-03 0.77 
TR(P) versus T(P) LGA Down Uhrf1bp1l 17085 -4.23 0.06 3.69E-04 2.36E-03 0.83 
TR(P) versus T(P) LGA Down Zfr 18114 -4.23 0.06 3.69E-04 2.36E-03 0.83 
TR(P) versus T(P) LGA Down Dpm1 5460 -4.23 0.07 3.72E-04 2.37E-03 0.80 
TR(P) versus T(P) LGA Down Rnf214 13925 -4.23 0.06 3.73E-04 2.37E-03 0.84 
TR(P) versus T(P) LGA Down Ppp1r36 12893 -4.23 0.15 3.73E-04 2.37E-03 0.64 
TR(P) versus T(P) LGA Down Ap1s2 2259 -4.23 0.09 3.76E-04 2.39E-03 0.76 
TR(P) versus T(P) LGA Down Sdpr 14362 -4.22 0.09 3.76E-04 2.39E-03 0.78 
TR(P) versus T(P) LGA Down Fyttd1 6780 -4.22 0.06 3.76E-04 2.39E-03 0.84 
TR(P) versus T(P) LGA Down Lgi2 9288 -4.22 0.15 3.77E-04 2.39E-03 0.64 
TR(P) versus T(P) LGA Down Morf4l1 10183 -4.22 0.05 3.81E-04 2.41E-03 0.86 
TR(P) versus T(P) LGA Down Rrn3 14106 -4.22 0.05 3.84E-04 2.42E-03 0.87 
TR(P) versus T(P) LGA Down Wdr65 17487 -4.22 0.14 3.85E-04 2.42E-03 0.67 
TR(P) versus T(P) LGA Down Ufsp1 17067 -4.22 0.07 3.86E-04 2.43E-03 0.81 
TR(P) versus T(P) LGA Down Avpi1 2730 -4.21 0.11 3.90E-04 2.44E-03 0.74 
TR(P) versus T(P) LGA Down Capsl 3447 -4.21 0.19 3.91E-04 2.45E-03 0.57 
TR(P) versus T(P) LGA Down Pdp1 12263 -4.21 0.13 3.96E-04 2.47E-03 0.69 
TR(P) versus T(P) LGA Down 1700026L06Rik 259 -4.21 0.23 3.99E-04 2.48E-03 0.51 
TR(P) versus T(P) LGA Down Rpl11 13995 -4.20 0.05 4.06E-04 2.52E-03 0.87 
TR(P) versus T(P) LGA Down Inpp4a 8551 -4.20 0.08 4.07E-04 2.52E-03 0.78 
TR(P) versus T(P) LGA Down Mb 9840 -4.19 0.10 4.13E-04 2.54E-03 0.74 
TR(P) versus T(P) LGA Down Stk39 15604 -4.19 0.10 4.14E-04 2.54E-03 0.76 






TR(P) versus T(P) LGA Down Sema3a 14411 -4.19 0.09 4.15E-04 2.54E-03 0.77 
TR(P) versus T(P) LGA Down B4galt6 2824 -4.19 0.10 4.15E-04 2.54E-03 0.74 
TR(P) versus T(P) LGA Down Paip2 12013 -4.19 0.07 4.17E-04 2.55E-03 0.82 
TR(P) versus T(P) LGA Down Fam110b 6163 -4.19 0.10 4.18E-04 2.56E-03 0.74 
TR(P) versus T(P) LGA Down Casc1 3479 -4.19 0.08 4.19E-04 2.56E-03 0.78 
TR(P) versus T(P) LGA Down Cyb561d1 4762 -4.18 0.09 4.19E-04 2.56E-03 0.77 
TR(P) versus T(P) LGA Down Hagh 7893 -4.18 0.09 4.23E-04 2.58E-03 0.78 
TR(P) versus T(P) LGA Down Tmem218 16343 -4.18 0.07 4.25E-04 2.59E-03 0.82 
TR(P) versus T(P) LGA Down Tctn2 15968 -4.18 0.11 4.25E-04 2.59E-03 0.72 
TR(P) versus T(P) LGA Down L3mbtl4 9153 -4.18 0.09 4.25E-04 2.59E-03 0.78 
TR(P) versus T(P) LGA Down Msx1 10365 -4.18 0.11 4.29E-04 2.60E-03 0.72 
TR(P) versus T(P) LGA Down Rtn4 14149 -4.18 0.10 4.29E-04 2.60E-03 0.74 
TR(P) versus T(P) LGA Down Chchd7 4061 -4.18 0.13 4.30E-04 2.60E-03 0.69 
TR(P) versus T(P) LGA Down Srrm4 15470 -4.18 0.12 4.32E-04 2.61E-03 0.70 
TR(P) versus T(P) LGA Down Nkiras1 10897 -4.17 0.11 4.35E-04 2.62E-03 0.73 
TR(P) versus T(P) LGA Down Ift57 8394 -4.17 0.07 4.38E-04 2.63E-03 0.83 
TR(P) versus T(P) LGA Down Ncoa7 10692 -4.17 0.12 4.38E-04 2.63E-03 0.70 
TR(P) versus T(P) LGA Down Rab3a 13419 -4.16 0.10 4.39E-04 2.64E-03 0.74 
TR(P) versus T(P) LGA Down Sars 14248 -4.16 0.06 4.40E-04 2.64E-03 0.85 
TR(P) versus T(P) LGA Down Akd1 2016 -4.16 0.17 4.44E-04 2.66E-03 0.61 
TR(P) versus T(P) LGA Down A030010E16Rik 1404 -4.16 0.10 4.46E-04 2.67E-03 0.75 
TR(P) versus T(P) LGA Down Hdac11 7949 -4.16 0.09 4.47E-04 2.67E-03 0.77 
TR(P) versus T(P) LGA Down Camk2n2 3414 -4.16 0.12 4.50E-04 2.67E-03 0.71 
TR(P) versus T(P) LGA Down Gipr 7018 -4.16 0.11 4.50E-04 2.67E-03 0.74 
TR(P) versus T(P) LGA Down Cacng2 3370 -4.15 0.12 4.51E-04 2.68E-03 0.71 
TR(P) versus T(P) LGA Down Clstn3 4272 -4.15 0.16 4.52E-04 2.68E-03 0.63 
TR(P) versus T(P) LGA Down Stx18 15637 -4.15 0.06 4.55E-04 2.69E-03 0.85 
TR(P) versus T(P) LGA Down Ccrn4l 3725 -4.15 0.13 4.56E-04 2.69E-03 0.69 
TR(P) versus T(P) LGA Down A930011O12Rik 1535 -4.15 0.07 4.57E-04 2.69E-03 0.81 






TR(P) versus T(P) LGA Down B3galt2 2797 -4.15 0.08 4.58E-04 2.69E-03 0.79 
TR(P) versus T(P) LGA Down Jakmip1 8727 -4.15 0.11 4.62E-04 2.71E-03 0.73 
TR(P) versus T(P) LGA Down Cltb 4274 -4.14 0.06 4.66E-04 2.72E-03 0.85 
TR(P) versus T(P) LGA Down Dcn 5076 -4.14 0.16 4.68E-04 2.73E-03 0.63 
TR(P) versus T(P) LGA Down Pde4a 12221 -4.14 0.09 4.68E-04 2.73E-03 0.76 
TR(P) versus T(P) LGA Down Mapk10 9772 -4.14 0.07 4.71E-04 2.74E-03 0.83 
TR(P) versus T(P) LGA Down Nr2f2 11049 -4.14 0.10 4.74E-04 2.75E-03 0.75 
TR(P) versus T(P) LGA Down Mirg 10081 -4.13 0.15 4.79E-04 2.78E-03 0.66 
TR(P) versus T(P) LGA Down Fbxo9 6464 -4.13 0.09 4.81E-04 2.79E-03 0.78 
TR(P) versus T(P) LGA Down 3110047P20Rik 743 -4.12 0.10 4.86E-04 2.82E-03 0.74 
TR(P) versus T(P) LGA Down Katnb1 8772 -4.12 0.04 4.88E-04 2.82E-03 0.90 
TR(P) versus T(P) LGA Down 2410004A20Rik 544 -4.12 0.11 4.88E-04 2.82E-03 0.72 
TR(P) versus T(P) LGA Down BC010981 2914 -4.12 0.10 4.93E-04 2.84E-03 0.74 
TR(P) versus T(P) LGA Down Ttc16 16828 -4.12 0.11 4.95E-04 2.85E-03 0.73 
TR(P) versus T(P) LGA Down 2900011G08Rik 700 -4.11 0.12 5.05E-04 2.90E-03 0.70 
TR(P) versus T(P) LGA Down Fkbp1a 6589 -4.11 0.06 5.06E-04 2.90E-03 0.85 
TR(P) versus T(P) LGA Down Cby3 3539 -4.11 0.09 5.06E-04 2.90E-03 0.77 
TR(P) versus T(P) LGA Down Rad23b 13467 -4.11 0.05 5.08E-04 2.91E-03 0.86 
TR(P) versus T(P) LGA Down Paqr6 12051 -4.11 0.12 5.10E-04 2.92E-03 0.71 
TR(P) versus T(P) LGA Down Plekha5 12608 -4.11 0.11 5.11E-04 2.92E-03 0.74 
TR(P) versus T(P) LGA Down Plekhg4 12619 -4.11 0.10 5.12E-04 2.92E-03 0.75 
TR(P) versus T(P) LGA Down Cnfn 4306 -4.10 0.07 5.18E-04 2.95E-03 0.81 
TR(P) versus T(P) LGA Down Csnk1a1 4625 -4.10 0.05 5.19E-04 2.95E-03 0.87 
TR(P) versus T(P) LGA Down Cnksr2 4314 -4.10 0.11 5.20E-04 2.95E-03 0.72 
TR(P) versus T(P) LGA Down Pnpo 12706 -4.09 0.12 5.24E-04 2.96E-03 0.71 
TR(P) versus T(P) LGA Down 1500011B03Rik 120 -4.09 0.10 5.25E-04 2.96E-03 0.75 
TR(P) versus T(P) LGA Down Cacnb2 3366 -4.09 0.07 5.25E-04 2.96E-03 0.82 
TR(P) versus T(P) LGA Down Wrb 17564 -4.09 0.06 5.25E-04 2.96E-03 0.83 
TR(P) versus T(P) LGA Down Nkpd1 10899 -4.09 0.12 5.25E-04 2.96E-03 0.72 






TR(P) versus T(P) LGA Down Armcx3 2473 -4.09 0.05 5.30E-04 2.98E-03 0.87 
TR(P) versus T(P) LGA Down 2010003D24Rik 408 -4.09 0.12 5.39E-04 3.03E-03 0.72 
TR(P) versus T(P) LGA Down Rhou 13799 -4.08 0.13 5.45E-04 3.05E-03 0.69 
TR(P) versus T(P) LGA Down 4921509J17Rik 810 -4.08 0.10 5.46E-04 3.05E-03 0.75 
TR(P) versus T(P) LGA Down Iqcg 8606 -4.08 0.19 5.46E-04 3.05E-03 0.59 
TR(P) versus T(P) LGA Down Orai2 11890 -4.08 0.08 5.47E-04 3.05E-03 0.80 
TR(P) versus T(P) LGA Down Snx32 15228 -4.08 0.04 5.51E-04 3.07E-03 0.89 
TR(P) versus T(P) LGA Down Itm2c 8704 -4.08 0.06 5.51E-04 3.07E-03 0.84 
TR(P) versus T(P) LGA Down Prpf39 13074 -4.07 0.07 5.58E-04 3.09E-03 0.82 
TR(P) versus T(P) LGA Down Zdhhc1 17746 -4.07 0.08 5.58E-04 3.09E-03 0.81 
TR(P) versus T(P) LGA Down Ppp3ca 12923 -4.07 0.14 5.61E-04 3.11E-03 0.67 
TR(P) versus T(P) LGA Down Pank4 12035 -4.07 0.04 5.62E-04 3.11E-03 0.88 
TR(P) versus T(P) LGA Down Rsph1 14126 -4.07 0.14 5.63E-04 3.11E-03 0.68 
TR(P) versus T(P) LGA Down Tacc1 15788 -4.07 0.07 5.65E-04 3.12E-03 0.83 
TR(P) versus T(P) LGA Down Cdh8 3885 -4.07 0.13 5.65E-04 3.12E-03 0.69 
TR(P) versus T(P) LGA Down 5330426P16Rik 1081 -4.07 0.07 5.66E-04 3.12E-03 0.81 
TR(P) versus T(P) LGA Down 2900006K08Rik 697 -4.06 0.11 5.69E-04 3.12E-03 0.73 
TR(P) versus T(P) LGA Down Ip6k2 8586 -4.06 0.08 5.72E-04 3.13E-03 0.80 
TR(P) versus T(P) LGA Down Zcchc7 17740 -4.06 0.09 5.74E-04 3.15E-03 0.77 
TR(P) versus T(P) LGA Down Arpm1 2488 -4.06 0.10 5.75E-04 3.15E-03 0.76 
TR(P) versus T(P) LGA Down Kif5a 8941 -4.06 0.09 5.84E-04 3.19E-03 0.79 
TR(P) versus T(P) LGA Down Usp33 17176 -4.06 0.05 5.85E-04 3.19E-03 0.86 
TR(P) versus T(P) LGA Down Pip4k2c 12501 -4.05 0.06 5.92E-04 3.22E-03 0.84 
TR(P) versus T(P) LGA Down Cdk9 3915 -4.05 0.05 5.92E-04 3.22E-03 0.87 
TR(P) versus T(P) LGA Down Ttc25 16837 -4.05 0.12 5.92E-04 3.22E-03 0.71 
TR(P) versus T(P) LGA Down 2810032G03Rik 660 -4.05 0.15 5.94E-04 3.23E-03 0.66 
TR(P) versus T(P) LGA Down D16H22S680E 4900 -4.05 0.09 5.98E-04 3.25E-03 0.78 
TR(P) versus T(P) LGA Down Timm9 16148 -4.05 0.05 5.99E-04 3.25E-03 0.87 
TR(P) versus T(P) LGA Down Usp29 17171 -4.05 0.11 6.03E-04 3.26E-03 0.74 






TR(P) versus T(P) LGA Down Gnl2 7491 -4.04 0.05 6.05E-04 3.26E-03 0.87 
TR(P) versus T(P) LGA Down Col6a1 4400 -4.04 0.09 6.08E-04 3.27E-03 0.78 
TR(P) versus T(P) LGA Down Ociad2 11232 -4.04 0.13 6.14E-04 3.30E-03 0.69 
TR(P) versus T(P) LGA Down Kptn 9069 -4.04 0.07 6.14E-04 3.30E-03 0.83 
TR(P) versus T(P) LGA Down Kifap3 8947 -4.04 0.09 6.14E-04 3.30E-03 0.78 
TR(P) versus T(P) LGA Down Bend6 3054 -4.03 0.15 6.18E-04 3.31E-03 0.66 
TR(P) versus T(P) LGA Down Mlf1 10102 -4.03 0.22 6.24E-04 3.33E-03 0.53 
TR(P) versus T(P) LGA Down Ccdc11 3557 -4.03 0.12 6.30E-04 3.35E-03 0.72 
TR(P) versus T(P) LGA Down Fbxo25 6442 -4.02 0.09 6.36E-04 3.38E-03 0.77 
TR(P) versus T(P) LGA Down Fabp3 6130 -4.02 0.15 6.38E-04 3.39E-03 0.65 
TR(P) versus T(P) LGA Down Pdxp 12275 -4.02 0.12 6.43E-04 3.41E-03 0.72 
TR(P) versus T(P) LGA Down Olfr1093 11292 -4.02 0.08 6.43E-04 3.41E-03 0.81 
TR(P) versus T(P) LGA Down Ccdc108 3554 -4.02 0.08 6.45E-04 3.42E-03 0.81 
TR(P) versus T(P) LGA Down Cd200 3750 -4.02 0.09 6.46E-04 3.42E-03 0.77 
TR(P) versus T(P) LGA Down Fn3k 6634 -4.01 0.07 6.51E-04 3.44E-03 0.82 
TR(P) versus T(P) LGA Down 1700045I19Rik 295 -4.01 0.17 6.52E-04 3.44E-03 0.62 
TR(P) versus T(P) LGA Down Creld1 4555 -4.01 0.06 6.57E-04 3.45E-03 0.84 
TR(P) versus T(P) LGA Down Zbbx 17669 -4.01 0.15 6.61E-04 3.47E-03 0.65 
TR(P) versus T(P) LGA Down Slmo1 15070 -4.01 0.05 6.61E-04 3.47E-03 0.87 
TR(P) versus T(P) LGA Down A330076H08Rik 1448 -4.01 0.16 6.62E-04 3.47E-03 0.65 
TR(P) versus T(P) LGA Down Dlec1 5294 -4.01 0.12 6.64E-04 3.47E-03 0.72 
TR(P) versus T(P) LGA Down Ddx55 5150 -4.01 0.06 6.64E-04 3.47E-03 0.85 
TR(P) versus T(P) LGA Down Hs6st2 8232 -4.00 0.12 6.67E-04 3.48E-03 0.72 
TR(P) versus T(P) LGA Down P4ha2 11983 -4.00 0.10 6.68E-04 3.48E-03 0.76 
TR(P) versus T(P) LGA Down 1700019L03Rik 225 -4.00 0.11 6.68E-04 3.48E-03 0.74 
TR(P) versus T(P) LGA Down Prosapip1 13062 -4.00 0.08 6.76E-04 3.51E-03 0.81 
TR(P) versus T(P) LGA Down Elp3 5867 -4.00 0.05 6.77E-04 3.52E-03 0.86 
TR(P) versus T(P) LGA Down Gcc2 6919 -4.00 0.07 6.80E-04 3.53E-03 0.82 
TR(P) versus T(P) LGA Down Zmat1 18146 -3.99 0.07 6.82E-04 3.53E-03 0.82 






TR(P) versus T(P) LGA Down Tspyl1 16805 -3.99 0.12 6.93E-04 3.58E-03 0.72 
TR(P) versus T(P) LGA Down Dlg2 5297 -3.99 0.10 6.96E-04 3.58E-03 0.76 
TR(P) versus T(P) LGA Down Zmynd8 18166 -3.99 0.09 6.96E-04 3.58E-03 0.77 
TR(P) versus T(P) LGA Down Elavl2 5837 -3.98 0.16 6.99E-04 3.60E-03 0.64 
TR(P) versus T(P) LGA Up Prokr1 13056 11.57 0.21 0 0 5.46 
TR(P) versus T(P) LGA Up Hoxa1 8164 11.43 0.27 0 0 8.21 
TR(P) versus T(P) LGA Up Etv4 6051 10.96 0.16 0 0 3.49 
TR(P) versus T(P) LGA Up Spry1 15413 9.69 0.19 0 0 3.50 
TR(P) versus T(P) LGA Up Chst7 4141 9.63 0.19 0 0 3.66 
TR(P) versus T(P) LGA Up Bves 3212 9.50 0.25 0 0 5.09 
TR(P) versus T(P) LGA Up Aldh1l1 2052 9.38 0.09 0 0 1.76 
TR(P) versus T(P) LGA Up Igfbp2 8410 9.24 0.21 0 0 3.91 
TR(P) versus T(P) LGA Up Hoxa7 8173 9.20 0.29 0 0 6.54 
TR(P) versus T(P) LGA Up Sept9 14456 9.18 0.09 0 0 1.83 
TR(P) versus T(P) LGA Up Igfbp3 8411 9.03 0.11 0 0 1.97 
TR(P) versus T(P) LGA Up Frk 6707 8.86 0.14 0 0 2.37 
TR(P) versus T(P) LGA Up Gsc 7732 8.83 0.22 0 0 3.76 
TR(P) versus T(P) LGA Up Apobec1 2309 8.76 0.14 0 0 2.41 
TR(P) versus T(P) LGA Up Traf4 16597 8.74 0.21 0 0 3.53 
TR(P) versus T(P) LGA Up Lgals3bp 9281 8.39 0.18 0 0 2.84 
TR(P) versus T(P) LGA Up Akr1b10 2022 8.33 0.10 0 0 1.76 
TR(P) versus T(P) LGA Up Lgals9 9286 8.32 0.12 0 0 2.04 
TR(P) versus T(P) LGA Up Fam5c 6322 8.30 0.09 0 0 1.72 
TR(P) versus T(P) LGA Up Slfn10-ps 15053 8.28 0.19 0 0 3.02 
TR(P) versus T(P) LGA Up Rsad2 14118 8.24 0.20 0 0 3.15 
TR(P) versus T(P) LGA Up Skap2 14708 8.22 0.14 0 0 2.18 
TR(P) versus T(P) LGA Up Fgfrl1 6553 8.16 0.10 0 0 1.74 
TR(P) versus T(P) LGA Up Gng12 7481 8.16 0.13 0 0 2.04 
TR(P) versus T(P) LGA Up Lpar6 9458 8.12 0.08 0 0 1.60 






TR(P) versus T(P) LGA Up Cspg4 4634 8.02 0.12 0 0 2.00 
TR(P) versus T(P) LGA Up Stat1 15566 8.01 0.15 0 0 2.30 
TR(P) versus T(P) LGA Up Hoxa2 8168 7.99 0.31 0 0 5.67 
TR(P) versus T(P) LGA Up Dusp6 5554 7.98 0.13 0 0 2.08 
TR(P) versus T(P) LGA Up Raet1a 13482 7.91 0.15 0 0 2.29 
TR(P) versus T(P) LGA Up Usp18 17160 7.88 0.19 0 0 2.80 
TR(P) versus T(P) LGA Up Irf7 8629 7.87 0.20 0 0 3.02 
TR(P) versus T(P) LGA Up Creb5 4549 7.86 0.07 0 0 1.50 
TR(P) versus T(P) LGA Up Herc6 7997 7.85 0.15 0 0 2.24 
TR(P) versus T(P) LGA Up Niacr1 10865 7.84 0.22 0 0 3.33 
TR(P) versus T(P) LGA Up Acadl 1649 7.83 0.11 0 0 1.82 
TR(P) versus T(P) LGA Up Klhl5 9020 7.79 0.08 0 0 1.57 
TR(P) versus T(P) LGA Up Ctsc 4697 7.79 0.18 0 0 2.62 
TR(P) versus T(P) LGA Up Tmem176b 16300 7.78 0.13 0 0 2.03 
TR(P) versus T(P) LGA Up Pmaip1 12670 7.77 0.23 0 0 3.41 
TR(P) versus T(P) LGA Up Rasal3 13544 7.77 0.09 0 0 1.60 
TR(P) versus T(P) LGA Up Parp9 12077 7.69 0.13 0 0 2.01 
TR(P) versus T(P) LGA Up F2r 6111 7.63 0.12 0 0 1.92 
TR(P) versus T(P) LGA Up Tmem37 16360 7.58 0.20 0 0 2.85 
TR(P) versus T(P) LGA Up Trib2 16643 7.58 0.12 0 0 1.87 
TR(P) versus T(P) LGA Up Hoxa5 8171 7.56 0.33 0 0 5.69 
TR(P) versus T(P) LGA Up Trim25 16658 7.48 0.13 0 0 1.93 
TR(P) versus T(P) LGA Up Zranb3 18186 7.47 0.05 0 0 1.33 
TR(P) versus T(P) LGA Up Ttpa 16881 7.46 0.19 0 0 2.68 
TR(P) versus T(P) LGA Up Pdgfra 12241 7.44 0.09 0 0 1.58 
TR(P) versus T(P) LGA Up Ddx58 5152 7.43 0.13 0 0 1.96 
TR(P) versus T(P) LGA Up Tmem176a 16299 7.43 0.13 0 0 1.92 
TR(P) versus T(P) LGA Up Lpcat1 9459 7.42 0.10 0 0 1.68 
TR(P) versus T(P) LGA Up Metrnl 9983 7.41 0.10 0 0 1.68 






TR(P) versus T(P) LGA Up Dll3 5309 7.33 0.14 0 0 2.00 
TR(P) versus T(P) LGA Up Irf8 8630 7.31 0.12 0 0 1.87 
TR(P) versus T(P) LGA Up Fam83d 6351 7.30 0.07 0 0 1.46 
TR(P) versus T(P) LGA Up Plekhf2 12615 7.29 0.09 0 0 1.60 
TR(P) versus T(P) LGA Up Ercc6l 5992 7.26 0.11 0 0 1.77 
TR(P) versus T(P) LGA Up Shmt1 14654 7.25 0.10 0 0 1.67 
TR(P) versus T(P) LGA Up Tmem144 16270 7.24 0.13 0 0 1.95 
TR(P) versus T(P) LGA Up Suclg2 15660 7.24 0.11 0 0 1.75 
TR(P) versus T(P) LGA Up Irgm1 8634 7.24 0.20 0 0 2.69 
TR(P) versus T(P) LGA Up Vav3 17242 7.21 0.12 0 0 1.83 
TR(P) versus T(P) LGA Up Hexb 8007 7.19 0.09 0 0 1.55 
TR(P) versus T(P) LGA Up Zc3hav1 17724 7.18 0.09 0 0 1.53 
TR(P) versus T(P) LGA Up Oas1f 11215 7.15 0.21 0 0 2.77 
TR(P) versus T(P) LGA Up Oas2 11216 7.13 0.20 0 0 2.66 
TR(P) versus T(P) LGA Up E2f2 5632 7.11 0.11 0 0 1.75 
TR(P) versus T(P) LGA Up Papss1 12046 7.10 0.05 0 0 1.27 
TR(P) versus T(P) LGA Up Tgif2 16067 7.09 0.17 0 0 2.27 
TR(P) versus T(P) LGA Up BC064078 2986 7.08 0.25 0 0 3.47 
TR(P) versus T(P) LGA Up Kras 9070 7.08 0.07 0 0 1.39 
TR(P) versus T(P) LGA Up Mdfic 9898 7.05 0.18 0 0 2.40 
TR(P) versus T(P) LGA Up Arhgap24 2387 7.05 0.06 0 0 1.34 
TR(P) versus T(P) LGA Up Sp100 15286 7.02 0.10 5.49E-07 3.46E-05 1.62 
TR(P) versus T(P) LGA Up Galnt3 6851 6.98 0.12 5.49E-07 3.46E-05 1.78 
TR(P) versus T(P) LGA Up Prr11 13088 6.97 0.09 5.49E-07 3.46E-05 1.53 
TR(P) versus T(P) LGA Up Ifi47 8363 6.96 0.21 5.49E-07 3.46E-05 2.76 
TR(P) versus T(P) LGA Up Arhgap18 2381 6.95 0.15 5.49E-07 3.46E-05 2.02 
TR(P) versus T(P) LGA Up Ifih1 8364 6.94 0.15 5.49E-07 3.46E-05 2.06 
TR(P) versus T(P) LGA Up Gpnmb 7564 6.94 0.06 5.49E-07 3.46E-05 1.35 
TR(P) versus T(P) LGA Up Tspan12 16786 6.93 0.14 5.49E-07 3.46E-05 1.93 






TR(P) versus T(P) LGA Up Cxcl11 4745 6.91 0.20 5.49E-07 3.46E-05 2.61 
TR(P) versus T(P) LGA Up Megf6 9956 6.91 0.19 5.49E-07 3.46E-05 2.52 
TR(P) versus T(P) LGA Up Galnt4 6852 6.90 0.11 5.49E-07 3.46E-05 1.71 
TR(P) versus T(P) LGA Up Isg15 8648 6.89 0.23 5.49E-07 3.46E-05 2.97 
TR(P) versus T(P) LGA Up Trim21 16655 6.88 0.15 5.49E-07 3.46E-05 2.01 
TR(P) versus T(P) LGA Up Mpeg1 10201 6.86 0.11 5.49E-07 3.46E-05 1.65 
TR(P) versus T(P) LGA Up Bst2 3180 6.85 0.23 5.49E-07 3.46E-05 2.95 
TR(P) versus T(P) LGA Up Oas1a 11210 6.84 0.18 5.49E-07 3.46E-05 2.37 
TR(P) versus T(P) LGA Up Rtp4 14157 6.82 0.27 5.49E-07 3.46E-05 3.63 
TR(P) versus T(P) LGA Up 6720463M24Rik 1227 6.82 0.11 5.49E-07 3.46E-05 1.68 
TR(P) versus T(P) LGA Up Etv6 6053 6.82 0.07 5.49E-07 3.46E-05 1.40 
TR(P) versus T(P) LGA Up Slc15a3 14749 6.82 0.12 5.49E-07 3.46E-05 1.78 
TR(P) versus T(P) LGA Up Rab31 13408 6.82 0.12 5.49E-07 3.46E-05 1.73 
TR(P) versus T(P) LGA Up Tlcd1 16166 6.80 0.09 5.49E-07 3.46E-05 1.53 
TR(P) versus T(P) LGA Up Hus1 8305 6.77 0.07 5.49E-07 3.46E-05 1.41 
TR(P) versus T(P) LGA Up Dhx58 5260 6.77 0.16 5.49E-07 3.46E-05 2.13 
TR(P) versus T(P) LGA Up Itpripl2 8713 6.76 0.10 5.49E-07 3.46E-05 1.61 
TR(P) versus T(P) LGA Up Reep3 13682 6.76 0.08 5.49E-07 3.46E-05 1.49 
TR(P) versus T(P) LGA Up Sh3bp4 14613 6.76 0.10 5.49E-07 3.46E-05 1.63 
TR(P) versus T(P) LGA Up Gm1966 7227 6.75 0.15 5.49E-07 3.46E-05 1.99 
TR(P) versus T(P) LGA Up Ppic 12837 6.73 0.19 5.49E-07 3.46E-05 2.40 
TR(P) versus T(P) LGA Up Slfn8 15056 6.73 0.21 5.49E-07 3.46E-05 2.67 
TR(P) versus T(P) LGA Up Ctsz 4710 6.73 0.07 5.49E-07 3.46E-05 1.41 
TR(P) versus T(P) LGA Up Xaf1 17582 6.72 0.19 5.49E-07 3.46E-05 2.40 
TR(P) versus T(P) LGA Up Eps8 5970 6.72 0.17 5.49E-07 3.46E-05 2.16 
TR(P) versus T(P) LGA Up Ifi44 8362 6.71 0.23 5.49E-07 3.46E-05 2.91 
TR(P) versus T(P) LGA Up Dpf3 5454 6.71 0.12 5.49E-07 3.46E-05 1.77 
TR(P) versus T(P) LGA Up Cav3 3511 6.71 0.20 5.49E-07 3.46E-05 2.48 
TR(P) versus T(P) LGA Up Trip13 16702 6.70 0.12 5.49E-07 3.46E-05 1.78 






TR(P) versus T(P) LGA Up Ltbr 9603 6.70 0.11 5.49E-07 3.46E-05 1.70 
TR(P) versus T(P) LGA Up Cdkn2a 3924 6.70 0.15 5.49E-07 3.46E-05 2.00 
TR(P) versus T(P) LGA Up Tbccd1 15888 6.68 0.03 5.49E-07 3.46E-05 1.17 
TR(P) versus T(P) LGA Up Ifit1 8365 6.65 0.25 5.49E-07 3.46E-05 3.15 
TR(P) versus T(P) LGA Up Tor1aip1 16546 6.65 0.07 5.49E-07 3.46E-05 1.38 
TR(P) versus T(P) LGA Up C1qtnf6 3269 6.62 0.17 5.49E-07 3.46E-05 2.13 
TR(P) versus T(P) LGA Up Slfn9 15057 6.61 0.28 5.49E-07 3.46E-05 3.57 
TR(P) versus T(P) LGA Up C2 3275 6.61 0.10 5.49E-07 3.46E-05 1.56 
TR(P) versus T(P) LGA Up Phf11 12386 6.61 0.24 5.49E-07 3.46E-05 2.94 
TR(P) versus T(P) LGA Up Vcan 17247 6.61 0.10 5.49E-07 3.46E-05 1.58 
TR(P) versus T(P) LGA Up Fcgr1 6483 6.60 0.15 5.49E-07 3.46E-05 1.97 
TR(P) versus T(P) LGA Up Adora2b 1854 6.60 0.10 5.49E-07 3.46E-05 1.57 
TR(P) versus T(P) LGA Up Itpr2 8710 6.59 0.12 1.10E-06 5.02E-05 1.74 
TR(P) versus T(P) LGA Up Rrs1 14116 6.59 0.06 1.10E-06 5.02E-05 1.32 
TR(P) versus T(P) LGA Up Cbfb 3515 6.58 0.11 1.10E-06 5.02E-05 1.68 
TR(P) versus T(P) LGA Up Fabp5 6132 6.57 0.20 1.10E-06 5.02E-05 2.45 
TR(P) versus T(P) LGA Up Plek 12602 6.57 0.10 1.10E-06 5.02E-05 1.59 
TR(P) versus T(P) LGA Up LOC100504864 9412 6.57 0.23 1.10E-06 5.02E-05 2.85 
TR(P) versus T(P) LGA Up 1500001M20Rik 110 6.56 0.08 1.10E-06 5.02E-05 1.42 
TR(P) versus T(P) LGA Up Tm7sf3 16196 6.55 0.10 1.10E-06 5.02E-05 1.58 
TR(P) versus T(P) LGA Up 2010002N04Rik 407 6.55 0.17 1.10E-06 5.02E-05 2.16 
TR(P) versus T(P) LGA Up LOC100504230 9403 6.54 0.12 1.10E-06 5.02E-05 1.69 
TR(P) versus T(P) LGA Up Fen1 6507 6.53 0.09 1.10E-06 5.02E-05 1.47 
TR(P) versus T(P) LGA Up Abtb2 1638 6.52 0.16 1.10E-06 5.02E-05 2.02 
TR(P) versus T(P) LGA Up Prkcq 13012 6.52 0.13 1.10E-06 5.02E-05 1.81 
TR(P) versus T(P) LGA Up Lims2 9326 6.51 0.12 1.10E-06 5.02E-05 1.70 
TR(P) versus T(P) LGA Up Rfc3 13717 6.51 0.09 1.10E-06 5.02E-05 1.52 
TR(P) versus T(P) LGA Up Cd48 3791 6.50 0.16 1.10E-06 5.02E-05 2.09 
TR(P) versus T(P) LGA Up Mrpl51 10293 6.50 0.08 1.10E-06 5.02E-05 1.41 






TR(P) versus T(P) LGA Up Mastl 9828 6.50 0.11 1.10E-06 5.02E-05 1.62 
TR(P) versus T(P) LGA Up Epn2 5963 6.49 0.10 1.10E-06 5.02E-05 1.53 
TR(P) versus T(P) LGA Up Tesk2 16013 6.47 0.08 1.10E-06 5.02E-05 1.41 
TR(P) versus T(P) LGA Up Alpl 2100 6.46 0.15 1.10E-06 5.02E-05 1.92 
TR(P) versus T(P) LGA Up Smpdl3b 15132 6.46 0.19 1.10E-06 5.02E-05 2.36 
TR(P) versus T(P) LGA Up H2-Ab1 7846 6.46 0.18 1.10E-06 5.02E-05 2.20 
TR(P) versus T(P) LGA Up Hip1 8042 6.40 0.13 1.10E-06 5.02E-05 1.76 
TR(P) versus T(P) LGA Up Sulf2 15667 6.39 0.15 1.10E-06 5.02E-05 1.91 
TR(P) versus T(P) LGA Up Fbp1 6412 6.38 0.23 1.10E-06 5.02E-05 2.81 
TR(P) versus T(P) LGA Up Lyn 9637 6.37 0.18 1.10E-06 5.02E-05 2.26 
TR(P) versus T(P) LGA Up D14Ertd668e 4897 6.37 0.20 1.10E-06 5.02E-05 2.38 
TR(P) versus T(P) LGA Up C430049B03Rik 3309 6.35 0.17 1.10E-06 5.02E-05 2.09 
TR(P) versus T(P) LGA Up Impa2 8524 6.35 0.12 1.10E-06 5.02E-05 1.73 
TR(P) versus T(P) LGA Up Acap1 1655 6.34 0.10 1.10E-06 5.02E-05 1.57 
TR(P) versus T(P) LGA Up 5430427O19Rik 1100 6.34 0.17 1.10E-06 5.02E-05 2.12 
TR(P) versus T(P) LGA Up Spry4 15416 6.34 0.21 1.10E-06 5.02E-05 2.56 
TR(P) versus T(P) LGA Up Ppp1r14b 12877 6.32 0.10 1.10E-06 5.02E-05 1.56 
TR(P) versus T(P) LGA Up Ccl4 3680 6.32 0.22 1.10E-06 5.02E-05 2.57 
TR(P) versus T(P) LGA Up Gbp3 6906 6.32 0.27 1.10E-06 5.02E-05 3.27 
TR(P) versus T(P) LGA Up 1300014I06Rik 105 6.31 0.12 1.10E-06 5.02E-05 1.67 
TR(P) versus T(P) LGA Up Prkd3 13017 6.31 0.10 1.10E-06 5.02E-05 1.56 
TR(P) versus T(P) LGA Up Aplf 2298 6.31 0.08 1.10E-06 5.02E-05 1.40 
TR(P) versus T(P) LGA Up Parp12 12069 6.30 0.14 1.10E-06 5.02E-05 1.88 
TR(P) versus T(P) LGA Up Tlr2 16178 6.29 0.17 1.10E-06 5.02E-05 2.10 
TR(P) versus T(P) LGA Up Eda2r 5691 6.29 0.14 1.10E-06 5.02E-05 1.86 
TR(P) versus T(P) LGA Up Ms4a6c 10341 6.28 0.13 1.10E-06 5.02E-05 1.78 
TR(P) versus T(P) LGA Up Ms4a6d 10342 6.27 0.15 1.10E-06 5.02E-05 1.95 
TR(P) versus T(P) LGA Up Cacng4 3372 6.27 0.10 1.10E-06 5.02E-05 1.55 
TR(P) versus T(P) LGA Up Serpinb5 14493 6.27 0.19 1.65E-06 6.19E-05 2.29 






TR(P) versus T(P) LGA Up Mad2l1 9677 6.26 0.13 1.65E-06 6.19E-05 1.75 
TR(P) versus T(P) LGA Up Mob1a 10160 6.26 0.08 1.65E-06 6.19E-05 1.40 
TR(P) versus T(P) LGA Up Mnda 10156 6.25 0.24 1.65E-06 6.19E-05 2.78 
TR(P) versus T(P) LGA Up H2-Aa 7845 6.25 0.20 1.65E-06 6.19E-05 2.42 
TR(P) versus T(P) LGA Up Piwil4 12521 6.25 0.11 1.65E-06 6.19E-05 1.58 
TR(P) versus T(P) LGA Up Srd5a1 15436 6.24 0.11 1.65E-06 6.19E-05 1.62 
TR(P) versus T(P) LGA Up Tnfsf10 16482 6.23 0.16 1.65E-06 6.19E-05 2.01 
TR(P) versus T(P) LGA Up Fadd 6134 6.22 0.08 1.65E-06 6.19E-05 1.44 
TR(P) versus T(P) LGA Up Mosc2 10191 6.22 0.08 1.65E-06 6.19E-05 1.40 
TR(P) versus T(P) LGA Up Arl11 2442 6.22 0.14 1.65E-06 6.19E-05 1.81 
TR(P) versus T(P) LGA Up Ptprc 13293 6.22 0.10 1.65E-06 6.19E-05 1.53 
TR(P) versus T(P) LGA Up Pde4b 12222 6.21 0.06 1.65E-06 6.19E-05 1.32 
TR(P) versus T(P) LGA Up Ifit2 8366 6.21 0.12 1.65E-06 6.19E-05 1.64 
TR(P) versus T(P) LGA Up Angpt2 2157 6.21 0.28 1.65E-06 6.19E-05 3.30 
TR(P) versus T(P) LGA Up Irf9 8631 6.21 0.18 1.65E-06 6.19E-05 2.17 
TR(P) versus T(P) LGA Up Lims1 9325 6.21 0.09 1.65E-06 6.19E-05 1.49 
TR(P) versus T(P) LGA Up Palb2 12021 6.19 0.07 1.65E-06 6.19E-05 1.34 
TR(P) versus T(P) LGA Up Gm2a 7271 6.18 0.10 1.65E-06 6.19E-05 1.56 
TR(P) versus T(P) LGA Up Tmem71 16398 6.16 0.13 1.65E-06 6.19E-05 1.75 
TR(P) versus T(P) LGA Up Gramd3 7671 6.16 0.12 1.65E-06 6.19E-05 1.64 
TR(P) versus T(P) LGA Up Dctd 5084 6.16 0.09 1.65E-06 6.19E-05 1.49 
TR(P) versus T(P) LGA Up Fgfr1op2 6549 6.16 0.08 1.65E-06 6.19E-05 1.44 
TR(P) versus T(P) LGA Up Gbp5 6908 6.15 0.15 1.65E-06 6.19E-05 1.93 
TR(P) versus T(P) LGA Up F630043A04Rik 6117 6.13 0.10 1.65E-06 6.19E-05 1.54 
TR(P) versus T(P) LGA Up Eif2ak2 5785 6.13 0.14 1.65E-06 6.19E-05 1.81 
TR(P) versus T(P) LGA Up Samd9l 14233 6.13 0.19 1.65E-06 6.19E-05 2.20 
TR(P) versus T(P) LGA Up Ptgr2 13251 6.13 0.05 1.65E-06 6.19E-05 1.22 
TR(P) versus T(P) LGA Up Cmtm3 4296 6.12 0.11 1.65E-06 6.19E-05 1.59 
TR(P) versus T(P) LGA Up 4632434I11Rik 776 6.12 0.17 1.65E-06 6.19E-05 2.02 






TR(P) versus T(P) LGA Up Rad18 13464 6.11 0.13 1.65E-06 6.19E-05 1.74 
TR(P) versus T(P) LGA Up Ccdc69 3635 6.11 0.12 1.65E-06 6.19E-05 1.66 
TR(P) versus T(P) LGA Up Vegfc 17257 6.10 0.08 1.65E-06 6.19E-05 1.42 
TR(P) versus T(P) LGA Up Tmem209 16336 6.10 0.07 2.20E-06 7.83E-05 1.33 
TR(P) versus T(P) LGA Up Lyz2 9660 6.09 0.16 2.20E-06 7.83E-05 1.98 
TR(P) versus T(P) LGA Up 1700066M21Rik 318 6.09 0.11 2.20E-06 7.83E-05 1.57 
TR(P) versus T(P) LGA Up Mlkl 10107 6.09 0.13 2.20E-06 7.83E-05 1.70 
TR(P) versus T(P) LGA Up Slc12a4 14736 6.09 0.13 2.20E-06 7.83E-05 1.76 
TR(P) versus T(P) LGA Up Cdc42ep1 3845 6.08 0.12 2.20E-06 7.83E-05 1.69 
TR(P) versus T(P) LGA Up Gstcd 7755 6.08 0.10 2.20E-06 7.83E-05 1.53 
TR(P) versus T(P) LGA Up Ctss 4708 6.07 0.17 2.20E-06 7.83E-05 2.05 
TR(P) versus T(P) LGA Up Prnd 13047 6.07 0.32 2.20E-06 7.83E-05 3.80 
TR(P) versus T(P) LGA Up 4930547N16Rik 948 6.05 0.12 2.20E-06 7.83E-05 1.69 
TR(P) versus T(P) LGA Up Entpd1 5917 6.04 0.09 2.74E-06 8.50E-05 1.46 
TR(P) versus T(P) LGA Up Tmem106b 16236 6.03 0.09 2.74E-06 8.50E-05 1.43 
TR(P) versus T(P) LGA Up Dhrs13 5238 6.03 0.09 2.74E-06 8.50E-05 1.47 
TR(P) versus T(P) LGA Up Dck 5069 6.03 0.08 2.74E-06 8.50E-05 1.41 
TR(P) versus T(P) LGA Up Tube1 16901 6.03 0.05 2.74E-06 8.50E-05 1.24 
TR(P) versus T(P) LGA Up Slfn2 15054 6.03 0.19 2.74E-06 8.50E-05 2.19 
TR(P) versus T(P) LGA Up Mmp15 10138 6.02 0.18 2.74E-06 8.50E-05 2.11 
TR(P) versus T(P) LGA Up Irf5 8627 6.02 0.10 2.74E-06 8.50E-05 1.53 
TR(P) versus T(P) LGA Up Ccrl2 3724 6.02 0.11 2.74E-06 8.50E-05 1.57 
TR(P) versus T(P) LGA Up Cdca3 3858 6.02 0.14 2.74E-06 8.50E-05 1.78 
TR(P) versus T(P) LGA Up Atp13a4 2623 6.02 0.09 2.74E-06 8.50E-05 1.46 
TR(P) versus T(P) LGA Up E330016A19Rik 5643 6.01 0.09 2.74E-06 8.50E-05 1.45 
TR(P) versus T(P) LGA Up Tmem194 16321 6.00 0.09 2.74E-06 8.50E-05 1.47 
TR(P) versus T(P) LGA Up BC013712 2916 6.00 0.11 2.74E-06 8.50E-05 1.58 
TR(P) versus T(P) LGA Up Rbpms2 13639 5.99 0.11 2.74E-06 8.50E-05 1.60 
TR(P) versus T(P) LGA Up Fzd9 6790 5.99 0.11 2.74E-06 8.50E-05 1.56 






TR(P) versus T(P) LGA Up Clec7a 4238 5.98 0.37 2.74E-06 8.50E-05 4.61 
TR(P) versus T(P) LGA Up Gbp7 6910 5.98 0.21 2.74E-06 8.50E-05 2.43 
TR(P) versus T(P) LGA Up Slc25a43 14848 5.97 0.10 2.74E-06 8.50E-05 1.51 
TR(P) versus T(P) LGA Up 5730559C18Rik 1132 5.97 0.10 2.74E-06 8.50E-05 1.48 
TR(P) versus T(P) LGA Up Eme1 5872 5.96 0.13 2.74E-06 8.50E-05 1.71 
TR(P) versus T(P) LGA Up Epx 5976 5.96 0.35 2.74E-06 8.50E-05 4.30 
TR(P) versus T(P) LGA Up Dennd2a 5187 5.95 0.13 2.74E-06 8.50E-05 1.72 
TR(P) versus T(P) LGA Up Myo1f 10540 5.95 0.15 2.74E-06 8.50E-05 1.88 
TR(P) versus T(P) LGA Up Nrm 11076 5.95 0.13 2.74E-06 8.50E-05 1.68 
TR(P) versus T(P) LGA Up Epsti1 5974 5.94 0.17 2.74E-06 8.50E-05 2.00 
TR(P) versus T(P) LGA Up Kcnip3 8816 5.94 0.14 2.74E-06 8.50E-05 1.79 
TR(P) versus T(P) LGA Up Zbp1 17672 5.93 0.19 2.74E-06 8.50E-05 2.16 
TR(P) versus T(P) LGA Up Htra2 8300 5.93 0.05 2.74E-06 8.50E-05 1.22 
TR(P) versus T(P) LGA Up Cd86 3814 5.92 0.13 2.74E-06 8.50E-05 1.73 
TR(P) versus T(P) LGA Up Ctsd 4698 5.92 0.11 2.74E-06 8.50E-05 1.56 
TR(P) versus T(P) LGA Up Cxcl10 4744 5.91 0.38 3.29E-06 9.94E-05 4.76 
TR(P) versus T(P) LGA Up Calcrl 3392 5.91 0.16 3.29E-06 9.94E-05 1.91 
TR(P) versus T(P) LGA Up Tmem106a 16235 5.91 0.09 3.29E-06 9.94E-05 1.47 
TR(P) versus T(P) LGA Up Irgm2 8635 5.91 0.20 3.29E-06 9.94E-05 2.25 
TR(P) versus T(P) LGA Up Cdc42se1 3850 5.90 0.09 3.29E-06 9.94E-05 1.44 
TR(P) versus T(P) LGA Up Nasp 10640 5.90 0.10 3.29E-06 9.94E-05 1.53 
TR(P) versus T(P) LGA Up Jam2 8730 5.89 0.10 3.29E-06 9.94E-05 1.51 
TR(P) versus T(P) LGA Up Itga4 8670 5.87 0.05 4.39E-06 1.32E-04 1.25 
TR(P) versus T(P) LGA Up Gas1 6877 5.87 0.11 4.94E-06 1.39E-04 1.54 
TR(P) versus T(P) LGA Up Fam84b 6357 5.86 0.09 4.94E-06 1.39E-04 1.43 
TR(P) versus T(P) LGA Up Lrrc25 9518 5.86 0.11 4.94E-06 1.39E-04 1.58 
TR(P) versus T(P) LGA Up Adam12 1763 5.86 0.16 4.94E-06 1.39E-04 1.89 
TR(P) versus T(P) LGA Up Itgax 8680 5.86 0.15 4.94E-06 1.39E-04 1.83 
TR(P) versus T(P) LGA Up Ifi27l2a 8359 5.86 0.31 4.94E-06 1.39E-04 3.57 






TR(P) versus T(P) LGA Up Htra3 8301 5.84 0.05 4.94E-06 1.39E-04 1.25 
TR(P) versus T(P) LGA Up Arhgap31 2393 5.84 0.06 4.94E-06 1.39E-04 1.26 
TR(P) versus T(P) LGA Up Klf3 8977 5.84 0.09 4.94E-06 1.39E-04 1.47 
TR(P) versus T(P) LGA Up Rnf122 13881 5.84 0.11 4.94E-06 1.39E-04 1.57 
TR(P) versus T(P) LGA Up Fbxo5 6460 5.84 0.10 4.94E-06 1.39E-04 1.51 
TR(P) versus T(P) LGA Up Tmem173 16296 5.83 0.11 4.94E-06 1.39E-04 1.56 
TR(P) versus T(P) LGA Up Pik3cg 12478 5.83 0.10 4.94E-06 1.39E-04 1.50 
TR(P) versus T(P) LGA Up Exoc4 6073 5.82 0.08 4.94E-06 1.39E-04 1.39 
TR(P) versus T(P) LGA Up Ulbp1 17088 5.82 0.16 4.94E-06 1.39E-04 1.94 
TR(P) versus T(P) LGA Up Gpc4 7547 5.82 0.11 4.94E-06 1.39E-04 1.55 
TR(P) versus T(P) LGA Up AI607873 1960 5.82 0.19 4.94E-06 1.39E-04 2.18 
TR(P) versus T(P) LGA Up Slc16a10 14752 5.81 0.04 5.49E-06 1.50E-04 1.20 
TR(P) versus T(P) LGA Up Kif15 8917 5.81 0.14 5.49E-06 1.50E-04 1.75 
TR(P) versus T(P) LGA Up Gna14 7459 5.81 0.13 5.49E-06 1.50E-04 1.67 
TR(P) versus T(P) LGA Up Eri1 6002 5.81 0.07 5.49E-06 1.50E-04 1.33 
TR(P) versus T(P) LGA Up Pros1 13061 5.81 0.10 5.49E-06 1.50E-04 1.49 
TR(P) versus T(P) LGA Up Wipf1 17534 5.79 0.11 5.49E-06 1.50E-04 1.56 
TR(P) versus T(P) LGA Up Fam89a 6359 5.79 0.21 5.49E-06 1.50E-04 2.30 
TR(P) versus T(P) LGA Up Bcl2l13 3025 5.78 0.08 5.49E-06 1.50E-04 1.38 
TR(P) versus T(P) LGA Up Cybb 4773 5.77 0.18 6.04E-06 1.56E-04 2.07 
TR(P) versus T(P) LGA Up Rhoq 13796 5.77 0.15 6.04E-06 1.56E-04 1.81 
TR(P) versus T(P) LGA Up Acot1 1686 5.76 0.16 6.04E-06 1.56E-04 1.91 
TR(P) versus T(P) LGA Up Car3 3459 5.75 0.26 6.04E-06 1.56E-04 2.79 
TR(P) versus T(P) LGA Up 6530418L21Rik 1219 5.75 0.17 6.04E-06 1.56E-04 1.97 
TR(P) versus T(P) LGA Up Mpzl1 10227 5.75 0.14 6.04E-06 1.56E-04 1.74 
TR(P) versus T(P) LGA Up Bcl6b 3031 5.74 0.15 6.04E-06 1.56E-04 1.83 
TR(P) versus T(P) LGA Up Cbr3 3526 5.74 0.19 6.04E-06 1.56E-04 2.10 
TR(P) versus T(P) LGA Up Ifi27l1 8358 5.73 0.18 6.04E-06 1.56E-04 2.01 
TR(P) versus T(P) LGA Up Stk17b 15591 5.73 0.16 6.04E-06 1.56E-04 1.85 






TR(P) versus T(P) LGA Up 2210411K11Rik 461 5.73 0.13 6.04E-06 1.56E-04 1.71 
TR(P) versus T(P) LGA Up H2-Q10 7862 5.72 0.14 6.04E-06 1.56E-04 1.77 
TR(P) versus T(P) LGA Up Hes6 8004 5.72 0.09 6.04E-06 1.56E-04 1.41 
TR(P) versus T(P) LGA Up H2-K1 7853 5.72 0.17 6.04E-06 1.56E-04 1.96 
TR(P) versus T(P) LGA Up Slc37a2 14933 5.72 0.14 6.59E-06 1.69E-04 1.71 
TR(P) versus T(P) LGA Up Ccdc14 3579 5.71 0.08 6.59E-06 1.69E-04 1.40 
TR(P) versus T(P) LGA Up Il1rn 8486 5.71 0.09 7.14E-06 1.69E-04 1.42 
TR(P) versus T(P) LGA Up Specc1 15337 5.70 0.09 7.14E-06 1.69E-04 1.41 
TR(P) versus T(P) LGA Up Lix1l 9350 5.70 0.10 7.14E-06 1.69E-04 1.46 
TR(P) versus T(P) LGA Up Ddx60 5155 5.70 0.25 7.14E-06 1.69E-04 2.67 
TR(P) versus T(P) LGA Up Tnfaip8 16459 5.70 0.08 7.14E-06 1.69E-04 1.39 
TR(P) versus T(P) LGA Up Tlr6 16182 5.70 0.18 7.14E-06 1.69E-04 2.06 
TR(P) versus T(P) LGA Up Icam1 8323 5.70 0.18 7.14E-06 1.69E-04 2.01 
TR(P) versus T(P) LGA Up Plcb2 12579 5.69 0.05 7.14E-06 1.69E-04 1.21 
TR(P) versus T(P) LGA Up Eci2 5683 5.69 0.09 7.14E-06 1.69E-04 1.44 
TR(P) versus T(P) LGA Up Oip5 11258 5.68 0.10 7.14E-06 1.69E-04 1.49 
TR(P) versus T(P) LGA Up Nkx2-2 10904 5.68 0.14 7.14E-06 1.69E-04 1.73 
TR(P) versus T(P) LGA Up Plk4 12642 5.67 0.16 7.14E-06 1.69E-04 1.86 
TR(P) versus T(P) LGA Up Trem2 16628 5.67 0.15 7.14E-06 1.69E-04 1.77 
TR(P) versus T(P) LGA Up Sowahc 15265 5.67 0.10 7.14E-06 1.69E-04 1.48 
TR(P) versus T(P) LGA Up Tdp2 15975 5.66 0.04 7.14E-06 1.69E-04 1.19 
TR(P) versus T(P) LGA Up Slc27a6 14870 5.64 0.12 7.14E-06 1.69E-04 1.60 
TR(P) versus T(P) LGA Up Tmem229a 16350 5.64 0.15 7.14E-06 1.69E-04 1.77 
TR(P) versus T(P) LGA Up Bax 2881 5.64 0.11 7.14E-06 1.69E-04 1.53 
TR(P) versus T(P) LGA Up Arl6ip6 2459 5.64 0.10 7.14E-06 1.69E-04 1.46 
TR(P) versus T(P) LGA Up Rnf213 13924 5.64 0.14 7.14E-06 1.69E-04 1.75 
TR(P) versus T(P) LGA Up Alg13 2072 5.64 0.07 7.14E-06 1.69E-04 1.33 
TR(P) versus T(P) LGA Up Smad5 15083 5.64 0.10 7.14E-06 1.69E-04 1.46 
TR(P) versus T(P) LGA Up Dlgap5 5305 5.63 0.07 7.14E-06 1.69E-04 1.33 






TR(P) versus T(P) LGA Up Chst3 4138 5.62 0.11 7.69E-06 1.78E-04 1.53 
TR(P) versus T(P) LGA Up Eci3 5684 5.62 0.09 7.69E-06 1.78E-04 1.44 
TR(P) versus T(P) LGA Up Gas2 6878 5.61 0.08 7.69E-06 1.78E-04 1.38 
TR(P) versus T(P) LGA Up Myc 10489 5.60 0.08 8.78E-06 2.02E-04 1.38 
TR(P) versus T(P) LGA Up BC055324 2978 5.60 0.13 8.78E-06 2.02E-04 1.65 
TR(P) versus T(P) LGA Up H2-D1 7848 5.60 0.18 8.78E-06 2.02E-04 1.98 
TR(P) versus T(P) LGA Up Gm8995 7406 5.60 0.16 9.88E-06 2.18E-04 1.86 
TR(P) versus T(P) LGA Up Elovl5 5863 5.59 0.09 9.88E-06 2.18E-04 1.42 
TR(P) versus T(P) LGA Up Nrp1 11079 5.59 0.09 9.88E-06 2.18E-04 1.39 
TR(P) versus T(P) LGA Up I830012O16Rik 8316 5.59 0.20 9.88E-06 2.18E-04 2.17 
TR(P) versus T(P) LGA Up Slc11a1 14732 5.58 0.11 9.88E-06 2.18E-04 1.52 
TR(P) versus T(P) LGA Up 2810417H13Rik 678 5.58 0.15 9.88E-06 2.18E-04 1.79 
TR(P) versus T(P) LGA Up Dsn1 5510 5.58 0.12 9.88E-06 2.18E-04 1.57 
TR(P) versus T(P) LGA Up Pyhin1 13355 5.58 0.13 9.88E-06 2.18E-04 1.63 
TR(P) versus T(P) LGA Up Ggh 6984 5.58 0.11 9.88E-06 2.18E-04 1.53 
TR(P) versus T(P) LGA Up Lsm11 9579 5.58 0.11 9.88E-06 2.18E-04 1.53 
TR(P) versus T(P) LGA Up Gbp4 6907 5.58 0.20 9.88E-06 2.18E-04 2.19 
TR(P) versus T(P) LGA Up Ms4a4d 10338 5.58 0.19 9.88E-06 2.18E-04 2.11 
TR(P) versus T(P) LGA Up Bmp4 3104 5.58 0.13 9.88E-06 2.18E-04 1.65 
TR(P) versus T(P) LGA Up Batf2 2879 5.58 0.19 9.88E-06 2.18E-04 2.10 
TR(P) versus T(P) LGA Up Mars2 9817 5.57 0.07 1.04E-05 2.29E-04 1.31 
TR(P) versus T(P) LGA Up Cd180 3746 5.56 0.11 1.15E-05 2.45E-04 1.52 
TR(P) versus T(P) LGA Up Sardh 14245 5.56 0.09 1.15E-05 2.45E-04 1.39 
TR(P) versus T(P) LGA Up Slc39a8 14957 5.56 0.13 1.15E-05 2.45E-04 1.66 
TR(P) versus T(P) LGA Up Brip1 3161 5.56 0.12 1.15E-05 2.45E-04 1.61 
TR(P) versus T(P) LGA Up Ncf2 10675 5.56 0.12 1.15E-05 2.45E-04 1.58 
TR(P) versus T(P) LGA Up Mtap 10377 5.56 0.09 1.15E-05 2.45E-04 1.43 
TR(P) versus T(P) LGA Up Osmr 11926 5.55 0.10 1.15E-05 2.45E-04 1.45 
TR(P) versus T(P) LGA Up Ogfr 11253 5.55 0.08 1.15E-05 2.45E-04 1.36 






TR(P) versus T(P) LGA Up Afmid 1888 5.55 0.08 1.21E-05 2.53E-04 1.33 
TR(P) versus T(P) LGA Up Cmtm6 4299 5.54 0.08 1.21E-05 2.53E-04 1.35 
TR(P) versus T(P) LGA Up Gm11127 7116 5.54 0.17 1.21E-05 2.53E-04 1.94 
TR(P) versus T(P) LGA Up Tlr7 16183 5.54 0.15 1.21E-05 2.53E-04 1.78 
TR(P) versus T(P) LGA Up Twsg1 16925 5.54 0.04 1.26E-05 2.61E-04 1.16 
TR(P) versus T(P) LGA Up 5930416I19Rik 1163 5.53 0.09 1.26E-05 2.61E-04 1.40 
TR(P) versus T(P) LGA Up Ccbl2 3546 5.53 0.12 1.26E-05 2.61E-04 1.59 
TR(P) versus T(P) LGA Up Ick 8327 5.53 0.05 1.26E-05 2.61E-04 1.23 
TR(P) versus T(P) LGA Up Calu 3404 5.52 0.09 1.32E-05 2.70E-04 1.41 
TR(P) versus T(P) LGA Up Ndufa9 10728 5.51 0.06 1.32E-05 2.70E-04 1.27 
TR(P) versus T(P) LGA Up C330027C09Rik 3305 5.51 0.14 1.32E-05 2.70E-04 1.72 
TR(P) versus T(P) LGA Up Tap1 15833 5.50 0.19 1.43E-05 2.89E-04 2.09 
TR(P) versus T(P) LGA Up Gm22 7256 5.50 0.09 1.43E-05 2.89E-04 1.43 
TR(P) versus T(P) LGA Up Nek8 10784 5.50 0.10 1.43E-05 2.89E-04 1.47 
TR(P) versus T(P) LGA Up Lcp1 9238 5.49 0.08 1.43E-05 2.89E-04 1.34 
TR(P) versus T(P) LGA Up Prkd1 13015 5.49 0.14 1.43E-05 2.89E-04 1.71 
TR(P) versus T(P) LGA Up Ifit3 8367 5.49 0.14 1.48E-05 2.89E-04 1.68 
TR(P) versus T(P) LGA Up Fyb 6777 5.48 0.13 1.48E-05 2.89E-04 1.61 
TR(P) versus T(P) LGA Up Lrig1 9487 5.48 0.19 1.48E-05 2.89E-04 2.09 
TR(P) versus T(P) LGA Up Slamf6 14722 5.48 0.07 1.48E-05 2.89E-04 1.32 
TR(P) versus T(P) LGA Up Cd72 3805 5.48 0.20 1.48E-05 2.89E-04 2.11 
TR(P) versus T(P) LGA Up Bcdin3d 3011 5.48 0.05 1.48E-05 2.89E-04 1.20 
TR(P) versus T(P) LGA Up Mtbp 10389 5.48 0.10 1.48E-05 2.89E-04 1.44 
TR(P) versus T(P) LGA Up Gpr65 7630 5.47 0.16 1.48E-05 2.89E-04 1.80 
TR(P) versus T(P) LGA Up Spry2 15414 5.47 0.13 1.48E-05 2.89E-04 1.63 
TR(P) versus T(P) LGA Up Fyn 6779 5.47 0.09 1.48E-05 2.89E-04 1.43 
TR(P) versus T(P) LGA Up Hcls1 7938 5.47 0.09 1.48E-05 2.89E-04 1.39 
TR(P) versus T(P) LGA Up Abhd2 1618 5.46 0.11 1.54E-05 2.89E-04 1.52 
TR(P) versus T(P) LGA Up H2-Q5 7865 5.46 0.18 1.54E-05 2.89E-04 1.97 






TR(P) versus T(P) LGA Up Pola2 12723 5.44 0.08 1.54E-05 2.89E-04 1.34 
TR(P) versus T(P) LGA Up Gpr84 7637 5.44 0.15 1.54E-05 2.89E-04 1.75 
TR(P) versus T(P) LGA Up Hoxa4 8170 5.43 0.17 1.54E-05 2.89E-04 1.92 
TR(P) versus T(P) LGA Up E030003E18Rik 5589 5.43 0.21 1.54E-05 2.89E-04 2.19 
TR(P) versus T(P) LGA Up Fam195a 6274 5.43 0.09 1.54E-05 2.89E-04 1.41 
TR(P) versus T(P) LGA Up Hpse 8211 5.43 0.11 1.54E-05 2.89E-04 1.52 
TR(P) versus T(P) LGA Up Il4ra 8507 5.43 0.11 1.54E-05 2.89E-04 1.49 
TR(P) versus T(P) LGA Up Rab8b 13442 5.43 0.12 1.54E-05 2.89E-04 1.57 
TR(P) versus T(P) LGA Up D630039A03Rik 4960 5.42 0.11 1.54E-05 2.89E-04 1.50 
TR(P) versus T(P) LGA Up H2-Q8 7867 5.42 0.23 1.54E-05 2.89E-04 2.38 
TR(P) versus T(P) LGA Up Fsbp 6723 5.41 0.10 1.59E-05 2.93E-04 1.45 
TR(P) versus T(P) LGA Up Ppat 12821 5.40 0.05 1.59E-05 2.93E-04 1.20 
TR(P) versus T(P) LGA Up 1810010H24Rik 369 5.40 0.14 1.65E-05 2.93E-04 1.68 
TR(P) versus T(P) LGA Up Ets1 6047 5.40 0.11 1.65E-05 2.93E-04 1.52 
TR(P) versus T(P) LGA Up Cenpq 3986 5.39 0.14 1.65E-05 2.93E-04 1.71 
TR(P) versus T(P) LGA Up Tnfsf9 16489 5.39 0.06 1.65E-05 2.93E-04 1.25 
TR(P) versus T(P) LGA Up Mtmr14 10418 5.39 0.07 1.65E-05 2.93E-04 1.29 
TR(P) versus T(P) LGA Up Chrdl1 4111 5.38 0.19 1.65E-05 2.93E-04 2.02 
TR(P) versus T(P) LGA Up Lpin3 9469 5.38 0.12 1.65E-05 2.93E-04 1.56 
TR(P) versus T(P) LGA Up Olig2 11865 5.38 0.14 1.65E-05 2.93E-04 1.68 
TR(P) versus T(P) LGA Up Lin9 9334 5.38 0.07 1.65E-05 2.93E-04 1.29 
TR(P) versus T(P) LGA Up Klhdc5 8989 5.38 0.08 1.65E-05 2.93E-04 1.35 
TR(P) versus T(P) LGA Up Lpo 9471 5.38 0.32 1.65E-05 2.93E-04 3.30 
TR(P) versus T(P) LGA Up Sirt2 14692 5.37 0.08 1.65E-05 2.93E-04 1.33 
TR(P) versus T(P) LGA Up Trim30a 16664 5.37 0.19 1.65E-05 2.93E-04 2.05 
TR(P) versus T(P) LGA Up Oasl2 11219 5.37 0.29 1.65E-05 2.93E-04 2.99 
TR(P) versus T(P) LGA Up H2-Q2 7863 5.36 0.18 1.65E-05 2.93E-04 1.95 
TR(P) versus T(P) LGA Up Elovl2 5860 5.36 0.12 1.65E-05 2.93E-04 1.58 
TR(P) versus T(P) LGA Up Kif2c 8936 5.36 0.12 1.65E-05 2.93E-04 1.54 






TR(P) versus T(P) LGA Up Abcb1b 1582 5.35 0.06 1.65E-05 2.93E-04 1.27 
TR(P) versus T(P) LGA Up Tbxas1 15916 5.35 0.11 1.65E-05 2.93E-04 1.49 
TR(P) versus T(P) LGA Up Tmem111 16243 5.34 0.09 1.65E-05 2.93E-04 1.40 
TR(P) versus T(P) LGA Up Cflar 4037 5.34 0.05 1.65E-05 2.93E-04 1.22 
TR(P) versus T(P) LGA Up Axl 2748 5.34 0.12 1.76E-05 3.09E-04 1.57 
TR(P) versus T(P) LGA Up 1700040I03Rik 289 5.34 0.10 1.81E-05 3.09E-04 1.45 
TR(P) versus T(P) LGA Up Elk3 5846 5.33 0.10 1.81E-05 3.09E-04 1.43 
TR(P) versus T(P) LGA Up Pcdh12 12117 5.33 0.11 1.81E-05 3.09E-04 1.48 
TR(P) versus T(P) LGA Up Mcm8 9884 5.33 0.10 1.81E-05 3.09E-04 1.46 
TR(P) versus T(P) LGA Up Fgr 6558 5.33 0.18 1.81E-05 3.09E-04 1.93 
TR(P) versus T(P) LGA Up 1700029F09Rik 267 5.33 0.09 1.81E-05 3.09E-04 1.38 
TR(P) versus T(P) LGA Up Hyal2 8310 5.32 0.04 1.81E-05 3.09E-04 1.18 
TR(P) versus T(P) LGA Up Pld4 12598 5.32 0.12 1.81E-05 3.09E-04 1.58 
TR(P) versus T(P) LGA Up Klhl6 9021 5.32 0.15 1.81E-05 3.09E-04 1.75 
TR(P) versus T(P) LGA Up Lmo2 9370 5.32 0.10 1.81E-05 3.09E-04 1.45 
TR(P) versus T(P) LGA Up H2-D4 7849 5.32 0.17 1.81E-05 3.09E-04 1.90 
TR(P) versus T(P) LGA Up H2-T23 7869 5.31 0.21 1.81E-05 3.09E-04 2.19 
TR(P) versus T(P) LGA Up Pdha1 12244 5.31 0.04 1.81E-05 3.09E-04 1.18 
TR(P) versus T(P) LGA Up Thumpd3 16119 5.31 0.07 1.81E-05 3.09E-04 1.28 
TR(P) versus T(P) LGA Up Tgtp1 16078 5.31 0.20 1.81E-05 3.09E-04 2.09 
TR(P) versus T(P) LGA Up H2-Q7 7866 5.30 0.20 1.81E-05 3.09E-04 2.09 
TR(P) versus T(P) LGA Up Lmf1 9363 5.30 0.05 1.81E-05 3.09E-04 1.19 
TR(P) versus T(P) LGA Up Hsdl2 8251 5.30 0.10 1.87E-05 3.10E-04 1.42 
TR(P) versus T(P) LGA Up Tdg 15970 5.30 0.05 1.87E-05 3.10E-04 1.20 
TR(P) versus T(P) LGA Up Atad2 2569 5.29 0.12 1.87E-05 3.10E-04 1.57 
TR(P) versus T(P) LGA Up Emr1 5888 5.29 0.08 1.92E-05 3.10E-04 1.35 
TR(P) versus T(P) LGA Up Chst2 4137 5.29 0.14 1.92E-05 3.10E-04 1.64 
TR(P) versus T(P) LGA Up Mest 9977 5.29 0.19 1.92E-05 3.10E-04 2.02 
TR(P) versus T(P) LGA Up Hvcn1 8308 5.29 0.13 1.92E-05 3.10E-04 1.64 






TR(P) versus T(P) LGA Up A130010J15Rik 1411 5.28 0.08 1.92E-05 3.10E-04 1.33 
TR(P) versus T(P) LGA Up Pla2g7 12564 5.28 0.10 1.92E-05 3.10E-04 1.45 
TR(P) versus T(P) LGA Up Irf1 8621 5.28 0.11 1.92E-05 3.10E-04 1.49 
TR(P) versus T(P) LGA Up Mx2 10471 5.28 0.19 1.92E-05 3.10E-04 2.02 
TR(P) versus T(P) LGA Up Naif1 10612 5.28 0.04 1.92E-05 3.10E-04 1.17 
TR(P) versus T(P) LGA Up Rrm2 14104 5.27 0.18 1.92E-05 3.10E-04 1.90 
TR(P) versus T(P) LGA Up Cdh11 3868 5.27 0.07 1.92E-05 3.10E-04 1.28 
TR(P) versus T(P) LGA Up Rad51ap1 13470 5.27 0.17 1.92E-05 3.10E-04 1.83 
TR(P) versus T(P) LGA Up C3ar1 3307 5.26 0.11 1.98E-05 3.10E-04 1.49 
TR(P) versus T(P) LGA Up Rad54l 13476 5.26 0.13 1.98E-05 3.10E-04 1.60 
TR(P) versus T(P) LGA Up Tmem48 16373 5.26 0.10 1.98E-05 3.10E-04 1.43 
TR(P) versus T(P) LGA Up Ephx1 5956 5.26 0.14 1.98E-05 3.10E-04 1.66 
TR(P) versus T(P) LGA Up Vhl 17264 5.26 0.08 1.98E-05 3.10E-04 1.34 
TR(P) versus T(P) LGA Up Fam181a 6256 5.25 0.09 1.98E-05 3.10E-04 1.39 
TR(P) versus T(P) LGA Up Igtp 8438 5.25 0.26 1.98E-05 3.10E-04 2.54 
TR(P) versus T(P) LGA Up Pdlim5 12261 5.25 0.07 1.98E-05 3.10E-04 1.28 
TR(P) versus T(P) LGA Up Fancd2 6372 5.25 0.09 1.98E-05 3.10E-04 1.38 
TR(P) versus T(P) LGA Up Frrs1 6717 5.24 0.11 1.98E-05 3.10E-04 1.47 
TR(P) versus T(P) LGA Up H2afb1 7872 5.24 0.15 1.98E-05 3.10E-04 1.76 
TR(P) versus T(P) LGA Up Arhgap11a 2377 5.24 0.16 1.98E-05 3.10E-04 1.79 
TR(P) versus T(P) LGA Up Cdk2 3900 5.24 0.14 1.98E-05 3.10E-04 1.67 
TR(P) versus T(P) LGA Up Gpr160 7597 5.24 0.11 1.98E-05 3.10E-04 1.50 
TR(P) versus T(P) LGA Up Fam111a 6165 5.23 0.14 1.98E-05 3.10E-04 1.69 
TR(P) versus T(P) LGA Up Haus3 7912 5.23 0.13 1.98E-05 3.10E-04 1.61 
TR(P) versus T(P) LGA Up Zcchc24 17736 5.23 0.09 1.98E-05 3.10E-04 1.36 
TR(P) versus T(P) LGA Up Tor3a 16550 5.23 0.10 1.98E-05 3.10E-04 1.41 
TR(P) versus T(P) LGA Up Cd84 3813 5.23 0.18 1.98E-05 3.10E-04 1.90 
TR(P) versus T(P) LGA Up Dfna5 5212 5.23 0.03 1.98E-05 3.10E-04 1.12 
TR(P) versus T(P) LGA Up Lyrm5 9652 5.22 0.10 2.03E-05 3.17E-04 1.45 






TR(P) versus T(P) LGA Up Lyl1 9636 5.22 0.10 2.03E-05 3.17E-04 1.42 
TR(P) versus T(P) LGA Up Kank1 8760 5.21 0.13 2.09E-05 3.19E-04 1.59 
TR(P) versus T(P) LGA Up Cyp24a1 4792 5.21 0.25 2.09E-05 3.19E-04 2.43 
TR(P) versus T(P) LGA Up Cd40 3786 5.21 0.10 2.09E-05 3.19E-04 1.44 
TR(P) versus T(P) LGA Up Tnfrsf19 16471 5.21 0.13 2.09E-05 3.19E-04 1.62 
TR(P) versus T(P) LGA Up Slc25a15 14819 5.21 0.14 2.09E-05 3.19E-04 1.65 
TR(P) versus T(P) LGA Up Tmpo 16429 5.21 0.10 2.09E-05 3.19E-04 1.44 
TR(P) versus T(P) LGA Up Parp14 12070 5.21 0.17 2.09E-05 3.19E-04 1.82 
TR(P) versus T(P) LGA Up C230035I16Rik 3277 5.20 0.12 2.14E-05 3.27E-04 1.53 
TR(P) versus T(P) LGA Up Apoc1 2313 5.20 0.20 2.20E-05 3.34E-04 2.04 
TR(P) versus T(P) LGA Up Cxcl16 4749 5.20 0.14 2.20E-05 3.34E-04 1.64 
TR(P) versus T(P) LGA Up Iigp1 8440 5.19 0.32 2.31E-05 3.49E-04 3.14 
TR(P) versus T(P) LGA Up Vav1 17240 5.19 0.08 2.36E-05 3.56E-04 1.32 
TR(P) versus T(P) LGA Up Pcyox1 12191 5.19 0.06 2.36E-05 3.56E-04 1.24 
TR(P) versus T(P) LGA Up Foxc1 6663 5.19 0.18 2.36E-05 3.56E-04 1.93 
TR(P) versus T(P) LGA Up 9930014A18Rik 1390 5.18 0.13 2.42E-05 3.58E-04 1.59 
TR(P) versus T(P) LGA Up Cd68 3801 5.18 0.11 2.42E-05 3.58E-04 1.50 
TR(P) versus T(P) LGA Up Neu4 10799 5.18 0.16 2.42E-05 3.58E-04 1.76 
TR(P) versus T(P) LGA Up Orc1 11893 5.18 0.13 2.42E-05 3.58E-04 1.59 
TR(P) versus T(P) LGA Up Gjc3 7034 5.18 0.12 2.42E-05 3.58E-04 1.53 
TR(P) versus T(P) LGA Up P2ry6 11981 5.17 0.13 2.42E-05 3.58E-04 1.58 
TR(P) versus T(P) LGA Up Cdk2ap1 3902 5.17 0.09 2.42E-05 3.58E-04 1.36 
TR(P) versus T(P) LGA Up Cfb 4029 5.17 0.30 2.53E-05 3.67E-04 2.93 
TR(P) versus T(P) LGA Up Mlec 10101 5.17 0.07 2.53E-05 3.67E-04 1.30 
 
Table S2.3.  One versus rest SAM analysis of T(RP) LGA transcriptomes at 2 m after induction.   One versus rest significance of microarray 
(SAM) analyses identified 7949 and 2460 genes with significantly increased (Up) and decreased (Down) expression in LGA versus histologically 
normal brain and LGA with [TR(P)] versus without [T(P)] KrasG12D at FDR of 0.001 and 0.01, respectively.  This table lists the 500 most increased 
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Table S2.4.  KrasG12D immune LGA signature.   A 300 gene KrasG12D immune signature was identified by SAM of LGA transcriptomes with 










































RP+/- Normal     7 
RP-/- Normal     10 
T 
A2     11 
A3     3 
TP+/- 
A2     20 
A3     4 
TP-/- 
A2     15 
A3     3 
TR 
A2     10 
A3 3 3 20 










A3 6 6 18 
GBM 19 20 21 
TRP-/- 
A2     9 
A3 3 3 11 
GBM 5 5 16 
Total 41 43 226 
       
  Mean SD Min Max 
 Age at induction (days) 107.9 22.2 31 183 
  
Table S2.5.  TRP HGA cohort:  Mice aged to neurological morbidity.   Adult GFAP-CreER mice with various combinations of T, R, and P alleles 
were induced with 4OHT at ~3 m of age (mean 108, SD 22 d) and aged to neurological morbidity or sacrificed healthy at 7-19 m.  Uninduced 
GFAP-CreER mice (N=2), induced mice lacking GFAP-CreER (N=7), and induced GFAP-CreER mice with wild-type (WT), P, R, or RP oncogenic 























Mutated Samples (%) 
 
Gene 
Mutated Samples (%) 
 
Gene 
Mutated Samples (%) 
 
Gene 
Mutated Samples (%) 
Gain Loss Total 
 
Gain Loss Total 
 
Gain Loss Total 
 
Gain Loss Total 
 
Gain Loss Total 
Ccnd2 67 67 67 
 
Met 67 0 67 
 
Braf 69 0 69 
 
Foxo2 5 0 5 
 
Mdm4 24 0 24 
Stat1 21 0 21 
 
Egfr 2 5 7 
 
Kras 69 0 69 
 
Pten 0 5 5 
 
Trp53 2 7 10 
E2f6 0 7 7 
 
Erbb2 2 5 7 
 
Raf1 67 0 67 
 
Akt2 0 2 2 
 
Cdkn2a 0 2 2 
E2f7 0 7 7 
 
Pdgfb 7 0 7 
 
Map2k4 2 10 12 
 
Akt2s2 0 2 2 
 
Mdm2 0 2 2 
Myc 7 0 7 
 
Pdgfa 5 0 5 
 
Dab2 10 0 10 
 
Akt5 2 0 2 
 
Trp53bp1 2 0 2 
Stat3 2 5 7 
 
Fgf1 2 0 2 
 
Mapk9 2 7 10 
 
Pik3ca 2 0 2 
     Stat5a 2 5 7 
 
Fgfr1 2 0 2 
 
Map2k3 2 5 7 
 
Pik3r5 2 0 2 
     Stat5b 2 5 7 
 
Igf1r 0 2 2 
 
Map3k3 2 5 7 
 
Pdpk2 0 0 0 
     Ccna1 5 0 5 
 
Pdgfrb 2 0 2 
 
Mapk12 5 2 7 
 
Pik3r2 0 0 0 
     E2f2 2 2 5 
 
Erbb3 0 0 0 
 
Mapk7 2 5 7 
 
Rheb 0 0 0 
     E2f8 0 5 5 
 
Igf1 0 0 0 
 
Rab25 5 0 5 
 
Tsc2 0 0 0 
     Jak2 0 5 5 
 
Kdr 0 0 0 
 
Hras1 0 2 2 
 
Tsc5 0 0 0 
     Ccnd1 0 2 2 
 
Kit 0 0 0 
 
Map3k2 2 0 2 
          Ccne1 0 2 2 
 
Pdgfra 0 0 0 
 
Mapk1 2 0 2 
          Cdk6 0 2 2 
 
Vegfa 0 0 0 
 
Mapk3 0 2 2 
          Cdkn2a 0 2 2 
 
Vegfb 0 0 0 
 
Map2k1 0 0 0 
          E2f1 2 0 2 
      
Map2k2 0 0 0 
          E2f3 0 2 2 
      
Map2k5 0 0 0 
          E2f5 2 0 2 
      
Map3k1 0 0 0 
          Jak1 0 2 2 
      
Map3k4 0 0 0 
          Rbl1 2 0 2 
      
Map3k5 0 0 0 
          Src 2 0 2 
      
Mapk14 0 0 0 
          Ccnb1 0 0 0 
      
Mapk4 0 0 0 
          Cdc25a 0 0 0 
      
Mapk6 0 0 0 






Cdk2 0 0 0 
      
Mapk8 0 0 0 
          Cdk4 0 0 0 
      
Rassf1 0 0 0 
          Cdkn1a 0 0 0 
                    E2f4 0 0 0 
                    Rb1 0 0 0 
                    Rbl2 0 0 0 
                    Stat2 0 0 0 
                     
Table S2.6.  CNA in Rb, RTK, MAPK, PI3K, and Trp53 pathway genes in TR(P) HGA.   Copy number gains and losses for the indicated Rb, RTK, 







Table S2.7. CNA in spatially distinct TR(P) HGA show evidence of clonal evolution 
Mouse ID CNA 
HGA 1 Location   HGA 2 Location 
Chromosome Start End   Chromosome Start End 
235344 
  BS   DI 
Gain 
6 3407797 149520604 
 
1 84771143 96148343 
    
5 24498907 40604784 
    
5 43178200 45514283 
    
6 3386664 125527378 
    
13 55502290 74249044 
    
19 37295134 37505277 
Loss 
2 86040946 90813486   11 52603926 121796672 
8 49770240 69609457   14 68219133 68432377 
10 91355355 116504740   15 42866402 54539782 
13 17168563 29133133         
13 116505113 120606172         
14 79020241 115431576         
16 66635653 86219861         
17 35948984 42090956         
 
        
236024 
  CTX   OFB 
Gain 
4 111551341 112104179 
 
4 111634766 112114746 
6 3734548 138332452 
 
6 3373820 106180182 
Loss 
1 109642970 119351601   None     
2 85392180 89836288         
5 9630570 19355183         
8 99365014 106947658         






13 116761502 120606172         
14 78985869 91624735         
14 105500491 112936324         
15 13453095 24598294         
15 42245596 54539782         
16 59482110 83786212         
 
        
244706 
   OFB   BS 
Gain 
6 3763705 138332452 
 
1 9863 169875650 
    
6 3024849 131473159 
Loss 
1 159251360 170278139   2 137186961 149502225 
1 175677083 176180255   4 144867593 146628899 
2 137634657 149072625   8 14227242 17834414 
4 144867593 146659327   11 33530019 47916916 
11 71035484 71319408   11 62582530 72429309 
13 116761502 118916994   12 26428637 31422158 
        13 116754485 119063864 
        16 59406082 90816204 
 
        
244939 
  CTX   OFB 
Gain 17 30169694 30650214 
 
6 3024849 105935318 
Loss 5 104804922 105242139   5 104488686 105176403 
 
        
245116 
  CTX   DI 
Loss 
4 111579573 112104179   2 136784609 149072625 
4 112114745 113386023   4 111579573 112091073 
12 16353603 30880108   4 112304580 113356036 
        12 16353603 31508274 
        13 116743684 119063864 
 







  CTX   OFB 
Loss 13 116754485 119072276   None     
         
CNA in Rb, RTK/MAPK/PI3K, and Trp53 pathway genes 
Mouse ID   Genotype Common CNA Unique CNA 
235344   TR 
Ccnd2, Braf, Kras, 
Raf1 
E2f7, Stat3, Stat5a, Stat5b, Erbb2, Met, Map2k3, Map2k4, 




Ccnd2, Met, Braf, 
Kras, Raf1 
E2f2 
244706   TRP+/- 
Ccnd2, Met, Braf, 
Kras, Raf1 
Stat1, Map2k4, Mdm4, Trp53 
244939 
 
TRP+/- None Ccnd2, Met, Braf, Kras, Raf1 
245116   TRP+/- None E2f6 
246270   TRP-/- None None 
 
Table S2.7.  CNA in spatially distinct TR(P) HGA show evidence of clonal evolution.   Six mice from Table S2.6 had HGA in two spatially 


























245304_BS 245304 TRP+/- BS S1 Classical Yes 4.27 No A3 
232366_BS 232366 TR BS S1 Mesenchymal Yes 3.52 No GBM 
235316_BS 235316 TR BS S1 Mesenchymal Yes 4.93 No GBM 
246742_CTX 246742 TR CTX S1 Mesenchymal Yes 4.83 No GBM 
236070_CTX 236070 TRP-/- CTX S1 Mesenchymal Yes 3.12 No A3 
245586_BS 245586 TRP-/- BS S1 Mesenchymal Yes 2.33 No A3 
233106_BS 233106 TRP+/- BS S1 Mesenchymal Yes 4.7 No GBM 
234451_OFB 234451 TRP+/- OFB S1 Mesenchymal Yes 4.24 No GBM 
236024_1_CTX 236024 TRP+/- CTX S1 Mesenchymal Yes 3.94 No GBM 
244190_BS 244190 TRP+/- BS S1 Mesenchymal Yes 3.06 No A3 
244706_2_BS 244706 TRP+/- BS S1 Mesenchymal Yes 3.32 No GBM 
245016_BS 245016 TRP+/- BS S1 Mesenchymal Yes 3.55 No A3 
245660_1_BS 245660 TRP+/- BS S1 Mesenchymal Yes 3.81 No GBM 
245662_BS 245662 TRP+/- BS S1 Mesenchymal Yes 3.48 No GBM 
245936_BS 245936 TRP+/- BS S1 Mesenchymal Yes 3.52 No GBM 
246300_BS 246300 TRP+/- BS S1 Mesenchymal Yes 4.17 No GBM 
246302_BS 246302 TRP+/- BS S1 Mesenchymal Yes 3.35 No GBM 
234458_DI 234458 TRP+/- DI S1 Neural No (Excluded) 4.7 No GBM 
235344_2_DI 235344 TR DI S2 Classical Yes 4.47 No GBM 
236024_2_OFB 236024 TRP+/- OFB S2 Classical Yes 3.94 No GBM 
235791_BS 235791 TR BS S2 Proneural Yes 4.27 No A3 
245665_OFB 245665 TRP-/- OFB S2 Proneural Yes 1.97 Yes A3 
233117_OFB 233117 TRP+/- OFB S2 Proneural Yes 3.68 No GBM 
241898_BS 241898 TRP+/- BS S2 Proneural Yes 4.6 No GBM 
244706_1_OFB 244706 TRP+/- OFB S2 Proneural Yes 3.32 No GBM 
245660_2_OFB 245660 TRP+/- CTX S2 Proneural Yes 3.81 No GBM 
242092_BS 242092 TR BS S3 Mesenchymal Yes 4.17 No A3 
234750_BS 234750 TR BS S3 Neural Yes 4.5 No GBM 






241102_DI 241102 TRP-/- DI S3 Neural Yes 3.25 No GBM 
242486_DI 242486 TRP-/- DI S3 Neural Yes 3.22 No GBM 
245237_DI 245237 TRP-/- DI S3 Neural Yes 2.1 No GBM 
246270_2_OFB 246270 TRP-/- OFB S3 Neural Yes 1.91 No GBM 
244189_DI 244189 TRP+/- DI S3 Neural Yes 3.91 No A3 
244605_CTX 244605 TRP+/- CTX S3 Neural Yes 4.14 No GBM 
244939_2_OFB 244939 TRP+/- OFB S3 Neural Yes 3.94 No A3 
245116_1_CTX 245116 TRP+/- CTX S3 Neural Yes 3.48 No GBM 
245116_2_DI 245116 TRP+/- DI S3 Neural Yes 3.48 No GBM 
235344_1_BS 235344 TR BS S3 Proneural Yes 4.47 No GBM 
246270_1_CTX 246270 TRP-/- CTX S3 Proneural Yes 1.91 No GBM 
233352_OFB 233352 TRP+/- OFB S3 Proneural Yes 4.24 No GBM 
243852_OFB 243852 TRP+/- OFB S3 Proneural Yes 4.17 No GBM 
244939_1_CTX 244939 TRP+/- CTX S3 Proneural Yes 3.94 No A3 
 
Table S2.8.  TR(P) HGA transcriptome samples.   Forty-three HGA samples from 36 TR(P) mice were utilized for transcriptome analyses in 
Figs. 6 and S17-19.  Initiating genotype did not correlate with HGA location or subtype (Fisher P≤0.6).  HGA subtype correlated with location 
(P=0.004) and human GBM (TCGA) subtype (P<0.0001).  Seven mice developed spatially distinct HGA; four pairs showed different HGA S1-S3 







Table S2.9.  HGA subtypes S1-S3 600-gene classifier 




























































































































































































































































































































































































































































































































































































































































































Table S2.7A.  GO lists from HGA S1 (Mesenchymal) Subtype SAM analysis 
Gene Set Name # Genes in Gene Set (K) # Genes in Overlap (k) k/K p value 
HEMATOPOIETIN_INTERFERON_CLASSD200_DOMAIN_CYTOKINE_RECEPTOR_ACTIVITY 32 12 0.375 2.11E-04 
CYTOKINE_BINDING 46 15 0.3261 2.18E-04 
EXTRACELLULAR_MATRIX_PART 57 16 0.2807 8.99E-04 
REGULATION_OF_PROTEIN_IMPORT_INTO_NUCLEUS 16 7 0.4375 1.61E-03 
PROTEINACEOUS_EXTRACELLULAR_MATRIX 98 22 0.2245 2.85E-03 
REGULATION_OF_NUCLEOCYTOPLASMIC_TRANSPORT 22 8 0.3636 3.06E-03 
EXTRACELLULAR_MATRIX 100 22 0.22 3.70E-03 
POSITIVE_REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 80 18 0.225 6.44E-03 
REGULATION_OF_INTRACELLULAR_TRANSPORT 25 8 0.32 7.43E-03 
BASAL_LAMINA 21 7 0.3333 9.49E-03 
BASEMENT_MEMBRANE 37 10 0.2703 1.07E-02 
REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 86 18 0.2093 1.38E-02 
LIPOPROTEIN_BINDING 18 6 0.3333 1.61E-02 
POSITIVE_REGULATION_OF_JNK_ACTIVITY 18 6 0.3333 1.61E-02 
POSITIVE_REGULATION_OF_MAP_KINASE_ACTIVITY 46 11 0.2391 1.93E-02 
INTERLEUKIN_RECEPTOR_ACTIVITY 19 6 0.3158 2.12E-02 
REGULATION_OF_JNK_ACTIVITY 20 6 0.3 2.72E-02 
I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 107 20 0.1869 3.15E-02 
GROWTH_FACTOR_BINDING 32 8 0.25 3.36E-02 
NON_MEMBRANE_SPANNING_PROTEIN_TYROSINE_KINASE_ACTIVITY 11 4 0.3636 3.53E-02 
ACTIVATION_OF_JNK_ACTIVITY 16 5 0.3125 3.62E-02 
ORGAN_MORPHOGENESIS 144 25 0.1736 4.01E-02 
PROTEIN_KINASE_CASCADE 282 44 0.156 4.62E-02 
RAS_PROTEIN_SIGNAL_TRANSDUCTION 65 13 0.2 4.62E-02 
ACTIVATION_OF_MAPK_ACTIVITY 40 9 0.225 4.67E-02 
GLYCOPROTEIN_CATABOLIC_PROCESS 12 4 0.3333 4.80E-02 
LOW_DENSITY_LIPOPROTEIN_BINDING 12 4 0.3333 4.80E-02 
POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION 119 21 0.1765 4.87E-02 
 
Table S2.7B.  GO lists from HGA S2 (Proneural) Subtype SAM analysis 
Gene Set Name # Genes in Gene Set (K) # Genes in Overlap (k) k/K p value 
M_PHASE_OF_MITOTIC_CELL_CYCLE 83 26 0.3133 2.92E-08 
MITOTIC_CELL_CYCLE 148 37 0.25 3.46E-08 
MITOSIS 81 25 0.3086 7.48E-08 
RNA_SPLICING 82 25 0.3049 9.80E-08 
CELL_CYCLE_PROCESS 188 41 0.2181 3.73E-07 
CELL_CYCLE_PHASE 168 38 0.2262 3.77E-07 
M_PHASE 112 29 0.2589 4.77E-07 
RNA_PROCESSING 156 35 0.2244 1.33E-06 
CELL_CYCLE_GO_0007049 306 56 0.183 1.42E-06 






MRNA_METABOLIC_PROCESS 79 21 0.2658 1.16E-05 
MRNA_PROCESSING_GO_0006397 68 19 0.2794 1.39E-05 
CHROMOSOMAL_PART 96 23 0.2396 2.87E-05 
SMALL_NUCLEAR_RIBONUCLEOPROTEIN_COMPLEX 20 9 0.45 4.31E-05 
CHROMOSOME 123 26 0.2114 8.89E-05 
NUCLEAR_PART 548 78 0.1423 2.15E-04 
ENDONUCLEASE_ACTIVITY_GO_0016893 11 6 0.5455 2.37E-04 
REGULATION_OF_MITOSIS 40 12 0.3 2.58E-04 
CHROMOSOMEPERICENTRIC_REGION 31 10 0.3226 4.40E-04 
INTERPHASE_OF_MITOTIC_CELL_CYCLE 62 15 0.2419 6.18E-04 
SPLICEOSOME 44 12 0.2727 6.79E-04 
ENDORIBONUCLEASE_ACTIVITY 13 6 0.4615 7.43E-04 
NUCLEUS 1367 163 0.1192 1.23E-03 
DNA_REPLICATION 101 20 0.198 1.33E-03 
INTERPHASE 68 15 0.2206 1.71E-03 
SPINDLE 37 10 0.2703 2.03E-03 
MITOCHONDRIAL_SMALL_RIBOSOMAL_SUBUNIT 11 5 0.4545 2.31E-03 
ORGANELLAR_SMALL_RIBOSOMAL_SUBUNIT 11 5 0.4545 2.31E-03 
SMALL_RIBOSOMAL_SUBUNIT 11 5 0.4545 2.31E-03 
INTRACELLULAR_NON_MEMBRANE_BOUND_ORGANELLE 617 80 0.1297 3.00E-03 
NON_MEMBRANE_BOUND_ORGANELLE 617 80 0.1297 3.00E-03 
G1_S_TRANSITION_OF_MITOTIC_CELL_CYCLE 27 8 0.2963 3.01E-03 
REGULATION_OF_CELL_CYCLE 177 28 0.1582 5.72E-03 
PYRIMIDINE_NUCLEOTIDE_METABOLIC_PROCESS 9 4 0.4444 7.25E-03 
KINETOCHORE 25 7 0.28 7.66E-03 
RIBONUCLEASE_ACTIVITY 25 7 0.28 7.66E-03 
NUCLEAR_LUMEN 371 50 0.1348 8.60E-03 
RNA_SPLICINGVIA_TRANSESTERIFICATION_REACTIONS 32 8 0.25 9.28E-03 
RIBOSOMAL_SUBUNIT 20 6 0.3 9.34E-03 
RIBOSOME 39 9 0.2308 1.03E-02 
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS 1208 139 0.1151 1.08E-02 
COENZYME_BIOSYNTHETIC_PROCESS 10 4 0.4 1.12E-02 
MEMBRANE_ENCLOSED_LUMEN 440 57 0.1295 1.17E-02 
ORGANELLE_LUMEN 440 57 0.1295 1.17E-02 
MITOTIC_CELL_CYCLE_CHECKPOINT 21 6 0.2857 1.20E-02 
REGULATION_OF_MITOTIC_CELL_CYCLE 21 6 0.2857 1.20E-02 
CELL_CYCLE_CHECKPOINT_GO_0000075 47 10 0.2128 1.25E-02 
PROTEIN_DNA_COMPLEX_ASSEMBLY 48 10 0.2083 1.45E-02 
NUCLEOLAR_PART 16 5 0.3125 1.45E-02 
POSITIVE_REGULATION_OF_CELL_CYCLE 16 5 0.3125 1.45E-02 
 
Table S2.7C.  GO lists from HGA S3 (Neural) Subtype SAM analysis 
Gene Set Name # Genes in Gene Set (K) # Genes in Overlap (k) k/K p value 






SYNAPTIC_TRANSMISSION 172 46 0.2674 2.04E-03 
GROWTH_CONE 10 6 0.6 3.42E-03 
METABOTROPIC_GLUTAMATEGABA_B_LIKE_RECEPTOR_ACTIVITY 10 6 0.6 3.42E-03 
PROTEIN_SERINE_THREONINE_PHOSPHATASE_COMPLEX 10 6 0.6 3.42E-03 
NEUROTRANSMITTER_SECRETION 13 7 0.5385 3.50E-03 
TRANSMISSION_OF_NERVE_IMPULSE 187 48 0.2567 4.03E-03 
SITE_OF_POLARIZED_GROWTH 11 6 0.5455 6.39E-03 
GENERATION_OF_A_SIGNAL_INVOLVED_IN_CELL_CELL_SIGNALING 29 11 0.3793 8.17E-03 
REGULATED_SECRETORY_PATHWAY 15 7 0.4667 9.43E-03 
VOLTAGE_GATED_CALCIUM_CHANNEL_COMPLEX 15 7 0.4667 9.43E-03 
SYNAPSE 27 10 0.3704 1.38E-02 
NEURON_PROJECTION 20 8 0.4 1.64E-02 
L_AMINO_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY 17 7 0.4118 2.06E-02 
CALCIUM_CHANNEL_ACTIVITY 33 11 0.3333 2.31E-02 
KINESIN_COMPLEX 14 6 0.4286 2.57E-02 
VOLTAGE_GATED_CALCIUM_CHANNEL_ACTIVITY 18 7 0.3889 2.86E-02 
MICROTUBULE_ASSOCIATED_COMPLEX 47 14 0.2979 3.01E-02 
CATION_TRANSPORTING_ATPASE_ACTIVITY 11 5 0.4545 3.17E-02 
GLUTATHIONE_TRANSFERASE_ACTIVITY 15 6 0.4 3.65E-02 
SYNAPTIC_VESICLE 15 6 0.4 3.65E-02 
GLYCOSPHINGOLIPID_METABOLIC_PROCESS 12 5 0.4167 4.66E-02 
DENDRITE 16 6 0.375 4.99E-02 
MICROTUBULE_BASED_MOVEMENT 16 6 0.375 4.99E-02 
 
Table S2.10.  Gene ontology (GO) terms from TR(P) HGA subtype SAM analyses.   The top significant (p < 0.05) GO terms for TR(P) HGA 







Table S2.11. Transcriptomal subtypes in GEM 
HGA test set 




PN N NL CL MES 
S1 0 0 0 0 28 28 
S2 23 0 0 2 3 28 
S3 9 12 11 1 2 35 
Total 32 12 11 3 33 91 
Fisher's P<0.0001 
 
Table S2.11.  Transcriptomal subtypes in GEM HGA test set.   The GEM HGA test set consists of 38, 23, and 30 HGA from GSE22927, 
GSE29458, and GSE35917, respectively (100, 142, 144).  The TCGA subtype described in the original reports and the TR(P) HGA subtype (S1-S3) 







Table S2.12.  GFAP-CreER mice with p53 deletion and combinations of T121, Kras
G12D, and Pten deletion 
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 F 79 Sac 64 Normal   
241718 T;p53
+/-
 M 130 Brain tumor 301 GBM Fig. S20 
250643 T;p53
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 F 113 Sac 184 A2   
250644 TR;p53
+/-
 F 91 Sac 63 A2 CTX, OFB (Fig. S19) 
250651 TR;p53
+/-
 F 91 Sac 63 A2 CTX (Fig. S19) 
251213 TR;p53
+/-























































LGA (A2) 1 1 





 LGA (A2) 2 4 
 TR;p53
+/-










 HGA (A3) 4 3 
 Total 11 21 
        Mean SD Min Max 
Age at induction (days) 114.4 39.4 79 211 







Table S2.12.  GFAP-CreER mice with p53 deletion and combinations of T121, KrasG12D, Pten deletion.   Adult p53+/flox;GFAP-CreER mice 
with combinations of T, R, and P alleles were induced as previously described with 4OHT at ~3 m of age (mean 114, SD 39 d).  These mice were 
sacrificed between 2-6 m (mean 86, SD 61 d).  Astrocytomas from a subset of these mice were additionally analyzed by aCGH (Figs. S2.19 and 
S2.20).








Glioblastomas (GBM, WHO Grade IV) account for more than 85% of astrocytomas and are uniformly 
lethal.(179)  Their diffuse infiltration of normal brain makes complete surgical resection impossible and 
further eradicating tumor cells with radiation or chemotherapy remains difficult.  Thus, recurrence is 
almost certain, occurring in at least 90% of cases near the resection site.(180, 181)  This sobering clinical 
reality has fueled investigation of the biological mechanisms responsible for GBM migration and 
invasion, particularly the intracellular signaling pathways that govern these phenotypes.  The Cancer 
Genome Atlas (TCGA) catalogued oncogenic mutations and copy number alterations in GBM and 
showed that these abnormalities occur primarily in genes of three core intracellular pathways, namely 
the RB regulated G1/S cell cycle checkpoint, receptor tyrosine kinase (RTK) signaling, and TP53.  
Approximately 74% of human GBM harbored events in all three pathways, while less than 5% harbored 
events in only one of the three.(29)  In contrast, over 90% contained mutations in both RB and RTK 
pathway genes (http://tcga-data.nci.nih.gov/tcga/). 
RTK and their downstream effectors, RAS/MAPK and PI3K/AKT/mTOR, have received particular 
interest, as kinases within these pathways represent potential targets for therapeutic intervention (182).
                                                          
 
3
 A version of this was previously published as Vitucci, M., N. O. Karpinich, R. E. Bash, A. M. 
Werneke, R. S. Schmid, K. K. White, R. S. McNeill, B. Huff, S. Wang, T. Van Dyke and C. R. Miller (2013). 
"Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis." 
Neuro-Oncology: 2013;15(10):1317-29. 
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  RTK pathway kinases encoded by the EGFR, ERBB2, PDGFRA, MET, KRAS, PIK3CA, and AKT1 genes 
are frequently amplified or mutationally activated, whereas negative regulators of RAS and PI3K 
signaling, NF1 and PTEN, are frequently deleted or mutationally inactivated, respectively.(29)  Based 
upon these genetic alterations, 88% of GBM are predicted to harbor activated RTK signaling through 
these two effector arms and virtually all show RAS activation.(168, 169) 
However, clinical trial results with RTK-targeted therapeutics, particularly EGFR tyrosine kinase 
inhibitors (TKI), have been disappointing.(183)  EGFR is amplified or mutated in 36-45% of GBM,(29, 184) 
but only a small percentage of these tumors respond to EGFR TKI.  GBM exhibit both inter- and intra-
tumoral genetic heterogeneity and both neighboring and individual tumor cells can harbor 
amplifications in more than one distinct RTK gene.(185)  A recent mouse model study showed that Met 
may functionally compensate for EGFR signaling upon EGFR TKI-mediated inhibition, suggesting one 
potential resistance mechanism, particularly in the subset of GBM with EGFR and MET co-
amplification.(186)  In addition, co-expression of the constitutively active EGFRvIII extracellular domain 
truncation mutant and PTEN correlated with EGFR TKI response.  In contrast, loss of PTEN expression 
was associated with treatment failure, suggesting that uncoupling of PI3K signaling from EGFR may be 
an additional EGFR TKI resistance mechanism.(187) 
Since its discovery over ten years ago, the PTEN tumor suppressor gene has been extensively 
investigated.  The embryonic lethality observed in Pten-null mice underscores its importance during 
development.(74, 188)  PTEN is also critical in many cellular functions relevant to tumorigenesis, 
including proliferation, survival, migration, and invasion.(189)  Inactivating PTEN mutations or deletions 
are present in 30-40% of human GBM and TCGA identified it as the second most commonly mutated 
GBM gene.(29, 49)  A more complete understanding of the combinatorial roles of RTK signaling through 
RAS and PI3K effectors in GBM pathogenesis, particularly the migratory and invasive phenotypes that 
make treatment difficult, is therefore required to develop more effective, targeted therapies.(181) 
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To overcome this limitation, we have generated primary astrocytes from a series of conditional, 
genetically engineered mouse (GEM) models in which two of the three core GBM pathways were 
genetically targeted, either alone or in combination, all on a common C57Bl/6-based genetic 
background.  After Cre-mediated recombination, these mice express an N-terminal 121 amino acid 
truncation mutant of SV40 large T antigen (T121, hereafter called T) from the human glial fibrillary acidic 
protein (GFAP) promoter,(79) which inactivates all three Rb family proteins - Rb, p107, p130 - and 
ablates the G1/S cell cycle checkpoint.(190)  In addition, these mice have a constitutively active KrasG12D 
mutant (R)(147) and/or either heterozygous or homozygous Pten deletion (P+/- or P-/-).(40)  Our previous 
studies have shown that particular combinations of these three alleles recapitulate the histopathological 
progression from low-grade (WHO Grade II, A2) to high-grade astrocytomas (WHO grade III and IV, A3 
and GBM, respectively) upon recombination in adult GFAP+ mouse brain cells.(40)  Therefore, we 
hypothesized that these primary GEM astrocytes would provide a unique opportunity to dissect the 
individual and combinatorial roles of activated MAPK and PI3K signaling in biological processes relevant 
to GBM pathogenesis, including cellular growth (proliferation and apoptosis), migration, and invasion in 
vitro and tumorigenesis in vivo. 
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MATERIALS AND METHODS 
Genetically-engineered mice 
  Heterozygous TgGZT121 mice were maintained on a BDF1 background.(79)  Heterozygous 
KrasG12D conditional knock-in and PtenloxP/loxP mice were maintained on a C57/Bl6 background.(92, 147)  
All experimental animals were >94% C57/Bl6.  PCR genotyping was performed as previously 
described.(79, 92, 147)  Animal studies were approved by the University of North Carolina Institutional 
Animal Care and Use Committee. 
 
Primary astrocyte cultures 
Primary astrocytes were cultured as previously described.(79)  Briefly, cells were selectively 
harvested from the cortices of post-natal day 1-4 pups, manually dissociated by trituration in trypsin, 
and incubated at 37°C for 20 minutes.  Cells were pelleted, resuspended, and cultured in DMEM 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (complete media).  At 50% 
confluence, cells were infected at an MOI of 50 for 6 hours in complete media with a recombinant 
adenoviral vector expressing Cre recombinase from the constitutive cytomegalovirus promoter 
(Ad5CMVCre, University of Iowa Gene Transfer Vector Core).(191)  Following infection, cells were rinsed 
in PBS and cultured in complete media at 37°C in 5% CO2.  All immunoblot, cell growth, apoptosis, 
wound closure, collagen invasion, time lapse microscopy, microarray, and orthotopic allograft 
experiments were performed with genotype-confirmed primary astrocytes, under passage 10 post-
Ad5CMVCre infection, in log phase growth and cultured in complete media unless otherwise stated. 
 
Microarray analyses 
All original microarray data are publically available at the UNC Microarray Database 





Adult wild type C57Bl/6 mice (≥ 3 months old) were anesthetized with Avertin (250 mg/kg) and 
placed into a stereotactic frame (Kopf, Tujunga, CA).  Following a 0.5 cm scalp incision, 105 cells in 5 µL 
of 5% methylcellulose were injected into the right basal ganglia using coordinates 1, -2, and -4 mm (A, L, 
D) from the Bregma suture as previously described.(114) 
 
Statistics 
Apoptosis, viability, and time lapse microscopy data were analyzed using one-way ANOVA with 
Tukey’s multiple comparisons correction in GraphPad Prism 5 (GraphPad, San Diego, CA).  Wound 
closure data were analyzed using pairwise Student’s T tests.  Doubling times from cell growth assays 
were compared using one-way ANOVA with Tukey’s correction in Stata 10 (College Station, TX).  
Multiple linear regression, Kaplan-Meier plots, and log-rank analyses were conducted in Stata.  All 
comparisons were significant at α=0.05. 
 
Immunoblots 
One week post-Ad5CMVCre infection, primary astrocytes were harvested, lysed, and analyzed 
for induction of recombination using immunoblots to detect expression of T121 and Pten.  Immunoblot 
analyses of MAPK and PI3K signaling were also performed.  Briefly, equal amounts of protein were 
resolved by gradient (4-20%) SDS-PAGE (Bio-Rad, Hercules, CA) and transferred to nitrocellulose 
membranes.  Blots were probed overnight at 4°C using primary antibodies against SV40 T Antigen (Ab-2, 
1:1000, Calbiochem, San Diego, CA), Pten (1:1000, clone 6H2.1, Cascade Bioscience, Winchester, MA), 
GFP (B-2) (1:200, Santa Cruz Biotechnology, Santa Cruz, CA), and Gapdh (ab8245, 1:10000, Abcam Inc., 
Cambridge, MA), and Akt (#2967, 1:1000), p-Akt (Ser473, #9271, 1:500), p-S6 (Ser240/244, #2215, 
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1:2000), p-MEK1/2 (Ser221, #2338, 1:1000), and p-Erk1/2 (Thr202/Tyr204, #9101, 1:1000), all from Cell 
Signaling Technology, Danvers, MA.  Following incubation with HRP-conjugated secondary antibodies, 
blots were developed by enhanced chemiluminescence (Pierce Biotechnology, Thermo Fisher Scientific, 
Rockford, IL).  Films were scanned using a CanoScan8400F scanner (Canon, Lake Success, NY) and band 
intensities were quantified using ImageJ (NIH, Bethesda, MD). 
 
Cell growth 
In vitro proliferation of cultured primary astrocytes (3-4 independent isolates per genotype) was 
assessed using Guava ViaCount (Millipore, Billerica, MA) according to manufacturer’s instructions.  
Briefly, astrocytes were seeded in 24-well plates at 2.2 x 105 cells per well.  On days one, two, three, 
four, and seven, cells were stained with ViaCount.  Total viable cell numbers were determined using a 
Guava EasyCyte Plus flow cytometer using the ViaCount package of CytoSoft v5.3.  Doubling times were 
calculated using an exponential growth equation in GraphPad Prism 5 (GraphPad, San Diego, CA). 
 
Apoptosis and viability 
Apoptosis and viability were measured by flow cytometry using the Guava ViaCount Assay per 
manufacturer’s instructions.  After data acquisition on a Guava EasyPlus, gates for viable, apoptotic and 
dead cells were set according to the manufacturer’s instructions.  Percent apoptotic cells were 
calculated from at least two independent isolates per genotype in three replicate experiments.  For wild-
type and T astrocytes, apoptosis was quantified using the Caspase-Glo 3/7 Assay system (Promega, 
Madison, WI).  Cells were seeded in quadruplicate at 15,000 cells per well on optical-grade 96-well 
plates (BD Biosciences, Franklin Lakes, NJ) and luminescence was measured on an Ascent FL plate 
reader (Thermo Fisher Scientific).  Cell viability was determined on duplicate plates using the Cell Titer 
Glo assay (Promega) to control for potential differences in baseline metabolic activity.  Relative 
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apoptosis (ratio of luminescence for apoptosis and viability) was then calculated.  Mean relative 
apoptosis levels were determined in 4-10 replicate experiments per isolate from at least two 
independent isolates per genotype. 
 
Wound healing 
Wound healing assays were conducted as previously described.(192, 193)  Briefly, a scratch 
wound was created on confluent cell monolayers in 6-well plates using a 100 µl pipette tip and 
photographs were taken at 0 and 24 hours post-scratch using an Olympus IX81-ZDC inverted 
fluorescence microscope (Olympus Imaging America Inc., Center Valley, PA) equipped with a QImaging 
Retiga 4000R camera (QImaging, Surrey, BC, Canada).  The percentage of wound closure was calculated 
by measuring the open area using ImageJ.  Mean percent wound closure was determined in 
quadruplicate wells using 3-4 independent isolates per genotype. 
 
Time lapse microscopy 
Primary astrocytes were seeded in laminin-coated 6-well plates at 50,000 cells per well and 
allowed to adhere overnight.  Cell were imaged on an Olympus IX70 inverted microscope equipped with 
a LEP Precision Bioscan motorized stage and a Hamamatsu ORCA 7424 camera (Hamamatsu, 
Hamamatsu City, Japan).  During imaging, cells were incubated at 37°C with 70% relative humidity and 
CO2 was supplied by custom made culture dish lids fitted with tubes for each well. Images were taken 
every 3 minutes for 1 hour, exported as TIFF images, and compressed into QuickTime movies (Apple, 
Cupertino, CA).  Cell velocity was calculated frame by frame using the manual tracking module in ImageJ 
software (NIH, Bethesda, MD).  Cells that divided or moved out of frame during image acquisition were 
excluded from analysis.  Mean velocities were calculated from at least 100 cells in 3-8 replicate 





Experiments were performed as previously described.(194)  Briefly, astrocytes were seeded at 
50,000 cells per well in 200 µl of complete media in 96-well plates pre-coated with 100 µl of freshly 
autoclaved 1.5% Noble Agar (Sigma-Aldrich, St. Louis, MO).  Cells were incubated for 2 days at 37° C in 
5% CO2 or until they formed spheroids.  Using a 1000 µl pipette, spheroids were implanted in a mixture 
of bovine collagen (Organogenesis, Canton, MA), 10X EMEM (Lonza, Walkersville, MD), 200mM L-
glutamine (Mediatech, Inc., Manassas, VA), 2% fetal calf serum (Life Technologies, Grand Island, NY), 
and 7.5% NaHCO3 (Mediatech, Inc., Manassas, VA).  Embedded spheroids were overlaid with 1 mL of 
complete media and images of spheroid outgrowth were acquired daily for up to 5 days as described 
above for wound healing.  Percent invasion was quantified in 3-9 independent isolates per genotype 
using the threshold function in ImageJ. 
 
Pten plasmids 
Pten plasmids (xloxP(GFP)-wtPten) were generously provided by Dr. Serguei Kozlov (NCI-
Frederick, MD).  These vectors contain a modified MSCV promoter to drive wild-type Pten expression 
and include a separate PGK-GFP cassette to monitor transfection efficiency.  The corresponding empty 
vector (xloxP(GFP)) was used as a negative control.  For retroviral production, Phoenix packaging cells 
were transfected with the Pten constructs using FuGENE HD (Promega) according to manufacturer’s 
instructions.  Viral supernatants were collected and used to transduce astrocyte cultures for 24-48 hours 







Total RNA was isolated from astrocytes using an RNeasy Mini Kit (QIAGEN, Valencia, CA), RNA 
quality was confirmed with the Agilent Bioanalyzer (RNA Integrity Number > 7), labeled with the Agilent 
Low RNA Input Linear Amplification Kit (Agilent Technologies, Santa Clara, CA), and hybridized to Agilent 
Whole Mouse Genome 4×44 K microarrays (G4122-60520) per the manufacturer's protocol.  Stratagene 
Universal Mouse Reference RNA (Agilent, #740100) was co-hybridized to each array as a reference.  
Microarrays were scanned on an Agilent DNA Microarray Scanner with Surescan High-Resolution 
Technology (G2565CA). Images were analyzed using Agilent Feature Extraction Software. 
 
Microarray analyses 
Microarray data was normalized using Lowess on the Cy3 and Cy5 channels.  Analyses were 
performed on data present in at least 70% of experimental samples using genes with an absolute signal 
intensity of at least 10 units in both dye channels.(154)  Replicate probes were collapsed to genes by 
averaging.  Further analyses were performed using R system for statistical computing (R Development 
Core Team, 2006, http://www.R-project.org).  Samples from two batches scanned on different dates 
were combined using a nonparametric adjustment combatR(195) to form a data matrix on which cluster 
analysis was performed.  Probes were annotated with gene symbols using the Ensembl database 
through Biomart.(196)  Genes were median centered and the 2000 most variable genes across all cell 
lines were identified by median absolute deviation (MAD) scores.  Consensus clustering(158) was 
performed using the R package ConsensusClusterPlus(159) with 1000 iterations and 80% resample rate.  
Gene Set Analysis (GSA)(197) was performed with 1000 permutations.  Single sample Gene Set 
Enrichment Analysis (ssGSEA) was performed as described previously.(162)  For human TCGA GBM 
signatures, the top 250 genes most highly expressed in each subtype versus the remaining subtypes 
were used, as determined by Significance Analysis of Microarrays pairwise comparisons in Verhaak.(17)  
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High grade astrocytoma (HGA) signatures from Phillips, et al. were used as described.(18)  Neural 
lineage-specific gene signatures were composed of the top 500 genes associated with each distinct 
murine brain cell type as described in Cahoy.(108)  Curated gene sets version 3.0 were acquired from 
the Broad Institute (http://www.broad.mit.edu/gsea/msigdb).  For comparison to human gene sets, 
mouse genes were converted to the human orthologs according to the MGI database 
(ftp://ftp.informatics.jax.org/pub/reports/index.html#orthology).  All original raw microarray data are 
publically available at the UNC Microarray Database (http://genome.unc.edu) and have been deposited 
in Gene Expression Omnibus, accession number GSE40265. 
 
Inhibition of the PI3K pathway in TRP-/- astrocytes 
TRP-/- astrocytes at 50-60% confluence were treated with PI-103 (Cayman Chemical, Ann Arbor, 
MI), LY294002 (Cayman), and rapamycin (Sigma-Aldrich) at the lowest concentrations required to 
maximally inhibit their target kinases.  Immunoblots were probed for Akt, phospho-Akt, and phospho-S6 
as described above.  Fluorescent secondary antibodies from Invitrogen (A21429, A11029) were used to 
label mouse and rabbit primary antibodies.  Blots were scanned on Typhoon 9200 (GE Healthcare, 
Pittsburgh, PA) and analyzed using ImageQuant TL 7.0.  Protein levels in treated versus vehicle control 
treated astrocytes were normalized to Akt and compared at defined times after treatment to determine 
the earliest time and duration of maximal inhibition. 
 
Microarray analysis of PI3K inhibition in TRP-/- astrocytes 
TRP-/- astrocytes at 50–60% confluence were treated with each drug (inhibited samples).  Drug-
containing media was removed after 4 hours and replaced with complete media without drug. Total 
RNA was harvested at 4, 8, and 24 hours after media replacement (released samples). Cells were lysed 
with RNA lysis buffer and total RNA was extracted as described above.  The 4 hour inhibited treated 
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samples were compared to a pooled untreated TRP-/- reference to look for effects of an inhibitor.  To 
identify a PI3K activation signature after release from each drug, samples released from inhibition 
(released) were compared to a pooled reference of inhibited samples. Experimental (Cy5 CTP) and 
reference (Cy3 CTP) samples were mixed and co-hybridized overnight on the same microarrays as 
described above. Three TRP-/- isolates and microarrays per experimental condition were performed. 
 
Orthotopic allografts 
Immediately prior to injection, genotype-confirmed astrocytes were trypsinized, counted with a 
hemocytometer, washed with PBS, and suspended in serum-free DMEM with 5% methyl cellulose, as 
previously described.(114)  Adult mice (≥ 3 months) were anesthetized with Avertin (250 mg/kg) and 
placed into a stereotactic frame (Kopf, Tujunga, CA).  Following a 0.5 cm scalp incision, 105 cells in 5 µL 
were delivered intracranially to the right basal ganglia using coordinates 1, -2, and -4 mm (A, L, D) from 
the Bregma suture via a Hamilton syringe mounted in a repeating antigen dispenser (Hamilton, Reno, NV 
 
Histopathological evaluation 
Formalin-fixed, paraffin embedded (FFPE) brains were cut on a rotary microtome in serial 4-5 
µm sections, placed on glass slides, and stained with hematoxylin and eosin (H&E) on a Leica 
Microsystems Autostainer XL (Buffalo Grove, IL).  H&E stained slides were scanned on an Aperio 
ScanScope XT (Vista, CA) using a 20X objective and the resulting svs files were imported into an Aperio 
Spectrum web database.  Histopathological analysis, grading, and photomicrography was performed by 
CRM according to WHO 2007 criteria for human astrocytomas(5) using an Olympus BX41 microscope 





PI3K and MAPK signaling and growth of G1/S checkpoint-defective primary astrocytes 
To determine how targeted genetic disruption of Rb, Ras, and PI3K signaling affects 
tumorigenesis, we isolated and cultured primary cortical astrocytes from newborn mouse pups with the 
following genotypes:  T, TR, TPwt/loxP, TPloxP/loxP, TRPwt/loxP, and TRPloxP/loxP.  After infection with Ad5CMVCre 
to induce recombination, we performed a series of in vitro experiments to probe how these genetic 
events affect PI3K and Ras/MAPK signaling, proliferation, apoptosis, migration, invasion, and gene 
expression. 
The Rb family of G1/S cell cycle checkpoint regulatory proteins Rb1, p107, and p130 are 
encoded in mice by Rb1, Rbl1, and Rbl2.  Deletion of all three Rb family genes in mouse embryonic 
fibroblasts disrupts this checkpoint and enhances cell cycle entry.(190)  We confirmed that T-mediated 
inactivation of all three Rb family proteins disrupted the G1/S checkpoint, as T but not wild-type 
astrocytes continued to enter S phase and proliferate after serum starvation in media with 0.5% serum 
(data not shown).  Under normal growth conditions, T astrocytes showed essentially no activation of the 
PI3K pathway effectors Akt and S6 (Fig. 3.1A).  Moreover, p-Akt and p-S6 levels were similar to wild-type 
astrocytes (Fig. S3.1A).  These results demonstrate that a defective G1/S checkpoint alone does not 
activate PI3K signaling (Fig. 3.1A).  Pten deletion (TP+/- and TP-/-) increased PI3K pathway activation, as p-
Akt and p-S6 levels in TP-/- >> TP+/- >T astrocytes.  Kras activation (TR and TRP+/-) further increased Akt 
and S6 phosphorylation.  Akt and S6 phosphoprotein levels in at least two of three TR and TRP+/- isolates 
were similar to astrocytes completely lacking Pten (TP-/- and TRP-/-).  These results indicate that activated 
Kras, biallelic Pten deletion, or their combination potentiates PI3K pathway signaling in G1/S-defective 
astrocytes. 
We also measured MAPK pathway activation.  In at least two of three isolates per genotype, p-
Mek1/2 levels were TRP-/- > TRP+/- > TP-/- > TR >TP+/- > T > wild-type astrocytes (Figs. 3.1A and S3.1A).  
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These data suggest that Kras activation (TR) or Pten deletion (TP+/-, TP-/-) alone induce increased MAPK 
signaling that is augmented when these mutations are combined (TRP+/-, TRP-/-).  Maximum signaling in 
TRP-/-astrocytes highlights the combinatorial effects of these mutations on the two main RTK effector 
pathways. 
To determine how Rb, Ras, and/or PI3K pathway alterations affected cellular growth, cultured 
astrocytes from all six genotype combinations were counted over seven days and apoptosis was 
quantified.  Wild-type astrocyte numbers were essentially unchanged throughout the time course 
examined (Fig. 3.1B).  T astrocytes showed an increased growth rate (5.7 day doubling time) (Figs. 3.1B 
and C) and approximately 2-fold increased apoptosis (Fig. S3.1B) relative to wild-type astrocytes.  Similar 
results were observed in T-driven astrocytomas in vivo.(79)  TP+/- and TP-/- astrocytes grew faster 
(doubling times 4.1 and 3.4 days) and apoptosis in TP-/- was lower than T astrocytes (P<0.05).  Kras 
activation alone (TR) or in combination with Pten deletion (TRP+/-, TRP-/-) increased growth as TR, TRP+/-, 
and TRP-/- astrocytes displayed the shortest doubling times of 3.8, 3.4, and 2.0 days, respectively (Fig. 
3.1C).  Apoptosis levels in TR were lower than T (P<0.05) but similar to TP-/- astrocytes (P>0.05) (Figs. 
3.1D and S3.2), suggesting that the increased growth in TP-/- versus TR astrocytes is due to a higher 
proliferation rate in the former.  Apoptosis in TRP-/- astrocytes was lower than both TP-/- and TR (P<0.001 
and P=0.08, respectively) (Figs. 3.1D and S3.2).  Overall, these data suggest that activated Kras or Pten 
loss mitigate the apoptosis induced by T-mediated ablation of the G1/S checkpoint in cultured murine 
astrocytes.  Moreover, the proliferative and anti-apoptotic effects of T, R, and P combined (TRP-/-) 
produced the largest net positive effect on cellular growth. 
 
Both Kras activation and Pten loss contribute to G1/S-defective astrocyte migration in vitro 
We have previously shown that TR, TRP+/-, TRP-/- mice frequently develop high-grade 
astrocytomas (HGA), including GBM, whereas T, TP+/-, TP-/- mice develop low grade astrocytomas (LGA) 
that infrequently progress to HGA.(40)  Therefore, we hypothesized that G1/S-defective astrocytes with 
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activated Kras and/or Pten deletion would display enhanced migration in vitro.  To address these 
hypotheses, we evaluated migration using two different assays. 
Wound closure or “scratch” assays have been extensively used to examine the molecular 
mechanisms of migration.(198)  We used this assay to quantify astrocyte migration after 24 h.  Activated 
Kras, alone or in combination with Pten loss, significantly increased migration (Figs. 3.2A and B), as 2.8, 
2.8, and 1.9-fold increases in wound closure were evident in TR vs. T, TRP+/- vs. TP+/-, and TRP-/- vs. TP-/- 
astrocytes (P≤0.0005).  Monoallelic Pten deletion did not significantly affect migration of G1/S-defective 
astrocytes with (TR) and without (T) concomitant Kras activation (TRP+/- vs. TR, P=0.5; TP+/- vs. T, P=0.6).  
In contrast, biallelic Pten deletion increased migration 2.7-fold in TP-/- compared to T astrocytes 
(P=0.009) and migration nearly doubled (1.8 fold) in TRP-/- compared to TR astrocytes (P<0.0001).  These 
results show that either Kras activation alone or biallelic Pten deletion, with or without activated Kras, 
increased G1/S-defective astrocyte migration, and all three alterations resulted in maximal migration. 
Because wound closure can be achieved through a combination of cell migration, spreading, 
proliferation, and interaction with neighboring cells, we examined the cell autonomous genetic 
contributions to migration by tracking cellular movement over one hour using time lapse video 
microscopy and calculating the velocities of individual cells (Fig. 3.2C and videos SV1-4).  Wild-type 
astrocytes were relatively non-motile.  G1/S checkpoint disruption alone (T) increased mean cellular 
velocity 4.3-fold compared to wild-type astrocytes.  Activated Kras (TR) or Pten deletion (TP+/-, TP-/-) only 
slightly increased migration of G1/S-defective T astrocytes.  TR, TRP+/-, and TRP-/- astrocytes migrated 
faster than their counterparts without activated Kras.  Combining all three alterations in TRP-/- astrocytes 
resulted in maximal migration with a mean velocity of 47±2 µm/h.  Notably, genotype significantly 
influenced mean velocity (one-way ANOVA P<0.0001) and all pairwise genotype comparisons were 
significant (P<0.05) except T vs. TP-/-.  Multivariable regression analysis confirmed the independent 
contribution of all three alleles (P<0.001).  Taken together, these results showed that Kras activation 
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and/or Pten loss increased G1/S-defective astrocyte migration and that all three alterations resulted in 
maximal migration in both multicellular (Fig. 3.2B) and individual cell (Fig. 3.2C) contexts. 
We confirmed the effects of activated Ras and PI3K signaling on migration by examining wound 
closure in TRP-/- astrocytes upon pharmacological inhibition of mTOR, PI3K, and MEK with rapamycin, 
LY294002, and U0126, respectively (Fig. 3.2D).  S6 phosphorylation was virtually eliminated by 
rapamycin and LY294002 (Fig. S3.6) and decreased wound closure 22% and 45% (P≤0.0004).  U0126 
inhibited Erk phosphorylation (Fig. S3.3A) and decreased wound closure 35% (P<0.0001).  In contrast, 
combined inhibition of PI3K and MEK with LY294002 and U0126 decreased TRP-/- astrocyte wound 
closure 85% relative to untreated TRP-/- astrocytes (P<0.0001).  Moreover, combined LY294002/U0126 
treatment decreased TRP-/- astrocyte migration to similar levels as T astrocytes without activated Kras 
and deleted Pten (Fig. 3.2B), while minimally affecting viability at 24 hours (data not shown) or 5 days 
(Fig. S3.3B). 
 
Pten loss is necessary for G1/S-defective astrocyte invasion in vitro 
Astrocytomas are characterized by their ability to invade the surrounding brain parenchyma.  
We used our astrocyte panel to ascertain which core signaling pathway alterations were necessary for 
collagen invasion in vitro.(194)  T astrocytes showed minimal invasion over seven days (Figs. 3.3A and B).  
Invasion was only 40% higher in TR astrocytes (P=0.6), suggesting that Kras activation alone was 
insufficient for invasion.  However, a Kras effect was evident when combined with monoallelic Pten 
deletion, as TRP+/- showed 19-fold increased invasion compared to TP+/- astrocytes (P=0.01).  In contrast, 
a Kras-specific effect was not apparent when combined with biallelic Pten deletion, as TRP-/- showed 
only a 40% increase in invasion compared to TP-/- astrocytes (P=0.2).  Although monoallelic Pten deletion 
(TP+/-) produced a moderate (6-fold), statistically insignificant increase in invasion (P=0.09), biallelic Pten 
deletion (TP-/-) increased invasion 68-fold compared to T astrocytes (P<0.0001, Fig. 3.3B), suggesting that 
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Pten loss alone is sufficient to induce G1/S-defective astrocyte invasion.  Deletion of one (TRP+/-) or both 
(TRP-/-) Pten allele(s) increased invasion 85- (P=0.01) and 69-fold (P=0.001) over G1/S-defective 
astrocytes with activated Kras (TR).  Thus, while the invasion-related effects of Kras activation were 
evident in G1/S-defective astrocytes with heterozygous, but not homozygous Pten deletion, Pten loss-
mediated invasion was independent of Kras activation. 
In addition to proliferation and migration, genetic activation of Kras and Pten deletion maximally 
increased G1/S-defective astrocyte invasion in vitro (TRP-/-).  Therefore, we next confirmed the invasion-
related effects of activated PI3K and MEK signaling by examining TRP-/- astrocyte invasion after 
pharmacological inhibition of mTOR, PI3K, and MEK.  Whereas rapamycin, LY294002, and U0126 
inhibited TRP-/- astrocyte invasion 47%, 33%, and 49% (P>0.05), combined treatment with 
LY294002/U0126 significantly decreased invasion 90% (P=0.01, Fig. 3.3C).  Of note, all drug treatments 
minimally affected viability at 5 days (P>0.05, Fig. S3.3B). 
 
Pten restoration reduces proliferation, migration, and invasion 
The data above suggest that PI3K pathway activation induced by Pten loss is critical for G1/S-
defective astrocyte proliferation, migration, and invasion.  To confirm its role in these processes, we 
restored Pten expression by infecting TRP-/- astrocytes with a retrovirus encoding wild-type murine Pten.  
Pten expression was evident in approximately 60% of cells within 48 hours of infection and attenuated 
downstream PI3K signaling at p-Akt (56-73%) and p-S6 (68-85%).  In contrast, Pten restoration did not 
significantly alter MAPK signaling at p-Mek and p-Erk (Fig. 3.4A). 
Restoring Pten increased TRP-/- astrocyte doubling time from 1.8 to 2.7-3.4 days (Figs. 3.4B and 
C), growth rates similar to TR astrocytes without Pten deletion (Fig. 3.1B).  Pten also significantly 
reduced, but did not completely prevent, migration in the wound closure assay (P≤0.0002, Fig. 3.4D).  
GFP transfection did not significantly alter migration (Fig. 3.4D) compared to untransfected TRP-/- 
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astrocytes (Fig. 3.2B) (P=0.1).  These data are consistent with wound closure (Fig. 3.2B) and time lapse 
microscopy (Fig. 3.2C) experiments using TR astrocytes and confirm the Kras contribution to migration.  
Similarly, invasion was significantly decreased, but not prevented in Pten rescued TRP-/- astrocytes; 
instead, rescued TRP-/- cells showed 58% and 32% reduction in invasion compared to control, GFP-
infected TRP-/- cells at 3 and 5 days, respectively (P≤0.0003, Fig. 3.4E).  These data are consistent with 
data in Fig. 3.3C where TRP-/- invasion was only partially mitigated after pharmacologically inhibiting PI3K 
or mTOR. 
To confirm the Kras-independent effects of Pten on migration, we restored Pten in cells without 
activated Kras (TP-/-).  Wound closure was reduced to 7.6% (Fig. S3.4), levels comparable to T astrocytes.  
This demonstrated that Pten loss significantly contributed to migration in the absence of Ras activation. 
 
Activated MAPK and PI3K signaling in G1/S-defective astrocytes produces gene expression profiles 
similar to human proneural HGA 
 
Results above demonstrate that the phenotypic effects of Ras activation and Pten loss are 
contextual and complementary.  Next, we determined their effects on genome-wide transcriptome 
patterns using microarrays.  These experiments showed that cultured G1/S-defective astrocytes display 
distinct expression profiles depending upon the presence of activated Kras, Pten loss, or both.  
Consensus clustering of 23 samples identified 4 classes with high confidence (Fig. S3.5); three of these 
classes (22 samples) were used in subsequent analyses (see Supplemental methods).  Although different 
isolates from identical genotypes were sometimes present in different clusters, Class 1 contained only T 
and TP astrocytes, Class 2 contained all analyzed TR astrocytes, and Class 3 contained only TRP 
astrocytes (Fig. 3.5A).  Compared to Class 1 and 2, Class 3 (green bar) astrocyte transcriptomes were 
significantly enriched for migration, invasion, and stem cell signatures (Fig. 3.5B, Table S3.1).  These data 
are consistent with the above results demonstrating maximal migration and invasion in TRP astrocytes 
and suggest that these astrocytes may be stem-like and capable of initiating tumorigenesis. 
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Next, we examined whether these astrocytes were enriched for TCGA human GBM(17) and 
Phillips prognostic HGA(18) subtype signatures using gene set analysis (GSA) (Table S3.2) and single 
sample gene set enrichment analysis (ssGSEA) (Fig. 3.5C).  Class 3 TRP astrocytes were highly enriched 
for TCGA proneural and neural signatures (P≤0.003) and showed particularly low expression of the TCGA 
(P=0.09) and Philips (P=0.04) mesenchymal subtype signatures.  Individual Class 3 astrocytes were also 
enriched for Phillips proneural and proliferative signatures, but the entire group was not significantly 
associated with them (P≥0.1).  None of the HGA signatures were significantly enriched in Class 1 T/TP or 
Class 2 TR astrocytes, but several samples in these classes expressed low levels of proneural and neural 
signatures, further highlighting their dissimilarity to Class 3 TRP astrocytes. 
We then investigated expression of adult murine neural cell lineage-specific signatures.(108)  
Class 3 TRP astrocytes showed high expression of oligodendrocyte progenitor (OPC)-specific genes and 
low expression of cultured astrocytes-specific genes (Fig. 3.5D, Table S3.2), suggesting that the 
combination of Kras activation and Pten loss induces a more primitive expression pattern in G1/S-
defective astrocytes.  In contrast, Class 1 (T, TP) astrocytes showed low expression of OPC signature 
genes, but instead expressed cultured astrocyte-specific genes. 
 
A PI3K activation signature is enriched in human proneural GBM 
Because PI3K signaling activation caused by Pten loss was critical for proliferation, migration, 
and invasion of G1/S-defective TRP-/- astrocytes, we next defined gene signatures specific to activated 
PI3K signaling.  First, PI3K signaling was pharmacologically inhibited in TRP-/- astrocytes using the dual 
PI3K/mTOR inhibitor PI-103, the PI3K inhibitor LY294002, and the mTOR inhibitor rapamycin.  Each drug 
maximally inhibited Akt-mediated S6 phosphorylation within 2-4 hours of treatment and maximal 
inhibition lasted at least 24 hours, except LY294002, which lasted 4 hours (Fig. S3.6A-D).  To identify PI3K 
pathway signatures, we analyzed mRNA expression of drug-treated samples after 4 hours of inhibition 
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(inhibited) and 4, 8, and 24 hours after release from inhibition (released).  We used large average 
submatrices (LAS), an unsupervised significance-based biclustering method, to identify groups of 
coordinately expressed genes.(199) 
The top five biclusters, in order of decreasing statistical significance, consisted of genes highly 
expressed in the following contexts (data not shown): 1) all times after LY294002 release; 2) all inhibited 
samples regardless of the specific drug; 3) 24 hours after release from inhibition, regardless of the drug; 
4) all times after rapamycin release; and 5) all times after PI-103 release.  The fifth bicluster of genes 
highly expressed after PI-103 release was selected as the PI3K signature for further investigation (Table 
S3.3).  The first bicluster was excluded because the relatively high concentration of LY294002 (50µm) 
required to produce maximal inhibition of PI3K signaling showed slightly reduced viability relative to 
untreated TRP-/- cells at 24 hours (93±2%, data not shown), was likely to produce off target effects, and 
was less efficient than PI-103 in inhibiting Akt phosphorylation (Fig. S3.6D).  The second was excluded 
because we sought to identify genes that defined activated, not inhibited PI3K signaling.  The third was 
excluded because genes expressed only after 24 hours of drug release would not contain genes 
expressed at earlier time points.  The fourth was excluded because rapamycin-mediated inhibition of 
mTOR complex 1 (mTORC1) ablated S6, but not Akt phosphorylation (Fig. S3.6C).  Consequently, genes 
expressed upon rapamcyin release would represent only a distal PI3K pathway activation signature.  In 
contrast, PI-103 inhibits PI3K and both mTOR complexes and it efficiently reduced phosphorylation of 
both Akt and S6 in TRP-/- astrocytes (Fig. S3.6A).  Furthermore, Akt and S6 phosphorylation increased 
upon PI-103 release, suggesting that both proximal and distal PI3K pathway signaling resumed in TRP-/- 
astrocytes released from PI-103 (Fig. S3.6A, D, E).  We identified 518 genes (Table S3.3) with increased 
expression upon PI-103 release as a PI3K pathway activation signature and found that these genes 




Expression of PI3K signature genes was next examined in 434 human GBM from the TCGA(167) 
and was significantly different across the four subtypes (Fig. 3.6B).  Proneural GBM, in particular, 
showed significantly higher expression of PI3K signature genes by ssGSEA (Fig. 3.6C). 
 
Kras activation with or without Pten loss is necessary for G1/S-defective astrocyte tumorigenesis 
 
The complimentary effects of Kras activation and Pten loss produced highly proliferative, 
migratory, and invasive G1/S-defective astrocytes in vitro and their gene expression profiles correlated 
with human HGA subtypes.  Next, we used an allograft model system with syngeneic, 
immunocompetent hosts to investigate whether Kras activation and/or Pten loss was required for 
tumorigenesis in vivo.  Orthotopic injection of T, TR, TRP+/-, and TRP-/- astrocytes produced astrocytomas 
in 30%, 25%, 64%, and 60% of mice aged up to one year or neurological morbidity (Fig. 3.7A).  Three 
mice injected with T astrocytes developed small foci of LGA that failed to produce neurological 
symptoms and progress to HGA over the course of a year (Fig. S3.7A-D).  Four of six astrocytoma-bearing 
mice injected with TR astrocytes developed GBM (Figs. 3.7B and S3.7E-H).  Thus, while Kras activation 
was sufficient for malignant progression, TR GBM developed with long latency, as median survival was 
207 days (Fig. 3.7C).  In contrast, G1/S-defective astrocytes containing both activated Kras and Pten 
deletion progressed to HGA in >97% of mice injected with either TRP+/- or TRP-/-  astrocytes and 89% and 
83% of these mice developed GBM, respectively (Fig. 3.7B, S3.7I-P).  Pten deletion also significantly 
decreased the latency of G1/S-defective, Kras activated HGA, as the median survival of mice injected 
with TRP+/- and TRP-/- astrocytes was 57 and 36 days, respectively (P≤0.005) (Fig. 3.7C).  These results 
show that ablation of the G1/S checkpoint is sufficient to produce LGA, Kras activation is required for 
progression to HGA, and the combination of Kras activation and Pten deletion dramatically increases 
GBM incidence and reduces survival. 
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TRP (Fig. S3.7IJ and S3.7MN) were significantly more invasive than TR GBM (Fig. S3.7EF), which 
largely developed as well-circumscribed masses.  These findings are consistent with the increased 
invasion of TRP versus TR astrocytes in vitro (Fig. 3.3B).  Moreover, TRP GBM contained cells with both 
astrocytic and oligodendroglial morphology (Fig. S3.7L and S3.7P), a finding consistent with their 
proneural GBM and murine OPC like gene expression profiles in vitro. 
To further examine tumor initiation, we injected G1/S-defective astrocytes with (TR, TRP+/-, TRP-
/-) and without (TP+/-, TP-/-) activated Kras, sacrificed mice every 7 days for 4 weeks, and evaluated tumor 
incidence and histological grade.  Similar to T astrocytes, TP+/- and TP-/- astrocytes infrequently 
developed into LGA (Figs. 3.7D and S3.8).  In contrast, TRP+/- and TRP-/- astrocytes developed into LGA 
more efficiently.  Mitotically active HGA were evident in 40% and 10% of mice injected with these cells, 
but only one mouse injected with TRP-/- astrocytes developed a GBM within 28 days.  These results 
suggest that the increased incidence of HGA in mice injected with TRP astrocytes is likely due to more 




Virtually all human GBM contain RB pathway gene mutations that dysregulate the G1/S cell cycle 
checkpoint.  Most also contain RTK pathway gene mutations that activate RAS/MAPK and PI3K 
signaling.(29)  We therefore used G1/S checkpoint-defective cortical murine astrocytes to examine the 
individual and combined effects of Ras/MAPK and/or PI3K pathway dysregulation on multiple cancer-
related phenotypes in vitro.  Both Kras activation and Pten loss induced MAPK and PI3K signaling (Fig. 
3.1).  Kras activation, but not Pten loss, increased proliferation and reduced apoptosis of cultured T121
+ 
astrocytes in vitro (Fig. 3.1D).  We have previously shown that T121 induces both proliferation and 
apoptosis in neonatal, T121-driven astrocytomas in vivo and that Pten loss potentiates progression by 
reducing apoptosis.(92)  These findings suggest that Kras and Pten signaling perturbations may affect 
G1/S-defective astrocyte growth by distinct mechanisms depending on their patterns of co-occurrence.  
The role of Pten in p53-dependent apoptosis has long been recognized, but increasing evidence suggests 
that nuclear Pten directly regulates mitosis.(200)  Decreasing Pten induces expression of cell cycle and 
chromosome stability genes and proliferation of mouse embryonic fibroblasts.(201)  Moreover, Pten 
deletion in embryonic mice increases astrocyte proliferation in vitro and in vivo.(202)  Conversely, 
exogenous PTEN expression in human glioma cells decreases proliferation and lengthens cell cycle 
transit from G2/M to G1.(203)  Therefore, we conclude that Pten negatively regulates proliferation in 
G1/S-defective astrocytes. 
Kras activation and/or Pten deletion not only increased MAPK and PI3K pathway signaling and 
growth of G1/S-defective astrocytes (Fig. 3.1), but migration as well (Fig. 3.2).  However, their effects on 
invasion were contextual (Fig. 3.3).  Kras activation was insufficient for invasion in the absence of Pten 
deletion, suggesting that Ras-mediated invasion requires concurrent activation of PI3K signaling.  In 
contrast, monoallelic Pten deletion was sufficient to induce maximal invasion only in the presence of 
activated Kras (Fig. 3.3B).  Biallelic Pten deletion caused maximal invasion in both the presence and 
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absence of activated Kras (Fig. 3.3B) and Pten restoration significantly reduced invasion (Fig. 3.4E).  
However, Pten restoration did not completely abrogate migration and invasion, likely due to less than 
100% transfection efficiency.  Thus, a subpopulation of cells in these assays lacked Pten expression and 
thus retained their migratory and invasive properties.  These results indicate that Pten is a primary 
regulator of G1/S-defective astrocyte invasion and that the invasion-related effects of biallelic, but not 
monoallelic, Pten deletion are independent of activated Kras. 
Established human cell lines, such as U87MG, have previously been utilized in genetic gain and loss 
of function studies to investigate the molecular mechanisms of GBM migration and invasion in 
vitro.(204)  PTEN restoration has been shown to inhibit proliferation, migration, and invasion of human 
PTEN-null U87MG astrocytoma cells in vitro.(205)  PDGF-induced migration of U87MG cells has also 
been shown to be PI3K-, but not ERK-dependent,(206) and farnesyltransferase-mediated inhibition of 
Ras reduced U87MG migration in a PI3K dependent manner.(207)  However, established cell lines 
harbor widespread genomic alterations that frequently differ from their original tumor.(115, 208)  
Therefore, panels of established cell lines, each with distinct genomic landscapes, are typically employed 
to rule out cell line-specific effects.  Our use of an allelic series of genetically-defined astrocytes 
containing defined core signaling pathway mutations removes ambiguity associated with established 
human cell lines and provides a unique opportunity to clarify genotype-phenotype relationships in GBM 
pathogenesis.  Our data therefore confirm and extend studies that utilized established human 
astrocytoma cell lines to demonstrate that PTEN is a critical regulator of migration and invasion, and 
that RAS-dependent invasion requires PI3K/PTEN signaling. 
In addition to their effects on growth, migration, and invasion, mutations that activate Ras/MAPK 
and PI3K signaling produced three distinct gene expression clusters that correlated with mutation and 
pathway activation status (Fig. 3.5).  Activation of both pathways in cultured TRP astrocytes defined a 
transcriptomal class (Class 3) enriched for migratory, invasive, and stem-like signatures.  TRP astrocytes 
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also showed high expression of human proneural GBM and murine OPC signatures.  These findings are 
consistent with previous reports demonstrating similarity between proneural GBM and OPC.(17, 108)  
Conversely, an activated PI3K pathway signature defined in TRP astrocytes released from PI3K pathway 
inhibition was enriched in human proneural GBM (Fig. 3.6). 
The above data suggested that TRP astrocytes would form invasive astrocytomas in vivo.  We 
utilized a novel orthotopic allograft model with syngeneic, immunocompetent hosts to show that G1/S-
defective astrocytes with activated Kras and/or Pten deletion formed astrocytomas with penetrance 
that correlated with mutational status (Fig. 3.7).  Specifically, both Kras activation and Pten deletion 
were required for high penetrance tumorigenesis and efficient progression to HGA.  Similar results were 
obtained in conditional, inducible GEM in which these genetic mutations are targeted specifically to 
adult GFAP+ cortical astrocytes.(40)  These findings suggest that cortical astrocytes may serve as a 
potential astrocytoma cell of origin, particularly in tumors with G1/S checkpoint dysfunction, activated 
Kras, and Pten deletion. 
TRP allografts diffusely invaded normal brain and formed histopathological hallmarks of human 
astrocytomas, including perineuronal and perivascular sattelitosis, migration and invasion along white 
matter tracks, elevated mitoses, microvascular proliferation, and necrosis (Fig. S3.7).  These 
histopathological features contrast significantly with human U87MG GBM xenografts, which are poorly 
invasive in vivo,(114) and suggest that this model system will be useful for further dissection of the 
genetics of astrocytoma migration and invasion.  We conclude that the syngeneic, orthotopic TRP 
allograft model represents a significant improvement over traditional xenografts models that employ 
established human cell lines and immunodeficient mice. 
Consistent with the expression profiles of TRP astrocytes in vitro (Fig. 3.5) and the presence of 
oligodendroglial differentiation in vivo (Fig. S3.7), TRP allografts also showed enriched expression of 
human proneural GBM and murine OPC signature genes (manuscript in preparation).  The Rb family of 
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G1/S cell cycle proteins, Nf1, a negative regulator of Ras/MAPK signaling, and Pten have each been 
shown to regulate neural stem cell self-renewal and fate.(209-211)  These results suggest that combined 
dysregulation of Rb, Ras, and Pten reverts astrocytes to a progenitor-like state of gene expression. 
The use of gene expression profiling to characterize the molecular heterogeneity and improve 
diagnostic classification of specific types of brain tumors has recently brought significant attention to 
defining their cellular origins.  We utilized GEM models to show that the molecular heterogeneity of 
medulloblastoma, the most common primary brain tumor in children, has a cellular as well as genetic 
basis.(212)  Like HGA, multiple genomic subtypes of human medulloblastoma with distinct mutations 
exist.(213)  Furthermore, GEM models have shown that different initiating oncogenic mutations in 
specific cells of origin in the developing mouse cerebellum lead to distinct genomic subtypes of 
medulloblastoma that mimic their human counterparts. 
Gene expression profiling of human HGA has suggested that the subtypes may have distinct cellular 
origins.(17, 142)  GEM modeling studies have identified neural stem cells(70) and OPC(142) as potential 
candidate astrocytoma cells of origin.(139)  PDGF-driven murine GBM derived from adult Pten-null OPC 
were shown to have transcriptomes similar to human proneural GBM.(142)  Here we identified 
proneural and OPC-like expression specifically in G1/S-defective neonatal murine astrocytes with 
activated Kras and Pten deletion (Fig. 3.5D).  The presence of human proneural GBM and OPC-like 
expression profiles in both PDGF-driven GBM and TRP astrocyte-derived GBM allografts suggests that 
molecularly similar GBM can arise from at least two distinct genetic mechanisms and cellular origins.  
We speculate that multiple cell types can give rise to GBM and that different cells are uniquely 
susceptible, within defined developmental windows, to the transforming effects of particular 
combinations of core signaling pathway mutations.  These combined factors determine human 
astrocytoma transcriptomal subtype.  Such a unifying hypothesis would explain the associations 
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between transcriptomal subtype, mutational landscape, signaling pathway alterations, and neural 
signatures in human GBM.(17, 18, 20) 
The in vitro experiments described above show that growth, motility, and invasive phenotypes are 
differentially affected by specific genetic alterations in the RTK core GBM signaling pathway.  These 
alterations may ultimately dictate targeted GBM therapy.  As such, we have used MAPK and PI3K 
targeted drugs to reduce in vitro migration, invasion, and signaling in TRP astrocytes transcriptionally 
similar to human proneural GBM (Fig. 3.2D, 3.3C, S3.6).  Release of TRP astrocytes from pharmacological 
PI3K pathway inhibition identified a PI3K signature significantly enriched in human proneural GBM (Fig. 
3.6).  The findings that TRP astrocytes contained a PI3K activation signature enriched in proneural 
human GBM and produced proneural-like HGA allografts upon injection into syngeneic, 
immunocompetent brains suggest that proneural GBM may be uniquely sensitive to combination 
therapies targeting both RAS/MAPK and PI3K. The TRP allograft model of human proneural GBM will not 
only facilitate delineation of the molecular requirements for tumorigenesis and cellular origins of 
astrocytomas, but will also be useful for preclinical testing of drug combinations and elucidating 
potential mechanisms of resistance.  Moreover, the use of syngeneic, immunocompetent hosts will 





Figure 3.1.  MAPK and PI3K signaling and growth of G1/S-defective astrocytes with activated Kras 
and/or Pten deletion.   Representative immunoblots showing MAPK and PI3K pathway signaling in 
G1/S-defective astrocytes with activated Kras, Pten deletion, or both (A).  Growth of G1/S defective 
astrocytes in vitro.  Cell number was assessed by counting cells at days 1-7.  (B). Mean doubling times ± 
95% confidence intervals were calculated from the exponential growth curves in B (C).  Growth rates 
were significantly different across genotypes (P<0.0001).  Apoptosis in G1/S defective astrocytes in vitro 





Figure 3.2.  Kras activation and Pten loss increase G1/S-defective astrocyte migration.   
Representative photomicrographs of wound closure in T, TR, and TRP-/- astrocytes at 0 and 24 hours (A).  
Mean percent wound closure ± SEM at 24 hours (B).  Colors compare genotypes with and without 
activated Kras.  Mean velocity ± SEM of individual astrocytes measured using time lapse microscopy for 
one hour (C).  Colors compare genotypes with and without activated Kras.  Wound closure of TRP-/- 
astrocytes treated with 10 nM rapamycin (Rapa), 50 µM LY294002 (LY), 10 µM U0126, or both LY294002 





Figure 3.3.  Pten deletion is necessary for maximum G1/S-defective astrocyte invasion.  
Representative photomicrographs of collagen invasion of T, TR, and TRP-/- astrocytes at 4 days (A).  
Mean percent invasion ± SEM into collagen after 4 days (B).  Colors compare genotypes with and 
without activated Kras.  Collagen invasion of TRP-/- astrocytes treated with 10 nM rapamycin (Rapa), 50 
µM LY294002 (LY), 10 µM U0126, or both LY294002 and U0126 (C).  Mean percent invasion ± SEM is 




Figure 3.4.  Restoration of Pten expression limits growth, migration, and invasion in TRP-/- 
astrocytes.   Representative immunoblot of MAPK and PI3K pathway signaling in TRP-/- astrocytes after 
infection with retrovirus containing Pten or GFP cDNA (A).  Growth (B), doubling time (C), mean percent 
wound closure at 24 hours (D), and mean percent invasion into collagen at 1, 3, and 5 days (E) of Pten 
rescued versus non-rescued (GFP) TRP-/- astrocytes.  Mean doubling times ± 95% confidence intervals in 
C were calculated from the exponential growth curves in B.  All experiments are the mean of at least 
three independent experiments using different astrocyte isolations.  Error bars are SEM. 






Figure 3.5.  Gene expression profiling of G1/S-defective astrocytes with activated Kras and/or Pten deletion.   Consensus clustering of 22 
independently isolated astrocyte cultures identifies 3 clusters (A).  Individual isolates are repeated on the X and Y axes.  Darker shades of blue 
signify isolates that cluster together most often.  Single sample GSEA (ssGSEA) of the 15 most significantly enriched gene signatures from MsigDB 
in Class 3 (green) astrocytes (B).  ssGSEA of human GBM signatures (C).  ssGSEA of murine neural lineage signatures (D).  Red signifies higher 







Figure 3.6. A PI3K signature defined in TRP-/- astrocytes upon release from PI-103-mediated 
inhibition of PI3K signaling is enriched in human proneural GBM.   Heatmap of 518 genes with 
significantly increased expression in TRP-/- astrocytes after release from PI-103 (A).  A box and whiskers 
plot of the distribution of mean expression of PI3K signature genes (centroid) (B) and ssGSEA (C) shows 
that the PI3K signature is significantly enriched in human proneural (PN), but not neural (N), classical 





Figure 3.7.  G1/S-defective astrocytes form astrocytomas upon orthotopic injection into syngeneic, 
immunocompetent mouse brains.   Astrocytoma incidence in terminally-aged mice upon orthotopic 
injection of 105 astrocytes (A).  The number of mice injected per genotype is indicated.  The fraction of 
astrocytomas in panel A with histological features of high-grade astrocytomas (HGA) (B).  The number of 
astrocytomas detected per genotype is indicated.  Kaplan-Meier survival analysis of astrocytoma-bearing 
mice (C).  Median survivals were 36, 57, and 207 days for TRP-/-, TRP+/-, and TR astrocytes, respectively 
(P<0.0001).  The incidence of astrocytomas in mice sacrificed between 7 and 28 days post-injection with 







Figure S3.1.  MAPK and PI3K signaling and apoptosis in wild-type and G1/S-defective astrocytes.   
Representative immunoblots showing MAPK and PI3K pathway signaling in wild-type (WT) and G1/S-
defective (T) astrocytes (A).  Mean apoptosis relative to WT astrocytes (B) (P=0.03).  Error bars represent 






Figure S3.2.  Apoptosis in G1/S-defective astrocytes with and without activated Kras and/or Pten 
deletion.   Representative dot plots of live (L, green), apoptotic (A, red), and dead (D, blue) astrocytes of 
the following genotypes stained with Guava ViaCount and analyzed by flow cytometry:  (A) T, (B) TR, (C) 








Figure S3.1  Pharmacologic effects on signaling and viability.   U0126 (10µM) inhibits Erk 
phosphorylation in TRP-/- astrocytes 2 hours after treatment (A).  Rapamycin (10 nM, Rapa), LY294002 
(50 µM, LY), PI-103 (1 µM), U0126 (10 µM), and the combination of LY294002/U0126 minimally affect 
viability of TRP-/- astrocytes at 5 days after treatment (B).  Viability (percent live cells) for each treatment 
was determined by ViaCount staining and flow cytometry as described for Fig. S2 and was not 
significantly different across genotypes (P>0.05).  Values were normalized to untreated TRP-/- astrocytes.  






Figure S3.2.  Restoration of Pten reduces invasion in TP-/- astrocytes.   Mean percent wound 
closure of TP-/- astrocytes after infection with retrovirus containing Pten or GFP cDNA.  The overall mean 






Figure S3.3.  Consensus clustering of the transcriptomes of G1/S-defective astrocytes with and 
without activated Kras and Pten deletion.   Twenty-three independently isolated astrocyte cultures 
were examined (N= 2–5 isolates per genotype).  Consensus clustering with k=3 (A) and k=4 (B).  






Figure S3.4.  Pharmacologic inhibition of PI3K pathway signaling in TRP-/- astrocytes.   Time course 
of Akt and S6 phosphorylation in TRP-/- astrocytes treated for 2-24 hours with PI-103 (A), LY294002 (B), 
or (C) rapamycin.  Ratio of p-Akt normalized to total Akt in treated samples versus controls (black) 
relative to t=0.  Ratio of p-S6 normalized to total Akt in treated samples versus controls (red) relative to 
t=0.  Summary of the time (h) at which maximal inhibition occurred (tMax), the percent inhibition at tMax, 
and the duration of maximal inhibition (D).  Representative immunoblots of Akt, p-Akt, and p-S6 in TRP-/- 






Figure S3.5.  Histopathological features of astrocytomas derived from G1/S-defective astrocytes.  
Representative H&E stained sections of a grade II T astrocytoma (A-D), a grade IV TR GBM (E-H), two 
TRP+/- GBM (I-J and K-L), and a TRP-/- GBM (M-P).  GBM from both TRP+/- (L) and TRP-/- (P) cells show 
prominent oligodendroglial features.  Black arrows - perineuronal satellites; black arrowheads - mitoses; 
white arrows - necrosis; white arrowheads – microvascular proliferation.  Original magnification: 100X 
(A, E, I, M); 200X (K, O); 400X (B, C, F, G, J, L, N), 600X (D, H, P).  Scale bars for panels A, E, I, and M are 






Figure S3.6.  Incidence of astrocytomas over the first four weeks post-injection.   Tumor incidence 





Table S3.1.  ssGSEA ROC and P-values for the fifteen most and least enriched MSigDB gene 
expression signatures in Class 1-3 G1/S defective astrocytes. 
Rank Signature ROC p-value
1 WONG_IFNA2_RESISTANCE_DN 0.991 6.25E-06
2 NICK_RESPONSE_TO_PROC_TREATMENT_UP 0.982 1.25E-05
3 BIOCARTA_NKT_PATHWAY 0.982 1.25E-05
4 CHESLER_BRAIN_QTL_TRANS 0.964 3.75E-05
5 TOMLINS_PROSTATE_CANCER_DN 0.955 5.94E-05
6 BROWNE_HCMV_INFECTION_16HR_DN 0.955 5.94E-05
7 ROPERO_HDAC2_TARGETS 0.946 9.38E-05
8 MARSON_FOXP3_TARGETS_STIMULATED_DN 0.946 9.38E-05
9 SMID_BREAST_CANCER_NORMAL_LIKE_DN 0.946 9.38E-05
10 KORKOLA_YOLK_SAC_TUMOR_DN 0.938 0.000141
11 COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_DN 0.938 0.000141
12 GENTILE_UV_RESPONSE_CLUSTER_D2 0.938 0.000141
13 KORKOLA_CHORIOCARCINOMA_DN 0.929 0.00021
14 WILLIAMS_ESR2_TARGETS_UP 0.929 0.00021
15 CLAUS_PGR_POSITIVE_MENINGIOMA_UP 0.929 0.00021
15 CHEN_LVAD_SUPPORT_OF_FAILING_HEART_DN 0.0536 1
14 BIOCARTA_SARS_PATHWAY 0.0536 1
13 KANNAN_TP53_TARGETS_DN 0.0446 1
12 ZHAN_MULTIPLE_MYELOMA_HP_UP 0.0446 1
11 BIOCARTA_CARM1_PATHWAY 0.0446 1
10 KORKOLA_TERATOMA_UP 0.0357 1
9 NIKOLSKY_BREAST_CANCER_12Q13_Q21_AMPLICON 0.0268 1
8 GUTIERREZ_MULTIPLE_MYELOMA_DN 0.0268 1
7 KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_GANGLIO_SERIES 0.0268 1
6 KORKOLA_YOLK_SAC_TUMOR_UP 0.0179 1
5 LU_TUMOR_ENDOTHELIAL_MARKERS_UP 0.0179 1
4 REACTOME_G1_PHASE 0.0179 1
3 LU_TUMOR_VASCULATURE_UP 0.00893 1
2 ZHAN_MULTIPLE_MYELOMA_MF_DN 0.00893 1
1 VICENT_METASTASIS_UP 0 1
1 MCCABE_HOXC6_TARGETS_CANCER_DN 1 3.13E-06
2 LEE_NAIVE_T_LYMPHOCYTE 0.991 6.25E-06
3 SILIGAN_BOUND_BY_EWS_FLT1_FUSION 0.973 2.19E-05
4 SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_DN 0.964 3.75E-05
5 APPEL_IMATINIB_RESPONSE 0.964 3.75E-05
6 SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES 0.964 3.75E-05
7 KEGG_ADHERENS_JUNCTION 0.955 5.94E-05
8 NOJIMA_SFRP2_TARGETS_DN 0.946 9.38E-05
9 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_UP 0.946 9.38E-05
10 TOMLINS_PROSTATE_CANCER_UP 0.946 9.38E-05
11 BOYLAN_MULTIPLE_MYELOMA_C_D_DN 0.946 9.38E-05
12 ZHOU_INFLAMMATORY_RESPONSE_LPS_UP 0.938 0.000141
13 KANG_GIST_WITH_PDGFRA_UP 0.938 0.000141
14 TSAI_DNAJB4_TARGETS_UP 0.938 0.000141
15 SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER 0.938 0.000141
15 LOPEZ_MESOTELIOMA_SURVIVAL_TIME_UP 0.116 0.999
14 RODRIGUES_THYROID_CARCINOMA_UP 0.116 0.999
13 CLAUS_PGR_POSITIVE_MENINGIOMA_UP 0.116 0.999
12 PETRETTO_BLOOD_PRESSURE_UP 0.107 0.999
11 VALK_AML_WITH_FLT3_ITD 0.107 0.999
10 YANAGISAWA_LUNG_CANCER_RECURRENCE 0.107 0.999
9 KEGG_BIOSYNTHESIS_OF_UNSATURATED_FATTY_ACIDS 0.107 0.999
8 BIOCARTA_ERYTH_PATHWAY 0.107 0.999
7 JAERVINEN_AMPLIFIED_IN_LARYNGEAL_CANCER 0.0982 1
6 KEGG_ALZHEIMERS_DISEASE 0.0893 1
5 BARIS_THYROID_CANCER_UP 0.0804 1
4 LI_CYTIDINE_ANALOGS_CYCTOTOXICITY 0.0804 1
3 SPIRA_SMOKERS_LUNG_CANCER_DN 0.0804 1
2 REACTOME_GLUCOSE_METABOLISM 0.0714 1
1 LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_UP 0.0625 1
1 BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_CIS 1 5.86E-06
2 FERRARI_RESPONSE_TO_FENRETINIDE_DN 0.99 1.17E-05
3 ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_DN 0.962 7.04E-05
4 REACTOME_G_BETA_GAMMA_SIGNALLING_THROUGH_PLC_BETA 0.962 7.04E-05
5 KORKOLA_CHORIOCARCINOMA_UP 0.952 0.000111
6 MOOTHA_PGC 0.952 0.000111
7 KEGG_GLYCOLYSIS_GLUCONEOGENESIS 0.952 0.000111
8 REACTOME_MITOCHONDRIAL_FATTY_ACID_BETA_OXIDATION 0.952 0.000111
9 GAUSSMANN_MLL_AF4_FUSION_TARGETS_B_UP 0.943 0.000176
10 HO_LIVER_CANCER_VASCULAR_INVASION 0.943 0.000176
11 KEGG_RENIN_ANGIOTENSIN_SYSTEM 0.943 0.000176
12 REACTOME_ACTIVATION_OF_KAINATE_RECEPTORS_UPON_GLUTAMATE_BINDING 0.943 0.000176
13 LIU_PROSTATE_CANCER_UP 0.933 0.000264
14 PRAMOONJAGO_SOX4_TARGETS_DN 0.933 0.000264
15 OUELLET_CULTURED_OVARIAN_CANCER_INVASIVE_VS_LMP_UP 0.933 0.000264
15 SABATES_COLORECTAL_ADENOMA_SIZE_UP 0.0571 1
14 SHI_SPARC_TARGETS_DN 0.0571 1
13 YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_3 0.0571 1
12 BIOCARTA_NFKB_PATHWAY 0.0571 1
11 ELVIDGE_HIF1A_TARGETS_DN 0.0476 1
10 AMIT_DELAYED_EARLY_GENES 0.0476 1
9 NIELSEN_SYNOVIAL_SARCOMA_UP 0.0476 1
8 KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 0.0476 1
7 BIOCARTA_LONGEVITY_PATHWAY 0.0476 1
6 REACTOME_P130CAS_LINKAGE_TO_MAPK_SIGNALING_FOR_INTEGRINS 0.0476 1
5 KUROKAWA_LIVER_CANCER_CHEMOTHERAPY_DN 0.0381 1
4 LOPEZ_MESOTHELIOMA_SURVIVAL_UP 0.0381 1
3 MOREAUX_MULTIPLE_MYELOMA_BY_TACI_UP 0.0286 1
2 HSC_MATURE_FETAL 0.0286 1


































































































































Class 1 Class 2 Class 3 
Score p-value Score p-value Score p-value 
Cahoy 
Astrocyte -0.1108 0.22 -0.2929 0.044 0.2442 0.061 
Oligogendrocyte 0.0227 0.342 -0.0165 0.44 -0.0403 0.251 
Neuron -0.0354 0.371 0.0251 0.395 0.0411 0.367 
OPC -0.2484 0.031 -0.059 0.353 0.3101 0.005 
Cultured Astrocytes 0.2028 0.132 0.0694 0.372 -0.3756 0.006 
TCGA 
Proneural -0.1505 0.144 -0.0221 0.439 0.1476 0.155 
Neural -0.108 0.308 -0.0406 0.411 0.2824 0.127 
Classical -0.1566 0.079 -0.0734 0.265 0.0747 0.242 
Mesenchymal 0.2485 0.175 0.0833 0.389 -0.3857 0.092 
Phillips 
Proneural -0.1045 0.235 0.0179 0.427 0.0306 0.42 
Proliferative 0.0403 0.439 -0.0528 0.391 0.0355 0.458 
Mesenchymal 0.2877 0.172 0.0357 0.435 -0.4749 0.043 
        Signatures with statistically significant enrichment are highlighted for each class. 





Table S3.3  PI3K signature genes (N=518) defined by release of TRP-/- G1/S defective astrocytes 




































































































































































































































































































































































































































































































































































Radiation, but not temozolomide, is effective in an orthotopic allograft of proneural glioblastoma 
INTRODUCTION 
Diffuse gliomas are some of the most devastating and difficult-to-treat of all human cancers. 
Glioblastoma (GBM), the most common malignant glioma, has a median survival of 12-15 months, a 
statistic that has changed little over the last four decades due to relatively few advances in treatment 
(214)  Standard therapy for newly-diagnosed GBM patients currently consists of surgical resection 
followed by fractionated radiotherapy with concomitant and adjuvant temozolomide (TMZ) 
chemotherapy.  This regimen results in a modest, three-month survival benefit compared to radiation 
alone, but invariably fails to prevent tumor recurrence (28).   
Development of more effective treatments for GBM has been hindered by the intrinsic resistance of 
glioma stem cells to radiation and cytotoxic chemotherapy (39).  In addition, glioma cells isolated from 
mice or patients are often heterogeneous themselves due to additional acquired mutations. 
Comprehensive molecular profiling analyses of GBM have identified four different subtypes that 
correlate with alterations in commonly altered signaling pathways.(17, 18, 29). In light of these findings, 
genetically-engineered mouse models (GEMM) of gliomas that recapitulate the genetics and biology of 
their human counterparts have emerged as essential tools for the investigation of the genetics and cell 
and molecular biology of glioma initiation and progression (40, 42-46, 139, 215).  We have previously 
isolated and characterized G1/S-defective murine astrocytes with mutations in the commonly altered 
MAPK and PI3K signaling pathways (163), and showed that orthotopic injection into immunocompetent 
mice resulted in proneural-like high-grade astrocytoma (HGA) with high reproducibility, suggesting that
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 these cells can be used as an in vitro and in vivo model of proneural GBM.  Even though the cells 
had primitive expression profiles, it was undetermined whether they function as neural stem cells or 
not.   
Here, we evaluate the stemness of G1/S-defective astrocytes containing activated Kras and Pten 
deletion and demonstrate the utility of our orthotopic allograft by measuring longitudinal growth and 
response to standard of care treatment.  
 
MATERIALS AND METHODS 
Genetically-engineered mice   
Compound TRP mice were generated by crossing heterozygous TgGZT121 (79), Kras
G12D conditional 
knock-in (147), conditional Pten knock-out (92) and conditional-inducible hGFAP-CreERT2 (99) mice. All 
experimental animals were >94% of C57/B6 background.  Animal studies were approved by the 
University of North Carolina Institutional Animal Care and Use Committee (IACUC). 
 
Primary TRP astrocytes 
Primary astrocytes were cultured as previously described (79, 163). Briefly, cells were selectively 
harvested from the cortices of postnatal day 1-4 pups, manually dissociated by trituration in trypsin, and 
incubated at 37°C for 20 minutes. Cells were pelleted, resuspended, and cultured in DMEM 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (complete media). At 50% 
confluence, cells were infected at an MOI of 50 for 6 hours in complete media with a recombinant 
adenoviral vector expressing Cre-recombinase from the constitutive cytomegalovirus promoter 
(Ad5CMVCre, University of Iowa Gene Transfer Vector Core) (191). Following infection, cells were rinsed 
in PBS and cultured in complete media at 37°C in 5% CO2.   
Growth of TRP astrocytes as non-adherent spheroids (neurospheres) was performed by plating cells 
at clonal density (1 cell/µl) in mouse stem cell medium (SCM, Stemcell Technologies, Vancouver, 
 262 
 
Canada) supplemented with 20 ng/ml EGF and 20 ng/ml bFGF (Life Technologies, Grand Island, NY), and 
counting the number of neurospheres formed as a fraction of cells plated for 7 days.  These 
neurospheres were disassociated and reseeded for 6 consecutive passages as previously described 
(216).  To generate luciferase expressing cells, TRP-/- astrocytes were infected with retroviral particles 
containing MSCV-luc (a kind gift from Scott Lowe, Cold Spring Harbor Laboratory, Addgene #18782), 
followed by selection with hygromycin (300 µg/ml) and verified for stable luciferase expression with the 
OneGlo assay kit (Promega, Madison, WI).  U87MG cells were a kind gift from G. Yancey Gillespie 
(University of Alabama at Birmingham) (114).  U87MG cells stably expressing luciferase (U87FL) were a 
kind gift from C. David James (University of California, San Francisco) (217). 
   
Orthotopic allografts 
Orthotopic allografts with TRP astrocytes were carried out as previously described (163). Briefly, 105 
cells in 5 µL injected into right basal ganglia using coordinates 1, -2, and -4 mm (A, L, D) from the Bregma 
suture via a Hamilton syringe mounted in a repeating antigen dispenser (Hamilton, Reno, NV). 
Anchorage-independent growth 
After cells were exposed to ionizing radiation, 50,000 cells were resuspended at 10 ml in growth 
medium containing 5% agar (Becton-Dickinson, Franklin Lakes, NJ) and plated onto 100mm plates. Plates 
were supplemented with complete medium weekly and colonies consisting of more than 5 cells were 
counted 21 days later.  
 
Cell growth 
For cell growth studies in response to TMZ, cells were plated on 96-well plates, treated with 
increasing concentrations of TMZ and O6-benzylguanine (Sigma-Adlrich, St.Louis, MO) dissolved in 
DMSO, or  with 0.1% DMSO alone, and after 5 days assayed with the CellTiter 96 AQueous One Solution 





Cells were harvested 2 days post-treatment. DNA content was analyzed using Guava Cell Cycle 
Reagent on an Guava Easy Cyte Plus instrument according to the manufacturer’s instructions (EMD 
Millipore Corp, Billerica, MA). Cell cycle analysis was carried out with ModFit LT software (Verity 
Software House, Topsham, ME). 
 
Bioluminescence in vivo imaging 
Bioluminescence in vivo images were acquired from anaesthetized mice with an Ivis Kinetic System 
(PerkinElmer, Waltham, MA) 10-15 min after peritoneal administration of D-luciferin (PerkinElmer), and 
analyzed using Living Image software (PerkinElmer). 
 
Histopathological evaluation 
Animals were monitored multiple times per week and sacrificed upon neurological symptoms such 
as lethargy, loss of weight, deterioration in body condition, poor grooming, bulging skull, seizures, 
ataxia, or paralysis.  Brains were harvested, cut sagittally through the needle track, immersion fixed in 
10% neutral buffered formalin overnight, and stored in 70% ethanol prior to paraffin embedding.  
Formalin-fixed, paraffin embedded (FFPE) brains were cut on a rotary microtome in serial 4-5 μm 
sections, placed on glass slides, and stained with hematoxylin and eosin (H&E) on a Leica Microsystems 
Autostainer XL (Buffalo Grove, IL). H&E stained slides were scanned on an Aperio ScanScope XT (Vista, 
CA) using a 20X objective and the resulting .svs files were imported into an Aperio Spectrum web 
database. Histopathological analysis, grading, and photomicrography was performed by CRM according 
to WHO 2007 criteria for human astrocytomas (5) using an Olympus BX41 microscope equipped with a 






Cell monolayers were fixed with 4% para-formaldehyde for 10min, followed by incubation with 
primary or secondary antibodies in 0.05% Triton X100 – PBS buffer. All primary antibodies were 
obtained from EMD Millipore Corp, except GFAP (Dako Inc, Carpinteria, CA) and Tuj1 (Covance, 




Total RNA was isolated from astrocytes using an RNeasy Mini Kit (QIAGEN, Valencia, CA), RNA 
quality was confirmed with the Agilent Bioanalyzer (RNA Integrity Number > 7), labeled with the Agilent 
Low RNA Input Linear Amplification Kit(Agilent Technologies, Santa Clara, CA), and hybridized to Agilent 
Whole Mouse Genome 4×44 K microarrays (G4122-60520) per the manufacturer's protocol. Stratagene 
Universal Mouse Reference RNA (Agilent, #740100) was co-hybridized to each array as a reference. 
Microarrays were scanned on an Agilent DNA Microarray Scanner with Surescan High-Resolution 
Technology (G2565CA). Images were analyzed using Agilent Feature Extraction Software. 
 
Microarray analyses 
Microarray data was normalized using Lowess on the Cy3 and Cy5 channels. Analyses were 
performed on data present in at least 70% of experimental samples using genes with an absolute signal 
intensity of at least 10 units in both dye channels. Replicate probes were collapsed to genes by 
averaging. Further analyses were performed using R system for statistical computing (R Development 
Core Team, 2006, http://www.R-project.org). Probes were annotated with gene symbols using the 
Ensembl database through Biomart (196). Genes were median centered before principle components 
analysis. Single sample Gene Set Enrichment Analysis (ssGSEA) was performed as described 
previously(162). For human TCGA GBM signatures, the top 250 genes most highly expressed in each 
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subtype versus the remaining subtypes were used, as determined by Significance Analysis of 
Microarrays one-versus-rest comparisons in Verhaak (17). For comparison to human gene sets, mouse 





Data was analyzed with Prism 5 software (GraphPad Software, Inc, La Jolla, CA) and Stata 10 





G1/S-defective murine astrocytes with constitutively active Kras and Pten deletion display GBM 
stem cell features in vitro and in vivo 
We have previously generated G1/S cell cycle checkpoint-defective murine cortical astrocytes, 
harboring constitutively active Kras (KrasG12D) and homozygous Pten deletion (hereafter referred to as 
TRP).  TRP astrocytes have activated MAPK and PI3K signaling, which potentiates proliferation, 
migration, and invasion in vitro.   Upon orthotopic injection into syngeneic, immunocompetent mice, 
TRP astrocytes produced GBM with primitive, progenitor-like transcriptomal profiles similar to human 
proneural GBM.(163)  Cells with neural stem cell-like properties – variably referred to in the literature as 
brain tumor stem cells (BTSC), GBM stem cells (GSC), or more generically as cancer stem cells (CSC) - 
have been identified in human GBM (52) and GSC have been proposed as a source of the intrinsic 
resistance of GBM to radiation (55) and possibly temozolomide (218-221).   We therefore asked whether 
genetically-defined, TRP astrocytes function as cancer stem cells. 
We first examined their capacity for unlimited self-renewal.  When TRP astrocytes were grown in 
stem cell medium (SCM) at clonal density, neurospheres formed within 7 days (Fig. 4.1A) and were 
passaged at least 6 times. TRP astrocytes maintained their ability to form neurospheres at a frequency 
comparable to wildtype stem cells isolated from the early post-natal mouse subventriuclar zone (SVZ) 
propagated in parallel (Fig. 4.1A). When dissociated TRP neurospheres were returned to serum-
containing medium without growth factors, differentiation into neural, astroglial and oligoidendroglial 
lineages was observed (Fig. 4.1B, C). These results suggest that cultured TRP astrocytes possess 
functional properties of neural stem cells. They also expressed several molecular markers consistent 
with mouse stem cell characteristics such as Sox2, Nestin, A2B5, CD133 and Ki-67, (Fig. S4.1), which are 
also often found highly expressed in human glioblastomas (222-224).  
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If TRP astrocytes were glioblastoma stem cells in vivo, a single tumor stem cell should be able to 
proliferate and generate a heterogeneous GBM. To test this we injected serial dilutions of TRP 
astrocytes, as low as 100 cells, into mouse brains.  All injections resulted in GBM, causing death within 
70 days (Fig. 4.1D), which supports our in vitro data where 1-2% of TRP astrocytes gave rise to rapidly 
growing neurospheres. To test if these GBM could be passaged in vivo, we homogenized a primary 
allograft GBM and reinjected a single-cell suspension of 105 cells into syngeneic hosts. We observed 
secondary and tertiary GBM in all injected mice and median survivals were unchanged (Fig. 4.1E). In 
summary, TRP astrocytes display features of neural stem cells in vitro, and function as tumor initiating 
cells in vivo. 
 
Orthotopic injections of TRP astrocytes for a translational mouse model for GBM 
To investigate whether this allograft model could serve as translational research model, we injected 
105 cells in 84 mice over 7 independent experiments and found highly reproducible survival with a 
median of 26 days and 95% confidence interval 23-28 days, Fig. S4.2). To verify tumor presence, we 
carried out a thorough histopathological analysis of H&E stained brain sections according to the WHO 
criteria (5) (Fig. 4.2A, C, D). Tumors were 98% penetrant (76% GBM and 22% astrocytoma grade II or III).  
In brain sections collected 5 days after injection, the injected cells were T121-positive and visible as a 
well-defined cell-dense area in the diencephalon (Fig. 4.2A, B). Most tumors were located in near 
injection sites, but tumor cells also infiltrated the surrounding brain parenchyma (Fig. 4.2C, D). 
Characteristic hallmarks of GBM histopathology were also evident, including perineuronal and 
perivascular satellites, mitoses, invasion along white matter tracks, and pseudopalisading necrosis (Fig. 
4.2C, D).  These data demonstrate a high-incidence translational glioma model that generates GBM with 




TRP cells are sensitive to temozolomide and ionizing radiation treatment in vitro 
To assess the utility of the GBM allograft model for evaluation of therapeutic treatment, we first 
investigated the impact of radiation and chemotherapy in vitro. TRP cells demonstrated a 67% decrease 
of viability in a colony forming assay after a single dose of 2.5 Gy (Fig. 4.3A), which is similar to 
sensitivities observed using established human glioma cell lines (225, 226).  The alkylating agent 
temozolomide (TMZ) had an IC50 of 539 µM after 5 days (Fig. 4.3B).  However,  because the maximal 
blood plasma concentration in humans after oral TMZ administration does not exceed 50 µM (227), cell 
sensitivities in vitro above 100 µM TMZ have little translational relevance. In comparison, human U87 
glioma cells showed a higher sensitivity to TMZ compared to TRP cells (IC 50 = 24.57 µM, Fig. 4.3B) and 
growth was similar at physiologically relevant TMZ concentrations of 50 µM, similar to previously 
described experiments (228).  TRP cells did not show cell cycle arrest at the G2/M checkpoint at TMZ 
concentrations up to 100 µM.  This contrasted with U87 cells which had significant G2/M arrest after 
TMZ (Fig. S4.2) (229).  
 
Ionizing radiation but not TMZ treatment results in modest survival benefit 
To assess the in vivo effect of radiation and TMZ treatment in orthotopic allografts, we treated TRP-
injected mice on day 6 with 100 mg/kg/day TMZ for 5 consecutive days, with and without 3 concomitant 
doses of 5 Gy IR every other day. Survival of TMZ-treated mice (Fig. 4.4A) were not different from 
untreated animals (OS 22 and 21 days, respectively; p=0.8404), whereas animals that received radiation 
(XRT) showed significantly increased survival (OS = 33 days, P = 0.0001).  However, concomitant TMZ 
and XRT did not increase survival compared to XRT alone (OS = 32 days, P = 0.5351). Longitudinal 
magnetic resonance imaging (MRI) showed that tumors were detectable after 10 days in XRT-treated 
mice compared to 7 days in untreated mice, which reflects tumor growth retardation after treatment 
(Fig. 4.4B).  Volumetric measurements with MRI showed XRT-treated mice had a doubling time of 3.3 
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days versus 1.8 days for untreated mice, but histopathological analysis confirmed that all mice died with 
GBM.  
We also created luciferase-expressing TRP astrocytes and performed bioluminescence imaging (BLI) 
in order to account for viable diffuse tumor cells that are undetectable with contrast enhancing MRI.   
The BL signal from injected tumor cells and their progeny will correlate with the entire tumor size and 
allow calculation of tumor growth rates.  As a positive control for BLI we utilized luciferase-infected U87 
human glioma (U87FL) xenografts (Fig. S4.4A) (230). Survival of untreated and XRT-treated U87FL 
xenografts was not significantly different and they were thus used as a negative control for treatment 
with XRT.  (P=0.5, Fig. S4.4B).  
TRP cells were retrovirally infected with a luciferase-encoding plasmid to create TRPluc cells and 
verified that their BL signal remained stable for at least 7 in vitro cell passages (data not shown). TRPluc 
allografts treated with and without XRT showed similar survival to the parental cell line lacking 
luciferase, indicating that the luciferase plasmid did not affect survival (Fig. S4.4C). In vivo BLI of the 
same cohort indicated exponential growth (Fig. 4.4C). When TRPluc tumors were treated with XRT the 
BLI signal remained stable for about a week before increasing again, a doubling time of 3.5 days 
compared to untreated the 1.9 days doubling of TRPluc tumors, which is similar to the data obtained by 
MRI.  Histopathological analysis confirmed that all mice died with GBM. 
 
Radiation treatment leads to a switch from the proneural to the mesenchymal GBM subtype 
Having demonstrated that TRP GBM allografts are similar to human GBM in growth characteristics, 
histopathology, and response radio-chemotherapy, we next analyzed their genome-wide transcriptome 
patterns using DNA microarrays.  Because treatment with XRT showed a survival benefit, we assessed 
how untreated and XRT-treated tumors compared to human GBM.  Principle component analysis 
showed XRT-related influence in the second and fourth principal components, accounting for 20% of 
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total variation in the data (Fig. 4.4D).  Projection of human GBM subtype signatures on the untreated 
and XRT-treated GBM allografts using single sample gene set enrichment analysis (ssGSEA) identified 
significant enrichment of the proneural signature in untreated allografts (P < 0.001, Fig. 4.4E).  However, 
XRT-treated GBM were not enriched for the proneural subtype but were enriched in the mesenchymal 
signature (P = 0.005), suggesting that treatment with XRT influenced a change in expression from 




Here we have demonstrated that injection G1/S-defective coritical astrocytes with Kras activation 
and Pten deletion generate GBM in an orthotopic allograft model system.  These GBM were highly 
penetrant and aggressive with a reproducible median survival of 26 days.  They resembled human GBM 
histopathologically and molecularly. TRP GBM allografts were sensitive to radiation but not 
temozolomide, and relapsed after cessation of radiation which was comparable to human GBM treated 
with standard of care therapy (28).  We also showed that the TRP tumor initiating cells in this model 
function as neural stem cells and thus are a renewable source of glioma stem cells. This model combines 
the advantages of GEM and their genetically-defined mutations with a predictable and fast-growing 
allograft that can be used to discover and evaluate new treatment for GBM 
The allograft described in this manuscript offers several advantages over traditional GEM or 
xenografts.  First, short reproducible latency is an advantage over inducible GEM models, where the 
latency before tumor detection often exceeds 3 months and median survival can be as long as 5-7 
months (reviewed in (139)).  Additionally, many previous therapeutic studies tested compounds and 
different modes of radiation treatment for GBM in xenograft models by flank injection lacks the 
physiological relevant biology and structure of the brain.  Others offer a slight improvement by using 
orthotopic brain injections into nude or SCID mice, but these models are still limited by the use of 
genomically heterogenous human cell lines (208, 231), and mice without functioning immune systems.  
Patient-derived orthotopic xenografts are even better but still require the use of immunosuppressed 
mice and the genomic alterations are predetermined by the tumor harvested. Notably, we used 
wildtype C57B6/J mice as orthotopic allograft hosts and inject genetically defined cortical astrocytes. 
Therefore, in contrast to immunocompromised, xenograft recipients, our allografts more closely 
resemble the tumor environment found in human patients.  This model has the flexibility that other 
models lack, to incorporate additional gene manipulation through introduction of plasmids, viruses, or 
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mice with different mutations.  In addition, orthotopic injections can target different brain regions in 
order to model location-related differences in GBM biology or response to therapy. Our previous results 
with the conditional, inducible GEM described in Chapter II suggest location influences distinct gene 
expression signatures.  These factors may ultimately dictate future therapeutic options as well.  
Comparative genetic analysis of The Cancer Genome Atlas (TCGA) has defined abnormally 
functioning signaling pathways in GBM (17, 29).  TCGA identified 4 GBM subtypes based on their gene 
expression and signature genomic abnormalities. Expression of the GBM allograft described in this 
manuscript imitates human proneural GBM in vitro (163) and in vivo.  However, after radiation therapy 
the recurrent GBM resemble mesenchymal subtype rather than proneural, suggesting a radiation-
induced change in expression and subtype. A similar proneural to mesenchymal change was observed in 
patient-matched human GBM samples before and after radiation (18). This feature suggests TRP 
allografts respond similarly to human GBM at the molecular level, and that in addition to therapeutic 
and phenotypic readouts, they have the potential to model molecular responses to new compounds or 
treatment regiments. 
In summary, we have developed a translational research mouse model for GBM that can serve as a 
platform for development of novel therapies against glioma stem cells, or to model response to 
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Figure 4.1: TRP cells function as glioma stem cells in vitro and in vivo Adherent TRP cells form 
neurospheres in stem cell medium (SCM) after 7 days. Over 6 passages, about 1-2% of cells originating 
from dissociated neurospheres were able to form new neurospheres. In comparison, freshly isolated 
neural stem cells from the SVZ of 3 day old pups yielded similar numbers in parallel (A).  TRP 
neurospheres differentiated into all neural lineages (GFAP+, astrocytic; Tuji1+, neural; NG2+, 
oligodendritic; Nestin+, stem cell) within 5 days after NGF and EGF were removed and replaced with 
10% FBS (B, C).  Allograft tumors were passaged by dissecting the primary tumor and disassociating it 
into a single cell suspension of 105 cells that was immediately re-injected into another cohort to form 
secondary tumors (D).  The same procedure was repeated for tertiary allografts. Mean overall survival 




Figure 4.2. TRP allografts develop rapidly proliferating GBM Representative images of TRP 
allografts with GBM show T121+ cell bolus at the injection site 5 days after injection (A,B).  GBM 
primarily present at injection site in the diencephalon within 3 weeks and are visible as large H&E-dense 
tumor area, surrounded by less dense areas populated with invasive cells (C, D). TRP allografts are 
characterized by histopathologic features of GBM, including necrosis (C, black arrowhead), perineural 
(D, white arrowhead) and perivascular (D, white arrow) satellitosis, mitosis (D, black arrowhead), and 




Figure 4.3. TRP cells are sensitive to ionizing radiation and TMZ in vitro TRP cells were treated with 
increasing doses of ionizing radiation, and then plated on soft agar to assess anchorage-independent 
growth. Quantification of colonies formed after 21 days showed an exponential decrease in surviving 
cells as radiation increased (A).  TRP or U87MG cells were treated with increasing concentrations of 
temozolomide (TMZ) and assayed 5 days later with the MTS assay. While U87MG cells showed 
increasingly reduced growth at concentrations over 10µM TMZ, the growth rate for TRP cells did not 




Figure 4.4. TRP allografts respone to radiation but not temozolomide therapy Mice (N=40) were 
randomized to 4 treatment groups and subjected to 5 consecutive treatments with 100mg/kg TMZ on 
day 6-10 after injection (TMZ, green), or 3 doses of 5 Gy ionizing radiation each on days 6, 8 and 10 (XRT, 
red), concurrent TMZ+XRT (blue), or control treatment. Survival analysis showed median survival was 
20, 22, 33, and 32 days for the controls, TMZ, XRT, and TMZ+XRT groups, respectively, indicating that 
treatment with XRT (P < 0.0001) but not TMZ (P < 0.5) showed survival benefit (A).  Longitudinal MRI 
showed control-treated tumors grew exponentially in contrast to significantly retarded growth in XRT-
treated mice, though those tumors eventually resumed exponential growth (B).  TRPluc astrocytes that 
express luciferase allowed longitudional bioluminescence imaging (BLI) of 20 mice randomized and 
treated similarly with control or XRT-treatment to confirm the growth measurements determined by 
MRI (C).  Principle components analysis of untreated and XRT-treated tumors’ genome-wide gene 
expression indicated an influence of XRT in PC2 and PC4, which together accounted for 20% of total 
expression variation (D).  Projection of TCGA subtype signatures on untreated and XRT-treated allografts 
indicated untreated GBM allografts were enriched for the proneural (PN) signature, but XRT-treated 




Figure S4.1. TRP astrocytes express stem cell markers.  Monolayers of TRP astrocytes were fixed 
and stained with a panel of molecular markers. Strong expression of neural stem cell markers (e.g. Sox2, 
Nes, A2B5, CD133) was observed. Cells were CD44-positive and showed weak expression of CD15. All 




Figure S4.2.  Orthotopic allograft injections have reproducible survival. Survival statistics from 7 
independent experiments with TRP astrocyte injections (105 cells, N=84) (A). Astrocytoma formed with 
98% penetrance.   Histopathological analysis of H&E stained brain sections using WHO criteria 
determined 76% of the cohort developed GBM and 22% grade II or III astrocytoma.  Median survivals by 





Figure S4.3. TRP astrocytes are insensitive to temozolomide.  TRP or U87 cells were analyzed for 
cell cycle status by flow cytometry. The fraction of TRP cells in G2/M did not increase when treated with 
up to 100 µM TMZ for 2 days, whereas the number of U87 cells arrested in G2/M increased from 28-34% 
(0.1-10 µM) to 76% at 100 µM (A). The graph represents the mean percentages and SEM from 3 
independent experiments.  Representative data for cell cycle distribution in one individual experiment is 





Figure S4.4.  Bioluminescent Imaging in U87 and TRP cells.  5x105 U87FL cells were injected 
orthotopically into nude mice to monitor tumor growth using bioluminescent imaging (BLI) (A).  XRT 
treatment occurred as described earlier with 5 Gy on day 6, 8, and 10.  Median overall survival was 30 
days for untreated and 42 for XRT treated mice (B).  Survival of mice (N=20) injected with 105 TRPluc  
cells to allow longitudional bioluminescence imaging (BLI) of the developing tumor.  The median overall 
survival was 23 days and 30 days for the untreated and XRT-treated groups, respectively.  This is similar 







The previous chapters detail significant findings that should inform future glioma modeling.  
Collectively, they help define the requirements for astrocytoma initiation and progression, show the 
effects of these requirements on genome-wide expression, and suggest methods to evaluate standard 
and novel therapies in physiologically and molecularly relevant experimental systems.  In Chapter II, I 
described a conditional, inducible, adult GEM astrocytoma model that targeted GFAP-positive cells with 
disruption of the G1/S-checkpoint and RTK effector pathways using a fragment of SV40 large T antigen 
and targeted mutations to Kras and/or Pten.  Genetic fate mapping showed Kras and Pten mutations 
potentiated tumor initiation in G1/S-defective astrocytes throughout the brain, including in the cortex, 
diencephalon, brain stem, and olfactory bulb, to produce LGA.  These LGA showed oncogenic driver- and 
astrocyte location-specific transcriptome profiles, suggesting that both driver mutations and cellular 
origin contribute to LGA genomic heterogeneity.  Progression to high-grade astrocytomas (HGA) was 
typified by acquisition of CNA and transcriptome analysis of HGA revealed three subtypes that did not 
correlate with oncogenic driver mutations.  These three subtypes resembled human mesenchymal, 
proneural, and neural GBM and were evident in a test set of GEM HGA with different oncogenic drivers 
and cellular origins.  They expressed distinct neural lineage signatures and were correlated with 
astrocyte location.  These results suggest that oncogenic drivers influence LGA subtype and that regional 




 In Chapter III, we used isolated astrocytes from pups used in the above study, and induced 
recombination in culture to create genetically-defined, G1/S checkpoint-defective cortical murine 
astrocytes with constitutively active Kras and/or Pten deletion.  We systematically investigated the 
individual and combined effects of Kras activation and Pten loss on growth, migration, invasion, and 
gene expression and evaluated in vivo tumorigenesis using a syngeneic orthotopic allograft model 
system.  Activation of both RTK effector arms produced progenitor-like transcriptomal profiles that 
mimic human proneural GBM.  Additionally, allografts injected with these astrocytes resulted in in vivo 
tumorigenesis and produced highly invasive, proneural-like GBM.  These results suggest that cortical 
astrocytes can be transformed into GBM and that combined dysregulation of MAPK and PI3K signaling 
reverts G1/S-defective astrocytes to a primitive gene expression state.  This genetically-defined, 
immunocompetent model of proneural GBM will be useful for preclinical development of MAPK/PI3K 
targeted, subtype-specific therapies. 
 We extended these allograft experiments to evaluate the preclinical utility of TRP allografts by 
using standard-of-care fractionated radiation and concurrent temozolomide (28).  Radiation therapy 
significantly improved survival but concurrent temozolomide did not provide any additional benefit, nor 
did temozolomide alone.  Expression analysis suggested that radiation-therapy caused proneural 
allografts to switch to the mesenchymal subtype.   This work further validates the allograft as model of 
proneural GBM which can be used for development of subtype-specific therapies.  Furthermore, 
evidence of subtype switching suggests that, as targeted and subtype-specific therapies become more 
available, future therapy designs should be customizable and adaptable to account for the dynamic 






 The design of models that mimic glioma subtypes 
To date, three other studies have examined the transcriptomes of murine, adult HGA (100, 142, 
144), and only one of these employed conditional, inducible GEM and also analyzed genomic copy 
number(100).  We were able to make several important interpretations from the work described in 
Chapter II by using these other GEM HGA in the first documented example of using a validation, or test, 
set to confirm our discovered subtypes.  Since TCGA documented that certain genetic events, in the 
form of mutations or copy number changes, associated with subtype (17), it is often thought that GEM 
with mutations in those genes are adequate subtype-specific models.  However, this cannot be assumed 
in the absence of empirical evidence of gene expression that verifies transcriptomal subtype.  We 
showed in our discovery set that the three murine HGA subtypes S1-S3 did not correlate with their 
initiating oncogenic mutations, suggesting that Pten status does not specify subtype and similarly, Chow, 
Baker, and colleagues also showed that Rb1 status did not correlate with three murine HGA subtypes 
(100).  Importantly, when Trp53 was paired with Nf1 deletion—often thought of as a mesenchymal 
event—in neural stem cells the transcriptomal subtype of the resulting GBM was proneural (143).  This 
evidence illustrates the point that genotype alone may not be adequate to govern subtype in glioma 
GEM.  Therefore, in order to appropriately contextualize results, experimental transcriptome validation 
is required to label a GEM model as subtype-specific surrogate, regardless of its genotype.  This is of 
particular importance because the majority of glioma GEM have not been molecularly characterized 
(139).  Even though human glioma molecular characterization has progressed tremendously in the last 
decade (48), incomplete molecular  knowledge of historical glioma GEM currently precludes  a complete 






Brain heterogeneity and its influence on expression and tumorigenesis 
However, an important finding of our data in Chapter II was that murine HGA subtypes S1-S3 
correlated with tumor location.  These results suggest that location, microenvironment, or cell of origin 
influence molecular subtype.  Furthermore, HGA showed location-dependent CNA profiles suggesting 
that spatial variables might affect susceptibility to specific genomic gains and losses.  Current knowledge 
in these areas is far from conclusive, but continuous refinement of morphological and molecular 
characterization of different brain regions and cell types should help uncover the role they play in 
tumorigenesis and heterogeneity.    
The cellular and structural composition of the brain is very complex and human gene expression 
is characterized by distinct co-expression networks that vary according to age, brain region, and the 
distributions of cell lineages (222, 232).  Similarly, murine neural cell lineages have distinct gene 
expression profiles (108), and these have been shown to be enriched in particular GBM subtypes (17).  
In Chapter II, however, TR(P) GEM initiated tumorigenesis  primarily in astrocytes of adult mice and were 
still able to molecularly mimic 3 of 4 GBM subtypes.  This suggests that unaccounted for astrocyte 
heterogeneity and perhaps its interaction with regional brain niches influences subtype specificity.  
Unfortunately, little is known about astrocyte molecular heterogeneity.   
Astrocytes were long thought of as a mostly uniform population of cells that supported neurons.  
Now, however they are recognized to play diverse and complex roles in nearly all aspects of brain 
biology(146).  Moreover, astrocytic, neuronal, and oligodendrocytic molecular heterogeneity varies 
depending on their brain location (233), and astrocyte heterogeneity persists even within different 
regions of the cortex (234) and spinal cord (235).  Variable expression of oncogenes and tumor 
suppressors throughout cell lineages and brain regions could indicate regional susceptibility to 
tumorigenesis (236).  As “big data” from microarrays and sequencing becomes more prevalent, it will be 
critical to design future glioma models based on the discoveries of (intra)regional and (intra)cellular 
 286 
 
expression in the brain.  Our future studies will focus on identifying the cells of origin for astrocytomas 
within different brain regions and assess if regions influence tumor subtype. 
 
Identifying the cellular and spatio-temporal features that influence tumorigenesis and glioma 
molecular heterogeneity  
In order to determine if OFB HGA in TRP mice originate from GFAP-positive cells within the SVZ, 
future experiments will involve restricting recombination to the SVZ using local injection of lentiviral 
vectors that deliver GFAP-Cre.  Fluorescent lineage tracing will confirm that the targeted SVZ astrocytes 
migrate through the RMS to the OFB, and longitudinal analysis will determine if these cells initiate 
tumorigenesis in the OFB and progress to HGA.  Similar experiments can be done to target 
tumorigenesis to other brain regions.  Furthermore, the lentiviral vector can be packaged so Cre is 
driven by promoters other than GFAP.  Thus, subsequent molecular analysis of any resulting HGA will be 
used to inform how both regional and cellular specificity contribute to subtype and patterns of CNA.  In 
summary, these proposed experiments will extend the work detailed in Chapter II  in three important 
ways:   1) by locally injecting lentiviral Cre we target a small area within specific brain regions instead of 
the global recombination in GFAP-positive cells described previously; 2) by adjusting the promoter 
driving Cre we target specific cell types within these different regions; 3) fluorescent lineage tracing will 
allow definitive identification of tumor cells, and because the initial injection will be localized this will 
remove uncertainty in defining the cells of origin if the tumor has migrated and invaded other brain 
structures. 
In addition to an experimental design that allows for greater specificity than our previous 
experiments, these future experiments will incorporate high-throughput tools such as RNA-seq and 
exome sequencing.  Of these, exome sequencing has more potential to enhance our current knowledge.  
While RNA-seq will certainly be useful in identifying transcripts that are not printed on arrays and 
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providing greater resolution of known transcripts, thus far array-based expression analyses have 
permitted adequate comparisons between mouse and human gliomas.  In contrast, exome sequencing 
will fill a gap that has been largely unmet in murine HGA studies.  We and others (100) have examined 
genomic copy number using array CGH, but comprehensive large-scale sequencing is required to 
understand the mutation spectrum in GEM HGA models .  These two technologies will be particularly 
useful when applied to fluorescently-labeled targeted cells from mice with and without engineered 
mutations in order to view acute and longitudinal expression and mutation changes.  Such a design will 
allow analyses at a cellular and spatial resolution previously unavailable, and is the next logical extension 
from our broad regional analysis of LGA described in Chapter II.   We expect that data generated from 
these experiments aimed at uncovering molecular heterogeneity across brain regions will help address 
how  the spatio-temporal characteristics of astrocytes contribute to tumorigenic susceptibility, 
progression, acquisition of mutations, and expression subtype.   
 
Genetically-defined models to serve as the basis for designing preclinical models 
Experiments in Chapter III describe a genetically defined system in which to evaluate the effects of 
single and multiple signaling pathway mutations on the phenotypic characteristics of astrocytoma.  We 
have already discussed the difficulties with using human cell lines to examine phenotypic effects of 
genetic mutations.  Namely widespread mutations and alterations (208) preclude attributing individual 
abnormalities to specific phenotypic qualities, cultured human cells poorly recapitulate the expression 
of their parent tumor (115), and multiple clones and cell lineages within the tumor (185) complicate 
pinpointing how specific mutations transform particular cell lineages.  Creation of murine cell lines from 
GEM using lineage-restricted promoters can often address these shortcomings.   
As we included more mutation combinations in astrocytes harvested from GEM, their proliferation, 
migration, and invasion increased, and their transcriptomes became more primitive and stemlike.  
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Furthermore Kras activation and Pten deletion were necessary to efficiently form gliomas in orthotopic 
allografts.  These findings support the hypothesized requirements that GBM have mutations in the three 
core signaling pathways (17).  Therefore, creation of suitable cell lines should focus on meeting this 
criterion.  Using this guideline to create future tumor lines with different mutation permutations will 
allow “apples to apples comparisons” between cell lines that have different pathway member 
mutations.  Therefore, the determination of functional equivalence between mutations within the same 
signaling pathways should be able to be more accurately measured. 
Also, In Chapter III we defined a PI3k signature by analyzing TRP astrocyte transcription after release 
from a PI3K inhibitor.  This PI3K signature was found to be significantly associated with human proneural 
GBM.  These results reinforce the implication that GBM will require patient, or at least, subtype-
centered therapies.  One contributing reason many oncology drugs fail clinical trials is because they are 
administered to all patients with the disease rather than those who have been pre-screened (237), and 
therefore there is low statistical power to detect a positive result in the patient population that might 
benefit.  At the least, there is a need for larger trials and retrospective subtyping, and at best a more 
intelligent clinical trial design that includes prospective molecular enrollment criteria (238).  Taking 
advantage of preclinical mouse models that reflect disease subtypes can present opportunities for more 
sophisticated and multifaceted analyses earlier in the drug development pipeline (117, 123), potentially 
reducing costs and hastening decisions to proceed with or abandon therapies. 
 
The effect of therapy on gene expression in a preclinical model of HGA 
In many ways, Chapter IV is a continuation of the previous chapter, but focuses only on TRP 
astrocytes.  Earlier, we showed gene expression profiling that characterized TRP cells as stem like and 
proneural.  In Chapter IV we went on to verify that in addition to primitive expression patterns, these 
cells have stem cell properties of multilineage differentiation, self-renewal, are tumor initiating, and 
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express several key stem cell proteins.  Furthermore, TRP HGA allografts were profiled before and after 
treatment, which extended the analysis in Chapter III that was limited to only astrocyte cell lines.  And in 
contrast to the conditional, inducible GEM HGA described in Chapter II, TRP allograft HGA were all 
proneural.  This suggests that subtype expression is maintained when a subtype-specific cell line is used 
in an allograft, which can allow prescreening of animal or human cell lines before their inclusion in 
allografts or xenografts.  Follow-up experiments will be undertaken upon the identification of other 
subtype-specific cell lines, which we are actively generating.  Consistent and reproducible survival and 
subtyping of allograft HGA means they can potentially be used as preclinical models for development or 
evaluation of molecular therapeutics.  To evaluate this we replicated standard of care treatment for 
GBM and showed that radiation treatment had a significant survival benefit in TRP HGA allografts.  After 
radiation, TRP HGA were most similar to the mesenchymal rather than proneural subtype, which 
suggests radiation influences subtype switching.  It had previously been suggested that recurrent GBM 
shifted towards the mesenchymal subtype if they were not classified as such previously (18).  However, 
a different analysis of a small sample size of primary and patient-matched recurrent GBM after 
treatment indicated that there wasn’t a switch in subtype upon recurrence (27).  This question remains 
unanswered.  However, it is possible that a proneural to mesenchymal shift occurs easier than other 
subtype shifts, and the starting criteria may not have been met by the samples analyzed in the Murat 
dataset (27).  Alternatively, subtype switching could be a phenomenon that occurs when the recurrence 
is from a primary grade II or grade III astrocytoma (which are generally classified as proneural (17) that 
received treatment.  In our TRP allografts, radiation treatment occurred shortly after implantation, at 
which time the proneural tumor would have been lower-grade.  But by the time of GBM recurrence and 
animal death, its subtype was mesenchymal.  In support of this hypothesis, two out of three human 
proneural HGA that switched to mesenchymal were A3 initially and GBM at recurrence (18).  Currently, 
this explanation is little more than speculation, but it is apparent that TRP allograft HGA are more 
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mesenchymal after radiation.  The allograft model provides a means of testing this hypothesis, and the 
creation and implementation of other subtype-specific cell lines and allografts, or other proneural lines 
created using different mutations, should provide data to further evaluate this question.  
Overall, TRP allografts have most of the features desired in a preclinical model, particularly high 
penetrance, short latency, reproducibility, immunocompetence, microenvironment, and disease-
relevant expression (123). 
 
Preclinical HGA models of the remaining subtypes 
Thus far our orthotopic TRP allograft is limited because it only reproduces the proneural GBM 
subtype.  As previously stated we are actively investigating the creation of astrocytes with different 
mutations, which may yield models of the other subtypes.  In lieu of that data, we are attempting to 
merge the experimental designs of Chapter II and IV in attempts to acquire other subtype-specific 
allografts.  Inducible TR(P) mice described in Chapter 2 are unsuitable as a preclinical model because 
they are expensive and time consuming to create, and tumor latency is variable at 2-5 months.  
However, unlike the TRP astrocyte allograft, we have observed all 4 GBM subtypes in this model.  
Therefore, ongoing experiments involve passaging these induced HGA, by disassociation and direct 
orthotopic injection, into immunocompetent syngeneic mice as described in Chapter IV.  Expression 
subtyping will determine if the subsequent allograft HGA maintains the original tumor’s mouse and 
human subtype.  The creation of GEM that reproduce the other HGA subtypes while maintaining 
desirable criteria required for preclinical use is a prerequisite to using GEM for discovery and evaluation 
of subtype-specific responses to therapies, as well as discovering subtype specific therapies themselves. 
In the work described above, we used several complimentary approaches to model astrocytoma, 
define its requirements using GEM and cell lines, and measure response to therapy.  Further work must 
be completed to account for the influence of brain cell lineage and microenvironment on subtypes and 
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their mutation and CNA susceptibility.  Overall, use of specific mutations and molecular subtyping 
performed here and in other recent studies c (100, 142-145) suggests that there may be multiple means 
to generate similar subtypes.  It will be important to determine if there is an undefined commonality 
between these means to explain their similar ends.  Alternatively, subtype susceptibility may be as 
complicated and heterogeneous as the brain cellular and regional hierarchies from which the subtypes 
presumably arise.  Nonetheless, defining these specificities is a necessary step in the process of creating 
informative cell lines and preclinical models in which to perform biomarker discovery, drug 
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